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Abstract: Nature represents an amazing source of inspiration since it produces a great diversity of
natural compounds selected by evolution, which exhibit multiple biological activities and applications.
A large and very active research field is dedicated to identifying biosynthesized compounds, to
improve/develop new methodologies to produce/reuse natural compounds and to assess their
potential for pharmaceutical, cosmetic and food industries, among others, and also to understand their
mechanism of action. Here, the main results presented in each work are highlighted. The applications
suggested are mostly related to pharmacological uses and involve mainly pure natural compounds
and essential oils. These works are significant contributions and reinforce the dynamic field of natural
products applications.
Keywords: natural compounds; therapeutic applications; essential oils; antimicrobial; antitumor; SAR
1. Introduction
The compounds produced by nature exhibit a great diversity of chemical structures as a result
of the long, selective and evolutive process of species [1], and they constitute the active principles of
natural products which have always contributed, a lot, to improve human living conditions [2]. As
natural products have widespread uses in traditional medicine [3–5], and a wide range of biological
effects demonstrated scientifically, they possess high scientific and industrial value [6–9].
The properties demonstrated by natural compounds constantly encourage scientific research in
aspects that lead to significant advances in the identification of new natural compounds, evaluation of
the biological activity displayed, understanding of how they cause a biological effect, in the development
of new applications and in all cases with beneficial results for humanity.
Despite very significant advances in medicine, many diseases such as cancer, infections, diabetes
and cardiovascular diseases remain without affordable, effective and safe therapy. Due to this,
the most frequently explored area with relevant results is the development of new drugs from natural
sources [7,8,10–14], with natural product-based new drugs being 51% of small molecules approved
and launched in the market between 1981 and 2014 [15].
The demand for natural antimicrobial agents and anticancer drugs is a very active research
point [16–20] since cancer and infectious diseases are a significant cause of mortality worldwide [21].
Moreover, the World Health Organization predicts that the incidence of cancer will continue to rise to
over 11 million in 2030 [22]. More than 1700 clinical trials involving the natural vinca alkaloids to treat
cancer are registered currently on the clinicaltrials.gov platform [23]. Furthermore, the resistance and
undesirable side effects of antibiotics and antineoplastic agents used in the clinic [24,25] have become
pressing problems, leading to a continuous search for new inhibitors with new mechanisms of action.
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The application of natural compounds as antioxidant agents is also a hot topic [26–29], once
several diseases are, at least partially, a result of free radicals’ imbalance [26,30,31]. Overproduction of
oxygen free radicals, when associated with the deficiency in antioxidant repair or defence mechanisms,
will cause oxidative damage leading to disease development like cancer, inflammation, diabetes,
cardiovascular and aging-associated diseases [26,30–32].
Natural products are also applied as an ingredient in cosmetic preparations [33,34] and in the food
industry since they exhibit useful preservative properties [35,36].
The limited availability of a natural product is a difficulty when it is a promising molecule for an
application. Thus, recently, it has been proposed that several techniques that can improve the natural
product yield. It is the case of metabolomics, enable the rapid identification of novel compounds in
complex mixtures of natural products, metabolic engineering of cells endowed with the ability of
overproduction of new products and metagenomics exploring novel metabolites from microorganisms
present in several environments but which remain recalcitrant to culturing [37–39].
Natural compounds are privileged structures because of their structural diversity and multiple
biological activities. They are undoubtedly the ideal compounds for the rational design of new drugs
and the development of new chemical entities with therapeutic potential [8,14]. Thus, research on
natural compounds is necessary and very welcome.
This Special Issue is dedicated to present the most recent results about the development of natural
compounds applications. Ten original research works, organized by applications, and two reviews
are included in this Special Issue. Each of them contributes to the knowledge advance, insofar as
they present new applications for known products, new methodologies to obtain new products or
the evaluation of a given application, with the applications related to health promotion being the most
frequently considered.
2. Contributions
Several original papers included in this Special Issue involve the search for new antibacterial and
antifungal agents, mainly from secondary metabolites, their derivatives and essential oils of different
plant species. Essential oils are a mixture of volatile compounds, mainly mono-, di- and sesquiterpenes,
with high commercial value and a wide range of applications [19,40].
Piper caldense (Piperaceae family) is popularly used for the treatment of snakebites, stomach
problems and as a sedative [41]. The research presented by Bezerra et al. [42] shows that essential oils
from P. caldense leaf are composed, in major proportions, by sesquiterpenes such as caryophyllene oxide,
spathulenol, γ-cadinene and bicyclogermacrene. Although the essential oils do not show antifungal
activity against Candida albicans, they exhibit a synergistic effect with the antifungal fuconazole, which
increase their activity when used combined. This modulator effect is not observed at the highest
concentration. The ability of essential oils to cause complete inhibition of the hyphae prolongation was
also demonstrated, being an effect superior to fuconazole [42], which suggests their application as an
adjuvant in antimicrobial formulations.
Helianthus annus (Asteraceae, sunflower) has been used as a traditional medicine to treat a variety
of ailments, such as rattlesnake, spider, snake and scorpion bites, fevers [43,44], food poisoning [45],
burning sensation in the vagina and worms in the ears [46]. Lawson et al. [47] report the chemical
composition and antifungal activity of essential oils from the aerial parts of two cultivars of H. annuus,
“Chianti” and “Mammoth”, and wild-growing Helianthus strumosus. Analysis of these essential oils
shows they are qualitatively similar and dominated by monoterpenes, in particular sabinene, α-pinene,
β-pinene and limonene. The antifungal activity of essential oils and their main constituents were
evaluated against three opportunistic pathogenic fungal species, Aspergillus niger, Candida albicans and
Cryptococcus neoformans, which mainly affect immunocompromised patients. The essential oils of H.
annus “Chianti” and H. strumosus are the most active against C. neoformans and the authors consider
that the activity is due to both enantiomers of pinene.
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Carvacrol is a usual essential oils constituent, that exhibits activity against Penicillium digitatum,
a citrus crop fungal which causes significant economic losses [48], but whose mechanism of action is
not completely clarified. Using an innovative approach, metabolomics based on 1H-NMR analysis,
Wan et al. [49] determine the changes introduced into the P. digitatum metabolism and its energetic
balance when this fungus is treated with carvacrol. The results show this compound induces
ROS production on P. digitatum, which mainly disturbs the energy production by a decrease in
glycolysis followed by an augmentation in gluconeogenesis involving mainly alanine, aspartate and
glutamate metabolism.
Phenolic nor-triterpene are described in the literature as antibacterial agents against
Gram-positive bacteria [50–52]. Moujir et al. [53] report the antimicrobial activity of five
natural phenolic nor-triterpenes, isolated from Maytenus blepharodes and Maytenus canariensis,
and four pristimerin derivatives synthesized. The most active compound was the derivative
6α-hydroxy-2,3-diacetoxy-pristimerol which is more active than the positive control cephotaxime
against spore-forming bacteria and Staphylococcus epidermidis. A comprehensive structure/activity
relationship (SAR) study was performed with the aim of the rational design of antimicrobial agents
based on the phenolic nor-triterpene scaffold.
In addition to an application as antimicrobials, natural compounds, in pure form or as a mixture
like essential oils, are also investigated as therapeutic agents with a potential application on other
health problems like aging-associated diseases, cancer, diabetes or wounds.
Portulaca oleracea is used to alleviate a wide range of illnesses [54] and the extracts of this plant
are known to possess a strong in vivo antioxidant capacity [55,56]. Based on the potent antioxidant
activity of natural compounds oleracones isolated from this plant, Yoon et al. [57] carried out
the synthesis of oleracones D–F and evaluated their lifespan extension properties using the nematode
Caenorhabditis elegans as the experimental aging model. The oleracone E was the most active to extend
the lifespan of nematodes. Therefore, this compound should be considered in the development of
anti-aging formulations.
Another study where the antioxidant activity of natural compounds was assessed is proposed by
Tungmunnithum et al. [58]. They optimize and validate a new green and fast microextraction procedure
to obtain a phenolic acids-rich fraction from almond (Prunus dulcis) cold-pressed oil residue. The authors
identified and quantified some of the most abundant constituents, protocatechuic, p-hydroxybenzoic,
chlorogenic and p-coumaric acids and evaluated the antioxidant activity of this fraction. They suggest
it as a source of antioxidant natural compounds with applications in food preservation, as medicine
and in cosmetic preparations. Thus, it is given a contribution to value a very abundant by-product of
the almond oil industry.
Salvia miltiorrhizae is one of the well-known traditional herbal medicines that has increased its
scientific interest for its remarkable bioactivity against cardiovascular disease, renal damage, tumor
angiogenesis and tumor cell invasion [59,60]. Kang et al. [61] evaluate a series of compounds isolated
from S. miltiorrhizae Radix such as tanshinone IIA, rosmarinic acid, salvianic acid A, salvianolic acid B
and caffeic acid for their cytotoxic activity and mode of action against the HCT-116 cell line (human
colorectal cancer, one of the most commonly diagnosed malignant diseases [62]). Only a terpenoid,
tanshinone IIA, shows an inhibitory effect on cell survival (IC50 61.6 μg/mL). Morphological changes
observed by Hoechst staining, an increase in cleaved caspase-7 and -8 and Bax expression as well as
a decrease in Bcl-2 show this compound as an inducer of apoptosis which may be a useful chemotherapy
strategy for patients with colorectal cancer.
The flavonoid-type compounds named chalcones and flavanones are natural isomeric compounds
which exhibit a broad range of patented therapeutic applications [63]. Since they are chemically very
labile, chalcones and flavanones are also excellent scaffolds to medicinal chemistry and development
of new drugs [64–66]. In this context, the optimization of the aldol condensation synthesis route
by using unexplored bases to prepare hydroxylated and methoxylated chalcones and flavanones
proposed by Rosa et al. [67] is well come. The application of the synthesized compounds as cytotoxic,
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antioxidant, antibacterial and anticholinesterase agents were evaluated, and SAR are discussed.
The SAR study showed the same substituent group can cause an opposite effect on the level of different
biological activities, given as a significant contribution to better understand the medicinal chemistry of
these compounds.
Plants are also considered to be sources of natural compounds with antidiabetic activity, as shown
by Numonov et al. [68]. They studied the chemical composition of essential oils from Prangos pabularia
roots and describe it as a potent protein tyrosine phosphatase 1B (PTP-1B) inhibitor. Additionally,
the authors used docking studies and experimental procedures to indicate coumarin osthole, one of
the most abundant constituents, as probably responsible for the potent PTP-1B inhibition, a stronger
effect than the positive control, and thus support the use of P. pabularia roots’ essential oil and osthole
as antidiabetic agents.
Propolis and honey are valuable natural products with several health applications already
described in the literature [69,70]. However, the properties and chemical composition of these natural
products significantly depend on several factors such as the plant species used in their production [71].
Using different samples of Portuguese honey, propolis and a mixture of both, Afonso et al. [72] present
an original study where the antioxidant, anti-inflammatory and wound-healing activities of ethanolic
extracts of these samples were evaluated. The study demonstrates that propolis extracts have higher
phenolic compounds and flavonoid contents than honey extracts. On the other hand, the mixtures
of honey/propolis exhibit, in general, a significant wound-healing effect, but the propolis extract 2
(propolis from the red-honey box) is the most active sample, this activity being related to its high
antioxidant and anti-inflammatory effect.
The Special Issue also includes two review articles where the applications of natural sesquiterpene
lactones and rosmarinic acid as potential medicines are reviewed.
Moujir et al. [73] highlight ten natural sesquiterpene lactones, alantolactone, arglabin, costunolide,
cynaropicrin, helenalin, inuviscolide, lactucin, parthenolide, thapsigargin and tomentosin, critically
discussing the results of in vivo studies and clinical trials involving these compounds. The work
demonstrates the enormous potential of these compounds in the development of new drugs
especially for the treatment of oncological and inflammatory diseases. Their application as antifungal,
antitrypanosomal and analgesic agents is also discussed, although the most surprising results are
related to their sensitizing effect to the action of some clinical drugs, which means their application in
combination therapy. Some synthetic derivatives of these sesquiterpene lactones are also highlighted,
mainly because they demonstrate very significant improvements in pharmacokinetics and selectivity,
compared with the original compounds.
In its turn, Nadeem et al. review the therapeutic value of rosmarinic acid [74]. This natural phenolic
compound, very abundant on several edible species such as Rosmarinus officinalis, Ocimum tenuiflorum
and Thymus mastichina, exhibits a wide range of biological effects. The authors [74] present and
discuss scientific evidence of its antitumor, anti-inflammatory, antimicrobial, antidiabetic, antioxidant,
anti-aging, cardio and nephroprotective effects. Further, the mechanism of action is discussed, although
the authors identified this aspect as the knowledge gap that needs further investigation.
This Applied Sciences Special Issue emphasizes natural compounds’ potential for distinct
applications. The authors, from all over the world, contribute with valuable manuscripts to this Special
Issue, strengthening the high value of natural compounds and the dynamism of this research field.
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and agreed to the published version of the manuscript.
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Abstract: Infections by multiresistant microorganisms have led to a continuous investigation of
substances acting as modifiers of this resistance. By following this approach, the chemical composition
of the essential oil from Piper caldense leaf and its antimicrobial potential were investigated. The
antimicrobial activity was determined by broth microdilution method providing values for minimum
inhibitory concentration (MIC), IC50, and minimum fungicidal concentration (MFC). The essential oil
was tested as a modulator for several antibiotics, and its effect on the morphology of Candida albicans
(CA) strains was also investigated. The chemical characterization revealed an oil composed mainly of
sesquiterpenes. Among them are caryophyllene oxide (13.9%), spathulenol (9.1%), δ-cadinene (7.6%)
and bicyclogermacrene (6.7%) with the highest concentrations. The essential oil showed very low
activity against the strains of CA with the lowest values for IC50 and MFC of 1790 μg/mL and 8192
μg/mL, respectively. The essential oil modulated the activity of fluconazole against CA URM 4387
strain, which was demonstrated by the lower IC50 obtained, 2.7 μg/mL, whereas fluconazole itself
presented an IC50 of 7.76 μg/mL. No modulating effect was observed in the MFC bioassays. The effect
on fungal morphology was observed for both CA INCQS 40006 and URM 4387 strains. The hyphae
projection was completely inhibited at 4096 μg/mL and 2048 μg/mL, respectively. Thus, the oil has
potential as an adjuvant in antimicrobial formulations.
Keywords: pimenta d’água; Candida; fungistatic effect; inhibition of dimorphism; GC/MS
1. Introduction
Infections caused by fungi, are the major problem of hospital infections, mainly due to the
emergence of new infections and the generalized resistance to antibiotics [1]. Due to the rapid
resistance acquired by microorganisms the search for natural products with antimicrobial activity has
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been constant in recent years and drugs derived from plants have contributed largely to human health,
historically representing a source for the creation of new drugs [2].
One way of combating microbial resistance is the investigation of substances that can act as
resistance modifiers by combining common antimicrobial drugs with some phytochemicals, and in
some cases observed synergism [3,4].
Yeasts of the genus Candida are found as commensals in the human organism, however, because
of factors that disturb the dynamics of the host can favor the growth of these fungi, from superficial
infections to systemic infections [5]. Among the yeasts of this genus, Candida albicans stands out as the
main cause of infections, being a species with great ability to change its morphology, a necessary factor
for its virulence and pathogenicity [6,7].
For the treatment of infectious diseases, populations without access to medicines, especially those
from underdeveloped and developing countries, use medicinal plants to combat disease. Such use of
these vegetables is due to a number of advantages, such as their availability, low purchasing power
and being in popular knowledge for several generations [2,8]. Among the species of the Brazilian
flora, the genus Piper L. is one of the largest in the Piperaceae family, with 290 species and 45 varieties
occurring in Brazil [9]. Some species of the genus are used as a flavoring of food and treatment of
diseases [10]. A scientific study evidenced the antimicrobial potential of four species of the genus
against Staphylococcus aureus and three strains of Candida, including C. albicans [11]. Among the species
of the genus, Piper caldense C. DC., is popularly known in Brazil as “pimenta d’água” or “pimenta
d’arda”, being commonly used for the treatment of snake bites, sedative and stomach problems [10].
Research using P. caldense essential oil has revealed promising antimicrobial potential [12,13].
In view of the above problem, this study aimed to evaluate the antibiotic and modulator potential
of volatile terpenes of P. caldense against Candida albicans, as well as to determine if the natural product
is capable of reducing pleomorphism. Finally, it was evaluated by gas chromatography which terpenes
were present in the essential oil.
2. Results
2.1. Chemical Composition
The chromatographic analysis of the essential oil of P. caldense identified 25 phytochemical
constituents, corresponding to 94.3% of the total composition. Sesquiterpenes are the main class
observed, reaching a percentage of 89.7% of the sample. Monoterpenes were found in very low
concentration (4.6%). There were no major constituents (>20%) and no constituent in trace concentration
(<1%). All the identified phytochemicals are secondary metabolites, with caryophyllene oxide (13.9%),
spathulenol (9.1%), δ-cadinene (7.6%), and bicyclogermacrene (6.7%) as constituents with the highest
concentrations (Table 1).
2.2. Antifungal Activity
2.2.1. Cell Viability Curve and IC50
Regarding the antifungal activity of the essential oil of P. caldense, it was found that it has a low
antifungal effect against strains of C. albicans because the IC50 values were high, 2256.24 and 1790.24
μg/mL for the CA INCQS 40006 and CA URM 4387, respectively (Table 2) (Figures 1 and 2). However,
it was observed that for the C. albicans URM 4387 strains, the oil potentiated the effect of the drug
used, fluconazole, since it had an IC50 of 7.73 μg/mL alone, and when associated with the essential oil,
the value of evaluated parameter dropped to 2.7 μg/mL, i.e., a significant reduction. It is noteworthy
that for C. albicans 40006 strains, no potentiating effect was found for fluconazole but an antagonistic
effect, since there was an increase in the IC50 of the oil associated with fluconazole. Thus, based on the
behavior of the curve through non-linear regression, the IC50 values of P. caldense oil were clinically
irrelevant when evaluated alone.
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Table 1. Chemical composition of the essential oil of leaves from Piper caldense.
Compounds % AIlit MF
α-Pinene 2.5 935 C10H16
Camphene 2.1 952 C10H16
α-copaene 2 1381 C15H24
(E)-Caryophyllene 2.6 1426 C15H24
Aromadendrene 2.7 1445 C15H24
γ-muurolene 4 1478 C15H24
β-selinene 3.2 1490 C15H24
Bicyclogermacrene 6.7 1492 C15H24
Germacrene D 5.3 1493 C15H24
α-muurolene 4.2 1498 C15H24
δ-Cadinene 7.6 1520 C15H24
γ-Cadinene 3.3 1521 C15H24
α-Calacorene 2.2 1551 C15H20
β-Calacorene 1.9 1572 C15H20
Spathulenol 9.1 1576 C15H24O
Caryophyllene oxide 13.9 1580 C15H24O
Globulol 2.3 1594 C15H26O
Rosifoliol 1.3 1597 C15H26O
Humulene epoxide II 1 1619 C15H24O
1.10-di-epi-Cubenol 1.6 1624 C15H26O
1-epi-Cubenol 3.4 1638 C15H26O
epi-alfa-muurolol 3.1 1640 C15H26O
α-cadinol 4.2 1650 C15H26O
α-Muurolol 2.1 1651 C15H26O
Cadalene 2 1667 C15H18
Total sesquiterpenes 89.7
Total monoterpenes 4.6
Total identified (%) 94.3
AIlit—Arithmetic Retention Indices from literature; MF: Molecular Formula.
Table 2. IC50 of the essential oil of Piper caldense (EOPc) against Candida albicans.
Products Tested
Yeast
Candida albicans INCQS 40006 Candida albicans URM 4387
Fluconazole (FCZ) 7.76 μg/mL 7.73 μg/mL
EOPc 2256.24 μg/mL 1790.24 μg/mL
EOPc + FCZ 12.37 μg/mL 2.7 μg/mL
INCQS: National Institute for Health Quality Control. URM: University Recife Mycology.
Figure 1. Anti-Candida potential of essential oil of Piper caldense (EOPc) against strains of Candida
albicans 40006 INCQS.
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Figure 2. Anti-Candida potential of essential oil of Piper caldense (EOPc) against strains of Candida
albicans URM 4387.
2.2.2. Cell Viability Curve and Minimum Fungicidal Concentration (MFC)
In determining MFC it was considered those samples capable of inhibiting the growth of the
fungal colonies. Thus, for the CA INCQS 40006 line, none of the products alone or in combination were
able to totally inhibit colony growth, since MFC was ≥ 16,384 μg/mL (Table 3). However, there was
an MFC for the oil against CA URM 4387, in which fluconazole alone and combined with P. caldense
oil showed a much lower MFC, 16 μg/mL, so that the oil did not modulate the fungicidal effect of
fluconazole for this lineage (Table 3).
Table 3. Minimum fungicidal concentration (MFC) of essential oil of Piper caldense (EOPc) and
fluconazole associated and isolated against strains of Candida albicans.
Products Tested
Yeast
Candida albicans INCQS 40006 Candida albicans INCQS 40006
Fluconazole (FCZ) ≥16,384 μg/mL 16 μg/mL
EOPc ≥16,384 μg/mL 8192 μg/mL
EOPc + FCZ ≥16,384 μg/mL 16 μg/mL
INCQS: National Institute for Health Quality Control. URM: University Recife Mycology.
2.2.3. Activity of the Piper caldense in the Control of Virulence of Candida albicans
In the evaluation of the activity of the oil in the morphology of the yeasts of C. albicans, the effect
was caused by impoverishment of the culture medium, so that the yeasts project the hyphae and
pseudohyphae in search of nutrients. For the growth control of CA INCQS 40006 (Figure 3, Slides
1–7), it is possible to observe the formation of several hyphae (S1), whereas in the treatments with
fluconazole, there is a significant decrease in the hyphae projection (S2–4), resulting in a complete
inhibition of hyphae at concentration of 4096 μg/mL (S2). The EOPc showed a similar result, being as
effective as fluconazole.
For the CA URM 4387 strain, fluconazole at a concentration as low as 8 μg/mL could diminish the
virulence (Figure 4, S2). The oil at higher concentrations, such as 2048 μg/mL (S3), was able to inhibit
the hyphae projection; on the other hand, at concentration of 512 μg/mL (S5), there was a significant
decrease in hyphae projections.
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Figure 3. Effects of essential oil of Piper caldense on the dimorphism of Candida albicans INCQS 40006.
Slide (S1): Growth control; S2–4: Effect of fluconazole at concentrations 4096 μg/mL (S2), 2048 μg/mL
(S3), 1024 μg/mL (S4). S5–7: Effect of essential oil at concentrations of 4096 μg/mL (S5), 2048 μg/mL
(S6), 1024 μg/mL (S7). Display 400× increased.
 
Figure 4. Effects of essential oil of Piper caldense on the dimorphism of Candida albicans URM 4387.
Slide (S1): Growth control; S2: Effect of fluconazole at the concentration of 8 μg/mL. S3–5: Effect of the
essential oil at 2048 μg/mL (S3), 1024 μg/mL (S4), 512 μg/mL (S5).
3. Discussion
The genus Piper L. presents a high number of species with medicinal, insecticidal and condiment
applications, since the representatives are sources of volatile oils produced by the secondary
metabolism [14]. Some species of this genus present antifungal activities, such as Piper amalago
L. [15], Piper aduncum L. and Peperomia pelúcida (L.) Kunth [16], and antibacterial activity, among them
Piper betle L. [17]. Thus, the selection strategy of P. caldense for the investigation of the antimicrobial
activities of this study was based on chemotaxonomy, since there is a phylogenetic relationship
between P. caldense and other species of the genus and possibly in the evolutionary historical branch
the biosynthetic routes are similar [18].
The phytochemicals (monoterpenes and sesquiterpenes) of the essential oil of the species under
study were elucidated by Rocha et al. [19], however, there were marked differences in the constitution,
the first is that in our study, the caryophyllene oxide was the major constituent (13.9%), whereas in the
results of the aforementioned study this sesquiterpene is not present in the oil of leaves, but in the stem
essential oil (6.2%). In addition, Rocha et al. [19] states that the constituent in higher percentage is the
α-cadinol, reaching compose 19% of the total composition, and in our study this sesquiterpeno is in
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low percentages (4.2%). This variation is justified by several factors, both intrinsic and genetic, as well
as extrinsic factors such as geographic origin of the plant, cultivation, collection form, and especially
the period of the year that was collected [20–22].
Although the essential oil of P. caldense did not present antifungal activity in low concentrations
(≤500 μg/mL), it presented a modulating effect for fluconazole against strains of C. albicans URM 4387.
So that this finding is relevant, since the introduction of azole class antibiotics (miconazole, econazole,
ketoconazole, fluconazole and triazonazole) for the treatment of infections caused by Candida species, a
growing emergence of resistant Candida species has been observed [23,24].
The activity of caryophyllene oxide, an oxygenated terpenoid, was tested in the laboratory against
dermatophyte fungi, showing significant results, and their activity has been compared with antifungals
such as cyclopiroxolamine and sulconazole [12].
Silva [25], evaluating the antifungal activity of 2-geranyl-3,4-dihydroxybenzoic acid and
3-geranyl-4-hydroxyxidozoic acid, both substances isolated from the fruits of P. caldense, demonstrated,
respectively, a moderate and high activity against C. albicans strains (LM-86 and LM-111), so that the
first substance showed a MIC of 512 μg/mL for both strains and the second one 32 μg/mL, also for the
two strains. It is important to highlight that in our study the essential oil was used as the product, and
this is a mixture of mono and sesquiterpenes, whereas in the study mentioned above the substances
were derived from the benzoic acid prenylate, so that the chemical structures are quite different.
Inhibition of virulence of C. albicans strains by natural products was also shown by other scientists,
among them Santos et al. [26], who evaluated the essential oil of Eugenia uniflora L. (Myrtaceae) and
demonstrated that at concentrations of 8192 μg/mL there is inhibition of hyphal projection. Two other
species also from the same family that have the ability to inhibit the virulence of C. albicans are Psidium
brownianum Mart. ex DC. And Psidium guajava L., the former having medicinal properties and is used
to combat infections caused by fungi of the genus Candida [6,27].
The activities of the natural products, concerning the antimicrobial agents act by diverse
mechanisms of action such as the disintegration of the cytoplasmic membranes, destabilization
of the motor proton force (MPF), altering the polarization of the membrane, and the coagulation of the
cellular content [28–30].
4. Materials and Methods
4.1. Botanical Material
The collection of leaves of Piper caldense was performed in the municipality of Piraquara in the state
of Paraná, Brazil, under the coordinates 25◦29.693′ S and 49◦00.844′ W at 528 m elevation (Figure 5).
An exsicata was identified and deposited in the Herbarium of the Faculdades Integradas Espírita under
voucher 9.103.
4.2. Extraction of Volatile Terpenes and Determination of the Chemical Composition
Healthy P. caldense leaves were selected and dried in a incubator at 40 ◦C. After dehydration, the
leaves were crushed to increase their contact surface and maximize the extraction of their volatile
components. For such extraction, the hydrodistillation system was used, in which 50 g of the plant
material was placed in a volumetric flask with 1000 mL of distilled water, being constantly heated for
4.5 h, until the oil extraction [21].
For the chemical characterization of P. caldense essential oil, it was made by gas
chromatography-mass spectrometry (GC/MS). Initially, the essential oil was diluted in dichloromethane
to 1% concentration, then 1 μL of this solution was injected (1:20) into Agilent 6890 chromatograph,
coupled to Agilent 5973N mass selective detector, wherein the injector temperature was 250 ◦C. For the
separation of the constituents, helium gas was used as a carrier (1 mL/min) and an HP-5MS capillary
column with the following specifications: 5% phenyl-95%-dimethylpolysiloxane, 30 m × 0.25 mm ×
0.25 μm. For the heating ramp, the temperature started at 60 ◦C with a heating rate of 3 ◦C/min to
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240 ◦C, totaling 60 min. The mass detector was operated in the electronic ionization mode (70 eV), at a
rate of 3.15 s−1 sweeps and a mass range of 40 to 450 u. The transfer line was maintained at 260 ◦C, the
ion source at 230 ◦C and the analyzer (quadrupole) at 150 ◦C.
Figure 5. Location of the species Piper caldense in the municipality of Piraquara in the state of
Paraná, Brazil.
For quantification, the diluted samples were injected into an Agilent 7890A chromatograph
equipped with a flame ionization detector (FID), operated at 280 ◦C. We employed the same column
and analytical conditions described above except for the carrier gas used, which was hydrogen at a
flow rate of 1.5 mL/min. The percentage composition was obtained by the electronic integration of the
FID signal by dividing the area of each component by the total area (area%).
For the determination of chemical constituents, the mass of the constituents was compared with
the library (NIST and Wiley) e and also by their linear retention indexes, calculated from the injection
of a homologous series of hydrocarbons (C7-C26) and compared with data from the literature [31].
4.3. Drugs, Reagents, Solution Preparation and Fungal Strains
For the antifungal test, the essential oil stock solution was prepared from 0.15 g and diluted in
1 mL of dimethyl sulfoxide (DMSO). To obtain the initial concentration of 16,384 μg/mL, the stock
solution was diluted in sterile distilled water so that the DMSO concentration in the natural product
had no activity in the cells tested. The reference antifungal was fluconazole (Capsule-FLUCOMED),
diluted in sterile water at the same oil concentration [27]. For microbiological assays, two Candida
albicans strains were used: CA INCQS 40006 (standard strain), obtained from the Oswaldo Cruz Culture
Collection of the National Institute for Quality Control in Health (INCQS) and CA URM 4387 (clinical
isolate), provided by mycology collection of the Federal University of Recife (URM - University Recife
Mycology). For the antifungal activity test the culture media were used: Sabouraud Dextrose Agar
(SDA) and Sabouraud Dextrose Broth (SDB). For the fungal micromorphology evaluation test the
nutrient-poor Potato Dextrose Agar (PDA) culture medium prepared with solidification Agar was
used. The media were prepared according to the supplier’s guidelines (Difco®) and autoclaved at
121 ◦C within 15 min.
15
Appl. Sci. 2020 , 10 , 631
4.4. Determination of Minimum Inhibitory Concentration (MIC)
To perform this experiment the broth microdilution method was used according to Javadpour.
First the yeasts were inoculated in ASD and kept incubated at 37 ◦C for 24 h. Subsequently, the
inoculum were prepared by transferring small aliquots of the strains to tubes containing sterile saline,
the inoculum were compared to McFarland scale resulting in a concentration of 1 × 105 cells/mL.
96-well plates were filled containing in each well 100 μL of SDB and 10% fungal inoculum. The plates
were then microdiluted with 100 μL of the essential oil of P. caldense, where the well concentrations
were from 8192 μg/mL to 64 μg/mL. The last well was not diluted as a growth control. Media sterility
controls and substance dilution controls were also used, using only saline without fungal inoculum.
The plates were incubated at 37 ◦C for 24 h and subsequently read on a 630 nm wavelength ELISA
spectrophotometer (Thermoplate®). All assays were performed in triplicate and the results obtained
were used to construct the cell viability curve and the IC50 of essential oil and fluconazole [6,32]. MIC
was defined as the lowest concentration able to reduce the fungal growth curve.
4.5. Evaluation of Modulating Activity of Natural Product
The essential oil was tested at sub-inhibitory concentration (MIC/16) according to the method
proposed by Coutinho et al., 2008 [33]. The plates were filled with a solution containing SDB, fungal
inoculum and the essential oil, then 100 μL of fluconazole was mixed into the first well and serially
microdiluted at a ratio of 1:1 to the penultimate well, at 1 μg/mL. Control of culture media sterility and
antifungal dilution control were performed, and the MIC of fluconazole was also determined. The
tests were performed in triplicate and the plates were incubated at 37 ◦C for 24 h. The reading was
performed in an ELISA spectrophotometer (Termoplate®). The modulatory activity is defined when
used in combination. The natural product enhances the action of the antifungal, showing synergism.
If the opposite occurs and the natural product interferes with the action of the drug, the effect is
considered antagonistic.
4.6. Determination of Minimum Fungicidal Concentration (MFC)
After the MIC test, a sterile stem was placed in each well of the plates, first the stem was used to
mix the solutions contained in the wells, then small aliquots with medium, inoculum and essential oil
were transferred to Petri dishes containing solid medium SDA, for yeast subculture and verification
of cell viability. After 24 h of incubation, the plates were analyzed and the concentration at which
no fungal colony growth was observed is considered the Minimum Fungicidal Concentration of the
essential oil [34].
4.7. Effect of Natural Product on Fungal Morphology
To verify whether P. caldense volatile terpenes cause any change in fungal morphology by
inhibiting hyphae emission, micromorphological sterile chambers were mounted for yeast observation.
On the blade chamber (sterile) were poured 3 mL of medium PDA, poor nutrient for dilution, containing
the natural product in CFM/4 concentrations CFM/8 and CFM/16. Aliquots of fungal inoculum were
taken from SDA-containing Petri dishes to make two parallel strips in the solidified solid medium (PDA)
and then covered by a sterile coverslip. The chamberwere taken to the incubator and after 24 h (37 ◦C)
the culture was visualized under optical microscopy using a 400 X objective. A camera was attached to
the microscope for image capture. A control for yeast growth (with hyphal emission stimulated by
depletion of the medium) was performed, as well as a control with the reference antifungal fluconazole
was also used for comparative purposes [35].
4.8. Statistical Analysis
The IC50 was calculated by means of linear regression. Subsequently, data from P. caldense
antifungal assays were investigated by one-way analysis of variance (ANOVA), using the Bonferroni
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test and considered significant when p < 0.05. All analyzes were performed on the GraphPad Prism
6.0 software.
5. Conclusions
The essential oil of P. caldense presented mono- and sesquiterpene components, though not
presented a major constituent. In addition, it showed low antifungal activity for C. albicans strains but
was able to modulate the effect of standard drug (fluconazole) and decreased the virulence of these
strains. In this way, the oil has in its composition constituents that are promising in the formulation of
drugs used in the treatment of infectious diseases.
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Abstract: Helianthus species are North American members of the Asteraceae, several of which
have been used as traditional medicines by Native Americans. The aerial parts of two cultivars of
Helianthus annuus, “Chianti” and “Mammoth”, and wild-growing H. strumosus, were collected from
locations in north Alabama. The essential oils were obtained by hydrodistillation and analyzed by gas
chromatography—mass spectrometry. The Helianthus essential oils were dominated by monoterpene
hydrocarbons, in particular α-pinene (50.65%, 48.91%, and 58.65%, respectively), sabinene (6.81%,
17.01%, and 1.91%, respectively), β-pinene (5.79%, 3.27%, and 4.52%, respectively), and limonene
(7.2%, 7.1%, and 3.8%, respectively). The essential oils were screened against three opportunistic
pathogenic fungal species, Aspergillus niger, Candida albicans, and Cryptococcus neoformans. The most
sensitive fungus was C. neoformans with minimum inhibitory concentration (MIC) values of 78, 156,
and 78 μg/mL, respectively.
Keywords: Helianthus annuus; Helianthus strumosus; Aspergillus niger; Candida albicans; Cryptococcus
neoformans; α-pinene
1. Introduction
Helianthus L., the sunflowers, is a genus in the family Asteraceae, tribe Heliantheae, made up of 51
North American species [1]. Helianthus annuus L. (common sunflower) is native to North America and
the current range of wild forms of H. annuus are central and western United States, southern Canada,
and northern Mexico [2]. The common sunflower is one of the earliest domesticated plants in the
Americas. There is evidence that the plant was domesticated in Tabasco, Mexico, around 2600 B.C. [3],
and independently in the southeastern United States around 2800 B.C. [2,4]. Several Native American
tribes used H. annuus in traditional medicine [5]. For example, the White Mountain Apache used a
poultice of the crushed plants to treat snakebites; the Hopi used the plant as a spider bite medicine; the
Jemez applied the juice of the plant to cuts; the Pima used a decoction of the leaves to treat fevers [5];
and the Zuni natives of New Mexico used the roots to treat rattlesnake bites [6]. In addition, H. annuus
is used as a traditional herbal medicine in many locations where it has been introduced. Ethiopians use
H. annuus in teas to treat food poisoning [7]. In Bangladesh the seeds and/or the flowers are crushed
and used for snake bites, scorpion bites, and a variety of other ailments, such as burning sensation in
the vagina and worms in the ears [8].
Helianthus strumosus L. (woodland sunflower) is a rhizomatous perennial plant, growing up to
two meters tall and is native to eastern North America [9–11]. These plants are strongly aromatic.
Leaves are up to 10 cm long and cuneate to subcordate in shape. The composite flower heads can be
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up to 9 cm at the peduncle. The ray flowers are a dark yellow color with orange-brown disc flowers in
the center. These flowers are common along roadsides and in open fields and are sometimes found in
forests. The Iroquois used a decoction of the roots as an anthelmintic [5].
Invasive fungal infections are becoming increasingly common in immunocompromised patients,
such as those receiving cancer chemotherapy, transplant patients receiving immunosuppressant drugs,
and HIV patients [12]. The predominant fungal pathogens are Aspergillus spp. [13,14] and Candida
spp. [15,16] among others [12]. Aspergillus niger is a haploid filamentous parasitic fungus that is
commonly known for the disease “black mold” on fruits, vegetables, and nuts [17]. Aspergillus conidia
(fungal “spores”) are environmentally widespread and inhalation can lead to opportunistic pulmonary
aspergillosis, chiefly attributed to A. fumigatus, A. flavus, and A. tubingensis, as well as A. niger [18].
In immunocompromised individuals, however, the infection can progress to invasive systemic
aspergillosis [19]. Candida albicans is another opportunistic pathogenic fungus that commonly colonizes
the human body [20]. The organism can cause superficial infections of the mucosa, but can lead to
invasive candidiasis in immunocompromised patients [21]. Cryptococcosis is a fungal infection caused
by Cryptococcus neoformans [22]. The fungus is widespread in the environment and typically enters the
body through inhalation where it can cause pulmonary infection [23]. However, the organism has
the ability to cross the blood brain barrier and in immunocompromised patients, cryptococcosis can
lead to cryptococcal meningoencephalitis with increased intracranial pressure [24,25]. As part of our
continuing investigation of antifungal activity of essential oils [26] as well as essential oils from the
Asteraceae growing in north Alabama [27], we have collected and analyzed the essential oils from the
aerial parts of H. annuus and H. strumosus, and we have carried out in vitro antifungal screening of the
essential oils against A. niger, C. albicans, and C. neoformans.
2. Materials and Methods
2.1. Plant Materials
The two cultivars of H. annuus (“Chianti” and “Mammoth”) were cultivated, grown without
fertilizer or pesticides, in a rural area near Gurley in north Alabama (34◦38′29”N, 86◦24′39”W, elevation
199 m) and the aerial parts were collected on 4 and 6 August 2018. Aerial parts of H. strumosus
were collected on 10 August 2018 from wild-growing plants near Huntsville, Alabama (34◦42′42”N,
86◦32′35”W, elevation 354 m). The plants were identified by S.K. Lawson. Voucher specimens have
been deposited in the herbarium of the University of Alabama in Huntsville (20180729-183243 and
20190402-111732). The fresh plant materials (78.14, 80.32, and 65.47 g, respectively) were hydrodistilled
using a Likens–Nickerson apparatus with continuous extraction with dichloromethane for 3 h.
The dichloromethane was carefully evaporated, and the residual essential oils weighed using an
analytical balance to give the essential oils (82.3, 20.3, and 24.0 mg, respectively).
2.2. Gas Chromatographic—Mass Spectral Analysis
The Helianthus essential oils were analyzed by GC-MS with a Shimadzu GCMS-QP2010 Ultra
with a ZB-5 capillary column as previously described [28]. Identification of the chemical components
was carried out by comparison of the retention indices, calculated with respect to a homologous
series of normal alkanes using the arithmetic index [29], and by comparison of their mass spectra
with those reported in the Adams [30], NIST17 [31], FFNSC 3 [32], and our own in-house library [33].
Concentrations shown in Table 1 (average of three measurements ± standard deviations) are based on
peak integration without standardization.
22
Appl. Sci. 2019 , 9 , 3179
Table 1. Chemical compositions of Helianthus annuus “Chianti”, H. annuus “Mammoth”, and H.
strumosus aerial parts essential oils.







800 797 (3Z)-Hexenal 0.06 ± 0.01 Tr d tr
801 801 Hexanal 0.35 ± 0.02 0.24 ± 0.04 0.41 ± 0.03
810 796 2-Hexanol — — 0.07 ± 0.00
849 846 (2E)-Hexenal 1.13 ± 0.05 0.83 ± 0.05 1.96 ± 0.03
861 854 (2E)-Hexenol — — tr
864 863 1-Hexanol — — 0.09 ± 0.00
921 921 Tricyclene 0.37 ± 0.00 0.21 ± 0.01 0.18 ± 0.00
924 924 α-Thujene 0.17 ± 0.00 0.23 ± 0.01 0.1
932 932 α-Pinene 50.65 ± 0.32 48.91 ± 0.64 58.65 ± 0.14
946 945 α-Fenchene — — tr
948 946 Camphene 7.26 ± 0.03 3.72 ± 0.03 3.38 ± 0.02
952 953 Thuja-2,4(10)-diene 0.05 ± 0.01 — tr
971 969 Sabinene 6.81 ± 0.04 17.01 ± 0.18 1.91 ± 0.00
977 974 β-Pinene 5.79 ± 0.04 3.27 ± 0.01 4.52 ± 0.02
988 988 Myrcene 0.42 ± 0.01 0.30 ± 0.03 9.79 ± 0.03
1004 1003 p-Mentha-1(7),8-diene — — tr
1006 1002 α-Phellandrene — 0.08 ± 0.01 0.05 ± 0.01
1008 1008 δ-3-Carene — — tr
1016 1014 α-Terpinene — tr —
1024 1020 p-Cymene 0.06 ± 0.03 0.09 ± 0.01 0.07 ± 0.00
1028 1024 Limonene 7.20 ± 0.03 7.11 ± 0.11 3.79 ± 0.01
1030 1025 β-Phellandrene 0.24 ± 0.00 0.21 ± 0.14 0.29 ± 0.01
1031 1026 1,8-Cineole 0.06 ± 0.00 0.07 ± 0.02 tr
1034 1032 (Z)-β-Ocimene — — tr
1044 1044 (E)-β-Ocimene — tr 0.41 ± 0.01
1057 1054 γ-Terpinene 0.10 ± 0.00 0.25 ± 0.01 tr
1069 1065 cis-Sabinene hydrate — — tr
1084 1086 Terpinolene 0.10 ± 0.01 0.16 ± 0.01 tr
1099 1099 α-Pinene oxide 0.10 ± 0.01 — tr
1105 1100 Nonanal — — tr
1109 1108 p-Mentha-2,8-dien-1-ol 0.36 ± 0.00 0.10 ± 0.02 tr
1112 1114 (3E)-4,8-Dimethyl-1,3,7-nonatriene 0.09 ± 0.01 0.13 ± 0.02 0.18 ± 0.00
1121 1124 Chrysanthenone 0.05 ± 0.00 — —
1127 1122 α-Campholenal 0.33 ± 0.01 0.05 ± 0.01 0.06 ± 0.01
1140 1135 trans-Pinocarveol 0.37 ± 0.05 tr 0.06 ± 0.02
1141 1137 cis-Verbenol 0.10 ± 0.01 — tr
1145 1140 trans-Verbenol 1.50 ± 0.02 0.24 ± 0.02 0.26 ± 0.00
1163 1160 Pinocarvone 0.11 ± 0.01 tr tr
1171 1165 Borneol 0.73 ± 0.01 0.07 ± 0.02 0.12 ± 0.00
1180 1174 Terpinen-4-ol 0.09 ± 0.01 0.19 ± 0.01 tr
1187 1179 p-Cymen-8-ol 0.05 ± 0.01 — —
1195 1186 α-Terpineol — tr —
1195 1195 Myrtenal 0.29 ± 0.02 tr 0.10 ± 0.01
1206 1201 Decanal tr — —
1207 1204 Verbenone 0.28 ± 0.04 0.11 ± 0.01 0.07 ± 0.00
1219 1215 trans-Carveol 0.16 ± 0.00 — tr
1283 1287 Bornyl acetate 7.13 ± 0.04 3.02 ± 0.04 4.97 ± 0.01
1294 1298 trans-Pinocarvyl acetate 0.08 ± 0.01 tr tr
1382 1387 β-Bourbonene 0.21 ± 0.02 0.18 ± 0.01 tr
1386 1387 β-Cubebene tr tr tr
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Table 1. Cont.







1387 1389 β-Elemene 0.05 ± 0.01 0.17 ± 0.01 tr
1392 1392 (Z)-Jasmone — — tr
1416 1419 β-Ylangene 0.07 ± 0.01 0.15 ± 0.01 tr
1417 1417 β-Caryophyllene 0.33 ± 0.03 0.54 ± 0.09 0.84 ± 0.00
1427 1434 γ-Elemene — — tr
1428 1431 β-Gurjunene (=Calarene) 0.62 ± 0.01 0.86 ± 0.01 tr
1430 1432 trans-α-Bergamotene 0.06 ± 0.00 0.14 ± 0.03 tr
1442 1442 6,9-Guaiadiene tr tr —
1446 1453 Geranyl acetone tr tr —
1454 1452 α-Humulene 0.19 ± 0.02 0.29 ± 0.01 0.20 ± 0.00
1479 1484 Germacrene D 3.32 ± 0.03 6.84 ± 0.09 3.68 ± 0.02
1487 1489 β-Selinene 0.12 ± 0.01 tr tr
1493 1493 epi-Cubebol 0.12 ± 0.04 — —
1494 1500 Bicyclogermacrene — 0.16 ± 0.01 0.07 ± 0.01
1513 1514 Cubebol 0.14 ± 0.02 tr tr
1516 1522 δ-Cadinene tr 0.07 ± 0.00 tr
1547 1548 Elemol — tr 0.07 ± 0.01
1559 1561 (E)-Nerolidol 0.10 ± 0.02 0.09 ± 0.03 0.64 ± 0.03
1575 1574 Germacrene D-4β-ol 0.37 ± 0.02 0.46 ± 0.00 0.46 ± 0.00
1581 1582 Caryophyllene oxide 0.16 ± 0.09 tr 0.37 ± 0.01
1608 1608 Humulene epoxide II — — 0.05 ± 0.01
1636 1639 Caryophylla-4(12),8(13)-dien-5β-ol — — tr
1638 1643 Hedycaryol — — 0.10 ± 0.01
1641 1638 τ-Cadinol 0.18±0.01 tr 0.14 ± 0.01
1654 1649 β-Eudesmol 0.10 ± 0.02 — 0.16 ± 0.03
1655 1652 α-Cadinol — tr tr
1663 1665 Intermediol tr 0.56 ± 0.01 —
1683 1685 Germacra-4(15),5,10(14)-trien-1α-ol 0.13 ± 0.04 — 0.51 ± 0.01
1686 1687 Eudesma-4(15),7-dien-1β-ol — — 0.14 ± 0.00
1689 1690 (Z)-trans-α-Bergamotol — — 0.12 ± 0.01
1699 1695 6-epi-Shyobunol — — 0.05 ± 0.01
Monoterpene hydrocarbons 79.21 81.56 83.13
Oxygenated monoterpenoids 11.80 3.85 5.64
Sesquiterpene hydrocarbons e 4.97 9.40 4.79
Oxygenated sesquiterpenoids e 1.39 1.11 2.79
Green leaf volatiles 1.54 1.07 2.53
Others 0.091 0.13 0.18
Total Identified 99.01 97.12 99.05
a RI = Retention index determined with reference to a homologous series of n-alkanes on a ZB-5 column. b RI values
from the databases (NIST17 [31], FFNSC 3 [32], Adams [30], or Satyal [33]). c Average of three measurements ±
standard deviations. d tr = “trace” (<0.05%). e Sesquiterpenoids are considered tentatively identified based on MS
and RI.
2.3. Antifungal Screening Assays
The Helianthus essential oils were screened for antifungal activity against Aspergillus niger (ATCC
16888), Candida albicans (ATCC 18804), and Cryptococcus neoformans (ATCC 24607) using the broth
dilution technique as previously described [26,34]. Antifungal screening was carried out in triplicate.
3. Results and Discussion
3.1. Essential Oil Compositions
Hydrodistillation of Helianthus aerial parts gave pale yellow essential oils in 0.105%, 0.025%,
and 0.037% yield (w/w) for H. annuus “Chianti”, H. annuus “Mammoth”, and H. strumosus, respectively.
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The essential oil compositions for the three essential oils are compiled in Table 1. A perusal of the
table reveals that the three Helianthus essential oils are qualitatively similar. The major components
for H. annuus “Chianti” were α-pinene (50.65%), camphene (7.26%), limonene (7.20%), bornyl acetate
(7.13%), sabinene (6.81%), and β-pinene (5.79%). The essential oil of H. annuus “Mammoth” was also
dominated by α-pinene (48.91%), followed by sabinene (17.01%), limonene (7.11%), and germacrene D
(6.84%). H. strumosus essential oil was also rich in α-pinene (58.65%), as well as myrcene (9.79%) and
bornyl acetate (4.97%).
The compositions of H. annuus essential oils cultivated in north Alabama are very similar to those
reported by Adams and co-workers for populations growing in the southern plains of the United
States [35]. The essential oils of H. annuus from Pisa, Tuscany, Italy [36]; Lagos, Nigeria [37]; or from
western United States [35] had much lower concentrations of α-pinene and correspondingly higher
concentrations of germacrene D. In marked contrast to the essential oils of Helianthus, essential oils
of Rudbeckia fulgida Aiton and Rudbeckia hirta L. (Asteraceae, Heliantheae) from north Alabama were
devoid of α-pinene, but rich in sesquiterpene hydrocarbons [27].
3.2. Antifungal Activity
The Helianthus essential oils were screened for antifungal activity against three potentially
pathogenic fungi, Aspergillus niger, Candida albicans, and Cryptococcus neoformans, as shown in Table 2.
The most susceptible fungus was C. neoformans. Both H. annuus “Chianti” and H. strumosus essential
oils showed minimum inhibitory concentration (MIC) values of 78 μg/mL. It is tempting to suggest
that the major component, α-pinene, is responsible for the observed anti-Cryptococcus activity; all three
Helianthus essential oils have around 50% α-pinene. Furthermore, α-pinene has shown antifungal
activity against C. neoformans with an MIC around 70 μg/mL [38,39]. In addition, α-pinene-rich
(46.1% α-pinene) commercial Myrtis communis essential oil showed a similar antifungal activity
against C. neoformans (MIC = 78 μg/mL) [26]. Conversely, commercial Cupressus sempervirens
essential oil, with 49.7% α-pinene was less active against C. neoformans (MIC = 313 μg/mL) [26].
There may be synergistic or antagonistic effects of α-pinene with minor components. Limonene [39,40]
and β-pinene [39], have also shown antifungal activity against C. neoformans; camphene, however,
was inactive [41]. Although we do not know which of the enantiomers is present in the Helianthus
essential oils, we have screened both (+)- and (−)-α-pinene, (+)- and (−)-limonene, and (−)-β-pinene
against the three fungal strains, as shown in Table 2. Consistent with previous investigations,
(−)-β-pinene and (+)-limonene both showed activity against C. neoformans with MIC values of 39 and
78 μg/mL. Furthermore, both enantiomers of α-pinene were active against C. neoformans; MIC = 20 and
39 μg/mL for (+)- and (−)-α-pinene, respectively.
Table 2. Antifungal activities (minimum inhibitory concentration (MIC), μg/mL) of Helianthus essential
oils and major components a.
Material
Fungal Species
Aspergillus niger Candida albicans Cryptococcus neoformans
H. annuus “Chianti” 625 625 78
H. annuus “Mammoth” 625 625 156
H. strumosus 625 1250 78
(+)-α-Pinene 625 313 20
(−)-α-Pinene 156 625 39
(−)-β-Pinene 156 625 39
(+)-Limonene 1250 625 78
(−)-Limonene 2500 1250 313
Amphotericin B 0.78 0.78 1.56
a Each MIC determination was carried out in triplicate.
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4. Conclusions
Helianthus essential oils have been shown to be rich in α- and β-pinenes, sabinene, and limonene,
and have demonstrated poor antifungal activities against A. niger and C. albicans, but promising activity
against C. neoformans (although much lower activity than the reference antifungal drug amphotericin
B). These and other monoterpene-rich essential oils deserve further exploration as alternative and
complementary agents to combat fungal infections; further studies against more susceptible fungi
are recommended.
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Abstract: Carvacrol (5-Isopropyl-2-methylphenol), a volatile oil constituent, mainly exists in Labiaceae
family plants. Carvacrol has long been studied for its natural antifungal potential and food preservative
potential. However, its exact mode of action, especially against Penicillium digitatum (P. digitatum),
remains unexplored. Herein, a 1H-NMR-based metabolomic technique was used to investigate the
antifungal mechanism of carvacrol against P. digitatum. The metabolomic profiling data showed
that alanine, aspartate, glutamate, and glutathione metabolism were imbalanced in the fungal
hyphae. A strong positive correlation was seen between aspartate, glutamate, alanine, and glutamine,
with a negative correlation among glutathione and lactate. These metabolic changes revealed that
carvacrol-induced oxidative stress had disturbed the energy production and amino acid metabolism
of P. digitatum. The current study will improve the understanding of the metabolic changes posed by
plant-based fungicides in order to control citrus fruit green mold caused by P. digitatum. Moreover,
the study will provide a certain experimental and theoretical basis for the development of novel citrus
fruit preservatives.
Keywords: amino acid metabolism; carvacrol; metabolomics data; oxidative stress; Penicillium
digitatum
1. Introduction
Rotting of fruits and vegetables have been a frequent and serious problem for thousands of
years. Even in developed countries, the citrus yield loss reaches up to 25%, with developing countries
facing almost double this yield loss of citrus crop. This yield loss is causing serious annual economic
losses and creating hurdles for the development of the citrus fruits-related industry [1]. Citrus
fruits (Family Rutaceae, subfamily Aurantioideae) are highly susceptible to decay caused by more
than 20 postharvest fungal infections leading, to approximately half the crop wasted due to fungal
diseases [2]. Among various fungal strains, Penicillium fungi cause serious plant diseases and damage to
the citrus crop during storage, accounting for about 10–30% [3]. The P. digitatum infects the citrus fruits,
causes green mold disease, and generates huge (60–80%) yield losses under ambient conditions [4].
In order to control such fungal disease-mediated yield losses, prochloraz, imazalil, and thiabendazole
are extensively used as potential antifungal agents [5]. The literature reported serious health issues
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aroused by excessive use of certain routine and synthetic antifungal agents. Over the past few decades,
the intentions have been to ensure the hygiene and safety levels of fruit products along with promoting
maximum biodegradability. In order to achieve this ambition, researchers are still trying to screen
natural products with strong antifungal potential from plants. Moreover, it has also been tried to
explore new preservation technologies that can replace synthetic fungicides. Compared with synthetic
fungicides, natural antifungal substances have attained much attention in recent years [6–9].
Various essential oils refined from Melaleuca alternifolia have strong inhibitory effects on multiple
fungal strains, particularly P. italicum Wehmer and P. digitatum Sacc., and hence can be used as
natural preservatives in agricultural and food processing [10]. Previously we have reported that
cinnamaldehyde contained in cinnamon has a good antifungal effect against P. italicum and clarifies
the method for dynamic detection of the antifungal effect of cinnamaldehyde [11]. In addition, GC-MS
and GC-FID techniques successfully separated the essential oils components viz. limonene (87.02%),
linalyl acetate (53.76%) and linalool (39.74%) from peels, leaves and flowers of Citrus aurantium var
amara, neroli oil appeared as the best fungistatic agent, which reduced the P. digitatum sporulation to
25 % at a 50 mg/mL concentration of oil [12].
Carvacrol (5-Isopropyl-2-methylphenol) is the major volatile oil constituent from Labiaceae family
plants, such as oregano, mint, and thyme [13]. Carvacrol has many medicinal and edible applications,
including antifungal, antimicrobial, anti-inflammatory, insecticidal, antitumor, and other effects [14].
Carvacrol inhibited the growth of P. digitatum and P. italicum in in vitro and in vivo experiments
of lemon [15]. Another study in Morocco, reported that Thymus leptobotrys and T. riatarum have
carvacrol contents of 76.94% and 32.24%, respectively, and the former species has the highest bioactivity
among the tested plant species in that study. In addition, the study reported a complete inhibition of
germination of the spore of P. digitatum and P. italicum at 500 μL/L [16]. The results of the antimicrobial
activity assay showed that carvacrol, cinnamaldehyde, and trans-cinnamaldehyde significantly reduced
the growth of P. digitatum; particularly, the carviniol appeared as the most effective remedy to control
P. digitatum [17].
Metabolomics is an important part of systems biology, which is quite similar to genomics and
proteomics [18]. Metabolomics is distinguished from other related sciences in terms if its ability to
find the relative relationship of metabolites with physiological and pathological changes through
quantitative analyses of metabolites with low molecular weight (1000) [19]. Recently, the 1H-NMR
based metabolomics approach was used to reveal the antimicrobial mechanism, which generally
includes amino acid biosynthesis and energy-associated metabolism [20,21]. Although carvacrol
already been proved to have significant antifungal properties, the underlying mechanism is not clear
yet. In the current study, we applied the 1H-NMR-based metabolomics approach to evaluate the
antifungal potential of carvacrol on P. digitatum and explored the underlying antifungal mechanism.
Moreover, how carvacrol-induced oxidative stress disturbs the energy production and amino acid
metabolism in P. digitatum shall also be studied through metabolic profiles.
2. Materials and Methods
2.1. Chemicals
Carvacrol (purity 99%) purchased from Shanghai Aladdin Co., Ltd. (C804847), and because of its
insolubility in water, it was previously dissolved in ethanol (50%, w/w) to obtain a stock solution with a
proper concentration of 10 mg·mL−1.
2.2. Preparation of P. Digitatum Spores
The highly pathogenic fungus P. digitatum was isolated from an infected orange with typical green
mold symptoms and maintained on potato dextrose agar (PDA: 200 g peeled potatoes, 20 g glucose,
18 g agar powder and 1 L distilled water) medium plates at 25 ◦C. The preparation of P. digitatum spore
suspension was based on a previous method [22], and the tested pathogen was incubated at 25 ◦C for
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7 days. The seven-days-old plate was washed with sterile water and then gently dispersed by spread
bacteria beads to release spores. Finally, the spore suspensions were filtered through a sterile cotton
ball in a funnel to remove mycelia and PDA fragments and adjusted to the suitable concentration of
1 × 106 spores mL−1 with the aid of a hemocytometer.
2.3. Antifungal Effects of Carvacrol against P. Digitatum
The inhibitory effect of carvacrol on the mycelial growth of P. digitatum was determined as
previously reported [22]. Briefly, the 0, 0.0625, 0.125, 0.25, 0.5, and 1 mL of carvacrol stock solution
was diluted with 2, 1.9375, 1.875, 1.75, 1.5, 1 mL of sterile 0.5% Tween 80 and mixed with 18 mL of
PDA for obtaining the final concentrations of 0 (control), 0.03125, 0.0625, 0.125, 0.25, and 0.5 mg·mL−1.
The mycelial disks (5 mm in diameter), cut from the periphery of a seven-days-old culture using a
stainless-steel punch, was placed in the center of each Petri dish (90 mm in diameter). Then, all plates
were incubated at 25 ◦C for seven days. Four replicates were used per treatment and the experiment
was carried out at two separate times. Mycelial growth inhibition (MGI) of carvacrol treatment against
control was calculated using the following equation:
MGI (%) =
Dc−Dt
Dc− 5 × 100
where Dc and Dt were the mean colony diameter of control and treated sets, respectively.
The minimum inhibitory concentration (MIC) was defined as the lowest carvacrol concentration
that completely inhibited the growth of P. digitatum after 48 h of incubation at 25 ◦C. The minimum
fungicidal concentration (MFC) was considered the lowest concentration of carvacrol with no visible
fungal growth on a PDA plate after a following 5 days incubation at 25 ◦C [22].
2.4. The Effect of Carvacrol on Mycelial Weights and Water-Retention Rate
The effects of carvacrol on the wet and dry weights as well as the water-retention rate of P. digitatum
mycelial were determined by the method described by Tian et al. with some modifications [23]. Briefly,
100 μL of P. digitatum containing 106 spores mL−1 was inoculated into 50 mL of potato dextrose broth
(PDB) medium and then was incubated in a rotary shaker (150 rpm) at 25 ◦C. After shake incubating
for 48 h, the carvacrol solution at final concentrations of 0 (control), 0.03125, 0.0625, 0.125, 0.25 and
0.5 mg·mL−1 were added into the above-mentioned PDB and then incubated for 24 h at 25 ◦C in a
rotary shaker. The mycelia from the carvacrol treated and control PDB was collected by filtering used
a Buchner funnel and washed three times with sterile water. The wet weights of the mycelia were
measured, the mycelia were dried at 70 ◦C for 12 h, and the dry weights were then measured using an
analytical balance (Ms105, Mettler Toledo, Greifensee, Switzerland). The water-retention rates of the
carvacrol-treated and control groups were calculated using the following equation:




where Ww and Wd were the mean of wet and dry weights in carvacrol treated and control sets,
respectively.
2.5. Sample Preparation for 1H NMR Spectroscopy
The collected mycelial treated with MIC carvacrol for 4, 8 and 12 h respectively were washed three
times with pre-cooled PBS buffer solution and then added with 3.8 mL pre-cooled methanol-water
mixture (1/0.9, v/v). The mixture was placed on the ice for 4 min of sonication bathing, and then added
with 4 mL trichloromethane. After full oscillation, the mixture was centrifuged at 4 ◦C and 10,000 rpm
for 10 min. The upper methanol water phase was placed in the nitrogen blowing instrument (NBI,
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HSC-24B, Tianjin Hengao Technology Development Co. Ltd, Tianjin, China) to blow off the methanol,
and then the supernatants were freeze-dried, and then stored under −80◦C until NMR analysis [11].
In the NMR measurements, the samples were dissolved in 550 mL 99.8% D2O phosphate buffer
(0.2 M, pH = 7.0), which contained 0.05% (w/v) 3-(trimethylsilyl) sodium propionate -2, 2, 3, 3-d4
(TSP). After rotating for 15 s and centrifuging for 10 min at 12,000 rpm and 4 ◦C, the supernatant was
transferred to a clean nuclear magnetic resonance tube (5 mm) for analysis. The 1H-NMR spectrum was
recorded in the 298 K at 500 MHz nuclear magnetic resonance spectroscopy (Bruker Avance III, Bruker
Instruments, Darmstadt, Germany). Field-frequency locking with D2O and TSP was used as a reference
for chemical shift (1H, D 0.00). The carrpurcell-meiboom-gill sequence [90 (t-180-t) n-acquisition],
which is edited by lateral relaxation, has a total spin-echo delay (2 n t) of 40 ms. The spectra were
recorded in 64K data points with 128 scans, ranging from −5–15 ppm. By multiplying FIDS with
exponential weighting function (corresponding to line broadening at 0.5Hz), Fourier transform was
performed on the spectrum.
2.6. Spectral Pre-Processing and Data Analysis
All 1H NMR spectra were phase and baseline corrections, and the peak was manually calibrated
using Topspin software (Bruker BioSpin GmbH, version 3.5, Rheinstetten, Karlsruhe, Germany).
Then the peak was exported to ASCII file using Mestrec (version 4.9.6, Mestrelab Research SL, Santiago
de Compostela, Spain) and imported into R software (https://www.r-project.org/) for further analysis.
The region containing residual water signal was removed. The spectrum was combined with an
adaptive intelligent algorithm. Before multivariate data analysis, the remaining trash cans were the
probability quotient normalization and Pareto scale.
Orthogonal signal correction partial least squares discriminant analysis (OSC-PLS-DA) was used
to reveal the metabolic differences among groups. Score charts are used to show clustering between
categories, and load/s charts are used to identify different metabolites between two groups. Differential
metabolites are metabolites in the upper right quadrant and the lower left quadrant of the S diagram.
According to the correlation coefficient from blue to red, the loading graph is color coded. The model
was validated internally by repeated two cross-validations and externally by a permutation test.
2.7. Statistical Analysis
Data on the inhibitory effects of carvacrol on mycelial growth, mycelial weights, and water-retention
rate were analyzed by variance analysis (ANOVA) using the SPSS version 17.0 (SPSS Inc., Chicago, IL,
USA). The significant difference of means was performed with the Duncan’s test at p < 0.05.
3. Results
3.1. Effects of Carvacrol on P. Digitatum Mycelial Growth on PDA
The inhibitory effect of carvacrol on the growth of P. digitatum was quite obvious and a significant
growth inhibition on PDA medium was seen in a dose-dependent manner (p < 0.05) (Figure 1).
The increasing carvacrol concentrations had higher mycelial growth inhibition (MGI). As a whole,
over one-fifth of the P. digitatum mycelial growth was inhibited at 0.0625 mg/mL of carvacrol, but 0.125
mg/mL concentration inhibited more than half (54.84%) of the mycelial growth. The higher carvacrol
concentrations (0.25 and 0.5 mg/mL) completely inhibited the mycelial growth of P. digitatum (Figure 1).
Based on the observation of P. digitatum in mycelial growth on PDA medium with carvacrol
treatments at 0, 0.03125, 0.0625, 0.125, 0.25, and 0.5 mg/mL during the incubation period at 25 ◦C,
carvacrol treatments at the concentrations of 0.125 mg/mL and 0.25 mg/mL completely inhibited
P. digitatum in mycelial growth at the 2nd day and 7th days of incubation, respectively. Therefore,
the values of MIC and MFC were 0.125 mg/mL and 0.25 mg/mL, respectively (Figure 2).
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Figure 1. The antifungal efficacy of carvacrol on the in vivo mycelial growth inhibition (MGI) of P.
digitatum on PDA. Bars indicate the mean ± standard deviation (S.D.) and those labeled with different











Figure 2. The effect of the growth diameter of P. digitatum treated with different concentrations of
carvacrol (0, 0.03125, 0.0625, 0.125, 0.25, and 0.50 mg/mL) at 2 days and 7 days post-inoculation (dpi).
3.2. Effects of Carvacrol on Mycelial Weights in PDB
The mycelial weights of P. digitatum in carvacrol treatment and control groups are shown in
Table 1. The data showed that mycelial growth biomass was strongly inhibited with increasing the
carvacrol concentration. Initially, the wet and dry weights were 3.736 g and 0.393 g/100 mL at the
lower carvacrol concentration of 0.0625 mg/mL, respectively. At higher carvacrol concentrations (0.125,
0.25 and 0.50 mg/mL), the effect on mycelial weights was recorded at a significant level (p < 0.05) in
comparison with the control group.




Mycelial Weight (g/100 mL)
Water-retention Rate (%)
Wet Weight Dry Weight
0 4.868 ± 0.288 a 0.419 ± 0.011 a 91.38 ± 0.29 a
0.03125 4.487 ± 0.185 a 0.407 ± 0.008 a 90.89 ± 0.33 a
0.0625 3.736 ± 0.113 b 0.393 ± 0.015 ab 89.47 ± 0.48 b
0.125 3.065 ± 0.267 c 0.368 ± 0.016 bc 87.69 ± 0.77 c
0.25 2.895 ± 0.170 c 0.357 ± 0.012 c 87.57 ± 0.39 c
0.5 2.671 ± 0.232 c 0.345 ± 0.020 c 86.96 ± 0.65 c
Values are mean ± S.E. The data followed by different letters within the column are significantly different according
to Duncan’s test (p < 0.05).
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3.3. Effect of Carvacrol on Water-Retention Rate of P. Digitatum
Water is the main component in the fungal cell and account for about 90% of mycelial fresh
weight and plays an important role in regulating of cell osmotic pressure. The water-retention rate is
used as an index of lipid peroxidation that is related to membrane damage leading to cell aging. The
lower water-retention index shows higher membrane damages, and vice versa. The effect of carvacrol
on the water-retention rate of P. digitatum mycelia is shown in Table 1. Different concentrations of
carvacrol treatments were used to evaluate the mycelial membrane damage. The water-retention rate
of P. digitatum mycelia was decreased and treated by carvacrol in a dose-dependent manner. The results
demonstrate that the water-retention rate of P. digitatum mycelia was more significantly inhibited by
the higher concentrations (0.125, 0.25, and 0.50 mg·mL−1) of carvacrol.
3.4. Metabolites Identified in 1H-NMR Spectra
The representative 500 MHz 1H-NMR spectra of mycelia obtained from the control group and
MIC carvacrol administration group are shown in Figure 3. Chemical shifts assignments of metabolites
were shown in the Supplementary Material (Supplementary Table S1). Nuclear magnetic resonance
(NMR) was allocated by searching publicly-accessible metabolome databases (such as the Human
Metabonomics Database and Madison Qingdao Metabonomics Joint Database) based on chemical
changes reported in the literature.
Figure 3. The typical 500 MHz CPMG 1H-NMR spectra for 2 groups. Keys: 1. Isoleucine; 2. Leucine; 3.
Valine; 4. Lactate; 5. Alanine; 6. Lysine; 7. Putrescine; 8. 4-Aminobutyrate; 9. Acetate; 10. Glutamate;
11. Acetaminophen; 12. Succinate; 13. Glutamine; 14. Glutathione; 15. 5,6-Dihydrouracil; 16. Aspartate;
17. Sarcosine; 18. Phenylalanine; 19. Ethanolamine; 20. Choline; 21. Betaine; 22. Arginine; 23. Methanol;
24. Glycine; 25. π-Methylhistidine; 26. Uracil; 27. Tryptophan; 28. Xanthine; 29. Adenine; 30. Formate.
3.5. Multivariate Analysis of 1H-NMR Spectral Data
To evaluate the antifungal activity of carvacrol on P. digitatum, the OSC-PLS-DA model was
constructed and all NMR data obtained from the control group (CK) and carvacrol administration
group (D) at 4, 8 and 12 h were analyzed. In Figure 4B–D, each point manifested a sample, and each
clustering represented a corresponding metabolic pattern in different groups. Figure 4B shows that
the two groups were not well separated at 4 h. However, with the passage of time, the control group
and the drug group were separated further and further, and the CK and D groups were the furthest
away in the scores plot at 12 h (Figure 4D). This result shows that the metabolomic changes in D
group increased from 4 h to 12 h. At 12 h, the metabolic spectrum of group D changed fundamentally,
reflecting the rapid response of the strain to carvacrol. The trajectory plot (Figure 4A) also exhibited
a good separation between the CK and D groups, showing an apparent time-dependent antifungal
activity of carvacrol on P. digitatum.
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Figure 4. (A): Score trajectory of the OSC-PLS-DA analysis in the CK group and D group at 4, 8, 12 h.
(B–D): Scores plots of CK and D groups at 4 h, 8 h, and 12 h, respectively.
In the 12 h S-plot (Figure 5B), different shapes and colors of the dots show different metabolites.
The contribution of these metabolites to the group is related to their distance to the center; variables
farther away from the center contribute more to the group separation. On the basis of the correlation
coefficient, the 12-hours loading plots (Figure 5C,D) are coded with cold and warm tones, and the
correlation increases gradually from blue to red. Significant decrease of lactate, alanine, glutamate,
glutamine, glutathione, aspartate, sarcosine, phenylalanine, ethanolamine, choline, arginine, methanol,
glycine, π-Methylhistidine and xanthine, and marked increase of leucine, uracil, tryptophan and
adenine were found in the carvacrol dosed group.
 
Figure 5. OSC-PLS-DA analysis of NMR data at 12 h. (A) The OSC-PLS-DA Score plot. (B) S-plot.
(C,D) Color-coded loadings plots. The use of color bars, where red and blue represent metabolites,
is statistically significant or insignificant in facilitating the separation of groups. In the CK group,
the peak of the positive and negative states showed that the decrease and increase of metabolites were
correlated with the score plot.
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The results of the normality test of metabolites are shown in Table 2. The folding changes (FC) of
metabolites and their associated P values were calculated and corrected in color tables. Collapse change
values are color-coded after log conversion. Cell units were filled with red or blue to indicate the increase
or decrease respectively of metabolites in the carvacrol-treated group compared with the control group.
Table 2. Differential expression of metabolites between two groups at 12 h.
No Metabolites
D/CK
a FC b P
1 Isoleucine 0.04
2 Leucine 0.5 *
3 Valine −0.11
4 Lactate −0.52 *





10 Glutamate −0.41 *
11 Acetaminophen 0.04
12 Succinate −0.26
13 Glutamine −1.17 ***
14 Glutathione −0.65 *
15 5-6-Dihydrouracil −0.3
16 Aspartate −0.71 **
17 Sarcosine −1.02 **
18 Phenylalanine −1.65 ***
19 Ethanolamine −0.51 *
20 Choline −1.51 ***
21 Betaine 0.06
22 Arginine −1.86 ***
23 Methanol −0.75 **
24 Glycine −1.09 **
25 π-Methylhistidine −1 *
26 Uracil 1.13 **
27 Tryptophan 0.37 *
28 Xanthine −1.42 ***
29 Adenine 1.47 ***
30 Formate −0.07
a FC: Color-coded according to the fold-change value; Color coded according to the log2 (FC), red represents increased
and blue represents decreased concentrations of metabolites. Color bar
 
 .
b P values corrected by Benjamini-Hochberg methods were calculated based on a parametric Student’s t-test or a
nonparametric Mann-Whitney test (dependent on the conformity to the normal distribution). * p < 0.05, ** p < 0.01,
*** p < 0.001.
4. Discussion
The current study comprehensively evaluated the antifungal activity of carvacrol against
P. digitatum through 1H-NMR metabonomics. Following the important metabolites selected by
OSC-PLS-DA loading/S-diagram, METPA (http://www.metaboanalyst.ca) (Figure 6A) and KEGG
(http://www.genome.jp/kegg/) were used for path analysis to determine biologically significant
metabolic patterns and related pathways (Figure 6B–E).
Alanine, aspartate, glutamate, and glutathione metabolisms were imbalanced in the fungal hyphae
(Figure 6). These metabolisms were also found in the correlation network of D group at 12 h. A strong
positive correlation between aspartate, glutamate, alanine, and glutamine was seen, and a negative
correlation between glutathione and lactate was also observed. These metabolic changes revealed
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that carvacrol induced the generation of heavy oxidative stress to disturb the energy and amino acid
metabolism of P. digitatum (Supplementary Figure S1).
A significant decrease in the level of glutamate, glutamine, glycine and precursors of glutathione
was observed in the D group. As an ROS scavenger, the level of glutathione also markedly decreased in
the D group. Glutathione being endogenously expressed antioxidant enzyme that played an important
role in the protection of cells against ROS by quickly eliminating free radicals [24]. Glutathione was
consumed in large quantities in fungi against carvacrol-induced ROS. To sustain a certain level of
glutathione in fungus, the synthesis of glutathione from glutamate, glutamine and glycine has to be
enhanced [25], which will lead to the degradation of glutamate and glycine. In addition, a heavy load of
ROS could enhance peroxidation of membrane lipids, leading to damage the cellular membranes [26].
The decreased level of choline and ethanolamine were seen in the D group compared with the CK
group, and both are considered as the key players in the stability and integrity of cell membranes [27].
Therefore, any decrease in choline and ethanolamine may be due to excessive utilization for repairing
the damaged membranes caused by ROS which are indicators of decreased level of sarcosine in D
group [28]. In the current study, the sarcosine level in group D was lower than that in group CK,
and was linked with the decrease of choline and glycine levels. These results reflect the disturbance of
ROS to the sarcosine pathway caused by carvacrol.
The self-protection mechanism of fungus made it consume huge amounts of energy to avoid
ROS mediated stress and repair the cell membranes. In order to produce more ATPs, the aerobic
respiration in fungal hypha was enhanced while the glycolysis pathway was checked to a great
extent. Such reduction in glycolysis was supported by the decreased level of lactate in D group.
In addition, a marked decrease in phenylalanine, alanine, aspartate, and arginine levels was observed
in D group. The glycogenic amino acids underwent degradation [29] and reflected an enhancement in
the gluconeogenesis pathway that compensates the deficiency of glucose. The results further suggested
that carvacrol helps produce energy and amino acid metabolic disorders in P. digitatum.
A significant increase in the transcriptional initiators e.g., uracil and adenine were found in the D
group compared with the CK group (Table 2) [30]. The increased level of uracil and adenine revealed
that carvacrol caused RNA damage to P. digitatum.
In this pioneering study, the antifungal activity of carvacrol against P. digitatum was studied by
using the metabolomics approach based on 1H-NMR. Carvacrol can cause an abnormal metabolic
state of P. digitatum by interfering with different metabolic pathways such as energy and amino acid
metabolisms. Furthermore, carvacrol could also induce damage to the RNA molecules and ROS
production. Metabolomics provide a powerful and feasible tool for evaluating antifungal activity and
exploring its potential mechanism.
Figure 6. (A) In this study, metabolic analysis was used to analyze the pathway topology related to
antifungal activity. The term “log p” is the conversion of the original p value calculated from enrichment
analysis, and “impact” is the path impact value calculated from the path topology analysis. The bubble
area is proportional to the effect of each path, and the color indicates the importance from the highest
red to the lowest white. (B) Alanine, aspartate, glutamate metabolism; (C) glutathione metabolism.
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as potential antimicrobial agents.
Abstract: The emergence of pathogenic bacteria-resistant strains is a major public health issue.
In this regard, natural product scaffolds offer a promising source of new antimicrobial drugs.
In the present study, we report the antimicrobial activity against Gram-positive and Gram-negative
bacteria and the yeast Candida albicans of five phenolic nor-triterpenes (1–5) isolated from Maytenus
blepharodes and Maytenus canariensis in addition to four derivatives (6–9), three of them reported for
the first time. Their stereostructures have been elucidated on the basis of spectroscopic analysis,
including one-dimensional (1D) and two-dimensional (2D) NMR techniques, spectrometric methods,
and comparison with data reported in the literature. To understand the structural basis for the
antimicrobial activity of this type of compounds, we have performed an in-depth study of the
structure–activity relationship (SAR) of a series of previously reported phenolic nor-triterpenes.
The SAR analysis was based on the skeleton framework, oxidation degree, functional groups, and
regiosubstitution patterns, revealing that these aspects modulate the antimicrobial activity.
Keywords: Maytenus; celastroloids; semisynthesis; antibacterial activity; structure–activity relationship
1. Introduction
The resistance of common pathogens to standard antibiotic therapies is rapidly becoming a major
public health problem all over the world [1], and consequently, there is a need to develop new structural
and mechanistic classes of antibiotic agents. In this regard, the development of new antibiotics inspired
in natural product scaffolds seems the best short-term solution to address antibiotic resistance [2].
The Celastraceae family is distributed mainly in tropical and subtropical regions of the world
including North Africa, South America, and East Asia, and their species have a long history in
traditional medicine [3]. The most representative genus in this family is Maytenus, with more
than 225 species [4]. In the Amazonian region, species of this genus are well known for their
use in the treatment of rheumatism, gastrointestinal diseases, and as an antitumoral for skin
cancer [4]. The therapeutic potential of Maytenus species has been mainly attributed to celastroloids,
chemotaxonomic markers of the family [5]. The term celastroloid refers to methylenequinone
nor-triterpenes with a 24-nor-D:A-friedo-oleanane skeleton. Celastrol [6] and pristimerin [7] are
the first and most frequently reported celastroloids, and later on, this term was extended to related
phenolic nor-triterpenes [5,8] and their dimer and trimer congeners [9]. This particular class of natural
products shows a wide range of bioactivities, including cytotoxic [10,11], anti-inflammatory [12],
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antioxidant [13], antiparasitic [14], and insecticidal [15] properties. Concerning their antimicrobial
activity, pristimerin, tingenone, celastrol, and netzahualcoyone (Figure 1) exhibit inhibitory activity
against Gram-positive bacteria [8,16,17], and the mode of action of netzahualcoyone against Bacillus
subtilis and Escherichia coli has been investigated [18,19]. Regarding the phenolic nor-triterpenes, studies
on their antimicrobial activity, mechanism of action against Gram-positive bacteria, and preliminary
structure–activity relationship have been reported [20–25].
Figure 1. Most frequently reported antimicrobial celastroloids from Celastraceae species.
As part of an intensive investigation into antimicrobial metabolites from Celastraceae species, we
report herein on the minimal inhibitory concentrations (MICs) of five natural phenolic nor-triterpenes
(1–5) and four derivatives (6–9), three of them reported for the first time, against Gram-positive
and Gram-negative bacteria, and the yeast Candida albicans. The structure–activity relationship
study of compounds 1–9 was expanded by the known antimicrobial activity of a series of phenolic
nor-triterpenes (10–26), previously reported by our research group [20–23,25], to deepen our knowledge
of the structural requirements for their activity.
2. Materials and Methods
2.1. General Procedures
Optical rotations were measured on a Perkin Elmer 241 automatic polarimeter in CHCl3 at
25 ◦C, and the [α]D values are given in 10−1 deg cm2 g−1. UV spectra were obtained in absolute
EtOH on a JASCO V-560 instrument. IR (film) spectra were measured in CHCl3 on a Bruker IFS 55
spectrophotometer. 1H (400 or 500 MHz) and 13C (100 or 125 MHz) NMR spectra were recorded on
Bruker Avance 400 or 500 spectrometers; chemical shifts are given in ppm and coupling constants in
hertz. Samples were dissolved (CDCl3: δH 7.26, δC 77.0). EI-MS and EI-HRMS were recorded on a
Micromass Autospec spectrometer. Silica gel 60 (particle size 15–40 μm) for column chromatography
and silica gel 60 F254 for analytical (TLC) and preparative thin-layer chromatography (PTLC) were
purchased from Macherey-Nagel. Sephadex LH-20 was obtained from Pharmacia Biotech. Shimadzu
high-performance liquid chromatography (HPLC) equipment consisted of a pump LKB 2248 solvent
delivery module, SPD-6V detector set at 254 nm, using a semipreparative silica gel column (Waters
μ-Porosil®, 15 cm × 1.6 mm, particle size 10 μm). The mobile phase consisted of a mixture of
n-hexane-EtOAc (8:2) in isocratic mode with a flow rate of 9 mL/min. The degree of purity of the
compounds was over 95%, as indicated by a single peak in HPLC and NMR. All solvents used were
of analytical grade (Panreac), and the reagents, used without purification, were purchased from
Sigma-Aldrich. Pristimerin, used as starting material, was isolated from the root bark of M. blepharodes
and M. canariensis, as previously described [20,21].
2.2. Phenolic Nor-Triterpenes
The natural phenolic nor-triterpenes 1 (6-oxopristimerol) [20,26], 3 (7,8-dihydro-6-oxoiguesterol,
canarol) [27], 16 (6-oxotingenol) [20], 17 (3-O-methyl-6-oxotingenol) [20], and 20 (6-oxoiguesterol) [20] were
isolated from the root bark of Maytenus canariensis, and compounds 2 (7-hydroxy-6-oxopristimerol) [21,28],
4 (blepharodol) [21], 5 (7α-hydroxyblepharodol) [27], 10 (blepharotriol) [21], 12 (zeylasteral) [27,29],
13 (demethylzeylasteral) [21,29], 14 (zeylaterone) [27,29], 15 (demethylzeylasterone) [21,29], 22 (7-
oxoblepharodol) [21], and 25 (6-deoxoblepharodol) [21] from Maytenus blepharodes. Derivatives 11 (2,3-
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O-dimethoxyblepharodol) [21], 18 (2,3-O-dimethyl-6-oxotingenol) [20], 19 (2,3-O-diacetoxy-6-oxoting
enol) [20], 21 (2,3-O-dimethyl-6-oxoiguesterol) [20], 23 (2-O-methoxy-7-oxoblepharodol) [21], 24
(pristimerol) [21,30], and 26 (8-epi-6-deoxoblepharodol) [21] were obtained following the methodology
previously described [20,21]. The structures of these compounds are depicted in Figure 2. Moreover,
the semisynthesis of derivate 6, not previously described, was achieved by acetylation of pristimerin, a
main quinone–methide triterpene isolated from the root bark of Maytenus species [27]. In addition,
derivatives 7–9 were prepared by catalytic reduction and further acetylation of pristimerin. Derivative
7 is a known synthetic compound [31] whose 1H and 13C NMR data have not been previously assigned,
whereas derivatives 8 and 9 are reported herein for the first time (Scheme 1, Figures S1–S4.).
2.2.1. Preparation of Compound 6
To a stirred solution of pristimerin (31.0 mg) in pyridine (0.15 mL), anhydride acetic (0.1 mL) and
a catalytic amount of 4-dimethylamino-pyridine were added. The resulting orange-red solution was
stirred for 14 h at room temperature, until TLC showed complete conversion. This yellow solution
was concentrated under reduced pressure, and the residue was purified by preparative TLC using
n-hexane-EtOAc (1:1) as eluent to afford compound 6 (14.0 mg, 37.0%).
6α-Hydroxy-2,3-diacetylpristimerol (6). Pale yellow amorphous solid; [α]20D − 39.7 (c 0.15, MeOH);
UV (EtOH) λmax (log ε) 340 (7.3), 204 (7.4) nm; IR νmax (film) 3517, 2948, 2872, 1770, 1730, 1459, 1373,
1215, 1106, 758 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.59 (3H, s, Me-27), 1. 09 (3H, s, Me-28), 1.16 (3H, s,
Me-30), 1.24 (3H, s, Me-26), 1.35 (3H, s, Me-25), 2.29 (3H, s, OAc-3), 2.32 (3H, s, Me-23), 2.33 (3H, s,
OAc-2), 3.54 (3H, s, OMe-29), 5.06 (1H, dd, J = 3.0, 10.8 Hz, H-6), 5.76 (1H, d, J = 3.0 Hz, H-7), 7.03 (1H,
s, H-1). 13C NMR (125 MHz, CDCl3) δ 12.3 (q, C-23), 18.6 (q, C-27), 20.7 (q, C-26), 21.0 (q, OAc-2), 21.6
(q, OAc-3), 29.1 (t, C-15), 30.2 (t, C-21), 30.4 (t, C-12), 30.9 (t, C-19), 31.2 (s, C-17), 31.9 (q, C-28), 33.1
(q, C-30), 34.5 (t, C-22), 35.1 (t, C-11), 36.9 (t, C-16), 37.4 (q, C-25), 38.3 (s, C-9), 38.6 (s, C-13), 40.8 (s,
C-20), 44.6 (d, C-18), 44.8 (s, C-14), 51.9 (q, OMe-29), 66.4 (d, C-6), 116.9 (d, C-1), 117.5 (s, C-7), 128.7 (s,
C-4), 130.8 (s, C-5), 139.1 (s, C-3), 142.9 (s, C-2), 151.8 (s, C-10), 159.4 (s, C-8), 168.4 (s, OAc-2), 168.7 (s,
OAc-3), 179.2 (s, C-29); EI-MS m/z (%) 566 [M+] (39), 551 (14), 534 (52), 506 (32), 492 (100), 450 (42), 201
(95); EI-HRMS m/z 556.3032 (calcd. for C34H46O7, 556.3048).
2.2.2. Preparation of Compounds 7–9
A mixture of pristimerin (622.0 mg) and Pd/C 5% (100 mg) in acetic acid (15 mL) was stirred under
1 atmosphere of hydrogen for 3 h. The reaction mixture was filtered through a pad of celite, the solution
quenched by addition of saturated aqueous sodium bicarbonate solution, and the aqueous residue
extracted with dichloromethane (3 × 30 mL). Then, to the crude, pyridine (1.5 mL) dissolved in acetic
anhydride (1.5 mL) was added, and the reaction mixture was stirred for 12 h at room temperature.
Upon completion of the reaction, the solution was concentrated on a cold finger with liquid nitrogen.
The residue was purified by HPLC using n-hexane-ethyl acetate (8:2) as eluent to give compound 7
(21.9 mg, 2.9%, tR = 11.4 min), reported elsewhere [31], and derivatives 8 (76.4 mg, 10.3%, tR = 12.3 min)
and 9 (32.1 mg, 4.3%, tR = 12.6 min), not previously reported.
2,3-Diacetylpristimerol (7). Pale yellow amorphous solid; [α]20D − 15.5 (c 0.15, MeOH); UV (EtOH) λmax
(log ε) 278 (7.3), 203 (7.4), 201 (7.3) nm; IR νmax (film) 2927, 2870, 1775, 1729, 1649, 1371, 1214, 1188, 756
cm−1; 1H NMR (500 MHz, CDCl3) δ 0.58 (3H, s, Me-27), 1.08 (3H, s, Me-28), 1.17 (3H, s, Me-30), 1.22
(3H, s, Me-26), 1.35 (3H, s, Me-25), 2.06 (3H, s, Me-23), 2.28 (3H, s, OAc-2), 2.31 (3H, s, OAc-3), 3.06 (1H,
d br, J = 15.7 Hz, H-6β), 3.32 (1H, dd, J = 5.1, 15.7 Hz, H-6α), 3.55 (3H, s, OMe-29), 5.73 (1H, d, J = 5.1
Hz, H-7), 7.00 (1H, s, H-1). 13C NMR (100 MHz, CDCl3) δ 12.5 (q, C-23), 18.2 (q, C-27), 20.4 (q, OAc-2),
20.7 (q, OAc-3), 22.7 (q, C-26), 28.1 (t, C-6), 28.9 (t, C-15), 30.2 (t, C-12), 30.2 (t, C-19), 30.5 (t, C-22), 31.6
(q, C-28), 32.8 (q, C-30), 34.3 (q, C-25), 34.4 (t, C-11), 34.8 (s, C-17), 34.8 (t, C-21), 36.8 (t, C-16), 37.2 (s,
C-13), 37.5 (s, C-9), 40.4 (s, C-20), 43.7 (s, C-14), 44.4 (d, C-18), 51.5 (q, OMe-29), 116.7 (d, C-1), 116.9 (d,
C-7), 127.8 (s, C-4), 131.5 (s, C-5), 138.0 (s, C-3), 140.6 (s, C-2), 147.5 (s, C-10), 149.0 (s, C-8), 168.4 (s,
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OAc-2), 168.7 (s, OAc-3), 178.9 (s, C-29); EI-MS m/z (%): 550 [M+] (1), 535 (8), 475 (16), 322 (7), 229 (17),
149 (9), 57 (100); EI-HRMS m/z 550.3167 (calcd. for C34H46O6, 550.3192).
2,3-Diacetyl-6-deoxoblepharodol (8). Pale yellow amorphous solid; [α]20D – 29.5 (c 0.20, MeOH); UV
(EtOH) λmax (log ε) 278 (7.3), 203 (7.3), 201 (7.2) nm; IR νmax (film) 2937, 1773, 1730, 1462, 1371, 1213,
1040, 756 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.78 (3H, s, Me-27), 0.88 (3H, s, Me-26), 1.10 (3H, s,
Me-28), 1.60 (6H, s, Me-25, Me-30), 1.98 (3H, s, Me-23), 2.26 (3H, s, OAc-3), 2.30 (3H, s, OAc-2), 2.59 (1H,
dd, J = 11.8, 15.7 Hz, H-6α), 2.60 (1H, dd, J = 6.1, 15.7 Hz, H-6α), 3.59 (3H, s, OMe), 6.89 (1H, s, H-1).
13C NMR (100 MHz, CDCl3) δ 12.5 (q, C-23), 15.9 (q, C-26), 17.3 (q, C-27), 18.2 (t, C-7), 20.4 (q, OAc-3),
20.6 (q, OAc-2), 27.3 (q, C-25), 28.6 (t, C-6), 28.9 (t, C-21), 30.0 (t, C-12), 30.1 (s, C-17), 30.2 (t, C-19), 30.5
(t, C-15), 31.8 (q, C-28), 31.9 (q, C-30), 33.8 (t, C-11), 36.2 (t, C-22), 36.5 (t, C-16), 37.2 (s, C-9), 38.9 (s,
C-13), 39.4 (s, C-14), 40.5 (s, C-20), 43.5 (d, C-8), 44.5 (d, C-18), 51.5 (q, OMe-29), 116.2 (d, C-1), 129.4 (s,
C-4), 132.7 (s, C-5), 138.0 (s, C-3), 139.9 (s, C-2), 149.7 (s, C-10), 168.4 (s, OAc-3), 168.8 (s, OAc-2), 179.1
(s, C-29); EI-MS m/z (%) 552 [M+] (10), 510 (49), 495 (5), 468 (100), 453 (15), 249 (26), 190 (9); EI-HRMS
m/z 552.3457 (calcd. for C34H48O6, 552.3451).
2,3-Diacetyl-8-epi-6-deoxoblepharodol (9). Pale yellow amorphous solid; [α]20D – 29.5 (c 0.20, MeOH);
UV (EtOH) λmax (log ε) 277 (9.4), 203 (9.4), 200 (9.4) nm; IR νmax (film) 2956, 1771, 1728, 1643, 1370,
1214, 1184, 1039, 757 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.81 (3H, s, Me-27), 0.88 (2H, m, H-22), 1.08
(3H, s, Me-28), 1.16 (3H, s, Me-30), 1.21 (3H, s, Me-26), 1.42 (1H, m, H-8) 1.46 (3H, s, Me-25), 1.49 (1H,
m, H-18), 1.58 (1H, m, H-19β), 1.86 (2H, m, H-16), 2.02 (3H, s, Me-23), 2.21 (2H, m, H-22), 2.26 (3H, s,
OAc-3), 2.29 (3H, s, OAc-2), 2.35 (1H, d br, H-19α), 2.72 (2H, m, J = 16 Hz, H-6), 3.56 (3H, s, OMe), 6.98
(1H, s, H-1). 13C NMR (100 MHz, CDCl3) δ 12.6 (q, C-23), 18.9 (q, C-27), 20.4 (q, OAc-2), 20.7 (q, OAc-3),
26.5 (t, C-12), 25.8 (q, C-26), 28.6 (t, C-6), 30.0 (t, C-12), 30.1 (t, C-6), 30.2 (t, C-15), 30.5 (t, C-7), 30.6 (t,
C-19), 30.7 (s, C-17), 30.8 (t, C-21), 31.3 (q, C-28), 32.8 (q, C-30), 33.3 (t, C-11), 36.8 (q, C-25), 35.7 (t, C-22),
37.1 (t, C-16), 38.3 (s, C-14), 38.7 (s, C-9), 40.4 (s, C-13), 40.6 (s, C-20), 46.7 (d, C-18), 51.5 (q, OMe-29),
56.0 (d, C-8), 1193 (d, C-1), 128.0 (s, C-4), 135.4 (s, C-5), 137.5 (s, C-3), 140.2 (s, C-2), 148.5 (s, C-10), 168.4
(s, OAc-2), 168.8 (s, OAc-3), 180.7 (s, C-29); EI-MS m/z (%) 552 [M+] (9), 510 (43), 495 (10), 468 (100), 453
(22), 435 (6), 287 (13), 249 (25), 190 (22); EI-HRMS m/z 552.3457 (calcd. for C34H48O6, 552.3451).
2.3. Antimicrobial Activity
Strains used for determining antimicrobial activity included Bacillus subtilis ATCC 6051, B. alvei
ATCC 6344, B. cereus ATCC 21772, B. megaterium ATCC 25848, B. pumilus ATCC 7061, Staphylococcus
aureus ATCC 6538, S. epidermidis ATCC 14990, S. saprophyticus ATCC 15305, Enterococcus faecalis ATCC
29212, Mycobacterium smegmatis ATCC 19420, Escherichia coli ATCC 9637, Proteus mirabilis CECT 170,
(from Type Culture Spanish Collection), Pseudomonas aeruginosa AK 958 (from the University of British
Columbia, Department of Microbiology collection), Salmonella sp. CECT 456, Klebsiella oxytoca LMM2
(clinical isolate, University of La Laguna), and Candida albicans CECT 1039. The bacteria cultures
were developed in nutrient broth (NB) or brain heart infusion broth (for E. faecalis and M. smegmatis
containing 0.06% Tween 80), and the yeast was cultured in Sabouraud liquid medium at 37 ◦C.
All culture media were purchased from Oxoid. The minimum inhibitory concentrations (MICs) were
determined for each compound in triplicate by broth microdilution method (range 0.08–40 μg/mL) in
96 well microtitre plates, according to the M07-A9 of the CLSI (Clinical and Laboratory Institute) [32].
Wells with the same proportions of dimethyl sulfoxide (DMSO) were used as controls and never
exceeded 1% (v/v). The starting microorganism concentration was approximately 1–5 × 105 CFU/mL,
and growth was monitored by measuring the increase in optical density (OD) at 550 nm (OD550) with a
microplate reader (Multiskan Plus II, Tritertek, Huntsville, AL, USA) and viable count in agar plates.
The MIC was defined as the lowest concentration of compound that completely inhibits growth of the
organisms compared with that of the control after incubation time.
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3. Results and Discussion
3.1. Chemistry
Compounds 1–5, 10, 12–17, 20, 22, and 25 (Figure 2) were isolated, purified, and characterized in
our laboratory from two Maytenus species, M. blepharodes and M. canariensis, as previously described [20,
21,27]. Derivatives 11, 18, 19, 21, 23, 24, and 26, achieved by acetylation or methylation from natural
compounds, are described by González et al. [20] and Rodríguez et al. [21]. Moreover, derivatives
6–9 were prepared from pristimerin (Scheme 1). The semisynthesis of 6 was achieved by acetylation
of pristimerin, and derivatives 7–9 were obtained by catalytic reduction and further acetylation of
pristimerin, as described in the experimental section. Their structures were greatly aided by comparison
of their spectroscopic data with those previously reported for related compounds 24–26 [21]. Even so,
a complete set of two-dimensional (2D) NMR spectra (COSY, ROESY, HSQC and HMBC) was
acquired for the new derivatives to gain the complete assignment of the 1H and 13C NMR resonances
(see Experimental Section, Figures S1–S4). Derivative 7 was identified as the previously described
2,3-diacetylpristimerol [31], however, its 1H and 13C NMR assignments have not been previously
reported. Moreover, derivatives 6, 8, and 9 are described herein for the first time, and their structures
were elucidated as described below.
 
Figure 2. Natural and derivatives phenolic nor-triterpenes included in the SAR studies. SAR: structure–
activity relationship.
 
Scheme 1. Synthesis of analogues 6–9 from pristimerin.
45
Appl. Sci. 2019 , 9 , 2957
Derivative 6 was obtained as a pale yellow amorphous solid with [α]20D − 39.7 (c 0.15, MeOH).
The molecular formula, C34H46O7, was established by EI-HRMS (m/z 556.3048 [M+], calcd. 556.3032).
The IR absorptions revealed the presence of hydroxyl (3517 cm−1) and ester carbonyl (1770 and
1730 cm−1) groups and an aromatic ring (1459 and 758 cm−1). Two acetoxy and a carboxylic methyl
ester group in 6 were evident from the 1H NMR signals at δ 2.29 (3H, s), 2.33 (3H, s), and 3.54 (3H, s),
in combination with those in the 13C NMR (δ 20.6, 21.0, 51.9, 168.4, and 168.7). Besides the carbons of
acetoxy and methoxy groups, the 13C NMR and DEPT data revealed 29 carbon resonances, including
one carboxylic carbon, one aromatic ring, one trisubstituted double bond, one oxymethine carbon,
five sp3 quaternary carbons, one methine, seven methylenes, and six methyls. Analysis of 2D NMR
data, including HSQC, 1H-1H COSY, ROESY, and HMBC experiments, and comparison with data
reported for pristimerol (24) [30] indicated that 6 is a phenolic triterpene with a pristimerin framework.
In particular, HMBC correlations of Me-23 with C-3, C-4, and C-5; H-1 with C-2, C-3, C-5, C-9, and C-10;
H-6 with C-4, C-5, C-8, and C-10, and correlations of Me-25 with C-8, C-9, and C-10 established the
structure of A and B rings. The regiosubstitution of the acetate groups and the relative configuration
of H-6 were deduced by a ROESY experiment, showing ROEs (Rotating-frame Overhauser Effects)
between H-6/OMe-25, H-1/OAc-2, and Me-23/OAc-3 (Figure 3). Thus, the structure of 6 was established
as 6α-hydroxy-2,3-diacetoxy-pristimerol.
Figure 3. Selected HMBC (single arrow) and ROE (doubled arrow) correlations for compound 6.
Derivative 7 was assigned the molecular formula C34H46O6, determined by EI-HRMS. The mass
spectrum exhibited peaks characteristic to acetate groups (M+-15-60, m/z 475, CH3, CH3COOH).
This was confirmed by the 1H and 13C NMR spectra, which included signals for two acetyl groups (δH
2.28 (s), 2.31 (s), δC 20.4 (q), 20.7 (q), 168.4 (q), 168.7 (s)). Its 1H NMR spectrum showed signals for six
methyl groups (δH 0.58, 1.08, 1.17, 1.22, 1.35, and 2.06), a methoxy group at δH 3.55, a vinylic proton
at δH 5.73 (d, J = 5.1 Hz), and an aromatic proton at δH 7.00 (s). The 13C NMR spectrum displayed
34 signals, which were assigned to one methoxy, eight methyls, eight methylenes, three methines,
and fourteen quaternary carbons, including six sp2 and three carboxylic carbons. Extensive study of
the 2,3JC-H correlations (HMBC) allowed us to establish the structure of A and B rings and build the
nor-triterpene skeleton for 7. The regiosubstitution of the acetate groups was deduced by a ROESY
experiment, showing ROE effects between H-1/OAc-2 and Me-23/OAc-3. This data established the
structure of 7 as 2,3-diacetoxy-pristimerol.
Compounds 8 and 9, both with the molecular formula C34H48O6 (EI-HRMS), differ from that of
7 by the presence of two additional hydrogen atoms. The most remarkable difference in their NMR
spectra, when compared to that of compound 7, was the absence of the double bond C-7–C-8. Thus, in
the 13C NMR spectra of 8 and 9, the signals assigned to C-7 and C-8 resonated in the region of aliphatic
carbons (δC 18.2 and 43.5 in 8, and δC 30.5 and 56.0 in 9). Moreover, differences between 8 and 9 were
also observed for the chemical shifts of Me-25 (δH 1.60, δC 27.3 in 8, and δH 1.46, δC 36.8 in 9) and
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Me-26 (δH 0.88, δC 15.9 in 8, and δH 1.21, δC 25.8 in 9). Analysis of 2D COSY, HSQC, and HMBC spectra
allowed us to define their core structures. The ROE effects of H-8/Me-25 and Me-26 observed in a ROESY
experiment for compound 8, and those of H-8/Me-27 observed for compound 9, further supported
the stereochemical assignment for epimers 8 and 9. Their structures were also confirmed by chemical
correlations; hydrolysis of 8 and 9 yielded compounds whose spectroscopic data were identical to those
previously reported for 6-deoxoblepharodol (25) and 8-epi-6-deoxoblepharodol (26) [21], respectively.
Consequently, the structure of compounds 8 and 9 were deduced to be 2,3-diacetyl-6-deoxoblepharodol
and 2,3-diacetyl-8-epi-6-deoxoblepharodol, respectively.
3.2. Antimicrobial Evaluation
Compounds 1–9 were tested on Gram-positive and Gram-negative bacteria, and the yeast Candida
albicans by the broth microdilution method. Moreover, compounds 24–26, closely related to 6–9, were
also assayed against B. alvei, B. megaterium, and B. pumilus for SAR studies. The results (see Table 1)
showed that spore-forming bacteria, such as the genus Bacillus are more sensitive to these compounds,
among which compounds 6 and 24 exhibiting higher activity (MIC values of 1 and 2.5 μg/mL against
B. subtilis and B. cereus, respectively) than cephotaxime, used as a positive control. Furthermore, the
effectiveness against the Gram-positive cocci was restricted to compound 6 (S. epidermidis and E. faecalis,
MIC 5–2.5 and 20–10 μg/mL, respectively). On the other hand, compounds 1–9 were inactive against
the Gram-negative bacteria and the yeast C. albicans (MIC > 40 μg/mL), which is in line with previous
studies on this type of compound [20–23,25].
Table 1. Minimal inhibitory concentration (MIC, μg/mL) 1 against Gram-positive bacteria of phenolic
nor-triterpenes 2 and lipophilicity (clog P).
Compound S. a. S. e. S. s. E. f. B. s. B. a. B. c. B. m. B. p. clog P Reference
2 >40 >40 >40 >40 40–20 >40 40–20 40 >40 5.43
3 >40 >40 >40 >40 40–20 >40 40 >40 >40 6. 41
5 >40 >40 >40 >40 40–20 >40 >40 >40 >40 5.26
6 >40 5–2.5 >40 20–10 1 20–10 2.5 10–5 10–5 5.95
10 >40 >40 >40 >40 8–4 - >40 - - 5.42 [21]
12 40 20 >40 >40 10 7 12 20 25 5.67 [22]
13 25 20 40 >40 13 >40 20 >40 10 5.04 [22]
14 6 >40 >40 >40 3 4 5 4 6 5.21 [23]
15 >40 >40 >40 >40 13 >40 30 >40 >40 4.67 [23]
16 >40 >40 >40 >40 14–12 - >40 >40 >40 5.58 [20]
17 >40 >40 >40 >40 39–35 - >40 >40 >40 6.20 [20]
20 >40 >40 >40 >40 25 - 40 >40 >40 6.86 [20]
22 30 >40 >40 - 8–4 - 10 - - 5.79 [21]
24 >40 0.625 10–5 >40 1–0.5 5–2.5 2.5 20–10 5–2.5 7.09 [21]
25 >40 20–10 >40 >40 10–5 40–20 20–10 >40 20–10 6.41 [21]
26 >40 2 20–10 >40 5–2.5 10–5 10–5 40–20 >40 6.41 [21]
Control 3 2.5 2.5 0.6 >20 8 - 10 - >20 0.14
S. a.: Staphylococcus aureus, S. e.: S. epidermidis, S. s.: S. saprophyticus, E. f.: Enterococcus faecalis, B. s.: Bacillus subtilis, B.
a.: B. alvei, B. c.: B. cereus, B. m.: B. megaterium, B. p.: B. pumilus.—not assayed. 1 The experiments were carried out
in triplicate, and values represent average of MIC values. 2 All compounds were inactive against Gram-negative
bacteria (MIC > 40 μg/mL). Compounds (clog P) 1 (6.15), 4 (6.07), 7–9 (7.18, 6.90 and 6.90), 11 (6.38), 18 (6.47), 19
(5.44), 21 (7.17), and 23 (5.72) were inactive against all microorganisms assayed. 3 Cephotaxime was used as a
positive control.
3.3. Structure–Activity Relationship Analysis
The influence of substitution patterns of the phenolic nor-triterpenes on their antimicrobial
activity was analyzed, taking into account three regions of the triterpene skeleton, the phenolic moiety,
the extended B-ring conjugation, and the triterpene scaffold (pristimerin, tingenone, or iguesterin).
This analysis revealed the following trends in the structure–activity relationship (SAR) (Figure 4).
Regarding the results obtained against Bacillus spp., the SAR studies suggest that: (a) A substituent at
C-4 seems essential for the activity. Thus, comparison of the activities (MICs against B. subtilis) of 14,
10, 12, and 1, whose only structural difference is the substituent at C4, showed that the most effective
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group at this position was a carboxylic acid (14), followed by hydroxyl (10) and aldehyde (12) groups,
while a methyl group, as in 1, led to a loss of activity. B. cereus, B. alvei, B. megaterium, and B. pumilus
showed similar behavior to B. subtilis (14 vs. 12); (b) Acetylation and methylation reduce activity, as
revealed by comparison of potency of the natural compounds with their corresponding analogues (7 vs.
24, 8 vs. 25, 9 vs. 26, 10 vs. 11, 16 vs. 17, 18, 19, and 20 vs. 21), except for compound 6 with an hydroxyl
group at C6 (6 vs. 7). This indicates that the hydroxyl group, which could interact with the receptor
as hydrogen-bond-donor (HBD), is the best functional group, suggesting that the hydrophilicity is
relevant for the activity; (c) Compounds with an unconjugated double bond at C-7 showed considerable
activity (e.g., 6 and 24), and reduction at C-7/C-8 results in a partial loss of antimicrobial activity (24 vs.
25 and 26); (d) The β-stereochemistry at C-8 increases two-fold the activity with respect to the H-8α, as
shown by comparing the MIC values of 26 and 25; (e) A substituent at C-7, in addition to the carbonyl
at C-6, is also relevant for the activity, being a ketone preferred to a hydroxyl group (22 > 5 vs. 4).
Figure 4. Most relevant structural features for phenolic nor-triterpenes against the most sensitive
microorganism, Bacillus subtilis.
Furthermore, the results obtained against Staphylococcus spp. suggest that: (a) the presence of a
carboxylic acid moiety at C-4 could strongly affect the antimicrobial activity against S. aureus since
its substitution by an aldehyde or a methyl group reduced or fully eliminated the activity (14 vs. 12
or 1); (b) moreover, replacement of the carboxyl group at C-29 by its methyl ester led to a partial loss
of activity (13 vs. 12); (c) compounds containing two carboxylic acid groups lacked activity, whereas
those with one carboxylic acid showed high activity (14 vs. 15); (d) the reduction of the double bond at
C-7/C-8 led to less activity (24 vs. 25 and 26 against S. epidermidis); (e) the β-stereochemistry at the C-8
position favored the activity with respect to the H-8α (26 vs. 25); (f) a hydroxyl group at C-6 affected
the activity against S. epidermidis (6 vs. 7). Taking into account these structural features, we propose a
hypothetical compound, 4-carboxy-6α-hydroxy-pristimerol, that would have a zeylasterone A-ring
(as in 14), an unconjugated B-ring (as in 6 and 24), and a pristimerin E-ring as being the most active
against Bacillus and Staphylococcus spp. (Figure 5).
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Figure 5. Structural requirements of phenolic nor-triterpenes based on SAR studies.
Some phenolic compounds primarily target the cytoplasmic membrane due to their hydrophobic
nature, and preferentially partition into the lipid bilayer [33], as was observed in our previous
works [22–25]. Therefore, for the purpose of correlating the antimicrobial activity with lipophilicity,
clog P values [34] of this series of compounds were calculated, including that of the hypothetical
compound, 4-carboxy-6α-hydroxy-pristimerol (clog P 4.88), and are shown in Table 1. Slight increases
in lipophilicity of 24 (clog P 7.09) and 25 and 26 (clog P 6.41) by acetylation (7, 8 and 9, respectively)
(clog P 7.18 and 6.90) led to a suppression of the antibacterial activity. Moreover, other factors must
be taken into account for the expression of the activity, such as the presence of an hydrogen-bond
donor (HBD) group, strategically positioned at C-4 (e.g., 14), C-6 (e.g., 6), or at C-2 and C-3 (e.g., 12
and 14) with clog P of 5.04, 5.95, and 5.67, respectively, which seems relevant for the activity. These
observations indicated that both lipophilicity and HBD factors are involved in the antimicrobial activity
of this type of compound.
4. Conclusions
In summary, the antimicrobial activity of five phenolic nor-triterpenes isolated from two Maytenus
species and those of four derivatives revealed that compound 6 showed significant activity against
Gram-positive bacteria, higher than cephotaxime, used as positive control. In order to understand
and further optimize the structural requirements for effective inhibition of bacterial growth in vitro,
an extensive SAR analysis of a series of nor-triterpene phenols was performed. This study suggests that
the phenolic moiety and carboxyl group at C-4 on the A-ring, a nonconjugated double bond system on the
B-ring, and the ring E, characteristic of pristimerin series, all contribute to the antimicrobial effectiveness.
Based on these findings, we propose a hypothetical lead compound, 4-carboxy-6α-hydroxy-pristimerol.
This comprehensive SAR study supports the future rational design of antimicrobial agents based on
the phenolic nor-triterpene scaffold.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/9/15/2957/s1,
Figures S1–S4: 1H and 13C NMR spectra of derivatives 6–9.
Author Contributions: Conceptualization, L.M. and I.L.B.; methodology, L.M. and I.A.J.; investigation, M.R.L.
and C.P.R.; data curation, L.M. and I.A.J.; writing-original draft preparation, I.L.B.; writing-review and editing,
I.L.B. and L.M.; supervision, L.M. and I.L.B.; and funding acquisition, I.L.B.
Funding: This study was supported by SAF2015-65113-C2-1-R and RTI2018-094356-B-C21 Spanish MINECO
co-funded by the European Regional Development Fund (FEDER) projects.
Acknowledgments: C.P.R. thanks the Cabildo de Tenerife (Agustín de Betancourt Program).
Conflicts of Interest: The authors declare no conflict of interest
References
1. Durand, G.A.; Raoult, D.; Dubourg, G. Antibiotic discovery: History, methods and perspectives. Int. J.
Antimicrob. Agents 2019, 53, 371–382. [CrossRef]
49
Appl. Sci. 2019 , 9 , 2957
2. Rossiter, S.E.; Fletcher, M.H.; Wuest, W.M. Natural products as platforms to overcome antibiotic resistance.
Chem. Rev. 2017, 117, 12415–12474. [CrossRef]
3. González, A.G.; Bazzocchi, I.L.; Moujir, L.M.; Jiménez, I.A. Ethnobotanical uses of Celastraceae. Bioactive
metabolites. In Studies in Natural Products Chemistry: Bioactive Natural Products; (Part D); Atta-ur-Rahman,
Ed.; Elsevier Science Publisher: Amsterdam, The Netherlands, 2000; Volume 23, pp. 649–738.
4. Niero, R.; de Andrade, S.F.; Cechinel, V.F. A review of the ethnopharmacology, phytochemistry and
pharmacology of plants of the Maytenus genus. Curr. Pharm. Des. 2011, 17, 1851. [CrossRef]
5. Gunatilaka, A.A.L. Triterpenoid quinonemethides and related compounds (celastroloids). In Progress in
the Chemistry of Organic Natural Products; Herz, W., Kirby, G.W., Moore, R.E., Steglich, W., Tamm, C., Eds.;
Springer: New York, NY, USA, 1996; Volume 67, pp. 1–123.
6. Chen, S.-R.; Dai, Y.; Zhao, J.; Lin, L.; Wang, Y.; Wang, Y. A mechanistic overview of triptolide and celastrol,
natural products from Tripterygium wilfordii Hook F. Front. Pharmacol. 2018, 9, 1–13. [CrossRef]
7. Yousef, B.A.; Hassan, H.M.; Zhang, L.-Y.; Jiang, Z.-Z. Anticancer potential and molecular targets of pristimerin:
A mini review. Curr. Cancer Drug Targets 2017, 17, 100–108. [CrossRef]
8. Alvarenga, N.; Ferro, E.A. Bioactive triterpenes and related compounds from Celastraceae. In Studies in
Natural Products Chemistry: Bioactive Natural Products; (Part K); Bioactive triterpenes and related compounds
from Celastraceae; Atta-ur-Rahman, Ed.; Elsevier Science Publisher: Amsterdam, The Netherlands, 2006;
Volume 33, pp. 239–307.
9. Bazzocchi, I.L.; Núñez, M.J.; Reyes, C.P. Diels-Alder adducts from Celastraceae species. Phytochem. Rev.
2018, 17, 669–690. [CrossRef]
10. Li, P.P.; He, W.; Yuan, P.F.; Song, S.S.; Lu, J.T.; Wei, W. Celastrol induces mitochondria-mediated apoptosis in
hepatocellular carcinoma Bel-7402 cells. Am. J. Chin. Med. 2015, 43, 137–148. [CrossRef]
11. Rodrigues, A.C.B.C.; Oliveira, F.P.; Dias, R.B.; Sales, C.B.S.; Rocha, C.A.G.; Soares, M.B.P.; Costa, E.V.;
Silva, F.M.A.; Rocha, W.C.; Koolen, H.H.F.; et al. In vitro and in vivo anti-leukemia activity of the stem bark
of Salacia impressifolia (Miers) A. C. Smith (Celastraceae). J. Ethnopharmacol. 2019, 231, 516–524. [CrossRef]
12. Dai, W.; Wang, X.; Teng, H.; Li, C.; Wang, B.; Wang, J. Celastrol inhibits microglial pyroptosis and attenuates
inflammatory reaction in acute spinal cord injury rats. Int. Immunopharmacol. 2019, 66, 215–223. [CrossRef]
13. Santos, V.A.F.F.M.; Santos, D.P.; Castro-Gamboa, I.; Zanoni, M.V.B.; Furlan, M. Evaluation of antioxidant
capacity and synergistic associations of quinonemethide triterpenes and phenolic substances from Maytenus
ilicifolia (Celastraceae). Molecules 2010, 15, 6956–6973.
14. Liao, L.M.; Silva, G.A.; Monteiro, M.R.; Albuquerque, S. Trypanocidal activity of quinonemethide triterpenoids
from Cheiloclinium cognatum (Hippocrateaceae). Z. Naturforsch C 2008, 63, 207–210. [CrossRef]
15. Avilla, J.; Teixidó, A.; Velázquez, C.; Alvarenga, N.; Ferro, E.; Canela, R. Insecticidal activity of Maytenus species
(Celastraceae) nortriterpene quinone methides against Codling Moth, Cydia pomonella (L.) (Lepidoptera:
Tortricidae). J. Agric. Food Chem. 2000, 48, 88–92. [CrossRef]
16. Moujir, L.; Gutiérrez-Navarro, A.M.; González, A.G.; Ravelo, A.G.; Luis, J.G. The relationship between
structure and antimicrobial activity in quinones from the Celastraceae. Biochem. Syst. Ecol. 1990, 18, 25–28.
[CrossRef]
17. González, A.G.; Ravelo, A.G.; Bazzocchi, I.L.; Jiménes, J.; González, C.M.; Luis, J.G.; Ferro, E.A.; Gutiérrez, A.;
Moujir, L. Biological study of triterpenoquinones from Celastraceae. Il Farmaco 1988, 43, 501–505.
18. Moujir, L.; Gutiérrez-Navarro, A.M.; González, A.G.; Ravelo, A.G.; Luis, J.G. Mode of action of
netzahualcoyone. Antimicrob. Agents Chemother. 1991, 35, 211–213. [CrossRef]
19. Moujir, L.; Gutiérrez-Navarro, A.M.; González, A.G.; Ravelo, A.G.; Jiménez, J. Biological properties of
netzahualcoyone: Conditions for activity. Biomed. Lett. 1991, 46, 7–15.
20. González, A.G.; Alvarenga, N.L.; Ravelo, A.G.; Jiménez, I.A.; Bazzocchi, I.L.; Canela, N.J.; Moujir, L. Antibiotic
phenol nor-triterpenes from Maytenus canariensis. Phytochemistry 1996, 43, 129–132. [CrossRef]
21. Rodríguez, F.M.; López, M.R.; Jiménez, I.A.; Moujir, L.; Ravelo, A.G.; Bazzocchi, I.L. New phenolic triterpenes
from Maytenus blepharodes.Semisynthesis of 6-deoxoblepharodol from pristimerin. Tetrahedron 2005, 61,
2513–2519. [CrossRef]
22. De León, L.; Beltrán, B.; Moujir, L. Antimicrobial activity of 6-oxophenolic triterpenoids. Mode of action
against Bacillus subtilis. Planta Med. 2005, 71, 313–319. [CrossRef]
23. De León, L.; Moujir, L. Activity and mechanism of the action of zeylasterone against Bacillus subtilis. J. Appl.
Microbiol. 2008, 104, 1266–1274. [CrossRef]
50
Appl. Sci. 2019 , 9 , 2957
24. De León, L.; López, M.R.; Moujir, L. Antibacterial properties of zeylasterone, a triterpenoid isolated from
Maytenus blepharodes, against Staphylococcus aureus. Microbiol. Res. 2010, 165, 617–626. [CrossRef]
25. López, M.R.; de León, L.; Moujir, L. Antibacterial properties of phenolic triterpenoids against Staphylococcus
epidermidis. Planta Med. 2011, 77, 726–729. [CrossRef]
26. Shirota, O.; Morita, H.; Takeya, K.; Itokawa, H. Cytotoxic aromatic triterpenes from Maytenus ilicifolia and
Maytenus chuchuhuasca. J. Nat. Prod. 1994, 57, 1675–1681. [CrossRef]
27. González, A.G.; Alvarenga, N.L.; Rodríguez, F.; Ravelo, A.G.; Jiménez, I.A.; Bazzocchi, I.L.; Gupta, M.P. New
phenolic and quinone-methide triterpenes from Maytenus species (Celastraceae). Nat. Prod. Lett. 1995, 7,
209–218. [CrossRef]
28. Ankli, A.; Heilmann, J.; Heinrich, M.; Sticher, O. Cytotoxic cardenolides and antibacterial terpenoids from
Crossopetalum gaumeri. Phytochemistry 2000, 54, 531–537. [CrossRef]
29. Gamlath, C.; Gunaherath, K.B.; Gunatilaka, A.A.L. Studies on terpenoids and steroids. Part 10. Structures
of four new natural phenolic D:A-friedo-24-noroleanane triterpenoids. J. Chem. Soc. Perkin Trans. I 1987,
2849–2853. [CrossRef]
30. Kamal, G.M.; Gunaherath, K.B.; Gunatilaka, A.A.L. Studies on terpenoids and steroids. Part 10. Structures
of four new natural phenolic D:A-friedo-24-noroleanane triterpenoids. J. Chem. Soc. Perkin Trans. I 1983,
2845–2850. [CrossRef]
31. Gunatilaka, A.A.L.; Wimalasiri, W.R. Studies on terpenoids and steroids. Part 22. Structure and some
reactions of pristimerin leucotriacetate. J. Chem. Res. S 1992, 1, 30–31. [CrossRef]
32. CLSI. Methods for Dilution Antimicrobial Susceptibility test for Bacteria that Grow Aerobically, 9th ed.; Approved
standard M07-A9; Clinical and Laboratory Standards: Wayne, PA, USA, 2012.
33. Barzic, A.I.; Ioan, S. Antibacterial drugs-From basic concepts to complex therapeutic mechanisms of polymer
systems. In Concepts, Compounds and the Alternatives of Antibacterials; Bobbarala, V., Ed.; Science, Technology
and Medicine: London, UK, 2015.
34. Software-Predicted Lipophilicity of the Compounds was Calculated with the ALOGPS 2.1
Program. Available online: www.vcclab.org/lab/alogps/accessibleviainterneton-lineLipophilicity/
AqueousSolubilityCalculationSoftware. (accessed on 20 May 2019).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Synthesis and Evaluation of the Lifespan-Extension
Properties of Oleracones D–F, Antioxidative
Flavonoids from Portulaca oleracea L.
Jeong A Yoon 1,†, Changjin Lim 2,†, Dong Seok Cha 3,* and Young Taek Han 1,*
1 College of Pharmacy, Dankook University, Chenan 31116, Korea; yja9477@naver.com
2 College of Pharmacy, CHA University, Pocheon 11160, Korea; koryoi@cha.ac.kr
3 College of Pharmacy, Woosuk University, Jeonbuk 55338, Korea
* Correspondence: cha@woosuk.ac.kr (D.S.C.); hanyt@dankook.ac.kr (Y.T.H.);
Tel.: +82-63-390-1578 (D.S.C.); +82-41-550-1431 (Y.T.H.)
† These authors contributed equally to this paper.
Received: 10 September 2019; Accepted: 24 September 2019; Published: 25 September 2019
Abstract: Plant-derived antioxidants have been widely used as supplementary health foods, as well
as having been regarded as drug candidates for aging and aging-associated diseases. Oleracones,
a novel series of flavonoids isolated from Portulaca oleracea L., possess potent antioxidative activities
and are expected to exhibit therapeutic potential on the aging process. The current paper describes
the concise sequential synthesis of oleracones D–F. Oleracones D and F were efficiently synthesized
via selective intramolecular oxa-Michael addition from oleracone E. In addition, we investigated their
possible lifespan-extension properties using Caenorhabditis elegans, which is excellently suited as an
experimental model to study aging. A significant longevity effect was observed when nematodes
were grown with 20 μM of oleracone E.
Keywords: oleracone; flavonoid; anti-aging; longevity; Portulaca oleracea L.; Caenorhabditis elegans;
total synthesis
1. Introduction
Aging is a complicated biological process that is controlled by a large number of genetic and
environmental factors [1–4]. Many theories have been proposed to account for the aging process, but
none of them offers a fully acceptable explanation. Among all the theories, the free radical theory
of aging, proposed by professor Harman in 1956 [5], has been extensively investigated. This theory
continues to be revised and remains a strong theory for the aging process until now. Free radical
theory explains that aging is caused by cumulative oxidative stress from free radicals, resulting in cell
death and, eventually, death of the organism [6]. Hence, this theory suggests that antioxidants that can
sacrificially scavenge ROS (reactive oxygen species) and/or RNS (reactive nitrogen species) are effective
for delaying the aging process. Indeed, early studies have indicated that plant-derived polyphenol
antioxidants, including curcumin, quercetin, and resveratrol, show therapeutic potential for aging
and aging-associated diseases [7,8]. In addition, other synthetic flavonoids have been continuously
reported as novel antioxidants exhibiting antiaging properties [9–12].
Portulaca oleracea L. is a well-known annual weed, one that is widely distributed in temperate
and tropical regions. This plant has been used for a long time, not only as an edible potherb, but
also as a traditional medicine in many countries, being used to alleviate a wide range of illnesses [13].
In addition to phytochemical research, many pharmacological studies have been performed using
the extracts or single compounds from Portulaca oleracea L. to reveal their therapeutic properties.
Interestingly, the extracts of this plant are known to possess not only a strong in vivo antioxidant
capacity, but also anti-aging activity in a d-galactose-induced mice model [14,15].
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Recently, oleracones, a novel series of flavonoids, were isolated from Portulaca oleracea L. by
Chinese researchers [16,17]. They reported the potent antioxidative potential of oleracones, which
allowed us to speculate that oleracones may also possess anti-aging properties [16,17]. The current
paper includes the concise sequential synthesis of oleracones and an evaluation of their possible
lifespan-extension properties using Caenorhabditis elegans, an excellent experimental model to study
aging. Among the reported oleracones, we planned to synthesize two homoisoflavones, oleracones
D (1) and F (2), and a dihydrochalcone, olereacone E (3), which exhibit potent antioxidative effects
(Figure 1).
Figure 1. The structures of oleracones D (1), F (2), and E (3).
2. Materials and Methods
2.1. Chemistry
2.1.1. General Information
Unless noted otherwise, all reactions were performed in dry solvents under anhydrous conditions
and argon atmosphere. The reaction flasks were flame-dried before use, and all solvents for extraction
and chromatography were reagent grade. All reagents were purchased from commercial suppliers
and were used without further purification. TLC (thin-layer chromatography) was conducted for
monitoring reaction progress with 0.25 mm silica gel plates (Merck, Kenilworth, NJ, USA). Silica gel 60
(230–400 mesh, Merck, Kenilworth, NJ, USA) was used for flash column chromatography with the
indicated solvents. 1H and 13C spectra were recorded on a Brucker Analytik ADVANCE digital 500
(500 MHz) (Billerica, MA, USA) or BRUKER AVANCE-800 (800 MHz) (Billerica, MA, USA). 1H-NMR
data are reported as follows: chemical shift, multiplicity (singlet, s; doublet, d; triplet, t; quartet,
q; broad b; and/or multiple resonances), coupling constant in hertz (Hz), and number of protons.
Chemical shifts are stated in ppm (parts per million, δ) downfield from tetramethylsilane (TMS) and
are referenced to the deuterated solvent (CDCl3 and DMSO-d6). IR (infrared) spectra were recorded
on a FT-IR-4200 (JASCO, Tokyo, Japan) spectrometer. Low- and high-resolution mass spectra were
acquired with JMS-700 (JEOL, Tokyo, Japan) equipment.
2.1.2. Experimental Section
(E)-3-(2-(Benzyloxy)phenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one (6). To a solution
of 4,6-dimethoxy-2-hydroxybenzophenone 4 (700 mg, 3.57 mmol) and 2-(benzyloxy)benzaldehyde
5 (1100 mg, 5.35 mmol) in ethyl alcohol (11 mL), KOH (400 mg, 7.14 mmol) was added at room
temperature. After stirring at the same temperature for 48 h, the reaction mixture was concentrated
in vacuo. The reaction mixture was quenched with 1N aqueous solution of hydrochloric acid and
extracted with EtOAc (ethyl acetate). The combined organic layer was washed with saturated sodium
bicarbonate solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. Purification
of the concentrated residue by flash column chromatography (EtOAc/n-Hexane = 1 : 40 to 1 : 10)
afforded 1500 mg (75%) of chalcone 6 as a yellow powder. m.p.: 114–115 ◦C; Rf = 0.25 (EtOAc :
n-Hexane = 1 : 10); 1H NMR (800 MHz, CDCl3) δ 14.37 (s, 1H), 8.17 (d, 1H, J = 15.8 Hz), 8.02 (d, 1H,
J = 15.7 Hz), 7.62 (dd, 1H, J = 1.5, 7.7 Hz), 7.46 (d, 2H, J =7.6 Hz), 7.39-7.37 (m, 2H), 7.33-7.30 (m, 2H),
7.00 (t, 1H, J = 7.5 Hz), 6.87 (d, 1H, J = 8.2 Hz), 6.10 (d, 1H, J = 2.3 Hz), 5.91 (d, 1H, J = 2.3 Hz), 5.20 (s,
2H), 3.83 (s, 3H), 3.72 (s, 3H); 13C NMR (200 MHz, CDCl3) δ 193.3, 168.4, 166.2, 162.6, 157.9, 138.1, 136.9,
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131.4, 129.5, 128.8, 128.5, 128.1, 127.3, 125.1, 121.2, 112.9, 106.6, 93.8, 93.8, 91.3, 70.5, 55.7, 55.7; IR (thin
film, neat) νmax 1620, 1595, 1553, 1452, 1344, 1213, 1107, 984, 816, 760 cm-1; LR-MS (Low-Resolution
Mass Spectroscopy) (FAB+) m/z 391 (M +H+); HR-MS (High-Resolution Mass Spectroscopy) (FAB+)
calculated for C24H23O5 (M + H+) 391.1545; observed 391.1541.
Oleracone E. (3). To a solution of chalcone 6 (500 mg, 1.28 mmol) in ethyl alcohol (10 mL), catalytic
amount of 5% activated palladium on carbon was added at room temperature. After stirring for 48 h
under H2 atmosphere, the reaction mixture was filtered through a pad of Celite and concentrated in
vacuo. Purification of the concentrated residue by flash column chromatography (EtOAc : n-Hexane = 1
: 10 to 1 : 3) afforded 340 mg (88%) of oleracone E (3) as a yellowish powder. The spectral data of 3
were consistent with previous data (Table S1). m.p.: 137–138 ◦C; Rf = 0.20 (EtOAc/n-Hexane = 1:5); 1H
NMR (500 MHz, DMSO-d6) δ 13.63 (brs, 1H), 9.30 (brs, 1H), 7.06 (dd, 1H, J = 1.5, 7.4 Hz), 6.99 (brtd,
1H, J = 1.6, 7.7 Hz), 6.77(dd, 1H, J = 1.0, 8.0 Hz), 6.70 (td, 1H, J = 1.0, 7.4 Hz), 6.11 (d, 1H, J = 2.4 Hz),
6.09 (d, 1H, J = 2.4 Hz), 3.82 (s, 3H), 3.80 (s, 3H), 3.20 (brt, 2H, J = 7.7 Hz), 2.81 (brt, 2H, J = 7.7 Hz); 13C
NMR (200 MHz, DMSO-d6) δ 205.4, 166.1, 166.0, 162.9, 155.5, 130.3, 127.7, 127.5, 119.5, 115.3, 106.0, 94.2,
91.2, 56.4, 56.1, 43.9, 25.5; IR (thin film, neat) νmax 1618, 1578, 1489, 1462, 1418, 1362, 1204, 1109, 999,
829, 758 cm-1; LR-MS (FAB+) m/z 303 (M + H+); HR-MS (FAB+) calculated for C17H19O5 (M + H+)
303.1232; observed 303.1226.
Oleracone F. (2). N,N-Dmethylformamide dimethyl acetal (0.053 mL, 0.40 mmol) was added to a
solution of oleracone E (3) (100 mg, 0.33 mmol) in toluene (5.5 mL) at room temperature. The reaction
mixture was refluxed for 2 h, and then cooled to room temperature. The reaction mixture was
concentrated in vacuo. Purification of the concentrated residue by flash column chromatography
(EtOAc : n-Hexane= 1 : 2) afforded 93 mg (90%) of oleracone F (2) as a yellow powder. The spectral data
of 2 were consistent with previous data (Table S2). m.p.: 224–225 ◦C; Rf = 0.23 (EtOAc/n-Hexane = 1:2);
1H NMR (500 MHz, DMSO-d6) δ 9.46 (s, 1H), 7.88 (s, 1H), 7.07 (dd, 1H, J = 1.5, 7.5 Hz), 7.01 (brtd, 1H,
J = 1.6, 7.7 Hz), 6.78 (dd, 1H, J = 1.0, 8.0 Hz), 6.70 (brtd, 1H, J = 1.1, 7.4 Hz), 6.61 (d, 1H, J = 2.3 Hz), 6.48
(d, 1H, J = 2.3 Hz), 3.86 (s, 3H), 3.81 (s, 3H), 3.52 (s, 2H); 13C NMR (200 MHz, DMSO-d6) δ 175.8, 164.1,
160.9, 160.0, 155.4, 151.9, 130.5, 127.9, 125.7, 123.8, 119.6, 115.6, 108.7, 96.4, 93.3, 56.5, 56.3, 25.6; IR (thin
film, neat) νmax 1643, 1595, 1566, 1454, 1373, 1207, 1152, 1078, 824, 752 cm-1; LR-MS (FAB+) m/z 313
(M + H+); HR-MS (FAB+) calculated for C18H17O5 (M + H+) 313.1076; observed 313.1078.
Oleracone D (1). To a solution of oleracone F (2) (150 mg, 0.48 mmol) in methylene chloride (5 mL),
1.92 mL of BCl3 (1 M solution in CH2Cl2, 1.92 mmol) was slowly added at 0 ◦C. After stirring for
1 h at the same temperature, the reaction mixture was quenched with H2O, diluted with methylene
chloride, stirred for an additional 1 h, and extracted with methylene chloride. The combined organic
layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo.
Purification of the concentrated residue by flash column chromatography (EtOAc : n-Hexane = 1:5)
afforded 114 mg (80%) of oleracone D (1) as a yellowish powder. The spectral data of 1 were consistent
with previous data (Table S3). m.p.: 154–155 ◦C; Rf = 0.31 (EtOAc : n-Hexane = 1 : 5); 1H NMR
(500 MHz, DMSO-d6) δ 12.76 (s, 1H), 9.47 (brs, 1H), 8.06 (s, 1H), 7.08 (dd, 1H, J = 1.4, 7.5 Hz), 7.03 (brtd,
1H, J = 1.6, 7.7 Hz), 6.81 (dd, 1H, J = 0.8, 8.0 Hz), 6.71 (brtd, 1H, J = 1.4, 7.4 Hz), 6.61 (d, 1H, J = 2.3 Hz),
6.38 (d, 1H, J = 2.3 Hz), 3.84 (s, 3H), 3.61 (s, 2H); 13C NMR (200 MHz, DMSO-d6) δ 181.6, 165.6, 161.6,
158.2, 155.4, 155.3, 130.4, 128.0, 125.0, 121.4, 119.5, 115.4, 105.5, 98.4, 92.8, 56.4, 25.0; IR (thin film, neat)
νmax 1647, 1585, 1510, 1435, 1368, 1240, 1163, 1051, 822, 754 cm-1; LR-MS (FAB+) m/z 299 (M + H+);
HR-MS (FAB+) calculated for C17H15O5 (M + H+) 299.0919; observed 299.0915.
2.2. Biology
2.2.1. C. elegans Maintenance
In this paper, we used wild-type N2 nematodes which were acquired from the Caenorhabditis
Genetic Center (CGC; University of Minnesota, Minneapolis, MN, USA). All nematodes were nurtured
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at 20 ◦C on an NGM (Nematode Growth Medium) agar plate with Escherichia coli OP50 as previously
reported [18]
2.2.2. Lifespan Assay
Lifespan assays were carried out under normal culture conditions. Age-synchronized nematodes
were collected by embryo isolation and L1 arrest. The as-obtained L1 stage nematodes were grown
on an NGM plate with or without of (1), (2), and (3). The survival rate of the test nematodes was
determined using a dissecting microscope (SMZ1500, Nikon, Tokyo, Japan). Nematodes that failed to
respond to prodding with the tip of a platinum wire were considered dead. Living nematodes were
transferred to a fresh NGM plate every 2 days.
2.2.3. Statistical Analysis
The results obtained from the lifespan assay were plotted using Kaplan–Meier analysis, and the
statistical significance between each group was analyzed using the log-rank test. The mean lifespan
data were presented as the mean ± standard deviation.
3. Results and Discussion
The retrosynthetic analysis for oleracones is outlined in Scheme 1. Homoisoflavone skeleton
was anticipated to be efficiently prepared via a deoxybenzoin route, one of the most popular
synthetic methods used for the preparation of isoflavonoids [19]. Therefore, homoisoflavone 2
and its O-demethylated analog 1 were planned to be obtained from dihydrochalcone 3. Oleracone
E (3) was anticipated to be prepared via an aldol condensation between commercially available
4,6-dimethoxy-2-hydroxybenzophenone 4 and 2-(benzyloxy)benzaldehyde 5.
Scheme 1. Retrosynthetic analysis of oleracones D (1), F (2), and E (3).
Our synthesis was commenced with an aldol condensation between commercially available
4,6-dimethoxy-2-hydroxybenzophenone 4 and 2-(benzyloxy)benzaldehyde 5 to give chalcone 6
(Scheme 2). Concurrent hydrogenation and hydrogenolysis of the O-benzyl group in chalcone
6 using 5% activated Pd on carbon under H2 atmosphere led to olereacone E (3) in 88% yield.
We envisaged the construction of the homoisoflavone skeleton of 1 and 2 via a selective
intramolecular oxa-Michael addition reaction of an enone moiety by the phenol group at the 2”-position
rather than the 2’-position of intermediate 6, resulting from condensation reaction between 3 and a
formyl reagent. According to our expectation, oleracone F (2) was obtained in high yield (90%) upon
stirring with N,N-dimethylformamide dimethyl acetal [20] in toluene under reflux condition, and
no regioisomeric by-products were observed. The high regioselectivity observed in the reaction was
attributed to the enhanced nucleophilicity of the phenol group at the 2”-position compared to that
at the 2’-position in 3, which can be supported by the electron-withdrawing effect of the carbonyl
group. Finally, selective O-demethylation of 2 using BCl3 afforded oleracone D (1) in high yield (80%).
The spectral data obtained for oleracones D–F (1–3) were consistent with those previously reported
data [16,17].
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Scheme 2. Synthesis of oleracones D (1), F (2), and E (3).
With the oleracones D–F (1–3) in hand, we examined their effects on the longevity of nematodes.
To test whether oleracones exhibit lifespan-extension activity, we performed a lifespan assay using
wild-type N2 nematodes at 20 ◦C, as described previously [21]. As shown in Figure 2A,B, all of the
oleracones tested could prolong the lifespan of the nematodes under standard culture conditions,
although the effectiveness of each compound was somewhat variable. At the maximum concentration
studied (20 μM), treatment with 3 and 2 extended the lifespan of nematodes by 13.8 and 11.8%,
respectively, compared with the control, while the efficacy of 1 (4.3% extension) was inferior to that
of 2 and 3. Interestingly, the longevity effect of 1–3 on nematodes did not show any correlation with
their radical scavenging activities (IC50 values: 11.73, 13.17, and 17.78 μM, respectively) [16,17]. These
results suggest the possibility that modulating aging-related factors may also cooperate with the direct
radical scavenging activity that produces the anti-aging effect. However, detailed information on the
underlying mechanism of the lifespan-extension properties of oleracone 1–3 remains to be defined.
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Figure 2. The longevity effect of oleracone D–F (1–3). (A) The lifespan curves obtained for
compound-treated (20 μM) and untreated wild-type nematodes under normal culture conditions.
(B) The change in lifespan observed for the compound-treated (20 μM) nematodes when compared to
the control. (C) The mean lifespan of compound-treated (5, 10, and 20 μM) and untreated wild-type
nematodes was calculated from the survival curves. The statistical difference between the curves was
analyzed using a log-rank test. * p < 0.05 compared with the vehicle alone. All experiments were
repeated in triplicate.
4. Conclusions
In summary, we concisely synthesized potent antioxidant homoisoflavones, oleracones D (1)
and F (2), from dihydrochalcone olereacone E (3), and investigated their potential lifespan extension
properties. Our results may shed light on the development of isoflavone-based anti-aging medications.
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Featured Application: A quick, green, and simple ultrasound-assisted microextraction was here
developed and validated for a quick and simple evaluation of total phenolic content from almond
oil residues for their valorization as a source of antioxidant compounds.
Abstract: Almond (Prunus dulcis (Mill.) D.A. Webb) is one of the most important nut crops both in terms
of area and production. Over the last few decades, an important part of the beneficial actions for health
associated with their consumption was attributed to the phenolic compounds, mainly accumulated
in almond skin. Interestingly, after cold-pressed oil extraction, most of these antioxidant phenolic
compounds are retained in a skin-enriched by-product, a so-called almond cold-pressed oil residue.
In Morocco, the fifth highest ranking producer in the world, this production generates an important
part of this valuable byproduct. In the present study, using a multivariate Box–Behnken design,
an ultrasound-assisted extraction method of phenolic compounds from Moroccan almond cold-pressed
oil residue was developed and validated. Response surface methodology resulted in the optimal
extraction conditions: the use of aqueous ethanol 53.0% (v/v) as a green solvent, applying an ultrasound
frequency of 27.0 kHz for an extraction duration of 29.4 min. The present ultrasound-assisted extraction
allowed substantial gains in terms of extraction efficiency compared to conventional heat reflux
extraction. Applied to three different local Beldi genotypes growing at three different experimental sites,
the optimal conditions for ultrasound-assisted extraction led to a total phenolic content of 13.86 mg/g
dry weight. HPLC analysis revealed that the main phenolic compounds from this valuable byproduct
were: chlorogenic acid followed by protocatechuic acid, p-hydroxybenzoic acid, and p-coumaric acid.
The accumulation of these phenolic compounds appeared to be more dependent on the genetic
background than on the environmental impact here represented by the three experimental culture
sites. Both in vitro cell free and cellular antioxidant assays were performed, and revealed the great
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potential of these extracts. In particular, correlation analysis provided evidence of the prominent roles
of chlorogenic acid, protocatechuic acid, and p-hydroxybenzoic acid. To summarize, the validated
ultrasound-assisted extraction method presented here is a quick, green, simple and efficient for
the possible valorization of antioxidant phenolic compounds from Moroccan almond cold-pressed
oil residues, making it possible to generate extracts with attractive antioxidant activities for future
nutraceutical and/or cosmetic applications.
Keywords: almond; antioxidant; byproducts; chlorogenic acid; design of experiment; phenolic acids;
ultrasound-assisted extraction
1. Introduction
Consumption of fruits, vegetables, nuts, and seeds has been associated with lower risks of chronic
and degenerative diseases [1–4]. Particularly, given their many beneficial effects on human health,
in recent decades, there has been growing interest in the consumption of nuts as a nutrient-rich food [3].
Produced and consumed worldwide, almond (Prunus dulcis (Mill.) D.A.Webb) is one of the most
popular nuts. It can be consumed in the form of whole nuts, flour, and beverages proposed in the
food industry. A large part of almond health benefits has been ascribed to their lipid profile [3,4].
Almond oil is also a sought-after and attractive component for many cosmetic formulations. Over the
last few decades, the part of the beneficial actions for health, but also of the growing interest for
industrial applications, ascribed to almond phenolics have become increasing [3–5].
The high antioxidant capacity of almond phenolics make it an attractive alternative to synthetic
antioxidants. Synthetic antioxidants were largely used to maintain the oxidative stability of emulsions
and commonly used in food products and pharmaceutical and cosmetic preparations. However,
synthetic antioxidants such as butylated hydroxyanisole (BHA) or butylated hydroxytoluene (BHT)
have adverse health effects, including carcinogenesis [6–8]. Therefore, the use of some of these
synthetic antioxidants is now prohibited for food applications in Japan, Canada, and Europe, and they
have been removed from what is generally recognized as a safe (GRAS) list. The replacement of
these widely criticized synthetic molecules with natural molecules would meet the expectations of
manufacturers and consumers. Therefore, it is now important to identify the natural antioxidants with
a pronounced and safer radical scavenging capacity for consumers. Despite their distinct lipophilicity
profile compared to BHA or BHT, some natural antioxidant phenolics have been shown to be as effective
as these synthetic antioxidants in stabilizing nonpolar systems such as bulk oil or different emulsion
types [9–11], in good agreement with the prediction of polar paradox theory [12]. Interestingly, after
cold-pressed oil extraction, most of the antioxidant phenolic compounds accumulated in the almond
skin are retained in a skin-enriched by-product [3,5,13], making this almond cold-pressed oil residue
(AOR) an attractive raw material for extraction and the valorization of these natural antioxidant
phenolics. In Morocco, the fifth highest ranking producer in the world, almond is the most important
nut crop both in terms of area and production value. Several local genotypes, called Beldi, which means
“from here” as opposed to acclimatized genotypes called Romi (i.e., from elsewhere) [14], are of special
interest [15]. The almond plantations cover a total area of 150,000 ha for an average annual production
estimated at 100,000 tons of unshelled products, of which 9% of this area which provides up to 14%
of the Moroccan almond production is located in Eastern Morocco (Figure 1) [15]. This production
generates an important part of byproducts, in particular of cold pressed almond oil residues. To date,
these by-products of almond oil have been used primarily for animal feed, as litter or for energy
production. However, upgrading to higher value-added sectors would significantly increase the
revenue from this byproduct valuation. With an average growth rate of 5% per year since 2010
and a large profit margin, the cosmetics market is a dynamic industry. However, this sector is very
competitive, with companies facing ever more restrictive environmental regulations (such as REACH in
62
Appl. Sci. 2020 , 10 , 3313
European Union), in addition to consumer pressures that push them to innovate and gradually shift to
more natural products and green production methods. The functional properties of several oleaginous
species of agro-waste, including their antioxidant activity, in relation to their high concentration in
phenolic compounds, have been documented [9,13,16–27]. The application of the biorefinery principle
to the recovery of natural antioxidants from almond by-products as cosmetic active ingredients would
therefore represent a good opportunity for the almond sector compared to their current use.
Figure 1. Parts of almond fruits leading to cold-pressed almond oil and its residue (AOR) used as
byproduct in the present study to extract phenolic compounds.
For optimal valorization of these natural co-products, the development of effective extraction
methods is necessary. In the past, there were many methods developed for the extraction of natural
antioxidants from various natural matrices based on conventional methods such as maceration or
Soxhlet extraction. More recently, green extraction methods including microwave-assisted extraction
or ultrasound-assisted extraction (USAE) have been found to be particularly effective [11,21,28–30].
These green extraction technologies have also aroused great interest for industrial applications, and
USAE is now considered as one of the most efficient energy saving processes in terms of duration,
selectivity, and reproducibility, operating under mid-extraction conditions [28]. It is accepted that the
improvement in extraction efficiency obtained using the USAE is based on both acoustic cavitation and
mechanical effects [28]. Indeed, ultrasound (US) produces an acoustic cavitation effect facilitating the
penetration of the extraction solvent. Therefore, easier release of the intracellular contents of the plant
material is observed through greater agitation of the solvent resulting in increased surface contact
between the solvent and the target compound as well as increased solubility of the target compound in
the solvent of extraction [28].
Here, we report on the development and validation of a USAE method for the extraction of
antioxidant phenolic acids from an enriched skin fraction made up of cold pressed AOR from Bedli
Moroccan genotypes produced in Eastern Morocco (Figure 1).
Recently, Prgomet et al. [13] have also developed a method for comparing the polyphenol fractions
from different almond byproducts including the skin using almond varieties from Portugal, but using
a conventional heat reflux method. An USAE method was developed by Kahlaoui et al. [18] for the
extraction of polyphenols from another almond byproduct: the hulls (the part surrounding the shell
itself surrounded by the thin skin; Figure 1) from Italian and Tunisian varieties. It is thus of special
interest to compare our method optimized using a different genotype, but more importantly either a
green extraction method or a different (by)product. The optimal extraction conditions of this USAE
using ethanol as a solvent were obtained through a multivariate technique (Behnken–Box design)
coupled with response surface methodology (RSM) and then validated according to international
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standards of the association of analytical communities (AOAC). This USAE was applied to investigate
the influence of the genetic and environment on the phenolic contents by considering three different
local Beldi genotypes growing at three different experimental sites. Both in vitro cell free and cellular
antioxidant assays were performed to evaluate the evolution of antioxidant activity of the corresponding
extracts. Finally, correlations linking phytochemical profile and antioxidant activities of the extracts
are presented.
2. Materials and Methods
2.1. Chemicals and Reagents
Extraction solvents (ethanol and water) used in the present study were of analytical grade (Thermo
Scientific, Illkirch, France). Reagents for antioxidant assays as well as standards (chlorogenic acid,
p-coumaric acid, protocatechuic acid and p-hydroxybenzoic acid) were purchased from Merck
(Saint-Quentin Fallavier, France).
2.2. Plant Materials and Culture Conditions
AOR were obtained from Moroccan almonds (local ecotypes Beldi) grown in 3 different pilot
locations in the Eastern Morocco (Sidi Bouhria (SID; 34◦44′13.6” N, 002◦20′15.0” W); Ain Sfa (AIN;
34◦46′42.4” N, 002◦09′28.9” W); Rislane (RIS; 34◦44′59.8” N, 002◦26′44.7” W)) using growing conditions
as previously described by Melhaoui et al. [15]. Almonds were then triturated using an oil screw
press (KOMET DD85G, IBG Monforts Oekotec GmbH & Co. KG, Monchengladbach, Germany)
and the residues were ground to ca. 100–150 μm particles using a blender equipped with rotating
blades (Grindomix GM 200 blender, Retsch France, Eragny, France) used as raw materials for
USAE optimization.
2.3. Ultrasound-Assisted Extraction Method Development
USAE was completed with an ultrasonic bath (USC1200TH, Prolabo, Sion, Switzerland) composed
of a 300 × 240 × 200 mm (inner dimension) tank, with electric power of 400 W corresponding to an
acoustic power of 1 W/cm2 and maximal heating power of 400 W. The variable frequencies of this
device can be selected thanks to a frequency controller, and it also has a temperature regulator as well
as an automatic digital timer. Each sample was placed in 50 mL quartz tubes equipped with a vapor
condenser, and was suspended in 10 mL extraction solvent. A liquid to solid ratio of 10:1 mL/g DW
(dry weight) was used and extraction was performed at 45 ◦C.
For Extraction optimization a Box–Behnken design was used and the resulting response surface
plots drawn with the help of XLSTAT2019 software (Addinsoft, Paris, France). For this purpose,
three variables (aqueous Ethanol (aqEtOH) concentration (X1), US frequency (X2), and extraction
duration (X3)) were studied and coded at three levels (−1, 0 and +1) as described in Table 1:
Table 1. Identity, code unit, coded levels, and actual experimental values of each variable used for




Ethanol concentration (% v/v) 1 X1 0 50 100
US frequency (kHz) X2 0 22.5 45
Extraction duration (min) X3 20 30 40
1 % volume/volume of ethanol (analytical grade) concentration in mixture with ultrapure water (HPLC grade).
The different batches were obtained by using the DOE (design of experiment) function of
XLSTAT 2019 (Addinsoft, Paris, France), which take values of selective variables at different levels
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(Table 2). The experiments were carried out in triplicate. Equation of the model for the extraction of
total phenolics from almond oil residues was calculated using the XLSTAT 2019 DOE analysis tool
(Addinsoft, Paris, France). The corresponding response surface plots were obtained with 3D option of
XLSTAT 2019 (Addinsoft, Paris, France).
Table 2. Results of Box–Behnken experimental design of USAE of TPC from AOR.
Run ID Run Order X1 X2 X3 Experimental TPC (mg/g DW) Predicted TPC (mg/g DW)
Obs1 10 0 +1 −1 7.93 ± 0.14 7.93
Obs2 6 +1 0 −1 6.16 ± 0.22 6.31
Obs3 1 −1 −1 0 5.03 ± 0.11 5.18
Obs4 17 0 0 0 11.33 ± 0.10 11.37
Obs5 15 0 0 0 11.37 ± 0.08 11.37
Obs6 7 −1 0 +1 7.51 ± 0.07 7.35
Obs7 12 0 +1 +1 9.06 ± 0.13 9.23
Obs8 4 +1 +1 0 6.01 ± 0.11 5.86
Obs9 18 0 0 0 11.41 ± 0.12 11.37
Obs10 5 −1 0 −1 5.52 ± 0.05 5.36
Obs11 13 0 0 0 11.32 ± 0.17 11.37
Obs12 2 +1 −1 0 5.54 ± 0.18 5.56
Obs13 8 +1 0 +1 5.18 ± 0.14 5.16
Obs14 9 0 −1 −1 7.69 ± 0.19 7.52
Obs15 11 0 −1 +1 6.88 ± 0.13 6.88
Obs16 16 0 0 0 11.44 ± 0.17 11.37
Obs17 3 −1 +1 0 7.66 ± 0.16 7.64
Obs18 14 0 0 0 11.35 ± 0.15 11.37
Experimental values are means ± RSD of 3 independent replicates.
2.4. Determination of Total Phenolic Content
After extraction, each extract was centrifuged for 15 min at 5000× g (Heraeus Biofuge Stratos,
Thermo Scientific, Illkirch, France) and the resulting supernatant filtered using a syringe filter (0.45 μm,
Merck Millipore, Molsheim, France) prior to analysis.
The total phenolic content (TPC) was determined spectrophotometrically using the Folin–Ciocalteu
reagent (Merck, Saint-Quentin Fallavier, France) and according to the protocol adapted for a microplate
reader described by Abbasi et al. [31]. Briefly, 10 μL of extract were homogenized with 180 μL of a
mixture composed of 4% (w/v) Na2CO3 (prepared in NaOH 0.1 M), 0.02% (w/v) potassium sodium
tartrate tetrahydrate and 0.02% CuSO4. Following a 10-min of incubation at 25 ◦C, 10 μL of the
Folin–Ciocalteu reagent were added, and the homogenized mixture was incubated for 30 min at
25 ◦C. Absorbance was measured at 650 nm with a spectrophotometer (BioTek ELX800 Absorbance
Microplate Reader, BioTek Instruments, Colmar, France). A standard curve (0–40 μg/mL; R2 = 0.998) of
gallic acid (Merck, Saint-Quentin Fallavier, France) was used to express the TPC in mg of gallic acid
equivalents per g DW (mg GAE/g DW).
2.5. Validation Parameters
Method validation was carried out using the recommendations of the association of analytical
communities (AOAC) in terms of precision, repeatability, and recovery as described in detail in
Corbin et al. [21].
For HPLC, 6-point calibration lines were obtained by means of diluted solutions of each authentic
commercial standard (Merck, Saint-Quentin Fallavier, France). Each sample was injected three times,
and arithmetic means were calculated to generate linear regression equations plotting was done by the
peak areas (y) against the injected quantities (x) of each standard. Coefficients of determination (R2)
were used for linearity verification. The limits of detection (LOD) and of quantification (LOQ) was
calculated using signal-to-noise ratios of 3:1 and 10:1, respectively.
65
Appl. Sci. 2020 , 10 , 3313
2.6. HPLC Analysis
After extraction, each extract was centrifuged for 15 min at 3000 rpm and the resulting supernatant
filtered using a syringe filter (0.45 μm, Millipore, Molsheim, France) prior to analysis. Separation
and identification of the main extract constituents was done by HPLC with a Varian system (Varian,
Les Ulis, France) composed of: Prostar 230 pump, Metachem Degasit, Prostar 410 autosampler,
Prostar 335 Photodiode Array Detector (PAD) and driven by Galaxie version 1.9.3.2 software (Varian,
Les Ulis, France). A Purospher RP-18 column (250 × 4.0 mm internal diameter; 5 μm) (Merck Chemicals,
Molsheim, France) was used for the separation performed at a temperature set at 35 ◦C. The mobile
phase was a mixture of: (i) A, which was acidified HPLC grade water with acetic acid (0.2% (v/v)),
and (ii) B, which was HPLC grade methanol. During the separation run, the mobile phase composition
varied according to a nonlinear gradient as follows: 8% B (0 min), 12% B (11 min), 30% B (17 min), 33%
B (28 min), 100% B (30–35 min), and 8% B (36 min) at a flow rate of 1 mL/min. Between each injection,
a 10-min re-equilibration time was applied. The detection of compounds was set at 295 and 325 nm
(corresponding to the λmax of the main compounds). Quantification was done based on assessment of
retention times of commercial standards (Merck, Saint-Quentin Fallavier, France).
2.7. Antioxidant Activities
2.7.1. In Vitro Cell Free DPPH Free Radical Scavenging Assay
The in vitro cell free DPPH (2,2-diphenyl-1-picrylhydrazyl) assay was used to evaluate the free
radical scavenging activity of the samples as described by the microplate protocol of Shah et al. [32].
2.7.2. In Vitro Cell Free ABTS Antioxidant In Vitro Cell Free Assay
ABTS (2,2-azinobis(3-ethylbenzthiazoline-6-sulphonic acid)) in vitro cell free antioxidant activity
of each extract was determined as described by Ullah et al. [33].
2.7.3. Cupric Ion Reducing Antioxidant Capacity (CUPRAC) In Vitro Cell Free Assay
CUPRAC assay was performed in a microplate as described by Drouet et al. [8].
2.7.4. Determination of Membrane Lipid Peroxidation Using Thiobarbituric Acid-Reactive Substances
(TBARS) Assay
An in cellulo antioxidant assay, using yeast cells, based on the measurement of membrane lipid
peroxide, was carried out with the thiobarbituric acid (TBA; Merck, Saint-Quentin Fallavier, France)
method as described by Garros et al. [34].
2.8. Statistical Analysis
Means and standard deviations of three to five independent replicates were used to present
the data. Model analysis (ANOVA) and 3D plots resulting from the combination of variables were
performed using XLSTAT 2019 and R analysis following the manufacturer’s instructions (Addinsoft,
Paris, France). A Student’s t-test was performed for comparative statistical analysis of the impact of the
different cultivation sites (XLSTAT 2019, Addinsoft, Paris, France). Correlation analysis was performed
with Past 3.0 (Øyvind Hammer, Natural History Museum, University of Oslo, Oslo, Norway) using
the Pearson parametric correlation test and visualized using Heatmapper [35]. Principal Component
Analysis (PCA) was performed with Past 3.0 (Øyvind Hammer, Natural History Museum, University
of Oslo, Oslo, Norway). Significant thresholds at p < 0.05 or p < 0.05, <0.01 and <0.001 were used for
all statistical tests and represented by different letters or by *, ** and ***, respectively.
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3. Results and Discussion
3.1. Development of the Ultrasound-Assisted Extraction Using Box–Behnken Design
Multivariate techniques are used very effectively to optimize the extraction method from complex
plant matrices such as food products and by-products [36]. Among the different multivariate techniques,
when three factors are considered, the Behnken–Box design is one of the most effective techniques [36,37].
The Behnken–Box matrix is a spherical and rotating design, which, viewed on a cube, consists of the
central point and the middle of the edges [36,37]. Many parameters can influence the extraction of
phenolic compounds from plant matrices [38], but three parameters are very widely distinguished
when developing an USAE method: the type of solvent used, the frequency of ultrasound applied and
the extraction time [11,21,30].
The choice of solvent is a crucial parameter to define when developing an extraction method.
Various solvents, including methanol, ethanol, or acetone, are regularly used for the extraction of plant
polyphenols [28,39]. Here, given our objective of developing an extraction method in accordance with
green chemistry principles for future nutraceutical and/or cosmeceutical applications of the resulting
extract, EtOH was considered as an extraction solvent. First, EtOH is one of the less toxic solvents
for humans and more respectful of the environment than other organic solvents such as methanol for
example [38,40]. In addition, its extraction capacity can easily be modulated by addition of water,
making it an ideal solvent for the extraction of a wide range of variable polarity polyphenols. Finally,
these two universal solvents (i.e., EtOH and water) are already widely used for various food and/or
cosmetic applications [11,28,30,38,40].
US frequency is a crucial parameter to consider because of its significant impact on the
extraction efficiency. Indeed, this parameter modulates the cavitation effect as well as the diffusion
coefficient of the target compound in the extraction solvent. Consequently, it improves the solubilization
of the compound in the extraction solvent, thus increasing the extraction efficiency [28]. In addition,
increasing US frequency can also lead to a drastic reduction in extraction time, thereby reducing energy
consumption, which is in accordance with the green chemistry principles [41]. However, depending
on the compound and the plant matrix subjected to the extraction, application of high US frequency
can alter the native structure of the compound, which not only decreases the extraction yield, but also
considerably reduces its biological activity, thus negating any valuation interest [30]. Therefore, during
the development of an USAE method, US frequency must be optimized very carefully depending on
the compound, and the plant matrix subjected to the extraction.
Finally, regarding the extraction time, it is important to consider that its increase does not
necessarily lead to any improvement in extraction yield, since, contrarily, a prolonged exposure to US
can lead to the increased degradation of the compound [30]. In addition, in order to reduce the impact
of energy consumption in the green chemistry context, optimizing the extraction time also appears to
be essential [41].
Having these considerations in mind, in order to develop a rapid, green and efficient USAE of
TPC for the valorization of AOR, we therefore considered a Behnken–Box matrix with the following
three parameters: aqEtOH concentration (X1), ultrasound (US) frequency (X2), and extraction duration
(X3) as described in Table 1.
Table 2 presents the experimental and predicted TPC obtained from almond oil residues for the
18 different observations (run ID) corresponding the different USAE conditions of the Behnken–Box
matrix having been determined randomly (run order) after an in silico-assisted procedure generated by
the XL-Stat2019.4.1 software.
Here, the TPC extracted from AOR ranged from: 5.03 mg/g DW (Obs3; obtained after 30 min
extraction in water bath (no US application) using pure water as extraction solvent) to 11.44 mg/g DW
(Obs16; obtained after 30 min at an ultrasonic bath running at a US frequency of 22.5 kHz using 50%
(v/v) aqEtOH as extraction solvent) (Table 2). These results provide a first indication on the interest of
using an ultrasound and on the choice of an extraction solvent. We noted a good repeatability of the
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central point (i.e., Obs4, 5, 9, 11, 16, and 18), with a mean TPC of 11.37 ± 0.05 mg/g DW corresponding
to a relative standard deviation (RSD) of 0.47%, thus highlighting the high reliability of these results.
Given the nature of the starting material used in the present study, this range of TPC is in fairly
good agreement with the data in the literature obtained with almond and/or almond by-products
from California, Portugal, Italia, and Tunisia [3,5,18,42].
A multiple regression analysis was applied to the model of the TPC as a function of the three
different extraction variables. Under the described conditions, the TPC (YTPC, in mg/g DW) as a
function of the three different extraction variables (Table 1) in the form of a polynomial equation was
(Table 3):
YTPC = 11.370 − 0.354X1 + 0.690X2 + 0.166X3 − 3.554X12 − 1.756X22 −
1.724X32 − 0.540X1X2 − 0.743X1X3 + 0.485X2X3
Table 3. Statistical analysis of the regression coefficients of USAE of TPC from AOR.
Source Value SD t P > |t|
Constant 11.370 0.059 193.27 <0.0001 ***
X1 −0.354 0.051 −6.943 0.00012 ***
X2 0.690 0.051 13.543 <0.0001 ***
X3 0.166 0.051 3.253 0.011 **
X12 −3.554 0.069 −51.516 <0.0001 ***
X22 −1.756 0.069 −25.459 <0.0001 ***
X32 −1.724 0.069 −24.988 <0.0001 ***
X1X2 −0.540 0.072 −7.495 <0.0001 ***
X1X3 −0.743 0.072 −10.305 <0.0001 ***
X2X3 0.485 0.072 6.731 0.00015 ***
SD standard deviation; *** significant p < 0.001; ** significant p < 0.01.
The statistical analysis of the regression coefficients confirmed the relevance of our choice in the
extraction variables and their respective levels for the development of the present USAE method if
we refer to the level of significance with which these variables influenced the extraction (Table 3).
The linear coefficients X1 (aqEtOH concentration) and X2 (extraction time) were statistically highly
significant at p < 0.001, with an X1 coefficient being negative (high EtOH concentration reduced TPC)
and X2 being positive (application of US treatment had a positive effect on TPC). An extraction duration
(X3) coefficient was also significant at p < 0.01, but with a coefficient value close to zero indicating that
a prolonged extraction period can lead to poorer extraction yield as a consequence of degradation as
described in the literature [30,41,43]. All the quadratic and interaction coefficients were statistically
highly significant at p < 0.001, but their values negative or close to zero indicated a negative or a lower
impact to the extraction efficient.
The results of the analysis of variance (ANOVA) and model fitting are presented in Table 4.
An elevated F-value (567.558) and low p-value (p < 0.0001) indicated the statistically highly significance
of the model that could predict TPC as a function of the variable values with a great precision. The low
non-significant value obtained for the lack of fit confirmed this trend. The value for the determination
coefficient (R2 = 0.997 (with adjusted value of 0.998) for the model as well as the coefficient value
(CV = 0.976) indicated the precision of the model as well as the adequacy between the model and
experimental values, respectively. The model precision in the prediction of the TPC is further depicted
by the predicted vs. experimental TPC plot presented in Figure S1.
To better understand the complexity of the model, 3D plots representing TPC as a function of the
extraction parameters were drawn (Figure 1).
The calculated, but small, values of the linear coefficients of the second-order polynomial equation
for X2 (US frequency) and X3 (extraction duration), as well as their interaction coefficient X2X3
(US frequency x duration) indicate that a controlled increase of these parameters will have a global
favorable consequences for the TPC extracted from AOR. However, their small values, in association
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with the negative values calculated for their quadratic coefficients (X22 and X32, respectively), but also
of all the coefficient involving aqEtOH concentration (i.e., linear coefficient X1, quadratic coefficient X12,
and the interaction coefficients X1X2 and X1X3), indicate that the TPC extracted from AOR according
to these extraction parameters will reach a maximum value before decreasing for high values of
these parameters. These considerations were clearly observed on the 3D plots (Figure 2). For each
3D plot, a first tendency was observed with a higher TPC extracted from AOR with increased aqEtOH
concentration, application of US as well as prolonged extraction time. However, after reaching a
maximal value for TPC extracted from AOR, a further increase in the aqEtOH concentrations as well as
application of higher US frequency and/or prolonged extraction duration resulted in a pronounced
drop of the TPC (Figure 2).
Table 4. ANOVA of the predicted model used for USAE of TPC from almond residues.
Source Sum of Square df Mean of Square F-Value p-Value
Model 106.071 9 11.786 567.558 <0.0001 ***
Lack of fit 0.166 8 0.021 - -
Residual 0.166 8 0.021 - -
Pure Error 0.000 0 - - -




df: degree of freedom; Cor. Total: corrected total; R2: determination coefficient; R2 adj: adjusted R2; CV variation
coefficient value; *** significant p < 0.001.
Figure 2. Predicted surface response plots of the TPC extraction yield (in mg/g DW) as a function of
aqEtOH concentration and US frequency, aqEtOH concentration and extraction duration, as well as US
frequency and extraction duration.
In various concentrations in mixture with water, aqEtOH solutions have been widely used as
eco-friendly solvents to extract a wide range of polyphenols from plant matrices [11,21,30,38,40]
including various almond products [13,18,44]. However, to obtain optimal results, the concentration of
aqEtOH must be adapted because it is very dependent on the polyphenolic compound(s) as well as on
the plant matrix considered [28,38,40]. Alongside, it is clearly established that, during USAE, high US
frequency associated with extended extraction duration could reveal destructive through the induction
of polyphenols oxidation, in particular in the presence of water [21,28,30]. Consequently, if these
parameters are not finely controlled (optimized), this can lead to a sharp reduction in the extraction
yield, quantitatively but also qualitatively with a drastic decay observed in the biological interest of
the sample extract [11,29,30]. Using the Box–Behnken matrix for optimizing these parameters and
using the resulting adjusted second order polynomial equation, optimal conditions for the extraction
of phenolics from our Moroccan AOR were: 53.0% (v/v) aqEtOH as solvent, 27.0 kHz for the US
frequency and an extraction duration of 29.4 min. Using these optimal conditions resulted in a TPC
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of 11.63 ± 0.15 mg/g DW (Figure 2). The optimal aqEtOH concentration obtained here is in line with
results obtained for almond phenolics extraction very recently described [13,18]), although the starting
byproduct material or the extraction method used were different from our study.
The present method was then validated in respect with the AOAC standards. According to these
standards, the parameter values of this validation procedure were adequate in terms of interday and
intraday precision, but also repeatability and stability (Table 5). Indeed, the RSDs of both intraday and
interday precisions were of 0.05 and 0.28%, respectively. The RSDs of the repeatability corresponding
to five different extraction repeats of five samples from the same batch was of 1.30%. The recovery
rates at three different addition levels of chlorogenic acid in the sample before extraction were between
100.26 and 101.13% reflect the accuracy of the present method.
Table 5. Validation parameters of the developed method for quantifying TPC from almond residues.
Precision (% RSD) Repeatability (% RSD) Recovery 1 (%)
Intraday Interday 0.5 1.0 2.0
0.05 0.28 1.30 100.26 ± 0.07 100.90 ± 0.80 101.13 ± 0.50
1 performed at 3 concentration level additions of gallic acid prior to extraction using optimal conditions with US
(i.e., 0.5, 1.0, and 2.0 mg/g DW additions). Means± SD standard deviations or % RSD of three independent extractions.
The efficiency of the present USAE method was compared with conventional heat reflux extraction
(HRE) using the same conditions, in particular an aqEtOH concentration (53.0% (v/v) and an extraction
time of 29.4 min. The difference between USAE and HRE being the application of an US frequency
of 27 kHz for the present optimized UASE extraction procedure, while no US was applied for the
HRE protocol operating in a classical water bath. The comparison of these extractions is depicted in
Figure 2. A significant gain of 30% in TPC extracted from AOR was observed with the optimized
USAE (11.63 ± 0.15 mg/g DW) as compared to conventional HRE (8.96 ± 0.21 mg/g DW) (Figure 3).
Increasing the extraction time for the HRE to one hour did not achieve performance levels similar to
those obtained with USAE (9.24 ± 0.37 mg/g DW). Consequently, it appears that the USAE method
developed in the present study is of real interest according to the principles of green chemistry [45],
not only in terms of the use of a renewable green solvent, but also in terms of reducing the energy
consumption. We hypothesize that this efficiency could be partly explained by the hot spot hypothesis
indicating that the cavitation bubbles, after their collapse, act as a microreactor locally generating,
in the surrounding solvent, a high temperature environment and pressure leading to more efficient





















11.63 ± 0.15 8.96 ± 0.21
Figure 3. TPC extracted from AOR using the optimal USAE (with US) conditions and comparison
with conventional heat reflux method (HRE; without US). Means ± SD standard deviations of three
independent extractions; *** significant at p < 0.001.
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3.2. Application to the Analysis of Samples from Different Cultivation Sites
The present USAE was then applied to the quantification of phenolics in samples from three
different local Beldi genotypes cultivated at three different locations in Eastern Morocco. In addition
to the TPC, the concentration in protocatechuic acid, p-hydroxybenzoic acid, chlorogenic acid,
and p-coumaric acid, reported as the main phenolic acids possibly accumulated in almond
by-products [3,5,13,18,42,44,46], were also determined by HPLC after comparison with authentic
commercial standards. Figure 4a shows a typical HPLC chromatogram, recorded at 325 nm, of the
AOR extract obtained after USAE and showing the sepration of these four important phenolic acids:
protocatechuic acid (1), p-hydroxybenzoic acid (2), chlorogenic acid (3), and p-coumaric acid (4)
(Figure 4b).
Figure 4. (a) Representative HPLC chromatogram (here with detection set at 325 nm) of an extract
prepared by USAE of AOR (Beldi cultivar) grown in the Ain Sfa (34◦46′42.4” N, 002◦09′28.9” W)
pilot location in the eastern Morocco; (b) structures and their corresponding numbers on the HPLC
chromatogram of the main phenolic compounds considered in this study: protocatechuic acid (1),
p-hydroxybenzoic acid (2), chlorogenic acid (3), and p-coumaric acid (4).
In order to quantify these four phenolic compounds in different samples, 6-points calibration curves
of the peak areas (y) against the injected amounts (x) of protocatechuic acid and p-hydroxybenzoic acid
at 295 nm and chlorogenic acid and p-coumaric acid at 325 nm were obtained with a linearity over wide
ranges from 0.5 to 200 mg/L of injected solutions and R2 greater than 0.999 (Table 6). The LODs ranged
from 0.12 to 0.22 mg/mL, and LOQ from 0.38 to 0.73 mg/mL, for protocatechuic acid and chlorogenic
acid, respectively (Table 6).
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Table 6. Quantification parameters of the HPLC method used to quantity protocatechuic acid,













Protocatechuic acid 23.69 295 0.5–200 y = 3.429 x + 0.814 0.9991 0.12 0.38
p-Hydroxybenzoic acid 28.46 295 0.5–200 y = 3.018 + 0.732 0.9993 0.21 0.68
Chlorogenic acid 31.02 325 0.5–200 y = 5.041x + 0.324 0.9997 0.22 0.73
p-Coumaric acid 33.07 325 0.5–200 y = 7.561x + 0.623 0.9992 0.14 0.47
Applied to the quantification of TPC, protocatechuic acid, p-hydroxybenzoic acid, chlorogenic
acid and p-coumaric acid in AOR resulting from samples of three different native Beldi genotypes (#1 to
#3) cultivated at three different pilot locations in the Eastern Morocco (Sidi Bouhria (SID); Ain Sfa (AIN);
Rislane (RIS)), the results are presented in Table 7.
Table 7. Variations in TPC, and protocatechuic acid, p-hydroxybenzoic acid, chlorogenic acid and
p-coumaric acid contents in AOR from samples of three different native Beldi genotypes produced at












SID#1 9.35 ± 0.63 bcd 1.33 ± 0.10 de 0.78 ± 0.02 d 5.53 ± 0.13 e 0.26 ± 0.05 ab
SID#2 11.78 ± 1.58 ab 1.84 ± 0.07 ab 1.02 ± 0.06 b 7.02 ± 0.19 bc 0.29 ± 0.07 ab
SID#3 11.79 ± 1.29 ab 1.75 ± 0.09 b 0.98 ± 0.02 b 6.97 ± 0.04 b 0.29 ± 0.06 ab
AIN#1 8.87 ± 0.31 d 1.29 ± 0.06 e 0.75 ± 0.03 d 5.29 ± 0.12 e 0.21 ± 0.04 b
AIN#2 11.29 ± 1.24 ab 1.66 ± 0.10 bc 0.95 ± 0.05 bc 6.69 ± 0.06 c 0.28 ± 0.05 ab
AIN#3 13.86 ± 0.91 a 2.03 ± 0.07 a 1.13 ± 0.02 a 8.14 ± 0.10 a 0.26 ± 0.20 a
RIS#1 9.34 ± 0.27 cd 1.36 ± 0.09 de 0.75 ± 0.04 d 5.34 ± 0.14 e 0.22 ± 0.03 b
RIS#2 10.69 ± 0.73 bc 1.51 ± 0.05 cd 0.87 ± 0.06 c 6.34 ± 0.05 d 0.29 ± 0.02 a
RIS#3 11.97 ± 1.51 ab 1.76 ± 0.02 b 1.00 ± 0.10 bc 7.12 ± 0.08 b 0.30 ± 0.02 a
Samples were AOR from three different native Beldi genotypes (#1 to #3) cultivated at three different pilot locations
in the Eastern Morocco: Sidi Bouhria (SID; 34◦44′13.6” N, 002◦20′15.0” W); Ain Sfa (AIN; 34◦46′42.4” N, 002◦09′28.9”
W); Rislane (RIS; 34◦44′59.8” N, 002◦26′44.7” W). Values are means ± SD of three independent replicates. Different
letters represent significant differences between the various extraction conditions (p < 0.05).
TPC ranged from 8.87 to 13.86 mg/g DW for extracts from samples AIN#1 and AIN#3, respectively;
sample from genotype #3 cultivated at Ain Sfa being 56.25% richer in TPC than genotype #1 cultivated
at the same location. The four quantified phenolic acids occurred for approximately 80% of the TPC.
In decreasing contents: (1) chlorogenic acid was the main phenolic accumulated in the sample extracts
with contents ranging from 5.29 ± 0.12 to 8.14 ± 0.10 mg/g DW for extracts from samples AIN#1 and
AIN#3, respectively (sample from genotype #3 cultivated at Ain Sfa being 53.87% richer in chlorogenic
acid than genotype #1 cultivated at the same location); (2) protocatechuic acid content ranged
from 1.29 ± 0.06 to 2.03 ± 0.07 mg/g DW for extracts from samples AIN#1 and AIN#3, respectively
(sample from genotype #3 cultivated at Ain Sfa being 57.36% richer in protocatechuic acid than
genotype #1 cultivated at the same location, corresponding to the highest observed variation range);
(3) p-hydroxybenzoic acid content ranged from 0.75 ± 0.03 to 1.13 ± 0.02 mg/g DW for extracts from
samples AIN#1 and RIS#1 for the lowest content vs. sample AIN#3 for the highest content (sample
from genotype #3 cultivated at Ain Sfa being 50.60% richer in p-hydroxybenzoic acid than genotype
#1 cultivated both at Ain Sfa and Rislane); (4) p-coumaric acid content ranged from 0.21 ± 0.04 to
0.30 ± 0.02 mg/g DW for extracts from samples AIN#1 and AIN#3, respectively (sample from genotype
#3 cultivated at Rislane being 42.85% richer in p-coumaric acid than genotype #1 cultivated at Ain
Sfa, corresponding to the lowest observed variation range). The concentrations determined here for
each phenolic compound were in the range of variations observed by Kahlaoui et al. [18] for different
varieties of almond byproducts from Italia and Tunisia. Extraction of phenolic compounds from a
variety of oilcakes such as hemp, canola, linseed, black cumin, sesame, fennel, sunflower, rapeseed,
camelina, or milk thistle has been reported [9,11,16,17,20–22,24–27]. The TPC obtained from AOR
using the present USAE method is at the top of the range compared to these other sources. Chlorogenic
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acid content has been reported to be high in sunflower oilcakes where its presence is problematic for
the valorization of its derived protein meal by-product [26]. The other phenolic acids from AOR have
been extracted from various oilcakes, such as flax, canola, and black cumin seedcakes for p-coumaric
acid [9,20,21,24], black cumin, and camelina for p-hydroxybenzoic acid [9], while protocatechuic acid
and p-hydroxybenzoic acid have been reported in camelina by-products [25]. Note that other types
of phenolics such as lignans and or flavonoids in flax, sesame, and milk thistle seedcakes have been
reported [16,21–24]. Interestingly, synergistic interactions between phenolic compounds could occur at
concentrations found in nature for antioxidant activity [47]. Antagonism have been also described [47].
Therefore, the different compositions, but also the concentrations observed in different oilseed cakes,
could result in different synergistic and/or antagonistic interactions towards their antioxidant capacity.
This hypothesis is going to deserve future studies. However, it is also important to consider that
these concentrations are subject to change as a result of both genetic and environmental influences as
observed in milk thistle, flax, sesame, but also in some almond cultivars [34,48,49].
Indeed, it is generally accepted that the genetic background, but also the environmental conditions,
such as the location (i.e., soil conditions) or the climate, could have a great influence on the accumulation
of phenolic compounds [3,18,34,42,46,50]. The present preliminary results obtained from three native
genotypes cultivated on the same year at three different location sites from Eastern Morocco suggested a
prominent influence of genetic over environment, since the impact of the genotype was more important
than the influence of the cultivation site. Indeed, for each considered cultivation sites, the genotype
#1 accumulated more phenolic compounds than the genotype #3, whereas both the highest and the
lowest accumulation were observed on the same location (i.e., Ain Sfa experimental site). Analyses
of the variance (ANOVA) confirmed this absence of any significant influence of the cultivation site.
Future works will be conducted with more genotypes as well as more experimental sites over
several cultivation years to confirm or infirm this trend. However, the prominent influence of
genetic background on the accumulation of phenolic compounds in almonds was reported by several
authors [3,18,42,46], whereas the influence of environmental conditions on the same genotype was
less studied. Bolling et al. [42] reported that the cultivation season influenced less polyphenolic
accumulation than the genotype. The influence of cultivation site of the same genotype will deserve
further works.
An improvement in the quantity of phenolic compounds produced in the future may also
be envisaged, in the future, by combining this USAE with base or acid hydrolysis to release the
wall-bound phenolics or extract further antioxidant compounds from lignin. A gain of 30% in
chlorogenic acid content was reported in sunflower seed cakes after the release of wall-bound phenolics.
Nonetheless, it has been stated that coupling US to base and/or acid extraction is highly destructive for
some forms of phenolic compounds [22]. The use of cell wall degrading enzymes such as cellulase
could be an alternative to destructive chemical hydrolysis [24]. USAE coupled with cellulase hydrolysis
of phenolic compounds have been already reported [51]. Future works will be dedicated to exploring
this possibility.
3.3. Determination of the Antioxidant Potential of the Extracts and Correlation Analysis
Our next goal was to ensure that the potential biological activities is retained during the
USAE procedure. For this, we then determined the antioxidant potential of these nine characterized
sample extracts from AOR by using both (1) in vitro cell free assays based on the chemistry of the
antioxidant reaction with different mechanisms—either proton transfer or electron transfer based assays,
as well as (2) in cellulo using eukaryotic yeast cells subjected to oxidative stress induced by UV either in
the presence and absence of the extracts to have an idea of their cellular antioxidant potential. Indeed,
if they were preserved, this antioxidant biological activity would be of such a nature as to be of interest
for both future nutraceutical and/or cosmetic applications of these AOR extracts.
The protective antioxidant action developed by plant extracts can be influenced by many
internal and external factors impacting their phytochemical compositions such as genetics (the use
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of different genotypes in our case) but also the environment (the use of different culture sites in
our case) [3,18,34,42,46,50]. Furthermore, their antioxidant activity is generally based on complex
mechanisms, which, in order to shorten, depending on the nature of the compounds present in
the extract, can be based in particular on radical scavenging mechanisms. Here, to get an idea relating
both to the antioxidant capacity but also to explore the possible mechanisms involved depending
on the composition of the extract, we used three different in vitro cell-free assays: the DPPH, ABTS,
and CUPRAC assays. These tests are based on different reaction mechanisms and could provide us
a raw idea of the chemistry involved in the radical scavenging activity of the extract. Based on the
chemical reaction involved, these in vitro cell free antioxidant assays can be roughly divided into
different categories, with an ABTS assay based on a hydrogen atom transfer reaction (HAT), a CUPRAC
assay based on an electron transfer reaction (ET), and the DPPH assay being considered as a mixed
assay [52,53]. The results of these antioxidant assays expressed in μM of Trolox equivalent antioxidant
capacity (TEAC) per gram DW for the nine extracts obtained after USAE of AOR are presented in
Table 8.
Table 8. Variations in in vitro cell free (ABTS, DPPH and CUPRAC) and cellular (TBARS) antioxidant
potential of extracts obtained from USAE of AOR from three different native Beldi genotypes produced
at three different pilot locations in Eastern Morocco.
Sample ID
ABTS
(μM TEAC/g DW 1)
DPPH
(μM TEAC/g DW 1)
CUPRAC
(μM TEAC/g DW 1)
TBARS
(% inhibition)
SID#1 233.10 ± 12.52 d 323.51 ± 19.12 a 198.07 ± 22.97 ab 51.81 ± 1.13 c
SID#2 361.81 ± 14.48 b 347.40 ± 7.73 a 141.04 ± 2.16 c 66.95 ± 1.74 a
SID#3 366.49 ± 12.97 b 341.17 ± 5.49 ab 129.69 ± 0.32 d 58.73 ± 1.18 b
AIN#1 216.94 ± 12.32 d 275.84 ± 34.88 b 205.92 ± 17.11 a 50.62 ± 2.46 c
AIN#2 276.37 ± 13.12 c 326.88 ± 30.16 ab 164.79 ± 14.02 b 51.81 ± 1.45 c
AIN#3 401.52 ± 11.44 a 357.33 ± 24.24 a 178.73 ± 19.10 ab 69.12 ± 0.34 a
RIS#1 238.07 ± 15.86 cd 319.73 ± 14.74 b 160.93 ± 13.74 bc 53.13 ± 1.01 c
RIS#2 244.91 ± 12.02 cd 315.60 ± 7.43 b 143.76 ± 5.24 bc 52.63 ± 1.65 c
RIS#3 391.29 ± 9.64 ab 351.07 ± 2.89 a 173.47 ± 26.29 abc 66.85 ± 2.57 a
1 TEAC: Trolox equivalent antioxidant capacity (TEAC); Samples were AOR from three different native Beldi
genotypes (#1 to #3) cultivated at three different pilot locations in the Eastern Morocco: Sidi Bouhria (SID); Ain Sfa
(AIN); Rislane (RIS). Values are means ± SD of 3 independent replicates. Different letters represent significant
differences between the various extraction conditions (p < 0.05).
Antioxidant activity ranged from 216.94 ± 12.32 to 401.52 ± 11.44 μM TEAC/g DW for ABTS assay,
and from 275.84 ± 34.88 to 357.33 ± 24.24 μM TEAC/g DW using a DPPH assay. For these two in vitro
cell free antioxidant assays, the AOR extract from the genotype #3 produced at Ain Sfa showed the
highest antioxidant capacity, whereas the extract obtained from the genotype #1 produced at the
same location displayed the lowest antioxidant values. On the contrary, results for CUPRAC assay,
ranging from 129.69 ± 0.32 to 205.92 ± 17.11 μM TEAC/g DW, showed that this genotype #1 produced at
Ain Sfa possessed the highest antioxidant capacity as compared to the genotype #3 from Sidi Bouhria.
Although interesting from a strictly predictive point of view based on chemical reactions,
these in vitro tests do not necessarily have a great similarity with in vivo systems. The validity of
these antioxidant data must therefore be considered as limited to an interpretation within the meaning
of the chemical reactivity with respect to the considered radicals generated in vitro, and have to
be confirmed in vivo. In order to have an improved understanding and better reflect the in vivo
situation, the antioxidant activity of these nine extracts has also been studied further for their capacity
to inhibit the lipid peroxidation membrane generated by oxidative stress induced by UV-C in yeast cells.
Yeast cells represent an excellent model for assessing antioxidant capacity in vivo in the context of
cellular oxidative stress [54]. It is indeed an attractive and reliable eukaryotic model, whose defense
and adaptation mechanisms to oxidative stress are well known and can be extrapolated to human cells
presenting mechanisms certainly more complex but well conserved with this model [55,56]. Here,
measured in vivo anti-lipoperoxidation activity (inhibition of malondialdehyde (MDA) formation),
determined using the TBARS assay, ranged from 50.62 ± 2.46 to 69.12 ± 0.34%. Therefore, this in
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vivo antioxidant evaluation assay confirmed the trend observed with the HAT-based in vitro assay,
and confirmed that the AOR extract from the genotype #3 produced at Ain Sfa showed the highest
antioxidant capacity, particularly as compared to extracts obtained from the genotype #1 produced at
the same location.
As shown in Figure 5, higher antioxidant capacity measured with HAT-based antioxidant assay
appeared systematically associated with a higher accumulation of phenolics, whereas association with
the ET-based antioxidant assay (i.e., CUPRAC) appeared more complex and not directly linked to the
accumulation of theses phenolics (Figure 5a).
 
Figure 5. (a) hierarchical clustering analysis (HCA) showing the relation between the phytochemical
composition and antioxidant activity of each extracts from AOR of Eastern Morocco obtained by USAE;
(b) principal component analysis (PCA) showing the discrimination of the different extracts from AOR
of Eastern Morocco obtained by USAE.
Principal component analysis was performed to further discriminate these nine samples (Figure 5b).
The resulting biplot representation accounts for 92.64% (F1 + F2) of the initial variability of the data as
shown in Figure 4b. The discrimination occurs mainly in the first dimension (PC1) which explains
85.76% of the initial variability. The loading plots (F) confirmed the strong link between phytochemical
composition, in particular the presence of the phenolics, and the HAT-based as well as cellular
antioxidant capacity.
In order to link the antioxidant capacity to the presence of a particular phytochemical, a Pearson
correlation analysis was applied (Figure 6).
This analysis provided evidence of the strong and highly significant correlation between both
HAT-based in vitro assays as well as cellular antioxidant assay and TPC of the extract, in particular with
the presence of chlorogenic acid, protocatechuic acid, and p-hydroxybenzoic acid (Figure 6, Table S1).
The presence of p-coumaric acid was significantly correlated with a DPPH assay only. On the contrary,
none of these phytochemicals, here analyzed, were significantly correlated with the in vitro ET-based
antioxidant CUPRAC assay.
75
Appl. Sci. 2020 , 10 , 3313
Figure 6. Pearson correlation analysis (PCC) of the relation between the main phytochemicals
(protocatechuic acid, p-hydroxybenzoic acid, chlorogenic acid and p-coumaric acid) from AOR extracts
obtained after USAE and the different antioxidant assays (ABTS, DPPH, CUPRAC and TBARS).
*** significant p < 0.001; ** significant p < 0.01; * significant p < 0.05; actual PCC values are indicated in
Supplementary Materials Table S1.
Altogether, these results showed a higher antioxidant activity, expressed in μM TEAC/g DW,
determined with the ABTS and DPPH assays as compared to the CUPRAC assay. Therefore, these results
suggested the prominence of the HAT- over the ET-based mechanism for the antioxidant action of
these extracts. In good agreement, several authors have reported an antioxidant activity of extracts from
various almond products based on HAT mechanism [18,42,44,46]. Similarly, a higher relation between
HAT assay and phenolic acids as compared to flavonoids have been previously reported [52,57].
This observation is also in line with the results of Liang and Kitts [58] that reported a relatively stronger
scavenging capacity of radicals generated by the ABTS and DPPH assays for chlorogenic acid, the main
phenolic acid of our AOR extracts, and its derivatives. The authors attributed this observation to the
available hydroxyl groups of these compounds. The presence of flavonoids has been also reported
in almond products [13,18,42,44,46]. Here, we cannot exclude the presence of flavonoids potentially
linked to the ET-based antioxidant activity evidenced by the CUPRAC assay. Prgomet et al. [13]) have
reported in the presence of flavonoids in almond skin (i.e., isorhamnetin derivatives). Future works
will be conducted to study in detail the flavonoid fraction of our AOR extracts. The cellular antioxidant
assay using yeast further confirmed the interest of this system to study natural antioxidant from
plant extracts [34,52] as also previously reported for other natural antioxidants such as thiamine
and/or melatonin [55,56]. Natural antioxidants have aroused increasing interest over the past decade
due to their possible use as an alternative to potentially dangerous synthetic antioxidants such as
butylated hydroxyanisole (BHA) or butylated hydroxytoluene (BHT) in various food or cosmetic
formulations [6–8]. Some natural antioxidant phenolics have already been shown to be as efficient
in stabilizing nonpolar systems such as bulk oil or various types of emulsions as these synthetic
antioxidants [7,9–11]. These preliminary results indicate a potential use as natural antioxidants of our
AOR extracts generated by the present validated USAE.
4. Conclusions
P. dulcis or the so-called almond is a rich source of antioxidant phenolic compounds that
are retained, after almond cold-pressed oil extraction, in a skin-enriched by-product which, thus,
represent an attractive starting material for their extraction. As natural antioxidants, these phenolic
compounds’ almond attracted much attention as alternatives to synthetic antioxidants in foods,
pharmaceutical, and cosmetic preparations. Here, using a multivariate Box–Behnken design coupled
with surface response methodology, we proposed an optimized and validated USAE of these phenolic
compounds from cold-pressed AOR. Optimal conditions for USAE were: aqEtOH 53.0% (v/v) as
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green solvent, US frequency 27.0 kHz and extraction duration 29.4 min. Following its optimization,
the present USAE method was validated according to international standards to ensure its precision and
accuracy in the quantitation of total phenolic content. The efficiency of the present USAE has allowed
substantial gains in terms of extraction efficiency compared to conventional heat reflux extraction—in
particular by a strong reduction in extraction time, which is of particular interest in the context of green
chemistry in terms of reduction of energy consumption, together with the use of a green extraction
solvent. The application of this method already makes it possible to suggest a higher impact of the
genetic background than of the environment on three genotypes cultivated on three experimental
sites. This method therefore opens the door to more complete studies on this subject. Finally, both
in vitro cell free and cellular antioxidant assays revealed the great potential of valorization of these
extracts as a source of natural antioxidants. To summarize, the present extraction method allows a
quick, green, simple, and efficient validated USAE for the possible valorization of antioxidant phenolic
compounds from Moroccan almond cold-pressed oil residues, making it possible to generate extracts
with attractive antioxidant activities for future nutraceutical and/or cosmetic applications.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/10/9/3313/s1,
Figure S1: Biplot representation of the linear relation between predicted vs. measured TPC in the 18 Box–Behnken
design sample extracts; Figure S2: Loading scores of the first and second axis of the principal component analysis;
Table S1: Actual values for PCC (Pearson Correlation Coefficient) showing the relation between the different
phytochemicals and antioxidant assays.
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Tenore, G.C.; Süntar, İ. Almonds (Prunus Dulcis Mill. DA Webb): A Source of Nutrients and Health-Promoting
Compounds. Nutrients 2020, 12, 672. [CrossRef]
5. Prgomet, I.; Gonçalves, B.; Domínguez-Perles, R.; Pascual-Seva, N.; Barros, A.I. Valorization challenges to
almond residues: Phytochemical composition and functional application. Molecules 2017, 22, 1774. [CrossRef]
6. Williams, G.M.; Iatropoulos, M.J.; Whysner, J. Safety Assessment of Butylated Hydroxyanisole and Butylated
Hydroxytoluene as Antioxidant Food Additives. Food Chem. Toxicol. 1999, 37, 1027–1038. [CrossRef]
7. Hano, C.; Corbin, C.; Drouet, S.; Quéro, A.; Rombaut, N.; Savoire, R.; Molinié, R.; Thomasset, B.; Mesnard, F.;
Lainé, E. The lignan (+)-secoisolariciresinol extracted from flax hulls is an effective protectant of linseed oil
and its emulsion against oxidative damage. Eur. J. Lipid Sci. Technol. 2017, 119, 1600219. [CrossRef]
77
Appl. Sci. 2020 , 10 , 3313
8. Drouet, S.; Doussot, J.; Garros, L.; Mathiron, D.; Bassard, S.; Favre-Réguillon, A.; Molinié, R.; Lainé, É.;
Hano, C. Selective Synthesis of 3-O-Palmitoyl-Silybin, a New-to-Nature Flavonolignan with Increased
Protective Action against Oxidative Damages in Lipophilic Media. Molecules 2018, 23, 2594. [CrossRef]
9. Mariod, A.A.; Ibrahim, R.M.; Ismail, M.; Ismail, N. Antioxidant activity and phenolic content of phenolic rich
fractions obtained from black cumin (Nigella sativa) seedcake. Food Chem. 2009, 116, 306–312. [CrossRef]
10. Aditya, N.P.; Hamilton, I.E.; Norton, I.T. Amorphous nano-curcumin stabilized oil in water emulsion: Physico
chemical characterization. Food Chem. 2017, 224, 191–200. [CrossRef]
11. Drouet, S.; Leclerc, E.A.; Garros, L.; Tungmunnithum, D.; Kabra, A.; Abbasi, B.H.; Lainé, É.; Hano, C. A Green
Ultrasound-Assisted Extraction Optimization of the Natural Antioxidant and Anti-Aging Flavonolignans
from Milk Thistle Silybum marianum (L.) Gaertn. Fruits for Cosmetic Applications. Antioxidants 2019, 8, 304.
[CrossRef] [PubMed]
12. Porter, W.L.; Black, E.D.; Drolet, A.M. Use of polyamide oxidative fluorescence test on lipid emulsions:
Contrast in relative effectiveness of antioxidants in bulk versus dispersed systems. J. Agric. Food Chem. 1989,
37, 615–624. [CrossRef]
13. Prgomet, I.; Gonçalves, B.; Domínguez-Perles, R.; Pascual-Seva, N.; Barros, A.I. A Box-Behnken Design
for Optimal Extraction of Phenolics from Almond By-products. Food Anal. Methods 2019, 12, 2009–2024.
[CrossRef]
14. Delplancke, M.; Aumeeruddy-Thomas, Y. Des semis et des clones. Rev. D’ethnoécologie 2017, 27. [CrossRef]
15. Melhaoui, R.; Fauconnier, M.-L.; Sindic, M.; Addi, M.; Abid, M.; Mihamou, A.; Serghini-Caid, H.; Elamrani, A.
Tocopherol Content of Almond Oils. Commun. Appl. Biol. Sci. 2018, 83, 75–77.
16. Sarkis, J.R.; Michel, I.; Tessaro, I.C.; Marczak, L.D.F. Optimization of phenolics extraction from sesame seed
cake. Sep. Purif. Technol. 2014, 122, 506–514. [CrossRef]
17. Wang, F.; Hu, J.-H.; Guo, C.; Liu, C.-Z. Enhanced laccase production by Trametes versicolor using corn steep
liquor as both nitrogen source and inducer. Bioresour. Technol. 2014, 166, 602–605. [CrossRef]
18. Kahlaoui, M.; Borotto Dalla Vecchia, S.; Giovine, F.; Ben Haj Kbaier, H.; Bouzouita, N.; Barbosa Pereira, L.;
Zeppa, G. Characterization of Polyphenolic Compounds Extracted from Different Varieties of Almond Hulls
(Prunus dulcis L.). Antioxidants 2019, 8, 647. [CrossRef]
19. Melhaoui, R.; Fauconnier, M.-L.; Sindic, M.; Addi, M.; Abid, M.; Mihamou, A.; Serghini-Caid, H.; Elamrani, A.
Tocopherol content of almond oils produced in eastern Morocco. In Proceedings of the 23rd National
Symposium for Applied Biological Sciences (NSABS), Brussels, Belgium, 8 February 2018; pp. 75–77.
20. Teh, S.-S.; Bekhit, A.E.-D.; Birch, J. Antioxidative polyphenols from defatted oilseed cakes: Effect of solvents.
Antioxidants 2014, 3, 67–80. [CrossRef]
21. Corbin, C.; Fidel, T.; Leclerc, E.A.; Barakzoy, E.; Sagot, N.; Falguiéres, A.; Renouard, S.; Blondeau, J.;
Ferroud, C.; Doussot, J.; et al. Development and validation of an efficient ultrasound assisted extraction
of phenolic compounds from flax (Linum usitatissimum L.) seeds. Ultrason. Sonochem. 2015, 26, 176–185.
[CrossRef]
22. Fliniaux, O.; Corbin, C.; Ramsay, A.; Renouard, S.; Beejmohun, V.; Doussot, J.; Falguières, A.; Ferroud, C.;
Lamblin, F.; Lainé, E.; et al. Microwave-Assisted Extraction of Herbacetin Diglucoside from Flax (Linum
usitatissimum L.) Seed Cakes and Its Quantification using an RP-HPLC-UV System. Molecules 2014,
3025–3037. [CrossRef] [PubMed]
23. Bourgeois, C.; Leclerc, É.A.; Corbin, C.; Doussot, J.; Serrano, V.; Vanier, J.R.; Seigneuret, J.M.; Auguin, D.;
Pichon, C.; Lainé, É.; et al. Nettle (Urtica dioica L.) as a source of antioxidant and anti-aging phytochemicals
for cosmetic applications. C. R. Chim. 2016, 19, 1090–1100. [CrossRef]
24. Renouard, S.; Hano, C.; Corbin, C.; Fliniaux, O.; Lopez, T.; Montguillon, J.; Barakzoy, E.; Mesnard, F.;
Lamblin, F.; Lainé, E. Cellulase-assisted release of secoisolariciresinol from extracts of flax (Linum
usitatissimum) hulls and whole seeds. Food Chem. 2010, 122, 679–687. [CrossRef]
25. Terpinc, P.; Polak, T.; Makuc, D.; Ulrih, N.P.; Abramovič, H. The occurrence and characterisation of phenolic
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Abstract: Colorectal cancer is one of the most frequently diagnosed cancers worldwide. The aim of
the present study was to simultaneously analyze compounds of Salviae miltiorrhizae Radix (SMR)
and determine their cytotoxic effects on HCT-116 human colorectal cancer cells. We established a
simultaneous analysis method of five compounds (salvianic acid A, salvianolic acid B, caffeic acid,
tanshinone IIA, and rosmarinic acid) contained in SMR, and found that among the various compounds
in SMR, tanshinone IIA significantly decreased cell viability in a concentration-dependent manner.
Hoechst staining also showed that both SMR and tanshinone IIA increased nuclear condensation,
suggesting induction of apoptosis. By Western blotting, we found that tanshinone IIA induced
apoptotic cell death, significantly increased Bax, but decreased Bcl-2 in the course of apoptosis.
Tanshinone IIA increased the expression of cleaved caspases-7 and -8. Tanshinone IIA was shown
to be an active ingredient of SMR that may be a useful chemotherapeutic strategy for patients with
colorectal cancer.
Keywords: colorectal cancer; Salviae miltiorrhizae radix; apoptosis
1. Introduction
Colorectal cancer is the third-most commonly diagnosed cancer worldwide [1]. Although surgery
plays a key role in the diagnosis and treatment of colorectal cancer, there are still increasing attempts
to stop the progression of this cancer via the application of new synthetic and naturally-occuring
compounds [2,3]. Bioactive compounds from plants have been screened for anticancer activities [4,5].
Approximately 50–60% of cancer patients in the United States utilize complementary and alternative
medicines with traditional therapeutic regimens, such as radiation therapy and chemotherapy [6].
Apoptosis pathways are important targets in cancer-related therapies, and insufficient apoptosis
results in uncontrolled cancer cell proliferation [7]. The use of natural phytochemicals for inhibiting
cancer cell proliferation and inducing apoptosis contributes to promoting cancer cell death [8,9].
Natural phytochemicals are multiple-target molecules found in plants and microorganisms, and they
exert strong anticancer activity [10,11]. Phytochemicals isolated from natural sources also exhibit
various beneficial effects against inflammation, cancer, and neurodegenerative disorders [10]. This
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broad spectrum of biological and pharmacological activities has made natural compounds suitable
candidates for treating multifactorial diseases, such as colorectal cancer.
Salviae miltiorrhizae Radix (SMR) is one of the well-known traditional herbal medicines and has
been used in Asian countries [8]. Recently, there has been increasing scientific attention towards SMR
for its remarkable bioactivity against cardiovascular disease, renal damage, tumor angiogenesis, and
tumor cell invasion [12–14]. In the last decade, accumulating evidence has shown that SMR exerts a
significant anticancer effect against promyelocytic leukemia, breast cancer, ovarian carcinomas, and
hepatocellular carcinoma (HCC) [15–17]. In a recent network pharmacology-based study on the anti-
HCC effect of SMR, 62 chemical compounds form SMR yielded 101 putative targets that played a
critical role in HCC via multiple targets and pathways, especially the EGFR and phosphatidyl-inositol
3-kinase (PI3K)/Akt signaling pathways [18]. However, the effect of SMR and its compounds on human
colon cancer cells has not been fully elucidated. The aim of the present study was to simultaneously
analyze the compounds of SMR and determine their cytotoxic effects on HCT-116 human colorectal
cancer cells.
2. Materials and Methods
2.1. Plant Materials
Salviae miltiorrhizae Radix (SMR) was obtained from Kwangmyungdag Medicinal Herbs (Ulsan,
Korea) and identified by Dr. Goya Choi, Herbal Medicine Resources Research Center, Korea Institute
of Oriental Medicine (HMRRC, KIOM; Naju, Korea). A voucher specimen (SMR-2-14-0073) was stored
at the herbarium of the HMRRC, KIOM.
2.2. Chemicals and Reagents
Five reference standard compounds, salvianic acid A (98.0%), caffeic acid (99.0%), rosmarinic
acid (97.0%), salvianolic acid B (98.0%), and tanshinone IIA (98.8%) were purchased from standard
manufacturers: Acros Organics (Pittsburgh, PA, USA), Merck KGaA (Darmstadt, Germany), and
ChemFaces Biochemical Co., Ltd. (Wuhan, China).
The solvents including methanol, acetonitrile, and water (HPLC-grade) and formic acid (≥98.0%,
ACS reagent-grade) for quantitative analysis were obtained from Merck KGaA (Darmstadt, Germany)
and J. T. Baker (Phillipsburg, NJ, USA), respectively.
2.3. Preparation of 70% Ethanol SMR Extract
Dried SMR (0.3 kg) was extracted with 70% ethanol (3.0 L, 3 times) for 1 h at room temperature by a
Branson 8510 ultrasonicator (Denbury, CT, USA). The extract solution was filtered with 150 mm Ø filter
paper (Whatman, Maidstone, Kent, UK) under vacuum, concentrated to remove the organic extract
solvent (ethanol) using a Büchi rotary evaporator R-210 (Flawil, Switzerland), and then lyophilized
using a Ilshin BioBase FD-5525L freeze-drier (Dongducheon, Korea) to obtain powdered extract. The
yield of lyophilized 70% ethanol extract of SMR was 69.8 g (23.3%).
2.4. HPLC Analysis of Five Components in SMR
HPLC analysis was conducted using the Prominence LC-20A Series instruments (Shimadzu,
Kyoto, Japan) consisting of a DGU-20A3 degasser, LC-20AT solvent delivery unit, SIL-20A auto sample
injector, CTO-20A column oven, and SPD-M20A photodiode array detector. All chromatographic data
were obtained and analyzed with the LabSolution software (Version 5.53; SP3, Kyoto, Japan). Five
components were separated using a reverse-phase SunFireTM C18 analytical column (4.6 × 250 mm, 5
μm; Waters, Torrance, CA, USA) at 40 ◦C with gradient solvent condition. The mobile phases consisted
of 0.1% (v/v) aqueous formic acid (A) and 0.1% (v/v) formic acid in acetonitrile (B) and were adjusted
following the gradient condition: 0–30 min, 10–60% B; 30–40 min, 60–100% B; 40–45 min, 100% B; 45–50
min, and 100–10% B. The re-equilibrium time was adjusted for 10 min. The flow rate of the mobile
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phase was 1.0 mL/min, and the injection volume of the standard and test solution was 10 μL each. For
quantitative determination of five marker components (salvianic acid A, caffeic acid, rosmarinic acid,
salvianolic acid B, and tanshinone IIA) in SMR, 200.0 mg of lyophilized SMR extract was liquefied
with 20 mL of 70% methanol and sonicated for 30 min. It was also diluted 20-fold for quantification of
salvianolic acid B. All samples were filtered using a membrane filter (0.2-μm, Pall Life Sciences, Ann
Arbor, MI, USA) before analysis.
2.5. Cell Culture
The human colon cancer cell (HCT-116) was purchased from the ATCC (American Type Culture
Collection, Manassas, VA, USA). The cell was maintained and grown in RPMI 1640 medium (Roswell
Park Memorial Institute 1640; Corning, Manassas, VA, USA) contained with 10% FBS (fetal bovine
serum; Gibco BRL, Carlsbad, MD, USA) and penicillin/streptomycin (Life Technologies, Waltham, MA,
USA). The condition of the incubator was 37 ◦C and humidified atmosphere containing 5% CO2.
2.6. Cell Viability Assay
The cell viability assay was assessed using an Ez-Cytox Kit (Dail Lab Service Co., Seoul, Korea)
based on the manufacturer’s instructions [19]. Briefly, the cells were seeded in a 96-well plate at 1 × 104
cells/well and then incubated. After 24 h, the cells were treated with the indicated concentrations of
each sample, and the cells were then incubated for 24 h. Following incubation, Ez-Cytox solution was
mixed with medium in each well and incubated for 1 h. The absorbance at 450/600 nm was determined
using a SPARK 10M (Tecan Group Ltd., Männedorf, Switzerland). The cell viability of 100% was
calculated from control cells.
2.7. Hoechst 33342 Cell Staining
Sample-induced nuclear condensation of HCT-116 cells was observed using Hoechst 33342
staining (Sigma Aldrich, St. Louis, MO, USA) [20]. Briefly, the cells were seeded in a 6-well plate at 4 ×
105 cells per well. Following incubation for 24 h, the cells were treated with various concentrations of
each sample, and the cells were then incubated for 24 h. Following incubation, Hoechst 33342 solution
was added to the cells and incubated for 10 min. The stained cells were observed using a CCD camera
conjugated IX50 fluorescent microscope (Olympus, Tokyo, Japan).
2.8. Western Blotting
The apoptosis signaling pathways of HCT-116 cells induced by samples were performed using
Western blot analysis [21,22]. Briefly, the cells were seeded in a 6-well plate at 4 × 105 cells/well and
then incubated. After 24 h, the cells were treated with the indicated concentrations of each sample, and
the cells were then incubated for 24 h. Following incubation, the cells were harvested with a scraper
and lysed with radio-immunoprecipitation assay buffer (Elpis Biotech, Daejeon, Korea). The protein
concentrations were calculated with the Pierce BCA Protein Assay Kit (Thermo Scientific, Carlsbad,
CA, USA). The protein samples were separated by electrophoresis in a SDS-PAGE. Then, the proteins
were transferred to PVDF membranes (Merck Millipore, Darmstadt, Germany). The membranes
were conducted blockading by 5% skim milk. Then, the membranes were probed with primary
antibodies for Bax, B-cell lymphoma 2 (Bcl-2), cleaved caspase-7, cleaved caspase-8, cleaved caspase-9,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and poly(ADP-ribose) polymerase (PARP)
followed by incubating with secondary antibodies for anti-rabbit IgG (Cell Signaling Technology, Inc.,
Danvers, MA, USA).
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2.9. Statistical Analysis
All experiments were performed in triplicate, and the quantitative data were shown as mean ±
SD. Statistical analysis using Student’s t-test was conducted and considered statistically significant
based on p-values less than 0.05.
3. Results and Discussion
In the present study, we analyzed five bioactive marker components found in SMR, consisting
of four phenolic acids (salvianic acid A, caffeic acid, rosmarinic acid, and salvianolic acid B) and one
terpenoid (tanshinone IIA). These compounds were separated with resolution >5.0 within 45 min
and retention times of 5.87, 11.11, 17.72, 20.42, and 42.51 min, respectively (Figure 1). The content of
rosmarinic acid, caffeic acid, salvianic acid A, salvianolic acid B, and tanshinone IIA in the samples
was 3.72, 0.123, 1.27, 64.36, and 4.96 mg/g, respectively.
Figure 1. Three-dimensional high-performance liquid chromatogram of 70% ethanol extract of Salviae
miltiorrhizae Radix.
We initially performed a cytotoxic evaluation using HCT-116 human colorectal carcinoma
cells. As shown in Figure 2, only tanshinone IIA significantly decreased cell viability in a
concentration-dependent manner, whereas 61.6 μM SMR showed approximately 50% suppression.
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Figure 2. Cytotoxic effect of 70% ethanol extract of Salviae miltiorrhizae Radix (SMR), salvianic acid A
(1), caffeic acid (2), rosmarinic acid (3), salvianolic acid B (4), and tanshinone IIA (5) on HCT-116 cells.
Many clinical anticancer drugs are known to exert their effects by inducing apoptosis [23].
Apoptosis is a gene-regulated response and, from the morphological point of view, is distinguished
by the specific structural changes in cells, such as plasma membrane bleb formation, cell and nuclear
shrinkage, oligonucleosomal DNA fragmentation, and chromatin condensation [24]. Morphological
analyses showed that both SMR and tanshinone IIA decreased the number of cells and induced signs
of cellular apoptosis, such as cellular shrinkage (Figure 3). Moreover, as shown in Figure 4, Hoechst
staining also showed that both SMR and tanshinone IIA increased nuclear condensation, suggesting
that SMR and tanshinone IIA successfully induced apoptosis, not necrosis, in human colorectal cancer
cells. However, tanshinone IIA was not cytotoxic to LLC-PK1 pig kidney epithelial cell, which is
normal cell lines, up to 100 μM (Supplementary Figure S1).
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Figure 3. Effects of 70% ethanol extract of Salviae miltiorrhizae Radix (SMR) and tanshinone IIA on
apoptosis in HCT-116 cells. (A) Morphology changes in HCT-116 cells. (B) Fluorescence microscopic
images of apoptotic HCT-116 cells stained with Hoechst 33342.
Two major molecular pathways that trigger programmed cell death are the caspase-mediated
intrinsic pathway, which is induced by cellular stresses, and the extrinsic pathway, which is related to
the death receptor [25]. Both pathways activate the apoptotic caspases, resulting in morphological and
biochemical cellular alterations related to apoptosis [26]. In addition, the extrinsic pathway controls
cell turnover by decreasing mutant cells. In the extrinsic pathway, cancer cell death is triggered by the
interaction with death ligands (such as tumor necrosis factor) and its death receptors. The cancer cell
death-initiating complex stimulates the activation of caspase-3 and -8, which are effector and starter
caspases, respectively [27,28]. The intrinsic pathway, which is typically activated in response to DNA
or cellular damage, stimulates the expression of proteins in mitochondria, such as cytochrome c, which
then activates caspase-3 and -9. [27,29]. It was also reported that after cleavage by caspase-9, caspase-3
inhibits reactive oxygen species production and is thus required for efficient induction of apoptosis,
whereas caspase-7 is required for apoptotic cell elimination [30]. In our present study, the expressions
of cleaved caspase-7 and -8 were significantly increased by tanshinone IIA, but there was no change in
that of cleaved caspase-9 (Figure 4).
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Figure 4. Effects of 70% ethanol extract of Salviae miltiorrhizae Radix (SMR) and tanshinone IIA on
apoptosis in HCT-116 cells. (A) Protein expression of PARP, Bax, Bcl-2, cleaved caspase-7, cleaved
caspase-8, cleaved caspase-9, and GAPDH. (B) Graph of relative protein expression. Data are the means
of experiments performed in triplicate. Data are presented as the mean ± SD. and were analyzed using
the Student’s t-test. * p < 0.05 versus non-treated cells.
Furthermore, anti- and pro-apoptotic Bcl-2 members play critical roles in the
mitochondria-mediated pathway. That is, the ratio of anti- and pro-apoptotic proteins (e.g., Bax/Bcl-2)
is considered as a determinant of survival or apoptosis of cancer cells [31]. Earlier studies have
reported that the anti-apoptotic Bcl-2 members, which consist of Bcl-xl, Bcl-2, Bcl-w, and Mcl-1, exert
an important role in the resistance of cancer cells to chemotherapy. Therefore, a reduction in Bcl-2 and
an increase in Bax stimulate the apoptosis process and eliminate cancer cells [32]. Our western blotting
analysis results showed increased Bax expression and decreased Bcl-2 expression in cells co-treated
with tanshinone IIA, which was stronger than SMR (Figure 4); however, no difference was observed in
poly (ADP-ribose) polymerase (PARP) expression, which is a parameter for stress and DNA damage
in cells.
In summary, we simultaneously analyzed five compounds (salvianic acid A, rosmarinic acid,
salvianolic acid B, caffeic acid, and tanshinone IIA) from SMR, and determined their cytotoxic effects
on HCT-116 human colon cancer cells. Among the five compounds in SMR, only tanshinone IIA
significantly decreased cell viability in a concentration-dependent manner. Both SMR and tanshinone
IIA increased nuclear condensation, suggesting that SMR and tanshinone IIA successfully induced
apoptosis. We also found that tanshinone IIA induced apoptotic cell death and significantly increased
cleaved caspases-7, -8, and Bax expression, as well as decreased Bcl-2 expression in the course of
apoptosis. Taken together, our data show that tanshinone IIA is an active ingredient of SMR and may
be a useful chemotherapeutic strategy for patients with colorectal cancer.
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Abstract: Chalcones and flavanones are isomeric structures and also classes of natural products,
belonging to the flavonoid family. Moreover, their wide range of biological activities makes them
key scaffolds for the synthesis of new and more efficient drugs. In this work, the synthesis of
hydroxy and/or methoxychalcones was studied using less common bases, such as sodium hydride
(NaH) and lithium bis(trimethylsilyl)amide (LiHMDS), in the aldol condensation. The results show
that the use of NaH was more effective for the synthesis of 2′-hydroxychalcone derivatives, while
LiHMDS led to the synthesis of polyhydroxylated chalcones in a one-pot process. During this
study, it was also possible to establish the conditions that favor their isomerization into flavanones,
allowing at the same time the synthesis of hydroxy and/or methoxyflavanones. The chalcones and
flavanones obtained were evaluated to disclose their antioxidant, anticholinesterasic, antibacterial
and antitumor activities. 2′,4′,4-Trihydroxychalcone was the most active compound in terms of
antioxidant, anti-butyrylcholinesterase (IC50 26.55 ± 0.55 μg/mL, similar to control drug donepezil,
IC50 28.94 ± 1.76 μg/mL) and antimicrobial activity. 4′,7-Dihydroxyflavanone presented dual
inhibition, that is, the ability to inhibit both cholinesterases. 4′-Hydroxy-5,7-dimethoxyflavanone
and 2′-hydroxy-4-methoxychalcone were the compounds with the best antitumor activity.
The substitution pattern and the biological assay results allowed the establishment of some
structure/activity relationships.
Keywords: chalcones; aldol condensation; biological activity; flavanones; cytotoxic;
antioxidant; anticholinesterase
1. Introduction
The (E)-1,3-diphenylpropen-1-ones, best known as chalcones, belong to the flavonoids family
and are an important class of natural products across the plant kingdom [1]. Structurally, these
compounds contain two aromatic rings, bonded by a three-carbon α,β unsaturated carbonyl bridge
(Figure 1), which are synthesized in plants as the C15 key intermediate in the biosynthesis of the other
flavonoids [2]. Flavanones are also naturally occurring compounds and are chalcones’ isomeric forms.
In fact, the equilibrium between chalcones and flavanones is common in nature and is regulated by
chalcone-isomerase [3].
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Figure 1. Basic chalcone structure.
Besides their natural occurrence, both chalcones and flavanones can be obtained synthetically
and are often used as the preferred starting material for the synthesis of other polycyclic aromatic
compounds [4]. Furthermore, they present great pharmacological potential with a wide variety of
biological activities, including antioxidant [5], anticancer [6–8], and antimicrobial activities [9–12], and
also the ability to treat cardiovascular diseases and their risk factors [13–16], among others [17].
On the other hand, cancer, neurodegenerative diseases, oxidative stress-related diseases and
multi-resistant bacterial infections are, after cardiovascular diseases, the top four health problems that
cause the most victims every year, leading to higher medicine consumption and putting great pressure
on the national health systems of many countries [18–24]. These problems occur either due to a lack of
effective medicines to treat diseases, such as neurodegenerative ones, or due to the increasing drug
resistance presented by numerous pathogenic bacteria and by some cancers. Therefore, exploring
well-known scaffolds as lead compounds will help in the battle against diseases that affect humanity.
Putting together the facts stated above, the synthesis of chalcone-based functionalized derivatives
remains a popular research objective. The most common and efficient approach to obtain the chalcone
nucleus is the aldol condensation of substituted acetophenones with proper substituted benzaldehydes
in the presence of a base, namely sodium or potassium hydroxide [25–28]. Despite the efficiency of
this method, when planning a synthesis some drawbacks should be considered. For instance, the
protection of the reagents’ hydroxyl groups should be done previously, the acetophenone hydrogen α
acidity should be analyzed, and by-products can be obtained if the bases are also good nucleophilic
species [29,30].
In this regard, the objective of this work is to synthesize hydroxy- and/or methoxychalcones by aldol
condensation, using the less common bases sodium hydride and lithium bis(trimethylsilyl)amide. Also,
this work studies their antioxidant, anticholinesterasic, antibacterial and antitumor activities, aiming
to establish some potential medicinal applications. Simultaneously, a structure/activity relationship
was established, and the isomeric equilibrium chalcone-flavanone was also studied.
2. Materials and Methods
2.1. General Methods
The 1H, 13C, HSQC and HMBC NMR spectra were measured on Bruker AMC 300 or 500
instruments, operating at 300.13 MHz and 75.47 or 500.13 and 125.75 MHz. Chemical shifts were
reported relative to tetramethysilane (TMS) in δ units (ppm) and coupling constants (J) in Hz.
Chromatographic purifications were carried out by prep. TLC on silica gel (Merck silica gel 60 F254),
the spots being visualized under a UV lamp (at 254 and/or 366 nm). Melting points were determined
with a Stuart scientific SPM3 apparatus and are uncorrected. The mass spectra were acquired using
ESI(+) with a Micromass Q-Tof 2TM mass spectrometer.
2.2. Synthesis of Chalcones and Flavanones
Synthesis of the compounds described below follows the general scheme outlined in 3.1 (Scheme 1).
2′-Hydroxy-4,4′,6′-trimethoxychalcone 1. Compound 1 was synthesized by mixing 2′-hydroxy-4′,6′-
dimethoxyacetophenone (661.3 mg, 3.37 mmol) dissolved in a minimum (~15 mL) amount of
tetrahydrofuran (THF) with sodium hydride (NaH) (2.5 equivalents), under nitrogen atmosphere at
room temperature. After 30 min of stirring, 4-methoxybenzaldehyde (1.2 equivalents) was added to
the reaction mixture and allowed to react for 3 h. The product was precipitated from the reaction
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mixture by pouring onto ground ice and acidifying to pH < 2 with HCl 37%. The solid was filtered
and washed with water until pH > 5. The crude product was crystallized from ethanol and the desired
compound 1 was obtained (928.1 mg, 88% yield).
2′-Hydroxy-4,4′,6′-trimethoxychalcone 1: yellow crystals (ethanol); m.p. 112.4–113.6 ◦C (Lit.
111–115◦ [31]). 1H NMR (300 MHz, CDCl3) δ 14.40 (1H, s, 2′-OH), 7.79 (2H, s br, H-α, H-β), 7.56 (2H, d,
J = 6.8 Hz, H-2, H-6), 6.92 (2H, d, J = 6.8 Hz, H-3, H-5), 6.11 (1H, d, J = 2.4 Hz, H-3′), 5.96 (1H, d, J = 2.4
Hz, H-5′), 3.92 (3H, s, 6′-OCH3), 3.85 (3H, s, 4′-OCH3), 3.83 (3H, s, 4-OCH3); 13C NMR (75 MHz, CDCl3)
δ 192.6 (C=O), 168.4 (C-2′), 166.0 (C-4′), 162.5 (C-6′), 161.4 (C-4), 142.5 (C-β), 130.1 (C-2, C-6), 128.3
(C-1), 125.1 (C-α), 114.4 (C-3, C-5), 106.3 (C-1′), 93.8 (C-3′), 91.2 (C-5′), 55.8 (6′-OCH3), 55.6 (4′-OCH3),
55.4 (4-OCH3); TOF-ESI-MS (+) m/z 315 [M+H]+, 337 [M+Na]+, 353 [M+K]+, 651 [M+Na+M]+.
5,7-Dihydroxy-4′-methoxyflavanone 4. The procedure to obtain this compound involved 3 different steps:
(a) The benzylation of the hydroxyl groups: the 4′ and 6′-hydroxyl groups in the starting material
2′,4′,6′-trihydroxyacetophenone were protected using the methodology described by Figueiredo [32].
Briefly, the 2′,4′,6′-trihydroxyacetophenone (2.7 g, 16.1 mmol), dissolved in a minimum amount of
dry dimethylformamide (DMF) (~20 mL), was mixed with K2CO3 (6 equivalents) under constant
stirring. Then, benzyl bromide (3 equivalents) was added and the reaction was performed at 150
◦C under reflux for 2 h. After that, the reaction mixture was filtered to remove the K2CO3 and
the inorganic salts washed with DMF. The filtrate was poured over crushed ice and the mixture
acidified to pH < 5 with HCl 20%. The precipitated 4′,6′-dibenzyloxy-2′-hydroxyacetophenone
was filtered and crystallized from ethanol (4.75 g, 85% yield).
(b) The aldol condensation: The synthesis of 4′,6′-dibenzyloxy-2′-hydroxy-4-methoxychalcone 2 was
performed by dissolving 4′,6′-benzyloxy-2′-hydroxyacetophenone (1.5566 g) in dried THF and
was then mixed with NaH (2.5 equivalents). After 10 min of stirring under nitrogen atmosphere
at room temperature, 4-methoxybenzaldehyde (1.2 equivalents) was added. The reaction was
finished after 3 h by pouring over crushed ice and addition of HCl 37% to pH < 2. The precipitate
was filtered and washed with water, and the crude product was crystallized from acetone to
afford 4′,6′-dibenzyloxy-2′-hydroxy-4-methoxychalcone 2 (1.6573 g, 80% yield).
(c) The benzyl group’s cleavage: The final step was deprotecting the hydroxyl groups at 4′ and 6′
positions by cleavage of the benzyl groups. This procedure was adapted from the method described
by Gomes et al. [33]. Briefly, 4′,6′-dibenzyloxy-2′-hydroxy-4-methoxychalcone 2 (567.0 mg) was
mixed with 40 mL of a mixture of HCl/Acetic acid (1:10) under stirring at 80 ◦C during 13
h. The reaction was finished by pouring the mixture over crushed ice, the solid formed was
washed with water until pH ~ 5 and then purified by TLC, eluting it twice in CH2Cl2, affording
5,7-dihydroxy-4′-methoxy-flavanone 4 (138.7 mg, 59%).
5,7-Dihydroxy-4′-methoxyflavanone 4. pale-yellow crystals (CHCl3); m.p. 191.7–193.3 ◦C (Lit.
193–194 ◦C [34]). 1H NMR (300 MHz, CDCl3) δ 12.05 (1H, s, 5-OH), 7.37 (2H, d, J = 8.7 Hz, H-2′, H-6′),
6.95 (2H, d, J = 8.7, H-3′, H-5′), 5.99 (1H, s broad, H-6), 5.98 (1H, s broad, H-8), 5.36 (1H, dd, J = 3.0 and
13.0 Hz, H-2), 3.83 (3H, s, 4′-OCH3), 3.10 (1H, dd, J = 13.0 and 17.2 Hz, H-3a), 2.78 (1H, dd, J = 3.0 and
17.2 Hz, H-3b); 13C NMR (75 MHz, CDCl3) δ 196.2 (C-4), 164.8 (C-7), 164.3 (C-5), 163.3 (C-8a), 160.1
(C-4′), 130.3 (C-1′), 127.8 (C-2,’ C-6′), 114.1 (C-3′, C-5′), 103.1 (C-4a), 96.7 (C-6), 95.5 (C-8), 79.0 (C-2),
55.4 (4′-OCH3), 43.1 (C-3); TOF-ESI-MS (+) m/z 287 [M+H]+, 611 [M+K+M]+.
4′-Hydroxy-5,7-dimethoxyflavanone 5. The synthesis of this compound also involved the 3 steps mentioned
above for compound 4.
(a) The benzylation of the hydroxyl groups: the 4-hydroxybenzaldehyde (1.3 g, 10.6 mmol) was
dissolved in a minimum of dry dimethylformamide (DMF) (~15 mL), and it was mixed with
K2CO3 (3 equivalents) under constant stirring. Then, benzyl bromide (1.5 equivalents) was added,
and the reaction was performed at 150 ◦C under reflux for 2 h. After that, the reaction mixture
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was filtered to remove the K2CO3 and washed with DMF. The filtrate was poured over crushed
ice and HCl 20% added until pH < 5. The precipitated 4-benzyloxybenzaldehyde was filtered
and crystallized from ethanol (1.8 g, 78%).
(b) The aldol condensation: The 2′-hydroxy-4′,6′-dimethoxyacetophenone (898.3 mg) was dissolved
in dried THF (~15 mL) and mixed with NaH (2.5 equivalents) at room temperature and under
N2 atmosphere. After 10 min, 4-benzyloxybenzaldehyde (1.2 equivalents) was added, and the
reaction was finished after 4 h by precipitation over crushed ice acidified with HCl 37% to pH < 2.
4-Benzyloxy-2′-hydroxy-4′,6′-dimethoxychalcone 3 was obtained by crystallization from ethanol
(1.433 g, 80%).
(c) The benzyl group’s cleavage: The chalcone 3 (330.6 mg) was mixed with 30 mL of a mixture of
HCl/Acetic acid (1:10) under stirring at 55 ◦C during 60 h. The reaction was finished by pouring
the mixture over crushed ice, the formed solid was washed with water until pH ~5 and purified
by TLC using hexane/ethyl acetate (1:1) as eluent, affording 4′-hydroxy-5,7-dimethoxyflavanone
5 as pale-yellow amorphous powder (21.0 mg, 8%).
4′-Hydroxy-5,7-dimethoxyflavanone 5: 1H NMR (300 MHz, CDCl3) δ 7.29 (2H, d, J = 8.5 Hz, H-2′, H-6′),
6.86 (2H, d, J = 8.5 Hz, H-3′and H-5′), 6.13 (1H, d, J = 2.3 Hz, H-8), 6.07 (1H, d, J = 2.3 Hz, H-6), 5.34
(1H, dd, J = 3.0 and 12.8 Hz, H-2), 3.86 (3H, s, 5-OCH3), 3.81 (3H, s, 7-OCH3), 3.03 (1H, dd, J = 12.8
and 16.6 Hz, H-3a), 2.78 (1H, dd, J = 3.0 and 16.6 Hz, H-3b); 13C NMR (75 MHz, CDCl3) δ 190.2 (C-4),
166.2 (C-7), 165.2 (C-8a), 162.3 (C-5), 156.4 (C-4′), 130.4 (C-1′), 127.9 (C-2′, C-6′), 115.7 (C-3′, C-5′), 105.8
(C-4a), 93.6 (C-8), 93.1 (C-6), 78.9 (C-2), 56.1 (5-OCH3), 55.6 (7-OCH3), 45.2 (C-3); TOF-ESI-MS (+) m/z
301 [M+H]+, 323 [M+Na]+, 623 [M+Na+M]+.
2′,4′,4-Trihydroxychalcone 6 and 4′,7-dihydroxyflavanone 7. The 2′,4′-dihydroxyacetophenone (226.7 mg)
was dissolved in dried toluene and mixed with 10 mL of a 1 mol.dm−3 solution of LiHMDS (6.6
equivalents), under nitrogen atmosphere, at room temperature. After 30 min, 4-hydroxybenzaldehyde
(1.2 equivalents) was added, and the reaction was stirred for 5 days. The reaction was finished, poured
over crushed ice and acidified to pH < 2 with HCl 37%. The mixture was extracted with CH2Cl2 and
purified by TLC, using a mixture of hexane and ethyl acetate (1:1) as eluent (twice). Compounds
2′,4′,4-trihydroxychalcone 6 and 4′,7-dihydroxyflavanone 7 were obtained as yellow amorphous
powder, respectively, 18.2 mg (5%) and 8.2 mg (2%). Approximately 80% of the starting acetophenone
was also recuperated.
2′,4′,4-Trihydroxychalcone 6: 1H NMR (300 MHz, acetone-d6) δ 13.69 (1H, s, 2′-OH), 8.12 (1H, d, J = 8.9
Hz, H-6′), 7.85 (1H, d, J = 15.4 Hz, H-β), 7.77 (1H, d, J = 15.4 Hz, H-α), 7.75 (2H, d, J = 8.6 Hz, H-2,
H-6), 6.94 (2H, d, J = 8.6 Hz, H-3, H-5), 6.48 (1H, dd, J = 2.4 and 8.9 Hz, H-5′), 6.38 (1H, d, J = 2.4 Hz,
H-3′); 13C-NMR (75 MHz, acetone-d6) δ 192.6 (C=O), 167.6 (C-4′), 166.2 (C-2′), 161.1 (C-4), 145.0 (C-β),
133.2 (C-6′), 131.7 (C-2, C-6), 127.4 (C-1), 118.2 (C-α), 116.8 (C-3, C-5), 114.2 (C-1′), 108.9 (C-5′), 103.7
(C-3′); TOF-ESI-MS (+) m/z 257 [M+H]+, 279 [M+Na]+, 535 [M+Na+M]+, 551 [M+K+M]+.
4′,7-Dihydroxyflavanone 7: 1H NMR (300 MHz, acetone-d6) δ 9.53 (1H, s, 7-OH), 8.60 (1H, s, 4′-OH), 7.74
(1H, d, J = 8.6 Hz, H-5), 7.42 (2H, d, J = 8.6 Hz, H-2′, H-6′), 6.91 (2H, d, J = 8.6 Hz, H-3′, H-5′), 6.59
(1H, dd, J = 2.3 and 8.6 Hz, H-6), 6.43 (1H, d, J = 2.3 Hz, H-8), 5.46 (1H, dd, J = 2.8 and 13.1 Hz, H-2),
3.06 (1H, dd, J = 13.1 and 16.7 Hz, H-3a); 2.68 (1H, dd, J = 2.8 and 16.7 Hz, H-3b); 13C-NMR (75 MHz,
acetone-d6) δ 190.5 (C-4), 165.2 (C-7), 164.5 (C-8a), 158.6 (C-4′), 131.2 (C-1′), 129.4 (C-5), 128.9 (C-2′,
C-6′), 116.1 (C-3′, C-5′), 115.1 (C-4a), 111.2 (C-6), 103,6 (C-8), 80.5 (C-2), 44.6 (C-3); TOF-ESI-MS (+) m/z
257 [M+H]+, 279 [M+Na]+, 513 [M+H+M]+, 535 [M+Na+M]+, 551 [M+K+M]+.
2.3. Biological Activities
Compound 2′-hydroxy-4-methoxychalcone 8 was provided by the Laboratory of Organic
Chemistry of the University of Aveiro, and the reactional conditions, yield and spectroscopic data are
reported by Silva et al. [35,36].
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2.3.1. DPPH Scavenging Activity
Antioxidant activity was assayed by the DPPH (1,1-diphenyl-2-picryl-hydrazyl) radical scavenging
assay [37]. Serial dilutions of studied or reference compounds (Trolox and quercetin) were carried out
in 96-well microplates, at different concentrations, ranging between 0.148 μg/mL and 150 μg/mL in
methanol. DPPH dissolved in methanol was added to the microwells, yielding a final concentration of
45 μg/mL, and the absorbance at 515 nm was measured in a Bio Rad Model 680 Microplate Reader
(Bio-Rad Laboratories, Inc., Hercules, CA, USA), after 30 min in the dark. In each assay, a control was
prepared, in which the sample or standard was substituted by the same amount of solvent. Percentage
of antioxidant activity (%AA) was calculated as:
%AA = 100 [1 − (Acontrol − Asample)/Acontrol]
where Acontrol is the absorbance of the control, and Asample is the absorbance of the chalcone/flavanone or
standard. All assays were carried out in triplicate and results expressed as EC50, i.e., as the concentration
yielding 50% scavenging of DPPH, calculated by interpolation from the %AA vs concentration curve.
2.3.2. ABTS Scavenging Activity
To determine ABTS radical scavenging, the method of Re et al. [38] was adopted. The stock
solutions included 7 mM ABTS solution and 2.4 mM potassium persulfate solution. The working
solution was prepared by mixing the two stock solutions in equal quantities and allowing them to
react for 12–16 h at room temperature in the dark. The solution was then diluted by mixing 1 mL
ABTS solution with the amount of methanol necessary to obtain an absorbance of 0.7 at 734 nm. Serial
dilutions of studied or reference compounds (trolox, quercetin) were carried out in 96-well microplates,
at different concentrations, ranging between 0.146 μg/mL and 150 μg/mL in methanol. ABTS solution
was then added to the microwells, and after 8 min of incubation the absorbance was taken at 405 nm
in a Bio Rad Model 680 Microplate Reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). In each
assay, a control was prepared, in which the sample or standard was substituted by the same amount of
solvent. Percentage of antioxidant activity (%AA) was calculated as:
(%) = [(Abscontrol − Abssample)]/(Abscontrol)] × 100
where Abscontrol is the absorbance of ABTS radical +methanol; Abssample is the absorbance of ABTS
radical + sample/standard. All assays were carried out in triplicate and results expressed as EC50, i.e.,
as the concentration yielding 50% scavenging of ABTS, calculated by interpolation from the %AA vs
concentration curve.
2.3.3. Anticholinesterasic Activity
The assay for measuring AChE and BuChE activity was modified from the assay described by
Ellman et al. [39] and Arruda et al. [40]. Briefly, 3 mM 5,5′-dithiobis [2-nitrobenzoic acid] (DTNB, 5 μL),
75 mM acetylthiocholine iodide (ATCI, 5 μL) or butyrylthiocoline iodide (BuTCI, 5 μL), and sodium
phosphate buffer 0.1 mol dm−3 (pH 8.0, 110 μL), and sample or standard (quercetin or donepezil)
dissolved in buffer containing no more than 2.5% DMSO were added to the wells, and serial dilutions
were carried out to obtain concentrations ranging between 0.293 μg/mL and 150 μg/mL (0.098 and
50 μg/mL for galantamine and berberine; 0.010 and 5 μg/mL for donepezil; 0.195 and 100 μg/mL for
quercetin), followed by 0.25 U/mL AChE or BuChE (10 μL). The microplate was then read at 415 nm
every 2.5 min for 7.5 min in a Bio Rad Model 680 Microplate Reader (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). For each concentration, enzyme activity was calculated as a percentage of the
velocities compared to that of the assay using buffer without any inhibitor. Every experiment was
done in triplicate.
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2.3.4. Antimicrobial Activity
Antibacterial activity against Gram-positive Bacillus subtilis DSM10 and Micrococcus luteus DSM
20030 and Gram-negative Escherichia coli DSM498 was assessed by the broth microdilution method, as
described by De León et al. [41]. The bacteria cultures were developed in nutrient broth (NB) at 30 ◦C
for B. subtilis and M. luteus and at 37 ◦C for E. coli. Briefly, compounds were added to the microplates
at a concentration of 200 μg/mL, and serial dilutions in NB were made until the concentration of
0.391 μg/mL. Then, the starting inoculum (1 × 105 CFU/mL) was added, and the bacterial growth
was measured by the increase in optical density at 550 nm with a Bio Rad Model 680 Microplate
Reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA), after 24 h of growth (48 h for M. luteus) at the
above-mentioned temperatures for each bacterial strain. Penicillin and streptomycin were used as
reference compounds. The IC50 was calculated as the concentration of compound that inhibits 50% of
bacterial growth by interpolation from the % of growth inhibition vs. concentration curve.
2.3.5. Antitumor Activity
Antitumor activity was determined by the method described in Moujir et al. [42]. A-549 (human
lung carcinoma) cell line, obtained from ATCC-LGC (American Type Culture Collection), was
grown as a monolayer in DMEM (Sigma) supplemented with 2% fetal bovine serum (Sigma),
1% penicillin–streptomycin mixture (10,000 UI/mL), p-hydroxybenzoic acid (2 × 104 mg/mL) and
L-glutamine (200 mM). Cells were maintained at 37 ◦C in 5% CO2 and 80% humidity in a SANYO
CO2 Incubator. Cytotoxicity was assessed using the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide] reduction assay. Cell suspension (2 × 104 cells/well) in
the lag phase of growth was incubated in a 96-well microplate with the compounds or the standards
(colchicine and paclitaxel) dissolved in medium, with the concentrations ranging between 0.195 μg/mL
and 200 μg/mL (0.010 μg/mL and 10 μg/mL for standards). After 48 h, MTT was added to the cells,
which were then allowed to incubate for 3–4 h, and the optical density was measured using a Bio
Rad Model 680 Microplate Reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 550 nm after
dissolving the MTT formazan with DMSO (100 μL). The percentage viability (IC50) was calculated
from the % of inhibition vs. concentration curve. All the experiments were repeated three times.
3. Results and Discussion
3.1. Chalcones and Flavanones Synthesis
The compounds obtained in this work were synthesized by aldol condensation between 4′- and/or
6′-substituted 2′-hydroxyacetophenones and either 4-hydroxy or 4-methoxybenzaldehydes, using
NaH and LiHMDS (Scheme 1).
Scheme 1. General procedure for the synthesis of chalcones and flavanones.
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Compounds 1 and 3 were synthesized, as far as we could confirm, using for the first time in the
aldol condensation the strong non-nucleophilic base NaH, which was used with success in similar
condensations [43,44]. The experimental results in the synthesis of chalcones 1–3, with very good
yields (~80%) and relatively low reaction times (3 to 4 h), proves that NaH is an effective and efficient
base in the aldol condensation when it is desired to obtain non-hydroxylated chalcones, other than at
the C-2′ position.
As referred above (Introduction), the hydroxyl groups present in the reagents require protection
before the aldol condensation because in the strong basic conditions used, the phenoxide ions can
undergo transformation into quinones and consequently prevent the formation of the desired chalcones.
So, in order to obtain the desired compounds (the ones bearing hydroxyl and/or methoxyl groups),
chalcones 2 and 3 need to be treated with acid to cleave the benzyl groups. The mixture used (HCl/AcOH)
is one of the less harsh conditions and, in fact, removed the benzyl groups, but the obtained products
were, in fact, flavanones 4 and 5 (Scheme 1). This can be explained by the acidic conditions used and the
fact that those conditions favor the chalcones’ isomerization into flavanones [45]. On the other hand,
these extra steps, the protection and deprotection of hydroxyl groups, contribute to decrease the overall
yield. For example, if we consider the synthesis of flavanones 4 and 5, their precursors’ chalcones 2
and 3 have excellent yields (80%), and the deprotection step, which produces the flavanones, is less
efficient. This demonstrates that, due to this step, the flavanones’ overall yield will be below 50%.
At the same time, the yields (Scheme 1) allowed the assumption that the deprotection of the ring A
hydroxyl groups is easier.
Since our purpose was the synthesis of chalcones bearing hydroxyl and methoxyl groups,
taking into consideration that these substituents might improve the activity, and that the synthesis of
flavanones 4 and 5 involves three steps, namely, (i) protection of the reagent’s hydroxyl groups, (ii) aldol
condensation and (iii) cleavage of the protecting groups, we envisaged the synthesis of the desired
chalcones using another base. Knowing that LiHMDS was used in the synthesis of hydroxylated
flavones without the protection step and with good results [46,47], we tested its use in the synthesis
of chalcone 6 (Scheme 1). The experimental results showed that, using LiHMDS as the base, it is
possible to synthesize polyhydroxylated chalcones in a one-pot process. However, although the desired
chalcone was obtained, the yield was very low and its isomeric form, flavanone 7, was also obtained.
It should be highlighted that this reaction was accomplished at room temperature, controlled by TLC
and finished after 5 days, when no more conversion was detected and 80% of the starting acetophenone
was recovered. These data suggest that the conversion rate is high and that the reaction does not occur
due to a lack of energy. We may suggest that using other sources of energy, such as a microwave, could
originate higher yields.
The synthesized compounds’ structures were confirmed by detailed analysis of their 1D and 2D
NMR spectra, MS spectra (e.g., in Figures S1–S9, supplementary material) and available literature data;
moreover, their purity was confirmed by UHPLC. Herein, chalcones’ and flavanones’ characterization
is briefly discussed.
The 1H NMR spectra of compounds 1–3 and 6 present the signal characteristics of chalcone structures:
(i) the resonance of the AB system assigned to the olefinic protons; (ii) doublets at δH 7.7–7.9 ppm with
J ~ 15 Hz, which confirms the E configuration of the α,β double bond; (iii) the signal at δC ~192 ppm
assigned to the carbonyl group; (iv) the singlet at δH 14.4–13.7 ppm assigned to 2′-OH proton signal
involvement in a hydrogen bond with the carbonyl oxygen atom; (v) two sets of doublets, with J = 6.8 Hz,
at δH 6.9–7.8 ppm, assigned to the protons of the para-substituted aromatic ring B (Figure 1).
The 1H, 13C and HSQC NMR spectra of chalcone 1 also display two sets of doublets at δH
5.9–6.1 ppm, with a meta-coupling constant (J = 2.4 Hz), that exhibit correlation with the signals
at 93.8 and 91.2 ppm, which indicates the presence of a tetra-substituted aromatic ring (ring A,
Figure 1). The three sets of singlets at δH 3.83–3.92 ppm, showing correlation with three signals at δC
55.4–55.8 ppm, are characteristic of three methoxyl groups. The MS spectrum of chalcone 1 showed
a signal at m/z 315 correspondent to [M+H]+, which agrees with the molecular formula C18H18O5.
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All the spectroscopic data and the melting point are in agreement with previously published data [31],
and additionally, the connectivities found in the HMBC NMR spectrum confirm compound 1 as
2′-hydroxy-4,4′,6′-trimethoxychalcone, also named flavokawain A.
The 1H and 13C NMR spectra of chalcone 6 show three sets of signals in the range of δC
6.38–8.12 ppm, characteristic of the a trisubstituted aromatic ring (ring A, Figure 1). The MS spectrum
showed a signal at m/z 257 corresponding to [M+H]+, which agrees with the molecular formula
C15H12O4. These data and the connectivities found in the HMBC spectrum confirm compound 6 as
2′,4′,4-tri-hydroxychalcone, also known as isoliquiritigenin [48].
Compounds 4, 5 and 7 are flavanones, and this fact is well confirmed by the presence of the signals
characteristic of ring C (Scheme 1): two double doublets at δH 2.68–3.10 and δH 2.68–2.78 assigned to
the protons H-3, and the double doublet at δH 5.34–5.46 ppm assigned to H-2 in coupling with H-3; the
signal at δ 196 ppm characteristic of the carbonyl group (C=O). Two sets of doublets at δH 7.29–7.42
(H-2′ and H-6′) and 6.86–6.95 ppm (H-3′ and H-5′), with orto-coupling constant of J = 8.7 Hz, indicate
the presence of a para-substituted aromatic ring (ring B).
The presence of the methoxyl group in the ring B of compound 4 is deduced from the singlet
at δ 3.83, correlating with the signal at δC 55.4 ppm. The MS data showed a signal at m/z 287
corresponding to the protonated molecule [M+H]+ that is in accordance with the molecular formula
C16H14O5. The spectroscopic data and the melting point are consistent with the published data for
isosakuranetin [33,49], and together with the connectivities found in HMBC spectrum, confirm that
compound 4 is 5,7-dihydroxy-4′-methoxyflavanone.
The signals found in the 1H and 13C NMR spectra of compound 5 are very similar to the ones
found for compound 4. The differences are the non-appearance of the signal at δH 12.05 ppm, which
confirms the absence of a 5-OH group; and the appearance of two singlets at δH 3.86 and 3.81 ppm,
which means that compound 5 has two methoxyl groups. The location of the two methoxyl groups and
the hydroxyl group were confirmed by the connectivities found in the HMBC spectrum of compound 5.
All the spectroscopic data are compatible with the structure of 4′-hydroxy-5,7-dimethoxyflavanone,
also named naringenin 5,7-dimethyl ether. Although compound 5 is not new, [50,51], to the best of our
knowledge, the full spectroscopic data are reported here for the first time.
The quasi-molecular ion at m/z 257, compatible with molecular formula C15H12O4, confirms that
compound 7 is an isomeric form of compound 6. The presences of two signals at δH 9.53 and 8.60 ppm
are assigned to 7-OH and 4′-OH, respectively, by the connectivities found in the HMBC spectrum.
Moreover, the spectroscopic data are identical to that previously published for 4′,7-dihydroxyflavanone,
also named liquiritigenin [52].
3.2. Biological Evaluations
The antioxidant, anticholinesterasic, antimicrobial and antitumor activities of the compounds
bearing hydroxyl and methoxyl groups were studied, and the results obtained are presented and
discussed in the following paragraphs. Compound 8, 2′-hydroxy-4-methoxychalcone, was not
synthesized in this work, but was included in the bioactivities study because it is, in structural terms,
one of the simplest 2′-hydroxychalcones and can be used as a reference and as a starting point to
analyze structure/activity relationships of the compounds that were synthesized.
3.2.1. Antioxidant Activity
In the DPPH (1,1-diphenyl-2-picryl-hydrazyl) scavenging test, the capacity of the compounds to
neutralize the DPPH radical via electron transfer is measured [53,54].
Nearly all the compounds had some antioxidant activity, which was concentration-dependent (see
Supplementary Materials, Figure S10), except for compounds 4 and 8, which only had a residual activity
at the highest concentration tested (150 μg/mL). Chalcone 6, the most active compound, presented
higher antioxidant activity than the isomeric flavanone 7 (Table 1), confirming that the conjugated
double bond improves the molecule’s ability to scavenge the DPPH radical [55].
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Table 1. Antioxidant activity of the synthesized compounds 1, 4–8.
Compounds and References
IC50 μg/mL (± SD)
DPPH ABTS
1 >150 >150
4 >150 140.15 (±0.03) a
5 >150 85.47 (±0.15) b
6 26.47 (±0.70) a 12.72 (±0.92) c
7 >150 >150
8 >150 >150
Trolox 7.25 (±0.09) b 2.68 (±0.08) d
Quercetin 3.01 (±0.03) c 0.57 (±0.02) e
In each column, the letters a, b, c, d, and e indicate significant differences (p < 0.05).
The results also confirm that the number of free hydroxyl groups influences antioxidant activity,
since compounds with a higher number of these groups present better activity [55], a fact that is also
confirmed by the lower activity of the compounds with more methoxyl groups (Figure 2).
Figure 2. Structure/activity relationships established for DPPH scavenging activity.
A previous work reported that compound 6 presented a low antioxidant activity in the DPPH
scavenging test [56] (86.92 ± 0.43% of DPPH inhibition at 150 μg/mL); however, since the maximum
concentration used in that work was about six times lower than the maximum tested concentration in
the present work, it does not conflict with the results herein reported.
Another test used was the ABTS (2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid))
scavenging assay. This assay measures the ability of compounds to neutralize the ABTS radical
by radical quenching via hydrogen atom transfer. However, it can also be neutralized by electron
transfer on some occasions, resulting in a higher sensitivity of this method when compared with the
DPPH assay [53,57]. Again, compound 6 was the one presenting the best activity, with an IC50 of
12.72 μg/mL (Table 1), which is another result that confirms the importance of the hydroxyl groups
in the chalcone scaffold for their ability to reduce and/or eliminate free radicals. This conclusion is
confirmed by the lower activity of chalcones 1 and 8, which have only one hydroxyl group. Compound
5 presents better activity than 4, which means that the relative position between the hydroxyl and
methoxyl groups is more important than the number of hydroxyl groups on the flavanone scaffold.
This is confirmed by the results obtained for compound 7, which has two hydroxyl groups, but only
one substituent in ring A, and presents lower activity than compounds 4 and 5 (Figure 3). It was
observed that the ABTS scavenging activity of the tested compounds is dose-dependent (Figure S11,
supplementary material).
 
Figure 3. Structure/activity relationships established for ABTS scavenging activity.
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3.2.2. Anticholinesterasic Activity
The results for acetylcholinesterase (AChE) inhibitory activity showed that compound 7 is the only
one which presents some activity at the maximum concentration tested (47.1± 3.6%, at 150 μg/mL). This
activity is less pronounced than the inhibition obtained for control compound donepezil (95.2 ± 0.4% at
50 μg/mL), a pure competitive inhibitor of AChE used clinically in early stages of Alzheimer’s disease.
The results suggest that the cyclization seems to increase the inhibitory activity of the compound, since
compound 7, which is a flavanone, is more active than compound 6, the respective chalcone. Also,
the existence of free hydroxyl groups in both A and B rings seems to be important because, out of the
three compounds with a flavanone structure (compounds 4, 5 and 7), only the one with a free hydroxyl
group in both C-7 and C-4′ (compound 7) shows activity. This is in agreement with the strong activity
revealed by quercetin, whose structure also possesses free hydroxyl groups in both rings A and B, like
compound 7. So, it can be concluded that the presence of hydroxyl groups in rings A and B of the
flavanone scaffold is crucial for the inhibition of AChE activity (Figure 4).
Figure 4. Structure/activity relationships established for antioxidant activity.
In terms of butyrylcholinesterase inhibition, compound 6 presented excellent activity, with a
percentage of inhibition of 96.0 ± 1.1% and IC50 of 26.55 ± 0.55 μg/mL, which are similar values to
the ones presented by donepezil (IC50 of 28.94 ± 1.76 μg/mL) and better than quercetin at the same
concentrations. This shows that, unlike what happens with acetylcholinesterase, the presence of
three hydroxyl groups in the chalcone scaffold highly favors the inhibition of butyrylcholinesterase
activity. The results presented by chalcones 1 (12.51 ± 0.82%) and 8 (0%) also confirm that, like with
acetylcholinesterase, the presence of methoxyl groups does not confer inhibitory activity to chalcones.
Compound 7 presents an activity very similar to the one observed for acetylcholinesterase
inhibition (46.26 ± 1.27%), meaning that it is a dual inhibitor, a much-appreciated feature in the search
for compounds with therapeutic potential towards Alzheimer’s disease. The presence of a hydroxyl
group in ring B of the flavanone scaffold increases its inhibitory effect, since flavanones 5 (36.30 ± 0.20%)
and 7 present higher activity than flavanone 4 (9.00 ± 1.30%), which has a methoxyl group in said
position (Figure 4). The compounds inhibited butyrylcholinesterase in a dose-dependent manner
(Figure S12, supplementary material).
3.2.3. Antimicrobial Activity
As observable in Table 2, most of the compounds tested inhibited the growth of gram-positive
bacteria, but none was effective against the gram-negative strain tested. This inhibition was found to
be concentration-dependent (Figures S13 and S14).
The most efficient compounds against Micrococcus luteus were 6 and 7, both with similar IC50,
which suggests that cyclization does not influence the toxicity of these molecules against this species.
These results are concordant with the literature, since it is described that these compounds presented
similar activity against Mycobacterium tuberculosis [58]. Although some compounds tested exhibit
an IC50 value greater than 200 μg/mL, the percent of growth inhibition exhibited at the maximum
concentration tested allows one to deduce some interesting structure/activity relationships, which are
discussed below. The chalcone 1 had no effect against M. luteus, while chalcone 8 presents 41.71% of
growth inhibition at 200 μg/mL. These results suggest that the presence of methoxyl groups at ring A
reduces its activity against this species. The same effect is observed when comparing the activity of
compounds 4 and 5 (Figure 5).
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Table 2. Antimicrobial activity of synthesized compounds 1, 4–8.
Compounds and
References
IC50 μg/mL (± SD)
M. luteus B. subtilis E. coli
1 >200 >200 >200
4 164.89 (±2.97) a 76.46 (±4.27) a >200
5 >200 >200 >200
6 23.78 (±2.04) b 9.33 (±0.25) b >200
7 23.64 (±2.24) b 20.48 (±3.13) c >200
8 >200 74.64 (±3.92) a >200
Penicillin 8.47 (±0.55) c 0.28 (±0.02) d >40
Streptomycin 0.59 (±0.02) d 15.86 (±0.21) e 14.45 (±1.73)
In each column, the letters a, b, c, d, and e indicate significant differences (p < 0.05).
Figure 5. Structure/activity relationships established for antibacterial effect against M. luteus.
Compound 5 inhibits 43.08% of bacterial growth at 200 μg/mL, while this value is almost double
for compound 4 (74.43 ± 1.95%), which confirms that the methoxyl groups at ring A decrease the
molecule’s antibacterial effect.
The strongest activity against Bacillus subtilis was displayed by compound 6 (IC50 = 9.33 μg/mL),
presenting even better activity than streptomycin (Table 2). The corresponding flavanone 7 has a higher
IC50 (20.48 μg/mL), which leads to the conclusion that the α,β unsaturated carbonyl bridge linking
ring A to ring B is important in the mode of action of the compounds against this bacterial strain.
The molecules with the higher numbers of hydroxyl groups are the ones with better activity, showing
that these groups also play an important role in the molecule’s mode of action against B. subtilis. Again,
the compounds with two methoxyl groups in meta positioning (1 and 5) were the ones with lower or
none antimicrobial activity. Comparing the results from compounds 4 and 7 (both flavanones with two
hydroxyl groups), one can conclude that the presence of the methoxyl group in ring B (compound 4)
reduces the compound’s activity against this bacterial strain (Figure 6).
Figure 6. Structure/activity relationships established for antibacterial effect against B. subtilis.
3.2.4. Antitumor Activity
Considering the antitumor activity of the studied compounds, it can be noticed that compounds 5
and 8 were the most active, presenting very similar IC50 values. Compounds 1 and 4 showed some
activity, although lower than the ones mentioned above (Table 3). However, none of the compounds
tested were as active as colchicine or paclitaxel, the reference compounds used (Table 3). It was also
observed that the inhibition of tumor cell growth is dose-dependent for all the compounds tested
(Figure S15, supplementary material).
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Table 3. Antitumor activity of the synthesized compounds 1, 4–8.
Compounds and References
IC50 μg/mL (± SD)
A549 Cell Line
1 101.23 (±0.42) a
4 135.89 (±2.61) b
5 93.42 (±2.42) c
6 >200
7 >200
8 93.31 (±2.45) c
Paclitaxel 5.96 (±0.48) d
Colchicine 2.78 (±0.71) d
In each column the letters a, b, c, d, and e indicate significant differences (p < 0.05).
Results for the activity of compounds 6 and 7 against the A549 cell line have already been reported
in the literature [7,59–61]; however, their activity was tested in order to facilitate the comparison of the
results, since all the compounds were tested in the same conditions. The results for compound 7 are
concordant with the literature, since it is reported that the effects of this compound in A549 cells is
limited to the inhibition of cell migration, without any effects on growth or cytotoxicity level [7,60].
Compound 6 did not present any activity, which was unexpected, since it is reported to possess
antitumor activity against several cell lines, including A549, by inhibiting proliferation and inducing
tumor cell apoptosis [59,61]. This can be explained by the fact that the authors used a much lower
cell concentration than the one used in the present work, and it has been proved that lower cell
concentrations are correlated with higher activities of the compounds tested [62].
From the results obtained, the only conclusions that can be drawn regarding structure/activity
relationships are that neither the α,β unsaturated carbonyl bridge nor the cyclization of chalcone into
flavanone have an influence in the inhibition of tumor-cell growth, since both chalcones and flavanones
presented interesting activities (Figure 7). Also, the presence of methoxyl groups has some importance
in the antitumor effect of the compounds, since compounds 6 and 7, which do not have methoxyl
groups, did not present any activity against the A549 cell line (Table 3). The influence of a methoxyl
group in synthetic polyphenolic compounds’ antitumor activity was not a surprise because it was
previously detected in our group [63].
Figure 7. Structure/activity relationships established for antitumor activity.
4. Conclusions
Hydroxylated chalcone/flavanone derivatives were synthesized using the less common bases
NaH or LiHMDS. Overall, it was shown that the use of NaH is efficient (~80% yield in 3–4 h) for
the synthesis of chalcones not hydroxylated other than at C-2′ position. However, if the desired
derivatives are polyhydroxylated chalcones, the use of LiHMDS is preferable, because the conversion
rate is good and it is a one-pot procedure that avoids the protection and subsequent deprotection steps,
a time-consuming procedure that also significantly decreases the total yield. Although the aim of this
work was to obtain the compounds for biological evaluation, we suggest microwave or ultrasound
irradiation as a better source of energy to increase the compounds’ yields, an aspect that is important
for their future applications.
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Some of the compounds synthesized presented interesting results in their bioactivities, with
chalcone 6 being the most active compound in terms of antioxidant, anti-butyrylcholinesterase and
antimicrobial activity. Its isomer, flavanone 7, showed activity against both acetylcholinesterase and
butyrylcholinesterase, which is an interesting result since this dual inhibition is a much-appreciated
feature in Alzheimer’s disease therapy. Also, it is interesting that these compounds can be obtained in
the one-pot methodology using LiHMDS.
Some important structure/activity relationships were established for all the activities tested, and
the most important are highlighted and summarized in Figure 8.
Figure 8. Summary of the most relevant structure/activity relationships established.
As shown in Figure 8, the free hydroxyl groups are essential to increase antioxidant,
anti-butyrylcholinesterase and antimicrobial activities. Not only their presence but also their number
increases the compounds’ activity, while methoxyl groups decrease it. The flavanone scaffold increases
the acetylcholinesterase inhibitory activity, while for the butyrylcholinesterase inhibition, the chalcone
scaffold appears to be better. This is another interesting result because it is known that these
compounds are isomers, and in biological systems they can exist in a controlled equilibrium. Regarding
the antimicrobial activity, it is possible to detect that the cyclization into flavanone has no effect against
the M. luteus strain, whereas against B. subtilis, the flavanone decreases the antibacterial activity. So,
it seems that the α,β unsaturated carbonyl bridge linking rings A and B is important to inhibit the
growth of the B. subtilis strain. Finally, it can be established that the presence of methoxyl groups in
both chalcones and flavanones increases the antitumor activity.
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Abstract: (1) Background: Almost 500 million people worldwide are suffering from diabetes. Since
ancient times, humans have used medicinal plants for the treatment of diabetes. Medicinal plants
continue to serve as natural sources for the discovery of antidiabetic compounds. Prangos pabularia
Lindl. is a widely distributed herb with large reserves in Tajikistan. Its roots and fruits have been used in
Tajik traditional medicine. To our best knowledge, there are no previously published reports concerning
the antidiabetic activity and the chemical composition of the essential oil obtained from roots of P.
pabularia. (2) Methods: The volatile secondary metabolites were obtained by hydrodistillation from the
underground parts of P. pabularia growing wild in Tajikistan and were analyzed by gas chromatography
(GC) and gas chromatography-mass spectrometry (GC-MS). Protein tyrosine phosphatase 1B (PTP-1B)
inhibition assay and molecular docking analysis were carried out to evaluate the potential antidiabetic
activity of the P. pabularia essential oil. (3) Results: The main constituents of the volatile oil of P. pabularia
were 5-pentylcyclohexa-1,3-diene (44.6%), menthone (12.6%), 1-tridecyne (10.9%), and osthole (6.0%).
PTP-1B inhibition assay of the essential oil and osthole resulted in significant inhibitory activity
with an IC50 value of 0.06 ± 0.01 and 0.93 ± 0.1 μg/mL. Molecular docking analysis suggests volatile
compounds such as osthole inhibit PTP-1B, and the results are also in agreement with experimental
investigations. (4) Conclusions: Volatile secondary metabolites and the pure isolated compound
(osthole) from the roots of P. pabularia exhibited potent antidiabetic activity, twenty-five and nearly two
times more than the positive control (3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic
acid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide)) with an IC50 value of 1.46 ± 0.4 μg/mL, respectively.
Appl. Sci. 2019 , 9 , 2362 ; doi:10.3390/app9112362 www.mdpi.com/journal/applsci109
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Keywords: Prangos pabularia Lindl.; volatile oil; PTP-1B; osthole; 5-pentylcyclohexa-1,3-diene;
antidiabetic activity
1. Introduction
Diabetes, or diabetes mellitus, is a chronic metabolic disease associated with high blood sugar
levels over a prolonged period [1]. In 2017, according to the International Diabetes Federation report,
approximately 425 million adults (20–79 years) had diabetes worldwide with 3.2 to 5.0 million deaths
from the disease [2]. Unfortunately, these numbers are gradually increasing in most countries.
From ancient times, humans have used medicinal plants for the prevention and the therapy of
diabetes mellitus. Medicinal plants serve as natural sources for the discovery of compounds with
antidiabetic activities. In this relation, Tajikistan has a rich flora with around 4550 species of higher plants
that represent great interest for the discovery of alternative medications for the treatment of diabetes [3].
Tajikistan is known for its diversity of environmental conditions, including climate, high altitudes,
mountainous soil and minerals, and a relatively large number of sunny days per year, factors that
can affect plant development as well as biosynthesis and accumulation of secondary metabolites [4,5].
Essential oils have applications in medicine, pharmaceutical, food, and cosmetic industries. They possess
possible health benefits with antioxidant, antimicrobial, antitumor, anticarcinogenic, anti-inflammatory,
anti-atherosclerosis, antimutagenic, antiplatelet aggregation, and angiogenesis-inhibitory activities.
Therefore, extensive research has been directed toward the use of medicinal plants to control diabetes
mellitus and its complications [6].
PTP-1B (protein-tyrosine phosphatase 1B) belongs to the protein tyrosine phosphatase (PTP) family.
It is also known as tyrosine-protein phosphatase non-receptor type 1 that is encoded by the PTPN1
gene [7,8]. PTP-1B is localized on the cytoplasmic face of the endoplasmic reticulum and contains
the essential catalytic cysteine [9]. The PTP-1B enzyme catalyzes the hydrolysis of phosphotyrosine
from specific proteins [10]. PTP-1B is considered to be a promising potential therapeutic target for
treatment of various diseases, including diabetes, obesity, and cancer [11]. It inactivates the insulin
signal transduction cascade by dephosphorylating phosphotyrosine residues in the insulin-signaling
pathway [12]. Natural, synthetic, as well as semi-synthetic compounds have shown prominent
antidiabetic activities by inhibiting PTP-1B activity [13].
Prangos pabularia Lindl., a member of the Apiaceae, is a widely distributed herb up to 150 cm high
with a thick cylindrical root and has large reserves in Tajikistan [14]. P. pabularia, locally known as
“Yugan”, is a well-known species of the genus in Tajikistan. It typically grows in mountainous areas
and limestone slopes at altitudes 780 to 3600 m above sea level [15]. Its roots and fruits are valued in
Tajik traditional medicine and are widely used as general tonics as well as for treatment of vitiligo [4,15].
P. pabularia has been used to treat leukoplakia, digestive disorders, scars, and bleeding [16]. The root
extracts of P. pabularia have been examined for cytotoxic activity; the dichloromethane extract of
P. pabularia roots demonstrated notable cytotoxicity on the HeLa carcinoma cell line [17]. P. ferulacea root
is used as an effective wound healing agent in traditional medicine of the western north of Iran [18].
Members of the Prangos genus are natural sources of phytochemicals, including coumarins and
terpenoids. Individual isolated pure compounds such as osthole and isoimperatorin showed the
highest inhibitory potency against the growth of human carcinoma cell lines. Osthole exhibited the
greatest cytotoxicity and was found to induce apoptosis in PC-3, H1299, and SKNMC cells at low
micromolar concentrations. Thus, osthole can be considered to be a promising lead in anticancer
drug discovery and development [17]. Several new compounds have been isolated from the essential
oil of Prangos species. A new bisabolene derivative was isolated from essential oil of the fruits of
Turkish endemic Prangos uechtritzii [19]. The 3,7(11)-Eudesmadien-2-one, a new eudesmane type
sesquiterpene ketone was isolated from Prangos heyniae H. Duman & M.F. Watson essential oil [20].
110
Appl. Sci. 2019 , 9 , 2362
The (2S)-3,5-Nonadiyne-2-yl acetate was isolated from Prangos platychlaena ssp. platychlaena fruit
essential oils [21].
Recently, we reported that the roots of P. pabularia are good sources of biologically active secondary
metabolites (coumarins) such as heraclenol, heraclenin, imperatorin, osthole, yuganin A, and others.
Yuganin A showed potent effects on the proliferation of B16 melanoma cells [22]. In a continuation
of this investigation, the current report presents the promising antidiabetic activity and the chemical
composition of volatile secondary metabolites of the underground parts of P. pabularia growing wild
in Tajikistan. There are several reports on the composition of the essential oils isolated from leaves,
fruits, and umbels of P. pabularia growing in Iran and Turkey [23–25], but, until now, there has been no
published reports on antidiabetic activity and volatile secondary metabolites of the underground parts
of P. pabularia.
2. Results and Discussions
2.1. Chemical Composition of Essential Oils
Volatile secondary metabolites were obtained by hydrodistillation of P. pabularia roots growing
wild in Tajikistan and were analyzed by gas chromatography (GC) and gas chromatography-mass
spectrometry (GC-MS). Identification of the oil components was based on their Kovats retention
indices (RI) determined by reference to a homologous series of n-alkanes and by comparison of
their mass spectral fragmentation patterns with those reported in the literature [26] and stored in
the MS library. Forty-two compounds were identified in the volatile oil accounting for 97.3% of the
composition; 5-Pentylcyclohexa-1,3-diene (44.6%), menthone (12.6%), 1-tridecyne (10.9%), and osthole
(6.0%) were identified as major constituents of the volatile oil obtained from roots of P. pabularia
(Table 1). The structure of the osthole was established on the basis one-dimensional (1D) NMR and
electrospray ionization (ESI)-MS spectroscopic studies, respectively [22]. The chemical structures of the
main components of the essential oil from the roots of P. pabularia are presented in Figure 1. The GC-MS
chromatogram of the volatile oil of P. pabularia is presented in Figure 2.
Figure 1. Structures of the main components of Prangos pabularia essential oil.
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Figure 2. The GC-MS chromatogram of the volatile oil of Prangos pabularia. 1. menthone; 2.
5-pentylcyclohexa-1,3-diene; 3. 1-tridecyne; 4. osthole.
2.2. NMR Data of Osthole
1H NMR (400 MHz, CDCl3): δ 6.23 (1H, d, J = 9.4 Hz, H-3), 7.61 (1H, d, J = 9.4 Hz, H-4), 7.28 (1H, d,
J = 8.6 Hz, H-5), 6.83 (1H, d, J = 8.6 Hz, H-6), 3.53 (1H, d, J = 7.3 Hz, H-11), 5.22 (1H, m, H-12), 1.67 (3H,
s, H-14), 1.84 (3H, s, H-115), 3.92 (3H, s, OCH3-7); 13C NMR (100 MHz, CDCl3): δ 161.49 (C-2), 113.11
(C-3), 143.87 (C-4), 126.32 (C-5), 107.47 (C-6), 160.34 (C-7), 118.10 (C-8), 152.95 (C-9), 113.14 (C-10), 22.06
(C-11), 121.25 (C-12), 132.75 (C-13), 18.06 (C-14), 25.91 (C-15), 56.17 (OCH3-7).
Acorenone, (E)-anethol,β-bisabolenal,β-bisabolenol,β-bisabolene, bicyclogermacrene, δ-3-carene,
chrysanthenyl acetate, β-caryophyllene, elemol, 3,7(11)-eudesmadien-2-one, geranial, germacrene D,
α-humulene, kessane, limonene, p-menth-3-ene, nerolidol, (Z)-β-ocimene, (E)-β-ocimene, α-pinene,
β-pinene, α-phellandrene, β-phellandrene, sabinene, γ-terpinene, α- terpinolene, m-tolualdehyde,
and 2,3,6-trimethyl benzaldehyde were reported as major components (≥10%) in the essential oil of
Prangos species (Table 2).
Table 2. The major compounds reported as chemical composition of essential oil from Prangos species.
Prangos Species Plant Part Major Components of the Essential Oil Ref.
P. acaulis aerial parts δ-3-carene (25.5%), α-terpinolene (14.8%), α-pinene (13.6%), limonene(12.9%), myrcene (8.1%) [27]
P. asperula fruits δ-3-carene (16.1%), β-phellandrene (14.7%), α-pinene (10.5%), α-humulene(7.8%), germacrene-D (5.4%) [28]
P. asperula fresh aerialparts
sabinene (43.5%), β-phellandrene (36.1%), (E)-nerolidol (15.2%),
p-menth-3-ene (14.9%), (E)-nerolidol (14.7%), p-menth-3-ene (13.3%) in stem
and leaves, α-phellandrene (11.9%) in fruits, β-myrcene (9.2%) in stem and
leaves; α-terpinene (8.3%) in fruits, β-phellandrene (7.9%) in flowers
[29]
P. asperula aerial parts 2,3,6-trimethyl benzaldehyde (18.4%), δ-3-carene (18.0%) and α-pinene(17.4%) [30]
P. asperula fruit sabinene (43.5%) [31]
P. ferulacea fruits α-pinene (57%) (vegetative stage), γ-terpinene (30.2–33.3%) and α-pinene(16.7–12.8%) [32]
P. ferulacea aerial parts (E)-anethol (95.5%) (flowering stage) [16]
P. ferulacea fruits chrysanthenyl acetate (26.5%), limonene (19.6%), α-pinene (19.5%) [33]
P. ferulacea aerial parts β-pinene (43.1%), α-pinene (22.1%) and δ-3-carene (16.9%) [34]
P. ferulacea aerial parts 2,3,6-trimethyl benzaldehyde (66.6%) [35]
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Table 2. Cont.
Prangos Species Plant Part Major Components of the Essential Oil Ref.
P. ferulacea aerial parts β-caryophyllene (48.2%), α-humulene (10.3%) and spathulenol (9.4%) [36]
P. ferulacea aerial parts α-pinene (36.6%) and β-pinene (31.1%) [37]
P. ferulacea roots β-phellandrene (32.1%), m-tolualdehyde (26.2%), and δ-3-carene (25.8%) [18]
P. ferulaceae fruits andumbels α-pinene and (Z)-β-ocimene [38]
P. heyniae fruits β-bisabolenal (18.0–53.3%), β-bisabolenol (2.3–14.6%) and β-bisabolene(10.1–12.1%) [39]
P. heyniae aerial parts
β-bisabolenal (1.4–70.7%), (8.2%), elemol (3.4–46.9%), kessane (26.9%),
β-bisabolene (14.4%), germacrene D (10.3–12.1%), germacrene B
3,7(11)-eudesmadien-2-one (16.1%) and β-bisabolenol (8.4%)
[20]
P. latiloba aerial parts geranial (26.8%) [31]
P. pabularia floweringaerial parts
α-pinene (32.4%), δ-3-carene (12.4%), germacrene D (8.1%), limonene (6.4%)
and bicyclogermacrene (6.2%) [40]
P. pabularia fruit bicyclogermacrene (21%), (Z)-β-ocimene (19%), α-humulene (8%), α-pinene(8%), spathulenol (6%), suberosin (2%) [24]
P. peucedanifolia floweringaerial parts α-pinene (38.1%), bicyclogermacrene (11.3%) and δ-3-carene (9.2%) [40]
P. uloptera aerial parts δ-3-carene (26.3%), α-pinene (15.4%), β-myrcene (9.0%), p-cymene (8.6%) [41]
P. uloptera aerial parts β-caryophyllene (18.2%), germacrene D (17.2%) and limonene (8.7%) [42]
P. uloptera seed α-pinene (41.9%) and β-cedrene (4.0%) [42]
P. uloptera aerial parts
α-pinene (20.3%), (E)-β-ocimene (19.6%), β-caryophyllene in fresh aerial
parts; β-caryophyllene (13.9%), α-pinene (13.6%), caryophyllene-oxide
(11.6%) in dried aerial parts; (9.9%), δ-3-carene (8.0%), germacrene D (6.0%)
in fresh aerial parts; spathulenol (7.8%) and germacrene D (4.7%) in dried
aerial parts
[43]
P. uloptera fruits germacrene D (17.6%), acorenone (16.9%), α-pinene (14.9%), and α-humulene(8.2%) [44]
Razavi reported that the composition of the essential oils isolated from leaves, fruits, and umbels
of P. pabularia collected from Iran were dominated by spathulenol, α-bisabolol, and α-pinene [25].
Bicyclogermacrene, (Z)-β-ocimene, α-humulene, α-pinene, and spathulenol were reported as the main
constituents of the essential oil of P. pabularia fruits collected from Turkey [24]. The chemical composition
of the root essential oil of P. pabularia differed from those from leaves, fruits, and umbels with regard
to predominance of sesquiterpenes and monoterpenes. In 2016, Tabanca and co-authors reported
that suberosin (1.8%) was identified in the essential oil obtained from fruits of P. pabularia. In present
work, 5-pentylcyclohexa-1,3-diene (44.6%), menthone (12.6%), 1-tridecyne (10.9%), and osthole (6%)
(an isomer of suberosin) were identified as the dominant constituents of the volatile oil of the roots
of P. pabularia. These major volatile compounds were not identified from the other Prangos species
(Table 2). Therefore, it confirms the different chemical composition from P. pabularia. Recently, we
reported that osthole was isolated from the chloroform extract of the roots of P. pabularia, and its
structure was elucidated by spectroscopic means, namely, high resolution electrospray ionisation mass
spectrometry (HR-ESIMS) and one-dimensional (1D) and two-dimensional (2D) nuclear magnetic
resonance (NMR) spectroscopy [22]. In addition, osthole was isolated from the hexane extract of the
fruits of P. asperula [30].
Both osthole and suberosin were found in Arracacia tolucensis var. multifida volatile oil [45].
The essential oil with the high coumarin content showed moderate in-vitro antibacterial activity against
representative Gram-positive and Gram-negative bacteria [45].
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2.3. Antidiabetic Activity of Essential Oil and Isolated Compound (Osthole)
The effect of the obtained essential oil and the pure compound (osthole) from P. pabularia
roots for its in vitro inhibition of the enzyme PTP-1B was determined. The essential oil
induced a PTP-1B enzymatic inhibition in a concentration-dependent manner with IC50 values
0.06 ± 0.01 μg/mL (p < 0.02), which is more than 25 times more potent than the positive
control (3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-(4-(thiazol-2-ylsulfamyl)-
phenyl)-amide) with IC50 1.46 ± 0.4 μg/mL (p < 0.05). The individual compound (osthole) also exhibited
strong inhibitory activity against PTP-1B, with IC50 values 0.93 ± 0.1 μg/mL (p < 0.01); it was also more
effective than the positive control. The dose response curves of the inhibition of the PTP-1B enzyme of
P. pabularia essential oil and osthole are shown in Figure 3.
Wang and co-authors presented a strategy based on GC-MS coupled with molecular docking
for analysis, identification, and prediction of PTP-1B inhibitors in the Himalayan cedar essential
oil. β-Pinene (49.3%), α-pinene (29.4%), α-terpineol (4.1%), and β-caryophyllene (3.7%) were the
main components of Himalayan cedar oil that inhibited PTP-1B with IC50 value 120.71 ± 0.26 μg/mL.
The docking results of the PTP-1B inhibitory activity of caryophyllene oxide was also in agreement
with its in vitro activity [46]. The IC50 value for PTP-1B inhibition for caryophyllene oxide was in the
range 25.8–31.3 μM [46,47]. New terpenoids cedrodorols A-B from Cedrela odorata showed inhibitory
PTP-1B activity with IC50 values 13.09 and 3.93 μg/mL, respectively [48]. In another study, Bharti and
co-authors reported the in vivo antidiabetic activity of Cymbopogon citratus essential oil with major
compounds, geranial (42.4%), neral (29.8%), myrcene (8.9%), and geraniol (8.5%), which were fully
supported by molecular docking predictions [49].
Figure 3. Dose response curve of inhibition of protein-tyrosine phosphatase 1B (PTP-1B) enzyme
for Prangos pabularia essential oil (A) (IC50 = 0.06 ± 0.01 μg/mL) and the pure compound osthole
(B) (IC50 = 0.93 ± 0.01 μg/mL).
Hong-Jen Liang investigated the hypoglycemic effects of osthole in diabetic db/db mice, and the
main mechanisms of these effects were elucidated using an in vitro cell-based assay and in vivo assays
using a diabetic db/db mouse model. Results showed that osthole significantly alleviated hyperglycemia
by activating PPARα/γ in a dose-dependent manner based on the results of the transition transfection
assay [50,51]. Wei-Hwa Lee reported that the western blot analysis revealed osthole to significantly
induce phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC)
as well as increase translocation of glucose transporter 4 (GLUT4) to plasma membranes and glucose
uptake in a dose-dependent manner [50]. These results suggest that the increase in the AMP:ATP ratio
by osthole had triggered activation of the AMPK signaling pathway, leading to increases in plasma
membrane GLUT4 concentration and glucose uptake level [52]. Other research has clearly shown that
osthole lowered fasting blood glucose (FBG) and improved insulin secretion. This may indicate partial
recovery from pancreatic damage, as indicated from histological characteristics [53].
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2.4. Molecular Docking
A molecular docking analysis was carried out on the 12 most abundant components from the
root essential oil of P. pabularia using the Molegro Virtual Docker program [54]. The MolDock “rerank”
docking energies as well as the scaled molecular docking energies are summarized in Table 3. There are
two ligand binding regions in human PTP-1B—the catalytic site and an allosteric site (Figure 4).
Nearly all of the ligands examined docked preferentially to the allosteric binding site in PDB 1T48,
and the best docking ligand was osthole. In the allosteric binding site, the coumarin rings are located in
a hydrophobic sandwich formed by Phe280 and Leu192 (Figure 5). Additionally, the aromatic residues
Trp291 and Phe196 form face-to-edge π interactions with the coumarin moiety. Residues Ala189 and
Glu276 surround the isopropylidene group of osthole. There are no apparent hydrogen-bonding
interactions in the docked osthole in the allosteric binding site.
A 
B 
Figure 4. Ribbon structure of human protein tyrosine phosphatase 1B (PTP-1B, PDB 1T48). The catalytic
site (A) and the allosteric binding site (B) are shown as green cross-hatched areas.
The active site of PTP-1B is composed of highly polar residues, including Arg24, Lys41, Arg47,
and Asp48, as well as the phosphate-binding loop, Cys215-Arg22 [55]. Therefore, the active site of
PTP-1B is not a likely target for the hydrophobic essential oil components of P. pabularia. Nevertheless,
the lowest-energy docked pose of osthole with the active site of PTP-1B (PDB 2HB1) has a scaled
docking energy of −103.0 kJ/mol. This docking pose of osthole shows π-stacking of the coumarin
moiety with Phe182 and Tyr46 and is held close to the catalytic site residues of Cys215 and Arg221
(Figure 6). In addition, there are hydrogen-bonding interactions between the osthole carbonyl oxygen
and the side chains of Lys120 and Arg221.
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Figure 5. The allosteric binding site of human protein tyrosine phosphatase 1B (PTP-1B, PDB 1T48)
with the lowest-energy docked pose of osthole.
Figure 6. The active site of human protein tyrosine phosphatase 1B (PTP-1B, PDB 2HB1) with the
lowest-energy docked pose of osthole. Hydrogen-bonding interactions are indicated by the blue
dashed lines.
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Ala and co-workers noted that “ . . . the active site of PTP-1B possesses very few desirable
drug-design features” and that the highly charged portions of the active site “ . . . significantly increases
the difficulty of designing potent inhibitors with acceptable membrane permeability” [55]. Thus,
we conclude that the likely binding site for the P. pabularia essential oil components is the hydrophobic
allosteric binding site, which is more consistent with the greater exothermic docking energies with the
allosteric binding site (PDB 1T48, Figure 4B) than with the enzyme active site (Figure 4A). Furthermore,
the docking energy for osthole is the most exothermic of the ligands examined, and this compound
represents 6.0% of the essential oil composition.
The most abundant component, 5-pentylcyclohexa-1,3-diene (44.6%), is a hydrocarbon,
and although the docking energies are somewhat lower for the allosteric site than those for other
essential oil components, the abundance of this compound may be a factor in the PTP-1B inhibitory
activity of P. pabularia root essential oil. Wiesmann and co-workers pointed out that allosteric inhibitors
“ . . . prevent formation of the active form of the enzyme by blocking mobility of the catalytic loop” [56].
3. Materials and Methods
3.1. Plant Material
The roots of P. pabularia Lindl. were collected from the Yovon region (38 18′47′′ N, 69 02′ 35′′ E
and 950 m above sea level) of Tajikistan in April 2017. The plant was authenticated by Doctor Farukh
Sharopov, and the voucher sample (No. TAS 23659-1) was deposited in the herbarium of the Xinjiang
Technical Institute of Physics and Chemistry Urumqi, Chinese Academy of Science. The air-dried
sample was chopped into small pieces and hydrodistilled for 3 h to give the yellow essential oil with
0.1% yield. Osthole was isolated from the roots of Prangos pabularia by silica gel column (100–200 mesh)
by elution of hexane ethyl acetate (20:1) [22].
3.2. Gas Chromatography
The quantification of the essential oil of P. pabularia was carried out by gas chromatography using
Shimadzu GC-2010 (Shimadzu, Kyoto, Japan) plus gas chromatograph, non-polar Phenomenex ZB-5
fused bonded column (30 m length × 0.25 mm inner diameter and 0.25 μm film thickness) and flame
ionization detector (FID). Helium was the carrier gas, and the flow rate = 1.5 mL/min with split mode.
The following temperature program was used: Initial temperature 120 ◦C held for 2 min, temperature
increased at a rate of 8 ◦C/min until 320 ◦C and then held for 10 min at 320 ◦C. Injector and detector
and injector temperatures were 310 ◦C and 320 ◦C, respectively. GC Solution software (version 2.53,
Shimadzu, Kyoto, Japan) was used for recording and integration. The percentages of each component
are reported as raw percentages based on peak area without standardization.
3.3. Gas Chromatographic-Mass Spectral Analysis
Compound identification of P. pabularia essential oil was carried out by gas chromatography-mass
spectrometry using Agilent 6890 GC, Agilent 5973 (Agilent Technologies, Palo Alto, CA, USA) mass
selective detector with electron ionization mass spectrometry (EIMS), (electron energy = 70 eV,
scan range = 45–400 amu, and scan rate = 3.99 scans/s), with HP-5ms capillary column (30 m length ×
0.25 mm inner diameter and 0.25 μm phase thickness). Helium was the carrier gas with a flow rate of
1 mL/min. Oven temperature program: Hold at 40 ◦C for 10 min, increase at 3 ◦C/min up to 200 ◦C,
and then increase at 2 ◦C/min to 220 ◦C. The injector and the interface temperatures were 200 ◦C and
280 ◦C, respectively. A 1% w/v solution of the essential oil in CH2Cl2 was prepared, and 1 μL was
injected with a splitless injection mode. Identification of the oil components was based on their Kovats
indices determined by reference to a homologous series of n-alkanes and by comparison of their mass
spectral fragmentation patterns with those reported in the literature (Adams 2007) and stored in the
MS databases (NIST 17, WILEY 10, FFNSC versions 1.2, 2, and 3).
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3.4. NMR and HR-ESIMS Analysis
NMR spectra were recorded on a Varian MR-400 (400 MHz for 1H and 100 MHz for 13C)
spectrometer (Palo Alto, CA, USA) in CDCl3. TMS (δ 0.00) signal was used as an internal standard for
1H NMR shifts, and CDCl3 (77.160 ppm vs. TMS) signal was used as a reference for 13C NMR shifts.
The HR-ESIMS data were collected with a QStar Elite mass spectrometer (AB SCIEX, Framingham,
MA, USA).
3.5. Antidiabetic Activity: PTP-1B Enzymatic Assay
The P. pabularia essential oil was screened for PTP-1B inhibition using pNPP (p-nitrophenyl
phosphate disodium salt) as the substrate. Both the essential oil sample and the enzyme were
pre-incubated at room temperature for 5 min before use. A buffer solution (178 μL of 20 mM HEPES,
150 mM NaCl, and 1 mM EDTA) was added to each well of a 96-well plate. The PTP-1B protein
solution (1 μL at a concentration 0.115 mg/mL) was added to the buffer solution, and then 1 μL of the
test solution and the positive control solution were added. The pNPP substrate (20 μL of 35 mM) was
added and mixed for 10 min. The plate was incubated for 30 min in the dark, and the reaction then
terminated by adding 10 μL of 3 M NaOH. The absorbance was then determined at 405 nm wavelength
using a Spectra Max MD5 plate reader (Molecular Devices, USA). The system without the enzyme
solution was used as a blank. Inhibition (%) = [(OD405 − OD405 blank)/OD405 blank] × 100. The IC50
was calculated from the percent inhibition values.
3.6. Molecular Docking
Molecular docking of PTP-1B with the major components found in P. pabularia root essential oil was
carried out on the X-ray crystal structures from the Protein Data Bank (PDB): 1T48, 1T49 [56], 2BGE [57],
2CMB [55], 2F71 [58], 2HB1 [59], and 3CWE [60]. The water molecules and the co-crystallized ligands
were removed from the protein crystal structures. Molecular docking for the essential oil components
with each of the protein structures was carried out using Molegro Virtual Docker, v. 6.0.1 (Molegro ApS,
Aarhus, Denmark) as previously described [61]. A total of 12 major essential oil components were
used in the docking study. The three-dimensional ligand structures were built using Spartan ’18 for
Windows, v. 1.2.0 (Wavefunction Inc., Irvine, CA, USA). For each docking simulation, a maximum
of 1500 iterations with a maximum population size of 50 and 100 runs per ligand was carried out.
MolDock re-rank scores were used to sort the poses generated for each ligand. In order to account for
the bias toward high molecular weights, the following scheme was used: DSnorm = 7.2 × Edock/MW1/3 ,
where DSnorm is the normalized docking score, Edock is the MolDock re-rank score, MW is the molecular
weight, and 7.2 is a scaling constant to bring the average DSnorm values comparable to Edock [62].
4. Conclusions
This study reports the chemical profiles of the essential oils from the roots of P. pabularia containing
5-pentylcyclohexa-1,3-diene, menthone, 1-tridecyne, and osthole as major compounds. The high
coumarin (osthole) content of the essential oil is particularly interesting in regard to the biological
activities of the plant. Our investigations clarified the use of essential oil from the roots of P. pabularia for
the development of formulations based on enzyme inhibition of PTP-1B. Based on molecular docking,
we conclude that secondary volatile metabolites (especially osthole) are likely responsible for the
inhibition of PTP-1B. Furthermore, the experimental data are also in agreement with the computational
investigation. The anti-diabetic activity of essential oil is related to the dominant volatile compounds,
which may be acting synergistically. Further confirmation of anti-diabetic activity of the essential oil
from P. pabularia needs more research efforts (especially in vivo antihyperglycemic activity), which may
be applied in food, agriculture, and medicinal industries as a source of anti-diabetic agent.
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39. Başer, K.H.C.; Özek, T.; Demirci, B.; Duman, H. Composition of the essential oil of Prangos heyniae H. Duman
et M. F. Watson, a new endemic from Turkey. Flavour Fragr. J. 2000, 15, 47–49. [CrossRef]
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Abstract: Honey and propolis are natural substances produced by Apis mellifera that contain flavonoids,
phenolic acids, and several other phytochemicals. The aim of this study was to phytochemically
characterize three different types of honey and propolis, both separately and mixed, and to evaluate
their wound-healing activity. Total phenolic compounds and flavonoids were determined using
the Folin–Ciocalteu’s and aluminum chloride colorimetric methods, respectively. The antioxidant
activity was evaluated by both the DPPH free radical scavenging assay and β-carotene bleaching test,
and the anti-inflammatory activity was determined by a protein denaturation method. To evaluate
the wound-healing activity of the samples, NHDF cells were subjected to a wound scratch assay.
The obtained results showed that dark-brown honey presents a higher concentration of phenolic
compounds and flavonoids, as well as higher antioxidant and anti-inflammatory activities. Propolis
samples had the highest concentrations in bioactive compounds. Examining the microscopic images,
it was possible to verify that the samples promote cell migration, demonstrating the wound-healing
potential of honey and propolis.
Keywords: honey; propolis; phenolic compounds; antioxidant; wound-healing activity; NHDF cells
1. Introduction
Honey is a natural substance produced by the western honeybee (Apis mellifera) from nectar and
exudates of flowers and trees. Honey contains flavonoids, phenolic compounds, and numerous sugars
in its composition, mainly glucose and fructose. It also contains small amounts of minerals, vitamins,
proteins, and enzymes [1–5].
Propolis is a resinous substance produced by the same species of bees, being composed of wax,
resinous secretions from plants, tree buds, pollen, and salivary enzymes. Propolis contains essential
oils and organic compounds such as phenolic acids and flavonoids [4,6–8]. Similarly to honey, propolis
also contains several minerals, vitamins, and enzymes [9]. This substance is used to protect the beehive,
acting as a natural sealant, antiseptic, and embalming agent [1,4,6–8,10].
The color and flavor of both honey and propolis vary according to the plant species used in
their production, health state of the bees, season, and the environmental conditions to which the
beehive is exposed [2–5]. The color of the honey can vary from deep brown to yellow, and propolis
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can be found in variations of green, red, or brown [6,7,11]. Differences in their composition result in
different biological activities [1,4,7,12]. Honey and propolis have been used in traditional medicine for
thousands of years mainly in burns and infected lesions [4,10]. Propolis was used primarily as an oral
antiseptic and in dermal lesions. In ancient Egypt, propolis was also employed in mummification [6].
The main mechanism of action of honey derives from its antioxidant and anti-inflammatory
activities [1,2,10]. The antioxidant potential of honey is due to the presence of phenolic compounds,
namely gallic acid and flavonoids, that promote the free radical scavenging [2,10]. Its anti-inflammatory
activity is associated with the ability to increase cellular proliferation, autolytic debridement, and
to stimulate the immune system, reducing edema and pain [10]. Propolis has a higher content
in flavonoids and phenolic acids than honey, which suggests that propolis should have a higher
antioxidant and anti-inflammatory activities [1,7].
Currently, an increasing interest in mixing propolis with honeys was verified, as products
including propolis are already available on the market. The commercial achievement of these products
is dependent of the level of acceptance and expectations of the consumers [1]. However, the potential
benefits of adding propolis to honeys is still to be scientifically validated.
Wounds are responsible for the consumption of large amounts of healthcare resources to ameliorate
the quality of life of patients, and so they represent a considerable health challenge. Several scientific
experiments have been performed to find novel compounds that possess wound-healing properties,
particularly from natural sources [13]. Honey was employed for the repair of battle wounds in both
World War I and in modern history. The healing activity of honey in infected wounds was initially
described in Europe and USA in mid-20th century [10]. Moreover, evidences suggest that propolis has
therapeutic activity, through quantitative and qualitative analyses of collagen types I and III expression
and degradation in wounds matrix, which suggests the favorable biochemical environment supporting
re-epithelization of propolis [11].
The first aim of this study was to phytochemically characterize different samples of honey
and propolis together with mixtures of propolis extracts with honey in different concentrations,
determining the contents in total phenolic compounds and flavonoids, as well as evaluating the
antioxidant and anti-inflammatory activities. The second purpose of this work was to evaluate the
in vitro wound-healing activity of the samples using normal human dermal fibroblasts (NHDF) by
means of the scratch assay.
2. Materials and Methods
2.1. Honey and Propolis Samples
Honey and propolis samples were collected from a Langstroth beehive in a mountainous forest in
the north central Portugal, specifically in the region of Sabugal (Guarda) during September 2018 (GPS
coordinates: 40◦23′33.5” N 7◦03′45.4” W).
Three different samples of honey and propolis were collected from the same beehive to maintain
consistent the conditions of production. Each honey sample was collected from a different box inside the
hive and was then filtered individually until there was no visible debris or particles. Propolis samples
were scraped from the boxes and frames of the hive and then separated according to the box from
which they were collected. All samples were stored individually in an appropriate sterilized container.
Dark-brown honey was considered as Honey 1 (H1), red honey was labeled as Honey 2 (H2), and
light-yellow honey was identified as Honey 3 (H3). Propolis samples were named according to the box
from which the honey samples were collected as Propolis 1 (P1), Propolis 2 (P2), and Propolis 3 (P3).
2.2. Propolis Extracts
The samples of propolis were grounded individually in a marble mortar at room temperature.
To start the extraction process, 100 mL of ethanol (Scharlab, Spain) were added to 14 g of each pulverized
propolis sample. The mixtures were left for 48 h under magnetic stirring at room temperature and in
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the absence of light. After 48 h, the mixtures were filtered and transferred to round bottom flasks to
evaporate the ethanol using a rotary evaporation system at 45 ◦C. To ensure the complete evaporation,
the round bottom flasks were kept in a vacuum oven for 24 h at 35 ◦C.
The propolis extracts were labelled as Propolis Extract 1 (PE1), Propolis Extract 2 (PE2), and
Propolis Extract 3 (PE3) and were frozen at −20 ◦C until they were used.
2.3. Mixtures of Honey with Propolis
Each propolis extract was added in a concentration of 0.3% (w/w) and 0.5% (w/w) to the Honey
1 (the one that presented the best results), according to the previously published work dealing with
the evaluation of the bioactive properties of honey with propolis [1]. The mixtures were prepared by
weighting the corresponding amounts of honey and propolis and mixing them to complete 100 g of
each mixture. To guarantee the complete homogenization, all mixtures were subjected to mechanical
stirring, after which they were stored at −20 ◦C until further use.
The mixtures were identified as Honey 1 followed by the corresponding Propolis Extract and
percentage added resulting in Honey 1-Propolis Extract 1 (H1PE1), Honey 1-Propolis Extract 2 (H1PE2)
and Honey 1-Propolis Extract 3 (H1PE3) at 0.3% or 0.5%.
2.4. Fourier-Transform Infrared Spectroscopy (FTIR)
FTIR was used to obtain spectra of the samples of honey, propolis and propolis extracts. These
spectra were obtained with 64 scans and a 4 cm−1 resolution, between 4000 and 600 cm−1 using a
Nicolet iS10 smart iTRBasic (Thermo Fisher Scientific, Waltham, MA, USA) model.
2.5. Phytochemical Characterization
For the phytochemical characterization, all the samples were diluted with methanol (Scharlab,
Spain).
2.5.1. Total Phenolic Compounds Determination
The phenolic compounds were determined by Folin–Ciocalteu’s colorimetric method [14,15],
using gallic acid as the standard. Initially, 450 μL of distilled water were mixed with 50 μL of each
sample or gallic acid (Sigma-Aldrich, USA) solution. Then, 2.5 mL of Folin–Ciocalteu’s reagent
(Sigma-Aldrich, USA) (0.2 N) were added, being the mixtures left for 5 min before the addition of 2 mL
of aqueous Na2CO3 (Sigma-Aldrich, USA) (75 g/L). The reaction mixtures were incubated for 90 min at
30 ◦C. After incubation, the content in total phenolic compounds was determined by colorimetry at
765 nm [14,15].
A standard curve was prepared using methanolic solutions of gallic acid at 500, 300, 250, 200, 150,
100, and 50 mg/L (y = 0.0010x; R2 = 0.9612). The total phenolic compounds content was expressed
as g of gallic acid equivalents (GAE)/100 g of sample (honey, propolis, and mixtures of honey with
propolis) [14,15].
2.5.2. Flavonoid Determination
The aluminum chloride colorimetric method was used to determine the flavonoids content
according to a previously implemented method [14,15]. To 500 μL of each solution, either the samples
or the quercetin (Sigma-Aldrich, USA) (used as standard), 1.5 mL of methanol, 0.1 mL of aluminum
chloride (Sigma-Aldrich, USA) 10% (w/v), 0.1 mL of 1 M potassium acetate (Sigma-Aldrich, USA) and
2.8 mL of distilled water were added. These solutions remained for 30 min at room temperature and
then the absorbances were measured using a spectrophotometer (Helios–Omega, Thermo Scientific,
USA) at 415 nm [14,15].
To construct the calibration curve, eight quercetin solutions were prepared in methanol with a
concentration of 200, 175, 150, 100, 75, 50, 25, and 12.5 μg/mL (y = 0.0146 x; R2 = 0.9887). The flavonoids
129
Appl. Sci. 2020 , 10 , 1845
content was expressed as g of quercetin equivalents (QE)/100 g of sample (honey, propolis, and mixtures
of honey with propolis) [14,15].
2.6. Antioxidant Activity Evaluation
For the antioxidant activity evaluation all the samples were diluted with methanol.
2.6.1. DPPH Free Radical Scavenging Assay
The DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical scavenging assay was used to evaluate
the antioxidant activity of the samples [16]. Briefly, to 100 μL of each sample, 3.9 mL of a 0.1 mM
DPPH (Sigma-Aldrich, USA) methanolic solution were added, being this mixture stirred until complete
homogenization. The control solution consisted in 100 μL of methanol with 3.9 mL of the DPPH
solution. The reaction mixtures were kept at room temperature in the absence of light for 30 min, time
after which the absorbances were read at 517 nm using a spectrophotometer (Helios–Omega, Thermo
Scientific, USA) [16].
The percentage of inhibition (%Inhibition) of DPPH free radical by the samples was determined
using the equation %Inhibition= [(Abscontrol −Absample)/Abscontrol]× 100, where Abscontrol corresponds
to the absorbance of the control and Abssample is the absorbance of each sample [14,15]. The results
were expressed as %Inhibition/100 g sample (honey, propolis, and mixtures of honey with propolis).
2.6.2. β-Carotene Bleaching Test
The β-carotene bleaching test was also employed to evaluate the antioxidant properties of the
samples [16]. Firstly, a β-carotene (Sigma-Aldrich, USA) solution in chloroform with a concentration of
20 mg/mL was prepared. To 500 μL of this solution 40 μL of linoleic acid (TCI Europe N.V., Belgium),
400 μL of Tween 40 (Riedel-de H¨aen, Germany) and 1 mL of chloroform (Scharlab, Spain) were added.
This mixture was transferred to a round bottom flask and subjected to a rotary evaporation system
at 45 ◦C to ensure complete evaporation of the chloroform. After this, 100 mL of water saturated
with oxygen were added to the mixture, forming an emulsion. Secondly, 300 μL of each sample
were transferred to test tubes and 5 mL of the previously prepared β-carotene emulsion were added.
The tubes were stirred until complete homogenization and were placed in a water bath at 50 ◦C for 1 h.
Using a spectrophotometer (Helios–Omega, Thermo Scientific, USA), the absorbances of the samples
were measured at 470 nm at the initial (t = 0 h) and final time (t = 1 h). The antioxidant activity was
determined as percentage of inhibition of β-carotene’s oxidation (%Inhibition) using the following
equation, %Inhibition = [(Abssample t = 1 h − Abscontrol t = 1 h)/(Abscontrol t = 0 h − Abscontrol t = 1 h)] × 100,
where Abscontrol corresponds to the absorbance of the control and Abssample is the absorbance of each
sample [14,15]. The results were expressed as %Inhibition/100 g sample (honey, propolis, and mixtures
of honey with propolis).
2.7. Assessment of In Vitro Anti-Inflammatory Activity
The anti-inflammatory activity was determined by evaluating the capacity of the samples to inhibit
protein denaturation [17]. Initially, a solution of bovine serum albumin (BSA) (Sigma-Aldrich, USA) at
1% (w/v) in phosphate buffer saline (PBS) solution was prepared. The pH of this solution was adjusted
to 6.8 using glacial acetic acid (Scharlab, Spain). Then, 100 μL of the samples diluted in methanol
were mixed, in test tubes pre-heated at 37 ◦C, with 900 μL of the BSA solution previously prepared.
The control was composed of distilled water. The tubes were then incubated for 10 min at 72 ◦C and after
this period cooled in ice for another 10 min. Finally, measurements of the absorbances were performed
using a spectrophotometer (Helios–Omega, Thermo Scientific, USA) at 620 nm. The percentage of
inhibition of protein denaturation (%Inhibition) was determined applying the following equation,
%Inhibition = 100 − [(Abssample × 100)/Abscontrol], where Abscontrol corresponds to the absorbance
of the control and Abssample is the absorbance of each sample [17]. The results were expressed as
%Inhibition/100 g sample (honey, propolis, and mixtures of honey with propolis).
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2.8. Evaluation of the In Vitro Wound-Healing Activity
2.8.1. Cell Culture
Normal human dermal fibroblasts (NHDF) cell line was maintained in RPMI-1640 culture medium
(Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, USA), 1%
mixture of antibiotic/antimycotic (Sigma-Aldrich, USA), 0.01 M of HEPES (Sigma-Aldrich, USA),
0.02 M of L-glutamine (Sigma-Aldrich, USA) and 0.001 M of sodium pyruvate (Sigma-Aldrich, USA).
Subsequently, the cells were incubated at 37 ◦C in an air incubator with a humidified atmosphere with
5% CO2 [18].
2.8.2. Wound Scratch Assay
The samples were tested for wound-healing activity by using the wound scratch assay [13,19].
NHDF cells were seeded in 12-well plates (4 × 104 cells/well) and cultured until a monolayer confluence
was reached. After the adhesion of the cells, the medium was removed from the wells and the cell
monolayer was scraped in a straight central line using a p200 micropipette tip, creating a scratch, with
reference points being marked in the plates. The wells were washed with PBS to remove floating cells
and cell debris. Then, the PBS was removed, the samples were prepared in RPMI-1640 and sonicated,
then they were added to the wells. Supplemented RPMI-1640 culture medium was added to the control
wells. After this, the plates were placed under a phase-contrast microscope and images were acquired
at the initial moment (t = 0 h). Then, the plates were incubated at 37 ◦C (5% CO2) and examined once
again under the microscope after 2, 24, and 36 h [13,19].
The size of the scratch zones was assessed manually using a digital image analysis tool (IC
Measure software version 2.0.0.161) (The Imaging Source, Germany) that allowed the estimation of the
distance between the injury margins. Using the IC Measure, the distance between the margins of the
lesion in the control at 0 h was estimated, which was considered the initial one and was used to scale
all other measurements to more easily compare the estimated distances of the injuries between the
samples and the control.
2.9. Statistical Analysis
The results were presented as mean values ± standard deviation. To determine the reproducibility
of the measurements, each assay was performed at least in triplicate. The calculated distance
between the margins of the injury were analyzed using the statistical program IBM SPSS Statistics 25
(https://www.ibm.com/analytics/spss-statistics-software) (IBM, Armonk, NY, USA). The significant
difference among means was analyzed by Student’s t-test (assuming the normal distribution of the
continuous variables). A level of p-value < 0.05 was considered significant.
3. Results and Discussion
3.1. FTIR Analysis of the Samples of Honey, Propolis, and Propolis Extracts
Regarding the honey samples and given the flora that exists at the place of harvest, it is expected
that Honey 1 was produced mainly during the autumn from species such as Arbutus unedo, Castanea
sativa, Quercus faginea, and Pinus pinaster. Honey 2 was produced during the summer from flowers
such as Rosa spp., Dahlia spp., Hydrangea spp., and flowers from fruit trees like Prunus avium, Malus
spp., Pyrus communis, and Prunus spinosa. Finally, Honey 3 was produced during the spring, when
most wildflowers and aromatic plants bloom (Papaver rhoeas, Chrysanthemum coronarium, Lavandula
stoechas, Rosmarinus officinalis, Baccharis trimera, and Thymus mastichina).
The propolis samples subsequently collected did not show a direct correlation with the honey
samples, because bees repair their hive continuously throughout the year, whenever this need arises,
so the conditions under which propolis is produced will not necessarily be the same conditions under
which honey is produced.
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The FTIR spectra of the samples of honey, propolis, and propolis extracts were recorded (Figure 1).
Figure 1. FTIR spectra of the samples.
The spectra of honeys show a water band at approximately 3300 cm−1 and 1650 cm−1. Near
2900 cm−1 it is possible to observe a band that may be associated with groups present in amino acids.
The bands between 1450 and 750 cm−1 may correspond to organic acids and to sugars commonly
present in honey, such as sucrose, glucose, and fructose. Even though the honey samples have been
produced in different seasons, they present quite similar spectra.
The spectra of propolis samples show approximately the same bands but with great dissimilarity
in terms of the intensity of the signal. In these spectra, it can be observed a water band at around
3400 cm−1, and very pronounced bands at nearly 2900 and 2850 cm−1 that may correspond to some
aliphatic compounds. The bands observed between 1650 and 1600 cm−1, as well as the bands between
1550 and 1400 cm−1 may be caused by the presence of flavonoids and other aromatic compounds.
The band at 1150 cm−1 may be due to the presence of hydroxyflavonoids. Some of the bands were not
considered and may be related to wax and other debris present in the samples. The spectra of propolis
extracts show approximately the same bands, but with lower intensity than the propolis samples.
The water band observed in both propolis samples and extracts is less pronounced than the
band registered in the honeys. In contrast, the bands identified as possible aromatic compounds and
flavonoids in propolis samples and extracts spectra are more pronounced. Finally, the sugar bands in
honey spectra are more evident and better outlined.
The results now obtained are in agreement with other previously published results for other
honey and propolis samples [20,21].
3.2. Phytochemical Characterization
Plant polyphenols present at least 8000 distinct known structures, being the most important class
of natural bioactive compounds, which exhibit various biological activities [22]. Honey presents three
classes of flavonoids with analogous structure: flavonols, flavones, and flavanones. Flavonoids are
responsible for the color, taste, and flavor of the honey and they also improve its beneficial health
effects [22]. Furthermore, the floral sources used by bees to produce honey, whose predominance
depends on seasonal and environmental issues, influences the phenolic composition and antioxidant
activity of honey.
The results of the phytochemical characterization of the samples regarding total phenolics and
flavonoids contents are presented in Table 1.
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Table 1. Total phenolic compounds and flavonoids content of the samples.
Samples
Total Phenolic Compounds Flavonoids
(g GAE/100 g Sample) 1 (g QE/100 g Sample) 1
H1 0.107 ± 0.016 0.007 ± 0.001
H2 0.046 ± 0.005 Not detected
H3 0.029 ± 0.003 Not detected
PE1 28.947 ± 1.329 5.494 ±0.335
PE2 21.747 ± 1.062 1.786 ± 0.029
PE3 28.667 ± 0.774 4.280 ± 0.123
H1PE1 0.3% 2.394 ± 0.227 0.290 ± 0.007
H1PE1 0.5% 3.324 ± 0.044 0.452 ± 0.012
H1PE2 0.3% 1.219 ± 0.049 0.115 ± 0.005
H1PE2 0.5% 1.750 ± 0.076 0.199 ± 0.018
H1PE3 0.3% 1.969 ± 0.071 0.054 ± 0.011
H1PE3 0.5% 3.506 ± 0.257 0.308 ± 0.006
1 Results expressed as mean ± standard deviation.
Total phenolic compounds content of honey samples ranged from 0.029 to 0.107 g GAE/100 g
sample, the values observed for propolis extracts ranged from 21.747 to 28.947 g GAE/100 g sample,
and finally for the mixtures of honey with propolis ranged from 1.219 to 3.506 g GAE/100 g sample.
The honey that presented the highest content in phenolic compounds is Honey 1 and the lowest content
can be found in Honey 3. These differences may be related with the different seasons in which the
honeys were produced, as mentioned above.
Propolis extracts showed a much higher concentration of phenolic compounds than honey samples,
with the highest content found in Propolis Extract 1 followed by Propolis Extract 3 and Propolis Extract
2. An increase in phenolic content was observed with the addition of higher concentrations of propolis
extracts to honey, and the highest value was obtained with H1PE3 at 0.5%.
Flavonoids were almost absent from honey samples. The only one that presents flavonoids in
its composition is Honey 1, but even this sample has a very low content. In contrast, the flavonoids
determined in the propolis extracts ranged from 1.786 to 5.494 g QE/100 g sample, and in the mixtures
ranged from 0.054 to 0.452 g QE/100 g sample. Propolis extracts showed a higher concentration of
flavonoids than honey samples, with the highest content in Propolis Extract 1 followed by Propolis
Extract 3 and Propolis Extract 2. An increase in flavonoid content was observed in all samples with the
addition of higher concentrations of propolis extract to honey, as expected.
The values of total phenolic compounds and flavonoids determined in the present work are very
similar to the ones obtained for selected Czech honeys [23].
3.3. Antioxidant and Anti-Inflammatory Activities
Honey is an important natural source of antioxidants and has potential therapeutic value in
several inflammatory diseases and in the treatment of heart disease, cancer, and cataracts, in addition
to its sweetening capacity and lower glycemic load [24]. The biological properties of honey comprise
antioxidant, antimicrobial, anti-inflammatory, and wound-healing activities [24].
In this work, the antioxidant activity of the samples was evaluated by two different methods that
measure distinct antioxidant properties (Table 2). The DPPH free radical scavenging assay is based on
the capacity of the samples to scavenge free radicals, while the β-carotene bleaching test allows the
indirect evaluation of the capacity of the samples to inhibit the lipid peroxidation [25].
133
Appl. Sci. 2020 , 10 , 1845
Table 2. Antioxidant and anti-inflammatory activities of the samples.
Samples
DPPH β-Carotene Bleaching Test Anti-Inflammatory Activity
% Inhibition/100 g Sample 1 % Inhibition/100 g Sample 1 % Inhibition/100 g Sample 1
H1 0.431 ± 0.023 0.809 ± 0.042 20.625 ± 0.884
H2 0.133 ± 0.019 0.684 ± 0.032 23.438 ± 3.094
H3 Not detected 0.349 ± 0.028 Not detected
PE1 92.506 ± 1.249 51.441 ± 4.477 15.000 ± 3.536
PE2 92.012 ± 0.258 48.660 ± 1.876 31.250 ± 1.768
PE3 93.245 ± 0.687 53.909 ± 2.328 48.750 ± 1.768
H1PE1 0.3% 8.271 ± 0.044 3.027 ± 0.070 36.408 ± 6.865
H1PE1 0.5% 8.119 ± 0.040 3.929 ± 0.105 28.571 ± 0.001
H1PE2 0.3% 7.921 ± 0.097 2.878 ± 0.096 40.049 ± 1.716
H1PE2 0.5% 8.154 ± 0.158 3.108 ± 0.049 45.238 ± 0.001
H1PE3 0.3% 8.165 ± 0.026 2.919 ± 0.106 36.408 ± 3.433
H1PE3 0.5% 8.396 ± 0.321 3.596 ± 0.089 40.476 ± 6.734
1 Results expressed as mean ± standard deviation.
The honey that presented the highest antioxidant activity measured by the DPPH assay was
Honey 1, opposed to Honey 3 that showed no relevant activity measured by this method. Propolis
extracts revealed extremely high levels of antioxidant activity across all samples, with Propolis Extract
3 presenting the highest value. An increase in the antioxidant activity was observed in all samples
with the addition of propolis extract to honey, however adding a higher concentration of propolis did
not result in a considerable rase in activity in most cases.
Concerning the results of β-carotene bleaching test, the honey that revealed the highest antioxidant
activity was once again Honey 1. The antioxidant activity of this honey measured by both methods is
related with the presence of great amounts of phenolic compounds, as previously mentioned. Propolis
extracts revealed high levels of antioxidant activity measured by β-carotene bleaching test as it was
also verified by DPPH assay.
Analyzing the data obtained throughout the different assays it was possible to verify that
dark-brown honey (H1) presented a higher content in phenolic compounds and flavonoids, followed
by red honey (H2) and finally by light-yellow honey (H3). These results were consistent with the
bioactive activity of the different samples. Since Honey 1 presented better phytochemical results, it was
used in all the mixtures of honey with propolis.
The anti-inflammatory activity was evaluated using an in vitro assay that studied the ability of
the samples to inhibit protein denaturation using a BSA solution (Table 2). It was noted that propolis
extracts reveal a higher anti-inflammatory activity than honeys. The honey that presented the highest
activity was Honey 2, and among the Propolis Extracts, PE3 revealed the highest activity. Generally,
an increase in the anti-inflammatory activity was observed in all samples when adding propolis
extract to honey. In a previous work involving Malaysian honeys, the authors concluded that the
anti-inflammatory activity may be attributed, at least in part, to the phenolic compounds [24].
3.4. Wound-Healing Activity
In the present study, NHDF cells were used in a scratch assay. Although all the preliminary
characterization data showed that the propolis extracts always presented better results than the other
samples under study, it was decided to also evaluate the wound-healing activity for all the samples
including the mixtures of honey with propolis.
It is already known that honey is not toxic against normal cells but is extremely cytotoxic to
the tumor or cancer cells, as it was previously described [26]. Similar results were found in propolis
extracts, which demonstrated cytotoxicity in human fibrosarcoma and colon adenocarcinoma cells
while presenting no cytotoxic action in normal human skin fibroblasts [27].
By using the microscopic images, it was possible to evaluate the evolution of the gap created in
the confluent cell monolayer in the presence of the samples (Table 3, Table 4, and Table 5).
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Analyzing the different images and comparing them to the control samples it is possible to say
that the honey that shows better results after 36 h is Honey 2 (Table 3), while the propolis extract that
presented better results was Propolis Extract 2 at 0.5% (Table 4); the best mixture is the honey with
propolis—H1PE3 0.3% (Table 5).
Examining all the images, it is possible to observe that the cells continue alive when incubated
with the samples. Moreover, it is clear that the samples promote cell migration, demonstrating the
wound-healing potential of honey and propolis.
Furthermore, by estimating the distance between the margins of the scratch (Table 6) the conclusions
were the same. For all the samples, except for Honey 3 at 2 h, a significant (p-value < 0.05) reduction of
the scratch was observed when compared to the control at the same time of incubation. In general, the
samples that showed the best results were the mixtures of honey with propolis. However, the sample
that presented the maximum activity was the Propolis Extract 2 at 0.5%.
Table 3. Microscopic images obtained from the scratch wound-healing assay with the honeys
(magnification: 100×).
Representative Image of the Cells at the Initial Moment (0 h)
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Table 4. Microscopic images obtained from the scratch wound-healing assay with the propolis extracts
(magnification: 100×).
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Table 5. Microscopic images obtained from the scratch wound-healing assay with the mixtures of
honey with propolis (magnification: 100×).











In opposition to what was previously observed [1], in the present work the obtained results
suggest that the effect of combining propolis with honey is not synergistic but just the combined effect
of honey and propolis. This may be due to the chemical composition of each particular honey that
will directly influence its bioactivities. In the honey samples now studied, the concentration in total
phenolic compounds is relatively lower than in other samples of honey [1]. Moreover, flavonoids were
not detected in the honey samples. These observations may explain the additive results observed for
the mixtures of honey with propolis, suggesting the contribution of the propolis compounds to the
biological activities.
Considering all the obtained results, it is possible to verify that the samples that presented higher
cell migration levels also presented higher bioactivity.
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During the inflammation process, honey promotes the release of inflammatory cytokines (TNF-α
IL-6, IL-1β, and NO) by monocytes, which might stimulate collagen synthesis by fibroblasts, playing
important roles in the initiation and amplification of this process [10]. The modulation of the severity
of inflammation can be associated with the anti-inflammatory properties of the polyphenols present
in honey. Honey initiates an active but controlled inflammation but does not let the inflammation to
develop in a chronic or exaggerated state, modulating the inflammatory phase of wound-healing [10].
The anti-ulcerous activity of honey and propolis can be attributed to flavonoids that can act alone or in
combination with other compounds such as sterols, terpinens, saponins, gums, and mucilage [4].
A recently published paper, in which the potential wound-healing properties of propolis was
evaluated, demonstrated that propolis promoted a marked increase in the wound repair capacity of
keratinocytes [28]. It was also proved that the regenerative properties of propolis are mainly due to
H2O2 (which is extracellularly released and passes across the plasma membrane) is able to modulate
intracellular mechanisms [28].
Table 6. Calculated distance between the margins of the injury.
Samples 0 h 1 2 h 1 p-Value 24 h 1 p-Value 36 h 1 p-Value
Control
1.00 ± 0.05
0.99 ± 0.05 0.818 0.99 ± 0.05 1.000 0.98 ± 0.05 0.817
H1 0.71 ± 0.04 0.002 * 0.59 ± 0.03 0.001 * 0.48 ± 0.02 0.001 *
H2 0.83 ± 0.04 0.011 * 0.37 ± 0.02 0.001 * 0.33 ± 0.02 0.001 *
H3 0.90 ± 0.05 0.062 0.57 ± 0.03 0.001 * 0.49 ± 0.02 0.001 *
PE1 0.3% 0.80 ± 0.04 0.006 * 0.78 ± 0.04 0.005 * 0.69 ± 0.03 0.002 *
PE1 0.5% 0.84 ± 0.04 0.014 * 0.81 ± 0.04 0.009 * 0.78 ± 0.04 0.005 *
PE2 0.3% 0.54 ± 0.03 0.001 * 0.39 ± 0.02 0.001 * 0.34 ± 0.02 0.001 *
PE2 0.5% 0.66 ± 0.03 0.001 * 0.52 ± 0.03 0.001 * 0.27 ± 0.01 0.001 *
PE3 0.3% 0.74 ± 0.04 0.003 * 0.62 ± 0.03 0.001 * 0.53 ± 0.03 0.001 *
PE3 0.5% 0.45 ± 0.02 0.001 * 0.41 ± 0.02 0.001 * 0.39 ± 0.02 0.001 *
H1PE1 0.3% 0.74 ± 0.04 0.003 * 0.63 ± 0.03 0.001 * 0.55 ± 0.03 0.001 *
H1PE1 0.5% 0.43 ± 0.02 0.001 * 0.43 ± 0.02 0.001 * 0.42 ± 0.02 0.001 *
H1PE2 0.3% 0.54 ± 0.03 0.001 * 0.37 ± 0.02 0.001 * 0.49 ± 0.02 0.001 *
H1PE2 0.5% 0.64 ± 0.03 0.001 * 0.58 ± 0.03 0.001 * 0.46 ± 0.02 0.001 *
H1PE3 0.3% 0.80 ± 0.04 0.006 * 0.44 ± 0.02 0.001 * 0.31 ± 0.02 0.001 *
H1PE3 0.5% 0.74 ± 0.04 0.001 * 0.45 ± 0.02 0.001 * 0.34 ± 0.02 0.001 *
1 Results expressed as mean ± standard deviation; * Indicates a significant result (p-value < 0.05).
4. Conclusions
This work demonstrated the biological potential of honey and propolis, particularly the
wound-healing activity, which is related with their antioxidant and anti-inflammatory properties.
Further studies should be performed to clarify the mechanism of action of honey and propolis by
which cell migration is stimulated.
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Abstract: Sesquiterpene lactones, a vast range of terpenoids isolated from Asteraceae species, exhibit
a broad spectrum of biological effects and several of them are already commercially available, such as
artemisinin. Here the most recent and impactful results of in vivo, preclinical and clinical studies
involving a selection of ten sesquiterpene lactones (alantolactone, arglabin, costunolide, cynaropicrin,
helenalin, inuviscolide, lactucin, parthenolide, thapsigargin and tomentosin) are presented and discussed,
along with some of their derivatives. In the authors’ opinion, these compounds have been neglected
compared to others, although they could be of great use in developing important new pharmaceutical
products. The selected sesquiterpenes show promising anticancer and anti-inflammatory effects, acting
on various targets. Moreover, they exhibit antifungal, anxiolytic, analgesic, and antitrypanosomal
activities. Several studies discussed here clearly show the potential that some of them have in
combination therapy, as sensitizing agents to facilitate and enhance the action of drugs in clinical use.
The derivatives show greater pharmacological value since they have better pharmacokinetics, stability,
potency, and/or selectivity. All these natural terpenoids and their derivatives exhibit properties that
invite further research by the scientific community.
Keywords: Asteraceae; sesquiterpene lactones; alantolactone; arglabin; parthenolide; thapsigargin;
in vivo study; anticancer; anti-inflammatory
1. Introduction
Traditional or folk medicine relies heavily on the use of compounds-rich plants, like those of
the Asteraceae family, of which many such species are commercially available in the form of herbal
preparations. These are particularly rich in a wide range of natural terpenoids named sesquiterpene
lactones [1] that, in some cases, are considered the active principles of such therapeutic plants [2].
Structurally speaking, sesquiterpene lactones are terpenes that have in common a basic structure
of 15 carbons (thus the prefix sesqui-) resulting from biosynthesis involving three isoprene units
with a cyclical structure along with a fused α-methylene-γ-lactone ring [3]. Sesquiterpene synthases
catalyze a common biosynthesis route for sesquiterpene lactones, based on the cyclization of farnesyl
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phosphate resulting from the 2-C-methyl-D-erythritol-4-phosphate (MEP) and mevalonate (MVA)
pathways of dimethylalyl diphosphate and isopentenyl diphosphate precursors in chloroplasts and
cytosol, respectively [4]. However, sesquiterpene lactones have very different chemical structures
regarding the type and position of the substituents, as well as the size of the non-lactone ring [5,6].
For this reason, in structural terms, sesquiterpene lactones are organized into several subclasses:
eudesmanolide (a 6/6 bicyclic structure), guaianolide and pseudoguaianolide (both 5/7 bicyclic
compounds), germacranolide (with a 10-membered ring) and xanthanolide (containing a non-cyclic
carbon chain and a seven-membered ring) [7,8] (Figure 1).
 
Figure 1. Basic chemical structure of each of the sesquiterpene lactone subclasses: eudesmanolide,
guaianolide, pseudoguaianolide, germacranolide, and xanthanolide.
Some of these subclasses have compounds that exhibit a wide range of biological activities. These
range from antitumor [9] to anti-inflammatory, including antimalarial, antimicrobial, antioxidant [10],
neuroprotective [11], hepatoprotective, and immune-stimulant properties [12,13]. Regarding the
structure/activity relationship of these compounds, it appears that the α-methylene-γ-lactone nucleus
has a crucial role in almost all their observed biological effects, such as cytotoxic, antitrypanosomal,
and anti-inflammatory actions [12,14]. Other specific structural moieties of sesquiterpene lactone seem
to influence their activity. For example, the presence of electrophilic sites associated with medium/high
lipophilicity increase antimycobacterial activity, while a double bond exo to the cyclopentenone
ring seems to favor anti-inflammatory activity [7,8,14]. The interaction of the α,β-unsaturated
cyclopentenone nucleus with the target depends largely on the geometry of the molecule, which is
also a factor that influences the level of activity exhibited by sesquiterpene lactones [7,15]. Moreover,
the number of alkylating groups in the structure of sesquiterpene lactones contributes to the level of
activity they display, two groups being the optimal number [7,15]. The structure/activity relationship
specific to each sesquiterpene lactone presented in this review will be discussed in detail throughout
Section 2. Scientific evidence shows an action mechanism common to sesquiterpene lactones. The structural
elements α-methylene-γ-lactone and α,β-unsaturated cyclopentenone act as alkylating groups on
proteins found in cells through Michael addition, especially their thiol groups. They thereby affect cell
functionality, i.e., gene regulation, protein synthesis, and cell metabolism [15–17].
In recent years, the scientific community has already shown an oustanding growth of interest in the
sesquiterpene lactones, largely due to the success of artemisinin—one of the best known—and the broad
spectrum of activities exhibited by this compound’s chemical family [18–20]. Thus, the high number
of studies published concerning their isolation from new natural sources, total and semi-synthetic
syntheses, and evaluation of pharmacological potential, is not surprising. Natural sesquiterpene
lactones exhibit poor pharmacokinetic properties due mainly to their low bioavailability, deriving
from low solubility in water. As a result, in order to overcome these limitations, research interest in the
synthesis of their derivatives has increased [21,22]. In addition, structural modification and synthesis
has also allowed for an in-depth knowledge of their chemical properties, as well as the establishment
of structure-activity relationships.
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In terms of health promotion, the applications of sesquiterpene lactones and their derivatives
are a key research area. From this point of view, in vivo, preclinical and clinical studies are those that
allow a more realistic assessment of their medicinal potential [23].
The literature on this topic is extensive, especially for the most successful compounds; however,
studies on less known sesquiterpenes and their derivatives show that these compounds deserve more
attention, since they could play an important part in future human health maintenance. Therefore, this
review aims to point out the results of the most impactful and recent in vivo and (pre)clinical studies
of these insufficiently explored compounds and derivatives, which could be a valuable alternative in
the development of new therapeutic drugs.
2. Sesquiterpene Lactones with Significant In Vivo Activity
2.1. Alantolactone
The eudesmanolide alantolactone (1) (C15H20O2) (Figure 2) was first isolated from Inula helenium
L. roots, and later was also found in other Inula species [24], as well as non-Inula spp. such as
Saussurea lappa C.B. Clarke [25] and Aucklandia lappa DC. [26].
Figure 2. Structure of alantolactone (1).
Alantolactone (1) is obtained mainly by extraction and purification from natural sources, although
its total synthesis is possible [27,28]. Modern laboratory techniques have resulted in a significant
increase in its extraction yield [29–31]. For example, ~3% pure alantolactone (1) yields were obtained
from Inula helenium roots by Zhao et al. [30], which meant a significant improvement over the ~1%
yields from the roots of Inula magnifica Lipsky [32].
Although alantolactone is associated with allergic contact dermatitis triggered by Inula
species [33–35], this compound was first described as anti-helminthic [36], with subsequent studies
demonstrating its tremendous potential, mainly as antitumor [37–40], anti-inflammatory [26,41],
and antioxidant [42] agent.
Regarding anticancer activity, the effect of alantolactone (1) on leukemia is well documented
and was recently reviewed by Da Silva Castro et al. [43]. Xu et al. [44] reported a positive and
significant effect (1) on B-cell acute lymphoblastic leukemia. In this study, 100 mg/kg (b.w.) doses
were intravenously administered every two days in leukemia xenografted NOC/SCID mice. Results
showed that treated mice lived an average of eight days more than non-treated mice (31.5 days after
xenografting in treated compared to 23.5 days in non-treated mice), without significant weight loss.
Before this study, Chun et al. [45] had also reported an in vivo antitumor effect on triple negative breast
cancer in mice. The researchers used only a 2.5 mg/kg (b.w.) dose every two days to treat athymic nude
mice xenografted with MDA-MB-231 cells. In this assay, alantolactone (1) reduced tumor size by over
half, and significantly reduced tumor weight by about half after 24 days. Alantolactone (1) also exhibits
in vivo activity against gastric cancer. Human gastric cancer cells (SGC-7901) were xenografted onto
nude athymic mice, which were treated with 15 mg/kg (b.w.) of alantolactone (1) injected every two
days [46]. Alantolactone (1) caused significant tumor growth inhibition and reduced Ki-67 and Bcl-2
expression (tumor associated proteins), without significant liver and kidney toxicity or impact on
mouse weight [46].
Alantolactone (1) has also proven to be an especially potent sensitizing agent. In fact, it exhibits a
synergistic effect with known chemotherapy drugs, such as oxaliplatin. Cao et al. [47] showed that a
10:2 mg/kg (b.w.) dose of alantolactone: oxaliplatin reduced tumor volume and weight by more than
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50% in athymic mice xenografted with colorectal tumor cells (HCT116). The anticancer effect increased
substantially when both compounds were used together, as opposed to alone. This result is in line
with that obtained by He et al. [48], according to which, using a small weekly injected dose of 3 mg/kg
(b.w.), tumor volume significantly decreased by around 75% in xenografted pancreatic cancer cells
(PANC-1), while increasing cancer cell chemosensitivity to oxaliplatin, revealing a synergistic action.
Alantolactone’s anticancer mechanism was also the main focus of several studies, some of them
mentioned in recent reviews [49,50] The authors attribute its activity to the multiple pathways it
activates. Alantolactone (1) acts as an alkylating agent leading to inhibition of key enzymes and proteins,
and as an apoptosis inducer in cancer cells at mitochondrial level by interacting with cytochrome
c. It promotes overproduction of reactive oxygen species (ROS) due to specific caspase activation,
by inhibiting autophagic deregulation, among other processes.
Beyond its anticancer activity, compound 1 also exhibits interesting anti-inflammatory activity.
Ren et al. [51] used the DSS-induced colitis mouse model to test alantolactone (1) anti-inflammatory
activity. A 50 mg/kg dose reversed colitis symptoms (bloody diarrhea, colon shortening and weight
loss), besides significantly reducing pro-inflammatory cytokine TNF-α expression (to about half that
of positive control) and IL-6 (by over 2.5 times compared to positive control) [51]. Wang et al. [41],
showed that a 10 mg/kg (b.w.) dose of alantolactone (1) significantly improved neurological function
and reduced cerebral edema in a traumatic brain injury mouse model. This neuroprotective effect was
attributed to alantolactone’s capacity to inhibit the NF-κB inflammatory pathway and the cytochrome
c/caspase-mediated apoptosis pathways [41]. To the best of our knowledge, no other authors have
elaborated on this interesting double action: the fact that alantolactone (1) can simultaneously activate
apoptotic pathways in cancer cells and inhibit these pathways in a cerebral edema model.
Seo et al. [52] described the neuroprotective effect of alantolactone (1) using amyloid β25–35-
induced ex vivo neuronal cell death and scopolamine-induced amnesia in mouse models meant to emulate
conditions common to neurodegenerative conditions like Alzheimer’s disease. A 1 μM alantolactone
(1) treatment increased cortical neuron viability to almost baseline control readings, and 1 mg/kg
(b.w.) significantly decreased scopolamine-induced cognitive impairments. It is a interesting to
note that this particular neuroprotective effect is attributed to a drop in ROS levels. High ROS
concentrations are associated with the neurodegenerative damage of Alzheimer’s disease. Again,
alantolactone (1) exhibits a double action: it raises ROS levels to induce apoptosis in murine models of
neurodegenerative damage.
The interesting advances with alantolactone (1) derivatives are also worth mentioning.
Kumar et al. [53] assayed three of the 17 thiol derivatives synthesized, at 10 mg/kg (b.w.) doses,
in mice showing that they have in vivo anti-inflammatory activity comparable to alantolactone (1).
The novel compounds shared alantolactone’s anti-inflammatory mechanisms. Another noteworthy
study involving alantolactone (1) derivatives was published in 2018 by Li et al. [54], testing 44 derivatives
for their ability to inhibit induced pulmonary fibrosis in mice. The results showed that 2 of these
compounds are particularly active at 100 mg/kg (b.w.), reducing the fibrotic area by more than 60%.
This is achieved by inhibition of the TGF-β1 pathway of myofibroblast differentiation. It should be
noted that no toxic effects were observed for either compound in the chronic toxicity test (seven days),
using a dose of 2 g/kg (b.w.) administered orally. Finally, a patent involving an alantolactone (1)
spiro-isoxazoline derivative was filed in June 2019 (US patent N◦ 20190185487) for the development
and production of these compounds that exhibit significant anti-inflammatory activity.
One factor which contributes to making alantolactone (1) very interesting as a future medicine is
its low toxicity. In work by Khan et al. [55], Kunming mice treated with 100 mg/kg (b.w.) alantolactone
(1) showed no significant signs of hepatotoxicity or nephrotoxicity, in line with the previously cited
work by He et al. [38]. This is especially important for alantolactone (1) as an anticancer drug, because
it is well known that the liver and kidneys are particularly susceptible to negative side effects from
chemotherapy approaches [56,57].
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Another engaging finding obtained by Khan et al. [55] is alantolactone’s ability to cross the
blood-brain barrier. It may thus become useful in the treatment of brain tumors or other conditions
involving the central nervous system (CNS), since the blood-brain barrier is the greatest obstacle for
drug delivery to those areas [58].
The metabolism and pharmacokinetics of alantolactone (1) have also been studied in vivo, with
future pre-clinical testing in mind. Research shows that alantolactone (1) exhibits low absorption and
is rapidly eliminated after intravenous and oral administration. Its metabolism involves conjugation
with thiol, and α, β-unsaturated carbonyl is the preferential structural metabolic site. The low aqueous
solubility of alantolactone (1) causes low oral bioavailability [59–61].
All these recent reports show there is great interest in alantolactone (1), and that it has potent
proven in vivo activities, mainly several different types of anticancer activity. This broad-spectrum
activity, combined with its synergistic action with known cancer therapy agents, shows alantolactone
(1) has great potential for future drug development. However, further research is necessary, especially
clinical trials, to identify its intracellular action sites and secondary targets and thereby elucidate its
mode of action.
2.2. Arglabin
Arglabin (2) (Figure 3), is a guaianolide sesquiterpene lactone with the chemical formula
C15H18O3, isolated from several species including Artemisia myriantha Wall. ex Besser [62,63],
Artemisia jacutica Drob [64], and Artemisia glabella Kar. and Kir. species [65] where the extraction yield
was 0.27% [66]. Fortunately, several synthetic and hemisynthetic methods for preparing compound 2
have been reported [66–70], allowing it to be provided in the quantities necessary for research and
medicinal applications.
Figure 3. Structure of arglabin (2).
The arglabin (2) molecule contains a 5,7,5-tricyclic ring structure with contiguous stereo centers [70].
Furthermore, it contains both an epoxide and an α,β-unsaturated Michael acceptor, two functional
groups that have important roles in its pharmacological activities [71]. There are many research lines
advancing towards more effective drugs on the basis of the arglabin (2) molecule. New arglabin (2)
derivatives have been obtained by chemical modification, the most successful being obtained via
amination followed by treatment with gaseous hydrochloric acid. This converts arglabin (2) into the
hydrochloride salt of the dimethyl amino adduct, which is very soluble in water [66,72]. This arglabin
(2) salt form was used in the therapy of several cancer types such as breast, lung, liver and esophageal
tumors in oncological clinics of Kazakhstan [73–75]. Treatment of an esophageal carcinoma patient
with compound 2 contributed to a significant reduction in tumor volume, favoring its regression and a
lower incidence of leucopenia [75].
In terms of mechanism of action, arglabin (2) inhibits farnesyl protein transferase enzyme [65,72].
It influences DNA synthesis in murine P388 lymphocytic leukemia cells [74]. Recently, Schepetkin and
co-authors [76] have reported that compound 2 inhibits T-cell receptor activation and anti-CD3-induced
movement of intercellular Ca2+ ions ([Ca2+]i), blocks ERK1/2 phosphorylation and depletes [GSH] in
Jurkat T cells.
The anticancer effect of Arglabin (2) was also demonstrated by He and colleagues [77] on
xenografted oral squamous cell carcinomas. They elucidated that tumor growth is inhibited via
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downregulation of relevant protein expression in the mTOR/PI3K/Akt signaling pathway and
impairment of mitochondrial membrane potential, leading to apoptosis.
Recently, the pharmacokinetic properties of arglabin (2) have been reviewed [72], highlighting that
it mainly accumulates in the liver, quickly reaches peripheral tissues and penetrates the blood-brain
barrier. Furthermore, according to the literature, arglabin (2) has no described adverse effects, since
it does not affect normal liver and kidney function or cause local irritative/allergenic reactions, nor
mutagenic or embryotoxic effects [66,72,78].
Besides anticancer activity, arglabin (2) demonstrated in vivo anti-arthritis activity in a rat model.
Arglabin (2) lowers the levels of inflammatory mediators and cytokines, and reduces expression of
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), COX-2 (cyclooxygenase-2) and
iNOS (inducible nitric oxide synthase) [79]. Abderrazak and co-authors [80] suggest that arglabin (2) is
a compound with great potential in inflammation and atherosclerosis therapy. Using a high-fat diet
ApoE2.Ki mouse model, experimental results [80] showed that arglabin (2) reduces inflammation by
decreasing IL-1β and IL-18 levels and increases autophagy apoptosis [81].
Studies carried out with arglabin (2) show its potential for developing new anticancer and/or
anti-inflammatory drugs, the main limiting factor being its low bioavailability. The preparation of
soluble active versions of compound 2, and/or new delivery systems may attract further interest in this
sesquiterpene lactone.
2.3. Costunolide
Costunolide (3) (Figure 4), has the same chemical formula as alantolactone (1) (C15H20O2). It is
a member of the germacranolide subclass and was first isolated from Saussurea costus (Falc.) Lipsch.
roots in 1960 [82]. It is present in many Asteraceae genera such as Inula [24], Lactuca and Helianthus [83],
but also those from other families like Magnoliaceae [84].
 
Figure 4. Structure of costunolide (3).
Biosynthesis of costunolide (3) is well documented and occurs through the mevalonate
pathway [85]. Briefly, the process starts with the cyclization of farnesyl pyrophosphate, forming
germacrene A. Next, the isoprenyl side chain of germacrene A undergoes hydroxylation by germacrene
A hydroxylase, followed by oxidation to germacrene acid. It is finally synthesized after oxidation and
cyclization of germacrene acid [85]. Some species are rich sources of costunolide (3), such as essential
oil of Saussurea lappa roots (yield ~3%), of which 52% was identified as costunolide (3) [86]. The total
synthesis of costunolide (3) has been described using different methods/strategies [87–89].
In a recent review [90], Kim and Choi detail the activities of custonolide (3) and discuss its
therapeutic potential. Like alantolactone (1), compound 3 also exhibits anticancer bioactivity against
different cancer cells via various routes. In fact, it acts as an apoptosis inducer, cell cycle regulator,
angiogenesis and metastasis inhibitor and can also reverse the drug resistance mechanism [91].
There are several recent publications describing in vivo costunolide (3) studies, such as the work
by Jin et al. [92] on costunolide’s anticancer effect on osteosarcoma xenografted mice. Results showed
a daily 20 mg/kg (b.w.) dose was enough to significantly reduce tumor weight by about half, as well as
reduce the number of lung metastases to around one third of that in the control group. Western blot
analysis of the tissues revealed this effect could be attributed to costunolide (3) inhibition of STAT3
transcription, a factor that is widely known to be linked to oncogenesis and cancer proliferation [93].
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It is interesting to note the similarity between previously mentioned STAT3 inhibitory activity by
alantolactone (1) [45]. To highlight another similarity, costunolide (3) also exhibits activity against
gastric adenocarcinoma in xenografted mice [94]. Results from this study showed costunolide (3)
induced caspase-mediated mitochondrial apoptosis in cancer cells and a 50 mg/kg (b.w.) dose on
alternate days significantly reduced tumor size to about half. It achieved very similar results to
the positive control cisplatin, a chemotherapeutic agent used in clinical treatment [94]. Interesting
to note is costunolide’s anticancer effect through telomerase reverse transcriptase inhibition [95], a
mechanism not known in alantolactone (1). As reported by the researchers, a 5 mg/kg (b.w.) dose
injected on alternate days in glioma xenografted mice significantly reduced tumor size by over
50%. This inhibition was associated with reduced telomerase activity, which leads to ROS-associated
apoptosis [95]. A subsequent work by the same research group also showed the same dose affects lipid
metabolism in glioma xenograft tumors, by lowering expression of FASN, SREBP-1, and PGC-1α [96],
which are key genes targeted for cancer treatment [97–99].
Beyond costunolide’s anticancer effect, it has also proven to be a potent anti-inflammatory
agent [90], as well as an antidiabetic, antihelminth, antimicrobial, antiulcer and antioxidant [91].
Its anti-inflammatory action has been well documented in vitro [84,100] and in vivo, appearing to be
linked to NF-κB pathway inhibition [101]. For example, costunolide (3) is able to suppress inflammatory
angiogenesis [102], alleviating gastric ulcers [103], and acute lung and liver damage [104–107].
Recently, studies have shown that costunolide (3) also exhibited anti-osteoarthritic effects [108].
In fact, treatment in rats with osteoarthritis causes attenuation of cartilage degeneration compared to
the control osteoarthritic group. The observed effect has been attributed to the inhibitory action of
this compound on the Wnt/β-catenin and NF-κB signaling pathways, and on the expression of matrix
metalloproteinases [108].
Costunolide (3) seems to be also a powerful antiasthmatic [109]. In this work, the researchers
treated asthma-induced mice with 10 mg/kg (b.w.) before an immune challenge. Results showed
a 61.8% inhibition of asthma-associated eosinophil increase, as well as significantly reducing lung
inflammation scores and mucin production [109].
Recently, it has been shown that costunolide (3) is an effective inducer of hair growth in mice [110].
For this assay, the researchers implanted mouse dermal cells, treated with 3 mM costunolide (3) for
two days. Results showed a 2.5-fold increase in induced hair follicles in the implanted treated cells,
and topically applied costunolide (3) significantly and visibly improved hair growth. The authors
claim this might be due to activation by compound 3 of key follicle-cell cycle pathways, including the
Wnt/b-catenin, Shh/Gli, and TGF-β/Smad pathways. It is worth mentioning the TGF-β/Smad pathway
was also mentioned in previous studies related to anti-inflammatory action of costunolide (3) [106].
Costunolide (3) derivatives have also proven to be highly interesting, with remarkable in vivo
effects. In recent work by Cala et al. in an agro-research context [111], many different functional groups
were added to the sesquiterpene backbone, yielding, among others, two amino and two methyl ether
derivatives with strong herbicidal activity. The etiolated wheat coleoptile assay indicated treatment
with these costunolide (3) derivatives had dose-dependent growth inhibition responses equivalent to
a widely used synthetic herbicide used as positive control. These results show there is potential for
some of these derivatives as bio-herbicides, but further studies are necessary. There was also another
interesting result of this work which the authors did not address, but is worth pointing out: two tested
thiol derivatives boosted coleoptile growth instead of inhibiting it, with one compound increasing
coleoptile length by ~30% with a 30 μM treatment. The general implication of these results is that
costunolide (3) modification can be powerful and versatile, capable of yielding diametrically opposed
bioactive compounds depending on the functional group added.
In conclusion, costunolide (3) is a highly multitalented and potent bioactive compound. Similar to
other sesquiterpene lactones such as the previously discussed alantolactone (1), much of its potential
for future drug development lies in its anticancer and anti-inflammatory effects. It is interesting that
there appears to be more work done with costunolide (3) derivatives than alantolactone (1) derivatives,
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which in general suggests greater interest of the scientific community in costunolide (3) as opposed to
alantolactone (1). With so many relevant publications in 2019 alone, we expect to see costunolide (3)
research ramping up to a pre-clinical stage very soon.
2.4. Cynaropicrin
Cynaropicrin (4) (Figure 5) is a guaianolide type sesquiterpene lactone with a chemical formula of
C19H22O6 and a 5,7,5 fused tricyclic skeleton [112].
 
Figure 5. Structure of cynaropicrin (4).
The sesquiterpene lactone cynaropicrin was isolated from artichoke (Cynara scolymus L.) in 1960
for the first time [113] and later it was found in Cynara cardunculus L. [114,115] and Cynara scolymus
L. species [116], being considered as a chemotaxonomic marker for artichoke plant species [112].
Cynaropicrin (4) was also found in many species of Asteraceae family such as Centaurea drabifolia
subsp. floccosa (Boiss.) Wagenitz and Greuter [117], Psephellus sibiricus (L.) Wagenitz [118], Rhaponticum
pulchrum Fisch. and C.A.Mey. [119], Moquinia kingii (H.Rob.) Gamerro [120], Saussurea calcicola
Nakai [121], Saussurea costus (Falc.) Lipsch. [122,123], Tricholepis glaberrima DC. [124], and many
others [112]. Yields of cynaropicrin (4) extraction from Cynara cardunculus L. leaves using ethanol, ethyl
acetate, dichloromethane and water were 56.9, 37.5, 40.3 and 13.6 mg/g dry weight, respectively [125].
The biological activities of cynaropicrin (4), as with other sesquiterpenic lactones, are related to
its pharmacophore γ-butyrolactone ring [112]. There are many studies reporting on the important
pharmacological activities of cynaropicrin (4), and plants rich in cynaropicrin (4), such as antitumor,
anti-inflammatory, antitrypanosomal, and antihepatitis C virus, among many others. Due to these
notable effects, cynaropicrin (4) will be suitable for the development of medicinal compounds [123].
Cynaropicrin (4) is the first natural product that in vivo potently inhibits the African trypanosome
diseases [126]. Using the acute model of mice infected with Trypanosoma brucei rhodesiense STIB 900,
when treated with two doses of 10 mg/kg (b.p.) per day, on the 7th day after infection, there was a 92%
reduction in parasitemia when compared to the untreated group. Additionally, selectivity indices of
7.8 were obtained for cynaropicrin (4) against L6 cells of rat myoblasts [127]. The action mechanism
is still under study to date, but is thought to be related to the interaction of compound 4 with the
trypanothione redox system in Trypanosoma brucei [127]. However, Da Silva et al. [128] demonstrated
that cynaropicrin (4) at a dose of up to 50 mg/kg (b.w.) per day has no effect in mice infected with
Trypanosoma cruzi, in either Y or Colombiana strains. The synthesis and semi-synthesis of several
cynaropicrin (4) derivatives allowed the structure/antitrypanosomal activity of these compounds to be
evaluated. It was concluded that the α-methylene-γ-lactone structure is indispensable to maintain
the biological effect, whereas 3-OH and 19-OH derivatization does not change the activity and some
types of side-chain promote the selectivity of the compound [129,130]. The in vivo evaluation of
some derivatives, using the Trypanosoma brucei rhodesiense acute mouse model, indicated that the
dimethylamino derivative exhibits much less toxicity than cynaropicrin (4), but also less activity [129].
Cynaropicrin (4) also showed the ability in vivo to delay the effects of skin photoaging, promoting
the proliferation of melanocytes and keratinocytes, by acting as inhibitor of NF-kB transcription
activity [131].
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2.5. Helenalin
Helenalin (5) (C15H18O4) (Figure 6), a 5/7-fused bicyclic sesquiterpene lactone that belongs to the
pseudoguaianolide subclass. It is very abundant in Arnica montana L. but is also identified in other
species from Arnica and Helenium genera and from Centipeda minima (L.) A.Braun and Asch. [132–136].
Figure 6. Structure of helenalin (5).
Alcohol extracts containing helenalin (5) and its derivatives have been used as a staple of
traditional herbal anti-inflammatory medicine for many decades [134]. For instance Arnica montana L.
solutions are used to treat rheumatism, arthritis, inflammation, hematoma, soreness, sprains, swelling
and muscle spasms from athletic activity etc., seasonally triggered arthritis, arteriosclerosis, angina
pectoris, postoperative conditions, and joint pain. The plant is used externally in creams, alcoholic
tincture, and ointment form but also taken highly diluted in homeopathic remedies [134]. Many such
preparations, even hair oil and shampoo, are commercially available from a range of suppliers in
healthfood shops and pharmacies almost worldwide [137]. Likewise, clinical trials have aimed to
assess topical Arnica applications, regarding possible reduction of laser-induced minor hematomas
and osteoarthritis-type symptoms. Orally administered homeopathic formulations are also widely
employed in the clinical setting to treat and manage conditions such as carpal tunnel, slow knee-surgery
recovery, tonsil and wisdom tooth extractions, facelifts, neuralgia, hysterectomy, venous surgery, hallux
valgus, heart-valve surgery, hemarthrosis, prolonged intravenous perfusion, joint sprains and strains,
muscle pain, etc. [133].
Helenalin (5) inhibits NF-κB transcription of inflammatory cytokines, which have an essential
role in both inflammation and cancer [138]. It also efficiently inhibits cancer cell proliferation through
a variety of action modes, e.g., telomerase inhibition [139], DNA and protein synthesis attenuation,
apoptosis induction and promoting reactive oxygen species generation [140]. It is noteworthy that
inhibition of NF-κB activation associated with another sesquiterpene, helenin, occurs in T-cells, B-cells
and epithelial cells in response to four different stimuli, nullifying kB-driven gene expression. Since this
activity does not affect transcription factors Oct-1, TBP, Sp1 or STAT 5, this NF-κB activation is probably
inhibited selectively [141,142]. Lyss et al. [141] described how helenalin modifies the NF-κB/IκB complex,
preventing IκB release. They proposed a molecular action mode for the anti-inflammatory influence,
which is different from other nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and
indomethacin. Furthermore, it targets Cys38 on p65, ablating DNA-binding [143], inhibiting neutrophil
chemotaxis and migration as well as 5-lipoxygenase and leukotriene C4 synthase activities [144].
Experiments performed by Schröder et al. [145] demonstrate that compound 5 inhibits platelet
aggregation induced by collagen, 5-hydroxytryptamine secretion and thromboxane formation,
depending its on concentration (between 3–300 μM). They concluded that helenalin inhibits platelet
function via interaction with platelet sulfhydryl groups in a way most likely associated with reduced
phospholipase A2 activity.
Helenalin (5) inhibited complete Freund’s adjuvant-induced arthritis and carrageenan-induced
paw edema in the rat [146]. Topical application of Arnica 3D gel (10%), combined with a 10 mA
microcurrent for 2 min also significantly improved wound healing in a linear incision wound model
in the rat back [147]. The evidence was consistent with a higher percentage of mature collagen
fibers and a significantly larger total number of cells in the wound, as assessed by structural and
morphometric analysis. According to this, different proportions of Arnica montana extracts alone or
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combined with other plants have been patented for their therapeutic potential [137]. Widrig et al. [148]
performed a randomized, double-blind study in 204 patients with osteoarthritis (OA) to compare
the effects of ibuprofen (5%) and Arnica montana gel (50 g tincture/100 g) containing helenalin
(5), 11α,13-dihydrohelenalin and its ester. The results show that short-term use, up to three weeks,
of Arnica gel improves pain and hand function in OA, indistinguishably from ibuprofen gel. Substantial
antiosteoarthritic activity by blocking transcription factors NF-κB and NF-AT is attributable to helenalin
and derivatives.
Boulanger et al. [149] demonstrated that helenalin (5), intraperitoneally delivered at 20 mg/kg in
lactating-Balb/C mice 9 and 3 h prior to infection, reduced intracellular growth of Staphylococcus aureus
in mouse mammary glands This suggests the compound interferes with host molecular mechanisms
and not directly with Staphylococcus aureus growth. The authors conclude helenalin might be worth
investigating as a potential treatment for Staphylococcus aureus-induced mastitis in bovine species.
There is however some concern regarding this treatment, mainly regarding helenin persistence in the
animal’s milk, and whether or not the therapeutic doses pose short- and long-term toxicity risks. It is
therefore imperative to further study and characterize its safety and pharmacological properties.
Valan et al. [150] showed that helenalin (5) has a significant biphasic positive inotropic effect
on the myocardium of guinea pigs at doses of 10−5–10−3 mol. Nevertheless, concentrations above
10−3 mol. cause an irreversible negative inotropic action leading to a blocking of muscle contraction.
The skin is susceptible to environmental damage by multiple agents, particularly solar ultraviolet
(UV), which induces skin hyperpigmentation disorders. Expression of heat shock proteins (HSPs,
particularly HSP70) is receiving consideration in the field of cosmetics, to reduce skin damage and
signs of aging. Usui et al. [151] isolated AM-2 (helenalin 2-methylbutyrate) from Arnica montana as a
good inductor of HSP70, with low cytotoxicity. Treatment of cultured mouse melanoma cells with
AM-2 or Arnica montana extract up-regulated the expression of HSP70 in a dose-dependent manner.
It also activated the transcription factor for hsp genes, i.e., heat shock factor-1. They concluded
that both Arnica montana extract and AM-2 are likely to show beneficial effects if incorporated in
hypopigmenting cosmetics.
Acute liver injury is a life-threatening syndrome frequently associated with hepatocyte damage and
characterized by oxidative and inflammatory responses. Li et al. [136] recently observed that intragastric
administration of helenalin (5) for 10 days significantly ameliorated hepatic injury induced previously
in mice with LPS/D-GalN. These results were evidenced by the attenuation of histopathological changes
and the decrease in serum aminotransferase and total bilirubin activities. Therefore, helenalin (5) shows
a hepatoprotective effect against damage induced by LPS/D-GalN. This in turn may be associated with
reduced hepatocyte apoptosis, by protection of mitochondrial function and oxidative stress inhibition
by Nrf2 pathway activation, as well as attenuating inflammation by inhibiting NF-κB activation.
The co-authors of that study [152] submitted Patent No. CN 110283151 in 2019 as a method for isolation
of helenalin from Centipeda minima and its application for treating hepatic fibrosis and inflammation.
Furthermore, the same authors [153] patented it for inhibiting hepatic stellate cell activation, showing
the advantages of reducing collagen deposition and synthesis of inflammation-related proteins,
promoting death of stellate cells, and its application in liver fibrosis treatment.
2.6. Inuviscolide
The guaianoline-type sesquiterpene lactone inuviscolide (6) (C15H20O3) (Figure 7) was identified
in Ferula communis (Apiaceae) and described to be the main metabolite in Inula viscosa (L.) Ait. [154].
Inuviscolide (6) inhibited in vivo inflammation in mice, as shown in the investigation performed
by Hernández et al. [155]. The authors used inuviscolide (6) and ilicic acid from Inula viscosa and found
that compound 6 influenced cell degranulation and leukotriene biosynthesis, as well as neurogenic
drive and glucocorticoid-like interactions. During the testing, ear and paw edema were induced
in Swiss female mice using phorbol esters or ethyl phenylpropiolate (EPP), and phospholipase A2
(PLA2) or serotonin, respectively. The drug dose was applied topically in the ear models but as
150
Appl. Sci. 2020 , 10 , 3001
subcutaneous or intraperitoneal injections in the paw models. For quantitation of leukotriene B4
(LTB4) formation, high-performance liquid chromatography (HPLC) was performed on rat peritoneal
neutrophils. The results showed that compound 6 reduced PLA2-induced edema with an ID50 of
98 μmol/kg. The results did not indicate that glucocorticoid response modifiers had an influence on
the edema induced by serotonin. In intact cells, inuviscolide (6) resulted in reduced generation of
LTB4 (IC50 value of 94 μM). The overall results indicated that compound 6 has an important role in the
anti-inflammatory activity of Inula viscosa, being more active than ilicic acid. The action mechanism was
suggested to be related to an interference with leukotriene synthesis and to PLA2-induced mastocyte
release of inflammatory mediators [156].
Figure 7. Structure of inuviscolide (6).
2.7. Lactucin and Its Derivatives Lactupicrin, and Lactucopicrin
Other compounds from the guaianolide subclass are lactucin (7) (C15H16O5) and its 8- and 15-
(4-hydroxyphenylacetate) derivatives lactupicrin (8) and lactucopicrin (9), respectively (Figure 8).
Dolejš et al. [156] and Ruban et al. [157] had previously described the chemical structure of lactucin (7).
These compounds are distributed within Asteraceae like Lactuca serriola [158], especially plants commonly
used in salads. Lactuca sativa (lettuce), Cichorium intybus (chicory and radicchio), and Cichorium endivia
(endive) have been reported to contain lactucin (7) and lactucin-related substances [159–164]. The content
depends largely on the species, variety and the part of the plant analyzed. In fact, lettuce guaianolide
content was high and reached concentrations between 61.7 mg/mL and 147.1 mg/mL in its latex [160]
and 2.9 mg/g to 36.1 mg/g in the overall plant, expressed as dry weight [162].
Figure 8. Structures of lactucin (7) and its derivatives lactupicrin (8) and lactucopicrin (9).
The biological activities of lactucin (7) and lactucin-related compounds had already attracted
interest at the end of the 19th century, as they were credited to be responsible for the bitter taste and
pharmacological effect of lactucarium or lettuce opium [165]. This is the condensed latex of wild
lettuce Lactuca virosa. This dried exudate was used in Europe for centuries with similar applications to
opium as an analgesic, antitussive, and sedative [163]. Due to its widespread use, it was described
and standardized in the United States Pharmacopoeia (USP) and the British Pharmaceutical Codex as
a sedative for irritable cough and as a mild hypnotic for insomnia [166–168]. Lactucopicrin (9) and
lactucin (7) were identified as its major active compounds, although compound 7 was suggested to be
one of the main metabolites related to the sedative and the sleep-promoting effects [163]. In an in vivo
study in mice, both substances were confirmed to be analgesics, with an activity equal to or greater
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than ibuprofen. In addition, when lactucin (7) and lactucopicrin (9) were administered to mice on the
hot plate, both compounds were revealed to have analgesic and sedative effects at concentrations of
15 and 30 mg/kg, respectively. Furthermore, in a spontaneous locomotor activity test, these compounds
were active at concentrations of 30 mg/kg [168].
Although the pure compounds currently are not easily available on the market, several lettuce
extracts and seed oils containing these sesquiterpene lactones as main active compounds are
commercialized, e.g., Sedan® (Pharco Pharmaceutical Company, Egypt). The sedative effects were
addressed in the pilot study by Yakoot et al. [169]. The authors investigated if lettuce seed oil was
efficient and safe to treat patients with sleep disorders. The results showed that the seed oil of L. sativa
was a potentially hazard-free agent, able to reduce sleeping difficulties and alleviate mild to moderate
forms of anxiety in geriatric patients, without showing side effects [169,170]. Additionally, the study
performed by Kim et al. [163] examined the sleep-inducing and sleep-prolonging effect of four lettuce
varieties. The seed and leaf extracts were evaluated using a four-week-old ICR mouse model to analyze
their effects on pentobarbital-induced sleep. The results showed that both extract types lengthened
sleep duration and significantly reduced sleep latency at both evaluated doses of 80 mg/kg and of
160 mg/kg [163]. Although these studies in patients were performed with plant extracts reported to
contain lactucin (7) and its derivatives as principal active pharmacological compounds, they confirm
that their application for treatment of anxiety and sleep disorders is worthy of further evaluation.
Additionally, the results showed that these sesquiterpenes might be assessed as potential alternatives to
currently used sleep-promoting, sedative, and anxiolytic agents, with their varied negative side-effects
and addiction-potential.
2.8. Parthenolide
Parthenolide (10) (Figure 9) has the same chemical formula as inuviscolide (6) (C15H20O3) and is
the best known sesquiterpene lactone in the germacranolide class. It was isolated for the first time from
feverfew leaves and flowerheads (Tanacetum parthenium (L.) (Sch.Bip.), a plant known in traditional
Chinese medicine for centuries to treat various ailments. Among them, it is used to relieve fever, pain
of different etiologies such as migraine and rheumatoid arthritis and even to treat insect bites [171].
Figure 9. Structure of parthenolide (10) and its derivatives DMAPT (11) and HMPPPT (12).
Compound 10 has been applied as an anti-inflammatory through specific inhibition of the signal
proteins IKK2, STAT3, and MAPK, along with the activity and expression of many inflammatory
mediators including COX, which is involved in the NF-κB mediated proinflammatory signal transduction
pathway [172]. It also exhibits antitumoral activity by proliferation inhibition in various cancer cell
types, including prostate, pancreas, cervical, breast, lung, colorectal, glioblastoma, multiple myeloma,
and leukemia [8,173]. There are numerous reviews describing the outstanding anti-inflammatory and
antitumor activities of parthenolide, its analogs, and derivatives upon different pathways in human
cancer cells [8,174–178].
Parthenolide (10) has a multitarget action mechanism. It triggers EGF receptor phosphorylation,
interferes with AP-1 [179] and the signal transducer and activator of transcription 3 (STAT3) [180] and
induces activation of c-Jun N-terminal kinase (JNK) [181]. Furthermore, the molecular mechanisms of
parthenolide action are strongly associated with DNA-binding inhibition of two transcription factors
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NF-κB [182,183], as well as the proapoptotic activation of p53, along with reduced glutathione (GSH)
depletion [184]. Parthenolide rapidly induces ROS generation [185,186], and lowers histone deacetylase
activity (HDAC) [187] and DNA methyltranspherase 1 (DNMT1) [188]. Additionally, parthenolide can
interfere with microtubule function through tubulin binding [189].
Recent advances regarding in vivo therapeutic applications of parthenolide (10), mainly focused
but not limited to anticancer and anti-inflammatory activities, are discussed below, together with the
synergistic effects and toxicity of compound 10 and some derivatives.
One of the advantages of parthenolide (10) is its cancer stem-cell selectivity while remaining
non-cytotoxic to non-tumor cells [190,191]. In this case, the molecular mechanism of parthenolide
involves induction of apoptosis through mitochondrial and caspase signaling pathways, and also an
increase in the cytosolic concentration of calcium, cell cycle arrest, and inhibition of metastasis [178,192].
Cholangiocarcinoma (CC) is an intrahepatic bile duct carcinoma with a poor prognosis due to
being chemoresistant. Parthenolide induced oxidative stress-mediated apoptosis in CC cells and the
Bcl-2-related family of proteins modulated that susceptibility [193]. Moreover, intraperitoneal injection
of parthenolide at 4 mg/kg caused significant inhibition of tumor growth and angiogenesis in the
xenograft model [194]. Recently, Yun et al. [195] demonstrated that low concentrations of parthenolide
(5–10 μM) suppressed HO-1 expression, enhancing oxidative stress by the PKC-α inhibitor Ro317549
(Ro) through inhibition of Nrf2 expression and its nuclear translocation. The effects of parthenolide
(10) and Ro at 2.5 mg/kg on tumor growth were tested using a xenograft nude mouse tumor model
with subcutaneously implanted ChoiCK and SCK cells. This assay indicated that their combined
application more effectively inhibited cancer cell growth inhibition as compared to treatment with either
compound by itself. Furthermore, the effect of parthenolide on the development of colitis-associated
colon cancer (CAC) was investigated using a murine model of azoxymethane (AOM)/dextran sulfate
sodium (DSS) induced CAC. This study showed that parthenolide administration (10) at 2 and
4 mg/kg can significantly inhibit the inflammation-carcinoma sequence and be crucial in experimental
CAC regulation. The mechanism of action involves decreased NF-κB p65 expression levels blocking
phosphorylation and subsequent degradation of κB-α inhibitor (IκBα) [196]. The authors conclude
that parthenolide (10) could be a novel chemopreventive agent for CAC treatment [196].
Oral cancer is one of the five most common cancers worldwide. Chemoprevention is a new
approach to cancer research, focusing more on the prevention, suppression, and reversal of the
carcinogenic process by the use of natural plant products and/or synthetic chemical compounds.
Thus, Baskaran et al. [197] tested the chemopreventive potential of parthenolide in DMBA-induced
hamster buccal pouch carcinogenesis (DMBA, 7,12-dimethylbenz[a]anthracene). Oral administration
of parthenolide (10) at 2 mg/kg b.w. completely prevented tumor formation and significantly reduced
the nefarious histopathological changes. In addition, the parthenolide treated group showed significant
improvement regarding antioxidants, detoxification enzymes and lipid peroxidation.
Glioblastoma, or glioblastoma multiforme (GBM), is the most aggressive type of brain cancer
and is very difficult to treat. Nakabayashi and Shimizu [198] examined the effect of compound 10
on tumor growth using a xenograft mouse model of glioblastoma, administering it intraperitoneally
(10 mg/kg/day) for 22 days. It significantly inhibited the growth of transplanted glioblastoma cells
with respect to the control group.
Zhang et al. [199] demonstrated that a high parthenolide dose (8 mg/kg/day) impedes initiation
of experimental autoimmune neuritis (EAN), an animal model for peripheral nervous system acute
inflammatory disease. This is achieved by parthenolide suppressing TNF-α, IFN-γ, IL-1β and IL-17
pathways and quickly decreasing Th1 and Th17 cells in the early stages. Although this anti-inflammatory
effect is short-lived, compound 10 also suppresses late-stage recovery of EAN models, along with
inhibiting the apoptosis of inflammatory cells. Such results suggest that parthenolide is not suitable
for nervous system autoimmune disease treatment.
Nitric oxide (NO) plays a key role in the etiopathology of central nervous system (CNS) diseases
like multiple sclerosis (MS). It has been proposed that inhibition of NO synthesis could prove a relevant
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mechanism of action in treating multiple sclerosis and migraine. Accordingly, Fiebich et al. [200]
investigated the effect of parthenolide (10) on iNOS synthesis and NO release using primary rat
microglia. The results indicated that compound 10 prevents iNOS/NO synthesis and inhibits the
activation of p42/44 mitogen-activated protein kinase (MAPK), but not IkBα degradation or NF-kB p65
activation. These results show parthenolide may be a potential therapeutic agent in the treatment of
CNS diseases.
Mechanisms of axon regeneration and optimal functional recovery after nerve injury are key
to in higher animals. However, insufficient growth rates of injured axons often lead to incomplete
peripheral nerve regeneration. Gobrecht et al. [201], demonstrated that a single parthenolide injection
at 5 nM into the injured sciatic nerve or its systemic intraperitoneal application was already enough to
significantly increase the number and length of regenerating axons in the distal nerve at three days
post-lesion. This application of parthenolide (10) appears to act on the great instability of microtubules
in promoting axonal growth, at least in the CNS [174]. For this reason, the efficacy of parthenolide is
very promising for a therapeutic promotion of nerve regeneration, since compound application and
recurrent treatments are facilitated, compared to invasive local nerve injections [202].
Pulmonary fibrosis (PF) in general and idiopathic pulmonary fibrosis (IPF) in particular, is a
disease for which there is no effective therapy. In vivo studies have shown that parthenolide (10),
via intragastric administration, inhibited the NF-κB/Snail pathway, attenuating bleomycin-induced
pulmonary fibrosis. Moreover, there were significant improvements in body weight and other
pathological changes associated with this disease [203].
NF-κB has been associated with the cardiovascular system; in fact, its function is related to the
protection of cardiovascular tissues against injuries. However, its activation can also contribute to
tissue pathogenesis, depending on the type of cells in which it is activated [204]. It is known that
myocardial infarct size could be reduced up to 60% by antagonizing NF-κB activity [205]. To achieve
this, parthenolide (10) at 250 or 500 mg/kg (b.w.) was administered intraperitoneally before reperfusion
in rats, and caused a significant improvement in myocardial injury, with a reduction in the oxidative
and inflammation state, consequently reducing infarct size [206]. However, Tsai et al. [207] reported
that a prolonged treatment in bEND.3 cells affected Ca2þ signaling in the endothelial cells that regulate
vascular tone; therefore, care should be taken on using this compound in experimental designs
and clinically.
Parthenolide (10) has relatively poor pharmacological properties, derived from its low solubility
in water and consequently reduced bioavailability, which limit its potential clinical use as anticancer
drug. To increase its solubility, a series of parthenolide derivatives were obtained by diastereoselective
addition of several primary and secondary amines to the exocyclic double bond [208,209]. N,N-
Dimethylaminoparthenolide (DMAPT) (11) (Figure 9) was selected as a leader compound according to
its pharmacokinetic, pharmacodynamic and bioavailability properties [209,210]. When formulated as
a fumarate salt, DMPAPT is 1000-fold more soluble in water than parthenolide and maintained the
anticancer activity because, DMAPT (11) is rapidly converted back to parthenolide in body fluids (10).
Recently, molecular studies indicate that DMAPT has a similar action to parthenolide [192,211–213].
DMAPT has approximately 70% oral bioavailability and induces rapid death of primary human
leukemia stem cells (LSCs) from both myeloid and lymphoid leukemias and is highly cytotoxic to bulk
leukemic cell populations. Pharmacological studies carried out by Guzman et al. [210] using both mouse
xenograft models and spontaneous acute canine leukemias demonstrate in vivo bioactivity. Indeed,
DMAPT eliminates human AML stem and progenitor cells without harm to normal hematopoietic stem
and progenitor cells, and eradicates phenotypically primitive blast-crisis chronic myeloid leukemia
(bcCML) and acute lymphoblastic leukemia (ALL) cells. Moreover, it inhibited metastasis in a mouse
xenograft model of breast cancer and enhanced the survival of treated mice [210].
DMAPT was assayed in a phase I trial against acute myeloid leukemia (AML), acute lymphoblastic
leukemia (ALL) and other blood and lymph node cancers [12,176]. However, a year later the clinical
trials were suspended [214].
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Radiotherapy is widely used in cancer treatment; however, the benefits can be reduced by
radiation-induced damage to neighboring healthy tissues. Morel et al. [215] demonstrated in mice
that DMAPT (11) selectively induces radio-sensitivity in prostate cancer cell-lines, while protecting
primary prostate epithelial cell lines from radiation-induced damage. Compound 11 has the advantage
of being well-tolerated orally without the need to adjust the administration time to radiation exposure.
Radiation-induced lung fibrosis is considered a critical determinant for late normal tissue complications.
Therefore, the same group [216] examined the radioprotective effect of DMAPT (11) on fibrosis in
normal tissues, according to the image-guided fractionated radiotherapy protocols used clinically.
The results obtained show that DMAPT reduced radiation-induced fibrosis in the corpus cavernosum
of the rat penis (98.1%) and in the muscle layer around the bladder (80.1%), and also the tendency
towards reduced collagen infiltration into the submucosal and muscle layers in the rectum. They
concluded that DMAPT could be useful in providing protection from the radiation-induced side effects
such as impotence and infertility, urinary incontinence and fecal urgency resulting from prostate cancer
radiotherapy [216].
On the other hand, radiation-resistant prostate cancer cells often overexpress the transcription
factor NFκB. Mendonca et al. [217] suggest that DMAPT might have a potential clinical role as
radio-sensitizing agent in prostate cancer treatment. This conclusion is based on the finding that
combined treatment of PC-3 prostate tumor xenografts with oral DMAPT and radiation therapy
significantly reduced tumor growth, when compared to those treated with either DMAPT or radiation
therapy alone.
Li et al. [218], obtained a novel parthenolide derivative, HMPPPT, a 13-substituted derivative
((3R,3aS,9aR,10aR,10bS,E)-3-((4-(6-hydroxy-2-methylpyrimidin-4-yl)piperidin-1-yl)methyl)-6,9a-dimethyl-
3a,4,5,8,9,9a,10a,10b-octahydrooxireno [2′,3′:9,10]cyclodeca[1,2-b]furan-2(3H)-one) (12) (Figure 9),
with better bioavailability and pharmacological properties than DMAPT. In vitro studies pointed to
compound 12 as the most promising derivative, from safety profile and ADME property standpoints.
The newly identified compound was shown to have pro-oxidant activity and in silico molecular
docking studies with components of the NF-κB pathway also supporting a pro-drug mode of action.
This mechanism included release of parthenolide and covalent interaction with one or more proteins
involved in that pathway [218]. The in vivo oral bioavailability study of compound 12 in murine
PK at 10 mg/kg indicated that it has advantageous pharmacological properties and therefore can
be considered an agent to be considered in therapy against drug resistant chronic lymphocytic
leukemia [218].
In the last few years, nanotechnology has provided many selective strategies for the detection
and treatment of cancer, overcoming the problems associated with conservative cancer diagnosis and
therapy. In this context, the development and testing of parthenolide (10) nanoencapsulation and
derivatives is a way to enhance its potential to provide effective pharmaceutical products for clinical
use and resolve drawbacks such as low bioavailability [219–222]. Accordingly, several patents for
elaboration of parthenolide and its derivatives in nanocarriers, and various pharmaceutical preparations
combined with other products, have been recently registered in China: patents N◦ CN 110292640, 2019;
N◦ CN108721276, 2018; N◦ CN1087211330, 2018; N◦ CN106366068, 2017; N◦ CN 109276553, 2017.
In recent years, parthenolide has been suggested for use in combination therapy with other
anticancer agents, to overcome obstacles in the treatment of cancer, such as a) different types of cancer
cells, b) resistance to chemotherapy, and c) drug toxicity to normal cells.
TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) is now being developed
as a promising natural immunity-stimulating molecule for clinical trials in cancer patients. However,
various malignant tumors are currently resistant. Kim et al. [223] investigated how parthenolide (10)
sensitizes colorectal cancer (CRC) cells to TRAIL-induced apoptosis. For this, HT-29 (TRAIL-resistant)
and HCT116 (TRAIL-sensitive) cells were treated with compound 10 and/or TRAIL. The results revealed
that parthenolide (10) increases induced apoptosis and upregulates DR5 protein level and surface
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expression in both cell lines, suggesting that combined therapy with TRAIL is a good strategy to
overcome the resistance of certain CRC cells.
Pancreatic cancer is a common malignancy with high occurrence worldwide, and a poor
survival rate. Recent research indicates that combination therapy with DMAPT (11) can enhance
the antiproliferative effects of gemcitabine in pancreatic cancer cells in vitro and in vivo [224].
Yip-Schneider et al. [225] showed that celecoxib (a cyclooxygenase 2 (COX-2) inhibitor) at 50 mg/kg/day
combined with DMPTA at 40 mg/kg/da has a significant inhibitory effect on tumor invasion of adjacent
organs and metastasis in pancreatic cancer induced in Syrian golden hamsters. It reduced NFκB activity,
and expression of prostaglandin E2 and its metabolite. They also demonstrated that compound 11
(40 mg/kg/day) in combination with sulindac (20 mg/kg/day) and gemcitabine (50 mg/kg twice weekly)
can delay or prevent progression of premalignant pancreatic lesions) in a genetically engineered mouse
model of pancreatic cancer [226]. Likewise, they demonstrated that DMAPT (11) (40 mg/kg/day) with
gemcitabine (50 mg/kg/day) considerably improved average survival, lowering the frequency and
multiplicity of pancreatic adenocarcinomas. This combination also significantly reduced tumor size
and the incidence of metastasis into the liver [227].
Parthenolide exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer
(TNBC) cell-line, however its success is scarce at low doses. In order to overcome this difficulty,
Carlisi et al. [228] tested a histone deacetylase inhibitor, SAHA (suberoylanilide hydroxamic acid),
which synergistically sensitized MDA-MB231 cells to the cytotoxic effect of parthenolide (10). It is
noteworthy that treatment with parthenolide alone increased the survival of cell pathway Akt/mTOR
and the consequent nuclear translocation of Nrf2, a protein regulating the expression of antioxidant
proteins that protect against the oxidative damage triggered by injury and inflammation, while
treatment with SAHA alone activated autophagy.
A phase 2 clinical trial indicated that actinomycin-D (ActD), a polypeptide antibiotic that
intercalates to DNA and inhibits mRNA transcription in mammalian cells, could be a potent drug
against pancreatic cancer. However, it is not a good candidate due to toxicity issues. Thus, given
the modes of action of DMPTA and Actinomycin-D (ActD), Lamture et al. [229] postulated that
combining both drugs would result in synergistic inhibition of Panc-1 pancreatic cancer cell growth,
since the inhibitory activity of DMAPT on FkB would enhance apoptosis induction by ActD, through
phosphorylation of c-Jun. Indeed, the combination of these two drugs produced a higher cell-death
percentage than each drug alone.
2.9. Thapsigargin
In 1978, the structure of thapsigargin (13) (C34H50O12) (Figure 10) was elucidated [230] for the
first time. It was found as the main component of Thapsia garganica L. [230,231], an umbelliferous
Apiaceae species distributed in the Mediterranean area. This plant has long been used in folk medicine
for treating common lung diseases (acute bronchitis and pneumonia) and dental pains [232]. The resin
from Thapsia garganica root was described in the French Pharmacopoeia [232].
Thapsigargin (13) yield ranged between 0.2–4.91% of the dry weight of leaves and roots
of Thapsia garganica and depends on the plant tissue, collection site (locality) and extraction
methods [231,233]. For example, classical maceration was more efficient than other methods such as
microwave-assisted extraction or simple extraction with liquid nitrogen [233].
Due to the importance of thapsigargin’s biological activities, there is great interest in its synthetic
and semi-synthetic preparation, thus several studies have been published on this subject [234,235].
Thapsigargin (13) is an inhibitor of the sarco/endoplasmic reticulum (ER) calcium ATPase (SERCA)
pump. The blockage of the SERCA pump results in malfunction of cellular calcium homeostasis
and exerts a critical role in normal cell metabolism, leading to apoptosis [236,237]. Moreover, this
sesquiterpene lactone causes apoptosis at all stages of the cell cycle.
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Figure 10. Structure of thapsigargin (13) and its derivative mipsagargin (14).
Compound 13 strongly inhibited all the subtypes of SERCA. The inhibitory constants (Ki) of
thapsigargin (13) were 0.21, 1.3, and 12 nm for SERCA1b, SERCA2b, and SERCA3a, respectively [238,239].
Its affinity with the SERCA1a pump is significantly reduced by removal of the acyl groups at O-3, O-8
and O-10 [240].
Thapsigargin (13) possesses interesting pharmacological properties; for instance, it induces expression
of the L-histidine decarboxylase enzyme responsible for converting L-histidine to histamine in cells [241].
It also evokes ROS generation in cells through calcium-ion mediated changes (mitochondrial
depolarization), which can result in cell dysfunction and damage [242,243]. In addition, compound
13 is known for its cytotoxic action against different cancer cell-lines, for instance melanoma [244],
insulinoma [245,246], neuronal [247], and breast [248].
The thapsigargin LD100 value is 0.8 mg/kg in mice [249]. Zhong et al. [250] proposed that
thapsigargin causes vomiting by triggering the phosphorylation of CaMKIIα (Ca2+/calmodulin
kinase IIα) and ERK1/2 (extracellular signal-regulated protein kinase 1/2) cascade in the brainstem.
Pharmacological preconditioning with the cell-stress inducer thapsigargin (0.3 mg/kg) protects against
experimental sepsis in male KM (Kunming) mice [237].
Thapsigargin (13) is widely used as an experimental tool for endoplasmic reticulum stress
inhibition and the discovery of new active therapeutic derivatives [232,251]. A new thapsigargin (13)
derivative named mipsagargin, (8-O-(12-aminododecanoyl)-8-O-debutanoyl thapsigargin)-Asp-γ-Glu-
γ-Glu-γ-GluGluOH (14) (Figure 10), has been developed for anticancer therapy, notably for the
treatment of prostate cancer. Mipsagargin (14) has the ability to link the C-8 with prostate-specific
membrane antigen (PSMA) peptide. It is a brand new example of a thapsigargin prodrug, which
is currently undergoing preclinical evaluation as a targeted chemotherapeutic agent with selective
toxicity against cancer cells [232,249]. Mahalingam and coauthors reported that mipsagargin (14) has
an acceptable pharmacokinetic profile in patients with solid tumors [252]. It is relatively well tolerated,
promoting prolonged disease stabilization in patients with advanced liver cancer [253].
2.10. Tomentosin
Tomentosin (15) (Figure 11), known also as xanthalongin, is a xanthanolide sesquiterpene lactone
with the same chemical formula as inuviscolide (6) and parthenolide (10) (C15H20O3). It has been
isolated from plants such as Dittrichia viscosa (L.) Greuter, Carpesium faberi C. Winkl. and Carpesium
macrocephalum Franch. and Sav. [254], Leucophyta brownii Cass. [255], the sunflower (Helianthus annuus
L.) [256] and Inula species [254,257]. Inula viscosa was widely used as a medicinal plant. A steam distilled
extract of its leaves and flowers yielding 2% of tomentosin (15) [258] exhibited anti-inflammatory,
antibacterial, and anticancer activities [257].
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Figure 11. Structure of tomentosin (15).
The biological activities of tomentosin (15) have been addressed in several studies focused on
anticancer, antifungal, and insecticidal activities.
Anticancer activity observed in vitro tests was confirmed by in vitro and in vivo studies performed
by Bar-Shalom et al. [259]. The authors found that application of an aqueous extract of Inula viscosa
leaves at a concentration of 300 μg/mL to colorectal cancer cells induced apoptosis, through activation
of caspases. During the subsequent in vivo study, mice transplanted with MC38 cells were treated
intraperitoneally with the extract at concentrations of 150 and 300 mg/kg. The results indicated that
tumor weight and volume were reduced significantly by this treatment after comparison with the
untreated control group. Furthermore, staining the paraffin section of the tumors showed inhibition
of cell proliferation, as well as induction of apoptosis. Interestingly, side effects, which often include
weight loss, impact on fur, and changes in behavior or kidney or liver functions, were not observed.
This suggests that the extract was non-toxic at the concentrations applied. However, this remains to be
confirmed [259].
Fungal infection of grapevines causes severe economic damage to grape producers. As several
fungicide-resistant strains of the pathogens have developed, efective fungicide application is becoming
more and more difficult. Therefore, natural products such as sesquiterpene lactones and plant extracts
may provide alternatives to current synthetic fungicides. The antifungal activity of six Inula viscosa
leaf extracts on downy mildew under field conditions was addressed in the study performed by
Cohen et al. [260]. This mildew is caused by the fungus Plasmopara viticola (Berk. and Curt.). The results
established that the effective concentration of oily paste extract in water required to control 90% of
the treated shoots in the field was lower than 0.125%. For whole vines, the required concentration
ranged between 0.30% and 0.37%. Additionally, the results did not appear to depend on seasonal
fluctuations. The evaluated leaf extracts contained 10.6% of tomentosin (15) and 10.6% of costic acid,
which were identified as the active principles with antifungal activity. The overall results indicated
that Inula viscosa extracts can be of great value as an alternative source for non-synthetic fungicidal
preparations to treat downy mildew infestations of grapes [260].
In an in vivo investigation performed by Ahern et al. [261] on insecticidal activity, the effect
of the stereochemistry of the lactone ring on feeding behavior of the herbivorous polyphagous
grasshopper Schistocerca americana (Drury) was addressed. Schistocerca americana is locally related
in the south of the U.S. to significant damage to crops when temporary mass populations occur.
To evaluate the antifeedant activity of diastereomeric sesquiterpene lactones, the study focused
on tomentosin (15) with a cis-configuration and the corresponding isomer xanthinosin with a
trans-configuration. The results showed both compounds were able to reduce plant consumption
by the insects. However, the trans-fused compounds were consumed less than the corresponding
cis-fused compounds. The results of this study not only permitted conclusions on the importance
of the stereochemistry-dependence of diastereomeric sesquiterpene lactones for insecticidal activity,
but also might help to understand the geographical distribution and evolution of different clades
among the Asteraceae family. The distribution of cis- and trans-fused compounds within plants of this
family is still not fully understood, in this study, 12.5% of the sampled Asteraceae genera contained
only cis-fused sesquiterpene lactones, 64% only trans-fused sesquiterpene lactones, and 23% both
types [261].
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3. Conclusions
Taking into account the research described above, the sesquiterpene lactones dealt with in this
review have proved to be very useful compounds with promising anticancer and anti-inflammatory
bioactivities in particular. For instance, alantolactone (1) was shown in vivo to be able to reduce tumor
size by over 50%, while increasing life expectancy and reducing pathological indicators across several
different cancer types. In addition, synergistic effects with well-known cancer therapeutics were also
reported. Arglabin (2) in salt form could be used to treat several cancers and possesses valuable
pharmacokinetic characteristics highly sought for in therapeutic drugs. It has no adverse effects
described in the literature. Antitrypanosomal, antitumor and anti-inflammatory activities are reported
for cynaropicrin (4). Another compound, helenalin (5), inhibits essential factors in both cancer and
inflammation, i.e., the NF-κB pathway and the transcription of inflammatory cytokines. Inuviscolide
(6) demonstrates potential as an anti-inflammatory therapeutic compound, being able to reduce rat ear
and paw edema and LTB4 generation in intact cells. Lactucin (7) and derivatives lactupicrin (8) and
lactucopicrin (9) have a strong potential as phytopharmaceutical agents for treatment of anxiety and
sleep disorders, being the main active components of long commercialized substances, e.g., Sedan®,
without observing side-effects.
Of all the sesquiterpene lactones reviewed in this work, parthenolide (10) and its derivatives
DMAPT (11) and HMPPPT (12) are those most mentioned in the literature, with several studies
particularly reporting their excellent anti-inflammatory and antitumor activities. Some work reveals
synergistic effects of these compounds with current anticancer drugs, favoring more potent and
selective antitumor action. Parthenolide derivatives have been designed and DMAPT (11) is 1000-fold
more soluble in water than the natural product, while maintaining a similar mechanism of action with
improved anticancer and anti-inflammatory activities.
Thapsigargin (13) has the particular capacity to cause endoplasmic reticulum stress and thus cell
apoptosis, an interesting pharmacological property to be retained or potentiated in derivatives aimed
at anticancer therapy. An example is mipsagargin (14), which is currently undergoing preclinical
evaluation for selective toxicity against cancer cells in tumor sites, with minimal side-effects for the
host. Another active compound is tomentosin (15), additionally with potential applications in cancer
but also as antifungal and antifeedant.
In summary, given the activities described in this review these sesquiterpene lactones exhibit
properties that justify more research by the scientific community, to drive preclinical and clinical
studies leading to development of new drugs.
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Abstract: Naturally occurring food-derived active ingredients have received huge attention for their
chemopreventive and chemotherapy capabilities in several diseases. Rosmarinic acid (RA) is a
caffeic acid ester and a naturally-occurring phenolic compound in a number of plants belonging
to the Lamiaceae family, such as Rosmarinus officinalis (rosemary) from which it was formerly
isolated. RA intervenes in carcinogenesis through different ways, including in tumor cell proliferation,
apoptosis, metastasis, and inflammation. On the other hand, it also exerts powerful antimicrobial,
anti-inflammatory, antioxidant and even antidepressant, anti-aging effects. The present review aims
to provide an overview on anticancer activities of RA and to deliberate its therapeutic potential
against a wide variety of diseases. Given the current evidence, RA may be considered as part of the
daily diet in the treatment of several diseases, with pre-determined doses avoiding cytotoxicity.
Keywords: rosemary; rosmarinic acid; anticancer; antidiabetic; cardioprotective; antioxidant;
oxidative stress
Appl. Sci. 2019 , 9 , 3139 ; doi:10.3390/app9153139 www.mdpi.com/journal/applsci173
Appl. Sci. 2019 , 9 , 3139
1. Introduction
Rosmarinic acid (RA) is an ester of caffeic acid and 3,4-dihydroxyphenyl lactic acid that occurs
in nature as phenolic compounds. Its molecular formula is C18H16O8 and is formally known
as (R)-α-[[3-(3,4-dihydroxyphenyl)-1-oxo-2 E-propenyl]oxy]-3,4-dihydroxy-enzenepropanoic acid
(Figure 1). The main sources of RA are plants belonging to the Boraginaceae family, subfamily
Nepetoideae. It was isolated for the first time in 1958 from the rosemary plant (Rosmarinus officinalis
L.), and recently it has been reported in Forsythia koreana (Rehder) Nakai, Hyptis pectinate (L.) Poit.,
Ocimum tenuiflorum L., Thymus mastichina (L.) L., and plants belonging to Lamiaceae family [1].
Figure 1. Chemical structure of rosmarinic acid.
RA has remarkable biological effects, including antiviral, antibacterial, anticancer, antioxidant,
anti-aging, antidiabetic, cardioprotective, hepatoprotective, nephroprotective, antidepressant,
antiallergic, and anti-inflammatory activities (Figure 2). RA and some rosemary extract-isolated
compounds, like carnosic and ursolic acids and carnosol have also shown to be able to reduce
the likelihood of tumor development in several body organs, such as stomach, colon, liver, breast,
and leukemia cells [2–4]. Thus, here we review the various therapeutic potentials of RA in this article.
2. Bioavailability of Rosmarinic Acid and Its Metabolic Changes in the Human Body
RA is partially metabolized to the coumaric acid and caffeic acid in the body of the rat [5], and the
hypolipidemic effect of RA may also be a consequence of the action of its metabolites. For example,
caffeic acid inhibited the synthesis of hepatic fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA
reductase and acyl-CoA:cholesterol acyltransferase activities and increased fatty acid β-oxidation
activity in high-fat diet-induced obese mice [6]. Caffeic acid and sinapic acid increased serum estradiol
concentrations in rats with estrogen deficiency, which may have contributed to the observed metabolic
effects [7]. In the rat ovary ovulation, external ovarian tissues such as fatty tissue, skin, bones and brain
are the source of estradiol. In these sites, C19 cannot be synthetized. Steroids C19 (androgens) can be
converted to estrogens by aromatase. Therefore, it seems possible that RA or its metabolites increase
the activity of aromatase. Caffeic acid increased estradiol and reduced total cholesterol concentrations
only in rats that were fed standard food containing soy, and these effects were not observed in rats
fed without soy with reduced phenolic acid contents [8]. It is therefore possible that at least some
of the RA effects reported depend on the diet. RA showed similar beneficial effects on some lipid
parameters and insulin resistance (HOMA-IR) as that demonstrated for sinapic acid in a parallel
study [7]. Moreover, RA had positive effects on expression of hepatic genes or proteins involved
in signaling insulin and glucose and lipid metabolism, such as insulin receptor substrate-1 (IRS-1),
5′ AMP-activated protein kinase (AMPK), phosphoenolpyruvate carboxykinase (PEPCK), glucose
transporter 2 (GLUT2), forkhead box protein O1 (FOXO1), sterol regulatory element-binding protein 1
(SREBP1), and carnitine palmitoyltransferase 1 (CPT1) in diabetic rats [9]. The possible mechanism of
action of RA on glucose and lipid metabolism may be mediated by peroxisome proliferator-activated
receptor (PPAR) peroxidation; RA has been shown to activate these receptors. It should be noted that
the lower RA dose (10 mg/kg) was sufficient to reduce the HOMA-IR index and the concentration
of fructosamine, while a higher dose (50 mg/kg) was required to reduce the total cholesterol and
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triglyceride levels in rats with estrogen deficiency. Moreover, RA and its metabolites can directly
neutralize reactive oxygen species (ROS) [10] and thereby reduce the formation of oxidative damage
products. The antioxidant activity of RA directly derives from its structure, namely the presence of
4 hydrogens in the phenolic system and two catecholic moieties, which give this compound polar
character. Electrochemical studies have shown that RA oxidizes in two steps. In the first step, the rest
of the caffeic acid is oxidized and in the second step the residue of 3,4-dihydroxyphenyl lactic acid.
Figure 2. Rosmarinic acid and its potential functions.
RA is therefore considered to be the strongest antioxidant of all hydroxycinnamic acid
derivatives [11]. Inhibition of the production of advanced glycation end products under the influence
of RA was previously presented in vitro and in vivo [12]. The use of RA in doses of 10 and 50
mg/kg in rats with estrogen deficiency did not affect the body mass. RA administered at a dose of
10 mg/kg of ovariectomized rats did not affect estradiol and progesterone concentrations compared
with ovariectomy control rats, whereas RA at a dose of 50 mg/kg of estradiol showed a trend of growth.
Orchids containing RA are often used in self-healing and daily diets, so it is possible to consume 5–10 g
of these plants daily in the form of infusions and spices [13]. RA is water-soluble, and according to
literature data, the efficacy of secretion of this compound in infusions is about 90% [14]. Accordingly,
it is possible to consume approximately 110 mg RA daily, i.e., approximately 1.6 mg/kg for adult
men weighing 70 kg. Increasing the concentration of reduced glutathione (GSH) in plasma due to
the use of RA was previously described in various models of diabetes [15]. RA has been shown to
stimulate the regulation of the catalytic subunits of the glutamate cysteine ligase (the enzyme involved
175
Appl. Sci. 2019 , 9 , 3139
in the biosynthesis of GSH) in the hematopoietic stem cells [16]. It can be assumed that the increase
in the concentration of GSH, after the administration of RA, was previously the result of the intense
biosynthesis of GSH rather than its recovery from the oxidized form. Moreover, it should be noted
that the RA appears to be absorbed into the rat mainly as its metabolites [5]. It is possible that these
metabolites also play a role in the observed increase in GSH concentration. Furthermore, serum
GSH/oxidized glutathione (GSSG) was calculated, as it is known to be an important indicator of redox
cell status as well as for the state of redox at the tissue and whole body [17]. The adventitious effect of
RA on redox homeostasis has been shown to increase the ratio of GSH/GSSG in serum rats.
3. Health Benefits of Rosmarinic Acid
3.1. Anticancer Potential
Several mechanisms have been proposed for RA anticancer activity (Figure 3). For instance,
in rats with colon cancer, RA at the concentration of 5 mg/kg body weight (b.w.) impaired
tumor formation and development, reduced lipid peroxidation by-products and pro-apoptotic
proteins expression, modulated xenobiotic enzymes, and increased apoptotic proteins expression [18].
In human liver cancer cell line, HepG2, transfected with plasmid containing ARE-luciferin gene,
RA predominantly enhances ARE-luciferin activity and promotes nuclear factor E2-related factor-2
(Nrf2) translocation from cytoplasm to the nucleus and also increases MRP2 and P-gp efflux activity
along with intercellular ATP level [19]. A study conducted by Wu et al. [20] reported that RA
inhibited CCRF-CEM and CEM/ADR5000 cells in a dose-dependent pattern but caused less cytotoxicity
towards normal lymphocytes. RA concurrently induced necrosis and apoptosis and stimulated
MMP dysfunction activated PARP-cleavage and caspase-independent apoptosis. RA also blocked
the translocation of p65 from the cytosol to the nucleus [20]. Moreover, it inhibits transcription factor
hypoxia-inducible factor-1α (HIF-1α) expression, which affects the glycolytic pathway; meanwhile,
it also suppressed glucose consumption and lactate production in colorectal cells [21]. RA also inhibits
micro RNAs and pro-inflammatory cytokines and thus may suppress the Warburg effects through
an inflammatory pathway involving activator of transcription-3 (STAT3) and signal transducer of
interleukin (IL)-6 [22]. Furthermore, RA inhibits HL-60 promyelocytic leukemia cells’ growth and
development and provides strong scavenging free radical effects, disturbing the balance of nuclear
deoxyribonucleotide triphosphate (dNTP) levels without affecting protein levels of RR (R1, R2, p53R2)
subunits, ultimately leading to apoptosis induction [23,24].
RA application, at a concentration of 5 mg/kg b.w. during 30 weeks in 1,2-dimethyldrazin
stimulated colon carcinogenesis in the rat at 20 mg/kg b.w. and significantly stopped tumor formation
and proliferation. RA supplementation also reduced tumor necrosis factor-α (TNF-α), cyclooxygenase-2
(COX-2) and IL-6 levels, and modulated p65 expression [25]. It is also able to inhibit the release
of the highly mobile group box 1 (HMGB1) and to slow down HMGB1-dependent inflammatory
responses in human endothelial cells, stopping HMBG1-mediated hyperpermeability and leukocytes
migration in mice [26]. RA supplementation primarily decreases aberrant crypt foci (ACF) formation
and multiplicity in rats [27].
RA inhibited APC10.1 cell growth that comes in Apc (Min) mouse model of colorectal
carcinogenesis [28]. Through oral administration, RA totally prevented skin tumor cells formation in
DMBA-induced mouse skin carcinogenesis and decreased lipid peroxidation byproducts levels [29].
It also inhibited human ovarian cancer A2780 cell line, disturbing the cell cycle at multiple phases and
stimulating apoptosis by modifying multiple genes expression, involved in apoptosis regulation [30].
RA induced the cell cycle arrest and apoptosis in prostate cancer cell lines (PCa, PC-3,
and DU145) [31]. These effects were mediated through modulation of histone deacetylases expression
(HDACs), specifically HDAC2; the aberrant expression of theses enzymes is related with the onset of
human cancer.
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In rats with 1,2 dimethylhydrazine-induced colon carcinogenesis, RA administration at dose of 2.5,
5, and 10 mg/kg b.w. led to a decrease in the number of polyps (50%), reversed oxidative markers (21%),
antioxidant status (38.6%), CYP450 contents (29.4%), and PNPH activities (21.9%) [32]. RA can also
inhibit adhesion, invasion, and migration of Ls 174-T human colon carcinoma cells through enhancing
GSH levels and decreasing ROS levels. Finally, RA may also inhibit colorectal carcinoma metastasis,
by reducing the extracellular signal-regulated kinase pathway and the number and weight of lung
tumors [33]. MDA-MB-231BO human bone homing breast cancer cells migrations are also inhibited by
RA, whereas the number and size of mineralized nodules in ST-2 murine bone marrow stoma cells
cultures raise [34].
RA also enhances chemosensitivity of human resistant gastric carcinoma SGC7901 cells [35].
The anticancer potential of RA analogues has also been tested. RA analogue-11 induces apoptosis
of SGC7901 via the epidermal growth factor receptor (EGFR)/Akt/nuclear factor kappa B (NF-κB)
pathway [36].
Figure 3. Mechanism of rosmarinic acid as an anticancer agent.
3.2. Antidiabetic Activity
RA supplementation increases the expression of mitochondrial biogenesis key genes, like sirtuin
1 (SIRT-1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α),
and mitochondrial transcription factor A (TFAM) via activation of AMP-activated protein kinase
(AMPK) in the skeletal muscle of insulin-resistant rats as well as in L6 myotubes. It also increased
glucose faster and decreased serine IRS-1 phosphorylation, while increasing the glucose transporter
type 4 (GLUT4) transfer [37].
In streptozotocin (STZ)-induced diabetic rats, RA exerted a noticeable hypoglycemic effect,
whereas in high-fat diet (HFD) fed diabetic rats it increased glucose utilization and ameliorated insulin
sensitivity. RA supplementation inverted the STZ- and HFD-induced increase in phosphoenolpyruvate
carboxykinase (PEPCK) expression in the liver and the STZ- and HFD-induced decrease in GLUT4
expression in skeletal muscle. RA exerts hypoglycemic effects and improves insulin sensitivity,
also increasing GLUT4 expression and decreasing PEPCK expression [38]. In addition, it also reverses
memory and learning defects through improving cognition in healthy rats, inhibiting hyperglycemia,
lipid peroxidation, and enhancing antioxidant defense system [39]. At a concentration of 10 mg/kg,
RA decreased TBARS levels in kidney and liver of STZ-induced diabetic rats. This effect was mainly
conferred by its ability to increase superoxide dismutase (SOD) and catalase (CAT) activity and to reverse
the decrease in ascorbic acid and of non-protein thiol levels in diabetic rats [40]. RA administration also
ameliorated oxidative stress markers in diabetic rats and water consumption and urination. Thus, it was
proposed that RA mitigates STZ-induced diabetic manifestations by protecting rat’s tissues against
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free radicals’ damaging effects [15]. At 100 mg/kg, RA significantly increased insulin index sensitivity
and reduced blood glucose, advanced glycation end-products, HbA1c, IL-1β, TNFα, IL-6, p-JNK,
P38 mitogen-activated protein kinase (MAPK), and NF-κB levels. Moreover, it significantly reduced free
fatty acids (FFA), triglycerides, serum cholesterol, AOPPs, lipid peroxides, and protein carbonyls levels
in plasma and pancreas of diabetic rats. The reduced activities of CAT, SOD, glutathione S-transferases
(GST), and glutathione peroxidase (GPx) and the reduced levels of vitamins C and E, ceruloplasmin,
and GSH in plasma of diabetic rats were also significantly recovered by RA application. Furthermore,
it protects pancreatic β-cells from oxidative stress in HFD-STZ-induced experimental diabetes [41].
The protective effects of RA (30 mg/kg) against hypoglycemia, hyperlipidemia, oxidative stress, and an
imbalanced gut microbiota architecture was studied in diabetic rats. The treatment decreased the levels
of fasting plasma glucose, total cholesterol, and triglyceride, exhibited an antioxidant and antiglycative
effect, showed protective effects against tissue damage and inflammation in the abdominal aorta,
increased the population of diabetes-resistant bacteria, and decreased the number of diabetes-sensitive
bacteria [12].
RA also reduced diabetes occurrence and preserved normal insulin secretion, ROS, and reactive
nitrogen species (RNS) by regulating antioxidant enzymes, and attenuating the pro-inflammatory
T helper 2 and T regulatory cells levels [42]. At a concentration of 10 mg/kg, RA treatment
significantly reduced lipid peroxidation levels in the hippocampus (28%), cortex (38%), and striatum
(47%) of diabetic rats [43]. In Wistar rats, RA administrated orally at 50 mg/kg for 10 weeks in
STZ-induced diabetes diminished endothelium-dependent relaxation accompanied by IL-1β, TNF-α,
preproendothelin-1, and endothelin converting enzyme 1 overexpression. It also provided aortic
endothelial function protection against diabetes-induced damage [44]. Finally, it significantly inhibited
the carbohydrate-induced adaptive increase of sodium-dependent glucose cotransporter 1 (SGLT1) in
the enterocyte brush border membrane [45].
3.3. Antimicrobial Activity
Regarding RA antimicrobial activity, it exerted antibacterial effects against Staphylococcus aureus
strains, and the lowest blocking concentration was found to be 0.8 and 10 mg/mL against S. aureus
and methicillin-resistant S. aureus (MRSA), respectively. Moreover, it displayed synergistic effects
with amoxicillin, ofloxacin and vancomycin antibiotics against S. aureus, and only with vancomycin
against MRSA. Time-kill analysis showed that using a combination of RA with antibiotics is more
effective than using individual antibiotics. Microbial surface components recognizing adhesive matrix
molecules (MSCRAMM) adhesion protein expression in MRSA and S. aureus was also significantly
suppressed by using a combination of RA with vancomycin rather than RA alone [46].
On the other hand, RA administration reduced biofilm formation in a concentration- and
time-dependent manner, suggesting that it could be used as an effective antimicrobial agent to kill the
planktonic cells activity and to reduces the biofilm formation activity in early-stage development [47].
RA also exerts inhibitory effects against Escherichia coli K-12 and Staphylococcus carnosus LTH1502
growth, through decreasing cell counts and cell number [48]. Under acidic conditions, RA was reacted
with nitrite ions to give 6,6-nitro and 6-dinitrorosmarinic acids. These compounds were active as
HIV-1 integrase inhibitors at sub-molecular levels and inhibited viral replication in MT-4 cells. Without
increasing cellular toxicity levels, RA nitration A strongly improved anti-integrase inhibition and
antiviral effects [49]. Moreover, RA also exerted antimicrobial effects against Enterobacteriaceae spp.,
Pseudomonas spp., lactic acid bacteria, yeast and mold, and psychotropic counts, as well as fate Listeria
monocytogenes inculcated in chicken meats [50]. Finally, RA also displayed inhibitory effects against
S. aureus cocktail through inducing morphological changes and reducing viable cells counts and
causing morphological changes in cheese and meat samples, such as cell shrinkage and appearance of
blabbing-like structures in cell surfaces [51–53].
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3.4. Cardioprotective Activity
RA at 25, 50, 10 mg/L had the capacity to maintain ATP levels in cells and inhibit the decrease in
H/R-induced cell viability, lactate dehydrogenase (LDH) leakage, and excessive ROS. It also inhibited
H/R-induced cardiomyocyte apoptosis and down-regulated p-AKt cleaved caspase expression [54].
The endothelial protein C receptor (EPCR) has a prominent role in inflammation and coagulation,
whereas its activity is significantly changed by ectodomain cleavage and release as the soluble protein
(sEPCR). RA has been found to be a strong anti-inflammatory agent. Monitoring RA effects in TNF-α,
phorbol-12-myristate 13-acetate (PMA), IL-1β and in cecal ligation and puncture (CLP)-mediated EPCR
shedding and underlying mechanisms, it was found that RA treatment led to a potent inhibition of
PMA, TNF-α, and IL-induced EPCR shedding through TACE expression suppression. Furthermore,
RA reduced extracellular regulated kinases (ERK) 1/2, PMA-stimulated p38, and c-Jun N-terminal
kinase (JNK) phosphorylation. These results support the upcoming use of RA as an anti-sEPCR
shedding reagent against IL-1β, TNF-α, PMA, and CLP-mediated EPCR shedding [55,56].
RA administration in fructose-fed rats (FFR) significantly enhanced insulin sensitivity, reduced
lipid levels, oxidative damage, and a p22phox subunit of nicotinamide adenine dinucleotide
phosphate reduced oxidase expression as well as prevented cardiac hypertrophy. RA lowered
fructose-induced blood pressure through decreasing angiotensin-converting enzymes activity and
endothelin-1 and increasing the level of nitric oxide (NO) [57]. RA also reduced fasting serum
levels of vascular cell adhesion molecule 1 (VCAM-1), inter-cellular adhesion molecule 1 (ICAM-1),
plasminogen-activator-inhibitor-1 (PAI-1), and increased GPX and SOD levels [58]. RA also intervenes in
many important steps of angiogenesis, including adhesion, migration, proliferation, and tube formation
of human umbilical vein endothelial cells (HUVEC) in a dose-dependent pattern. It also decreased IL-8
release from endothelial cells, H2O2-dependent vascular endothelial growth factor (VEGF) expression,
and intracellular ROS levels [59]. Finally, in H9c2 cardiac muscle cells, RA inhibited apoptosis by
decreasing intracellular ROS generation and recovering mitochondria membrane potential [60,61].
3.5. Antioxidant Activity
RA exhibited free radicals scavenging activity in hepatic stellate cells (HSCs) as a result of its
antioxidant effects by boosting GSH synthesis and participating in NF-κB-dependent inhibition of
MMP-2 activity. It also has the ability to reverse activated HSCs to quiescent cells and ultimately inhibits
MMP-2 activity. RNA interference-imposed knockdown of NF-κB abolished MMP-2 down-regulation
by RA. NF-κB inactivation mediated by RA could be blocked by the diphenyleneiodonium chloride,
a potent inhibitor of NADH/NADPH oxidase. Moreover, transfection of dominant-negative (DN)
mutant JNK1, p38α kinase, or extracellular signal-regulated kinases 2 (ERK2) had no such effect.
At once, RA suppresses lipid peroxidation (LPO) and ROS generation, whereas in HSC-T6 cells it
increases cellular GSH. Additionally, it significantly increases Nrf2 translocation and catalytic subunits
from glutamate cysteine ligase (GCLc) expression but was not able to modulate GCL (GCLm) subunits
and antioxidant response element (ARE)-mediated luciferase activity. GClc up-regulation mediated
by RA is inhibited by shRNA-induced Nrf2 knockdown. The knocking down of Nrf2 abolished
RA-mediated inhibition of ROS [16,62].
On the other hand, lycopene and RA administration reduced elevated blood urea nitrogen,
renal malondialdehyde (MDA), proapoptotic protein (Bax) immuno-expression, serum creatinine,
inducible nitric oxide synthase (iNOS), and autophagic marker protein (LC3/B) levels induced by
gentamicin. This combination also increased the reduced SOD, an antiapoptotic protein (Bcl2)
immuno-expression, GPx, and GSH levels and ameliorated gentamicin-induced histopathological
changes. Moreover, it also evidenced a greater protective effect than corresponding monotherapy [63].
The in vivo antioxidant defense system consists of antioxidant enzymes including CAT, GPx, SOD,
and nutritional antioxidants. Any disturbance in normal antioxidant defense system triggers several
diseases, including diabetes, cancer, atherosclerosis, and degenerative diseases [64]. In experimental
animals, carbon tetrachloride (CCl4) induced neurotoxicity, whereas CCl4 skin absorption, inhalation,
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and ingestion increased lipid peroxidation and reduced protein and antioxidant enzymes contents.
This molecule produces free radicals in the lungs, heart, blood cells, and kidney. Under aerobic
conditions, CCl4 is converted into highly reactive trichloromethyl radicals through the action of the
cytochrome P450 system [65].
Brain amyloid-β (Aβ) accumulation is a hallmark of Alzheimer’s disease (AD) and has an
important role in cognitive dysfunction [66]. At a dose of 0.25 mg/kg, RA significantly enhanced
cognitive function and object discrimination and recognition test. Furthermore, RA decreased the time
to reach the platform and increased the number of crossings over the removed platform, when compared
with Aβ25-35-induced group in Morris water maze test; moreover, it reduced NO and MDA levels in
kidney, brain, and liver [67]. RA also suppresses AD development by reducing amyloid β aggregation
by increasing monoamine secretion in mice [68].
RA also prevented oxidative stress in C6 glial cells by increasing cell viability and inhibiting
lipid peroxidation. It also decreased H2O2-induced COX-2 and iNOS expression at the transcriptional
level and down-regulated COX-2 protein expression and iNOS in C6 glial cells treated with RA [67].
It significantly reduced oxidative stress and increased antioxidant status in Wistar rats post-spinal cord
injury (SCI). RA also facilitated the inflammatory process through pro-inflammatory post-SCI and
down-regulated NF-κB [69]. It also exerted a significant cytoprotective effect through covering the
intercellular ROS in HaCat keratinocytes. RA also increased CAT, SOD, heme oxygenase-1 (HO-1),
and transcription factor Nrf2 expression and activity, markedly reduced by UVB radiation [70].
On the other hand, in G93A-SOD1 transgenic mice with amyotrophic lateral sclerosis (ALS),
RA application at a daily dose of 400 mg/kg significantly increased their survival by reliving function
motor neurons deficits. These types of systematic changes were closely correlated with a decrease in
neuronal loss and oxidative stress in ventral horns of G93A-SOD1 mice [71]. RA also increased SOD,
GSH and GPx activities and decreased MDA levels in kidney and liver of sepsis-induced rats [72].
RA also reduced threshold shift, attenuated noise-induced hearing loss, and promoted hair cells
survival. Moreover, it enhanced the endogenous antioxidant defense system by decreasing SOD
production and up-regulation and decreased 4-HNE expression [73,74]. SOD, CAT, and GPx activities
were increased through RA application at a dose of 50, 100, and 200 mg/kg. Furthermore, it induced
structural changes in the kidney and liver at a dose of 200 mg/kg [75,76].
3.6. Hepatoprotective Activity
Sepsis, shock, and renal artery stenosis are the major clinical problems of acute renal failure, usually
associated with high morbimortality rates. Ischemia-reperfusion (I-R) injury provokes cell damage,
cell death, tissue necrosis, multiorgan dysfunction and increases vascular permeability. These types
of physiopathological processes include RNS, ROS, neutrophils, cytokines, platelets, coagulation
system, endothelium, and xanthine oxidoreductase enzyme system activation. During I-R injury,
cell death occurs as a result of both apoptosis and necrosis [77–79]. RA modulates lipid peroxidation,
production of ROS, peroxynitrite formation, complement factors and proinflammatory mediators,
such as cytokines and chemokines. These processes are involved in hepatic diseases [80].
On the other hand, RA at dose of 150 mg/kg was able to treat rats with I-R, lowered lipid
peroxidation and nitro tyrosine levels, enhanced GSH contents, and reduced neutrophil infiltration,
hepatocellular damage, and all oxidative or nitrative stress markers. It also exerted anti-inflammatory
and antioxidant effects in the ischemic liver, protecting hepatocytes from ischemic injury [81,82].
Moreover, it also conferred marked protection against oxidative stress through increasing CAT and
GPx contents, thus preventing hepatic steatosis. Different RA derivatives have also been reported as
having anti-secretory and antiulcer effects in epithelial tissues, being able to heal gastric ulceration [83].
Indeed, RA led to a significant reduction in hepatic toxicity, including alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lipid peroxidation, and oxidized glutathione levels and improved
antioxidant effects of GPx, CAT, and SOD enzymes [26]. A marked improvement in liver serum
markers and histology and inflammatory process decrease were also stated after RA administration at
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a dose of 10, 25, and 50 mg/kg by gavage once daily for two consecutive days against CCl4-induced
hepatic necrosis. Furthermore, RA prevented α-smooth muscle actin (α-SMA) and transforming
growth factor β1 (TGF-β1) expression, suggesting profibrotic response suppression [84].
Peroxisome proliferator-activated receptor γ (PPARγ) is required for HSCs differentiation, and its
epigenetic repression carries on the HSCs activation. RA inhibits HSCs signaling and expression by
canonical Wnts as well as suppresses liver fibrosis progression and activation [85–87]. In CCl4-induced
rat liver fibrosis model, RA inhibited HSCs proliferation and TGF-βl, connective transforming growth
factor (CTGF), and α-SMA expression. Much evidence has shown that RA can decrease fibrosis grade
and ameliorate biochemical and histopathological morphology in CCl4-induced liver fibrosis [88].
In lipopolysaccharide (LPS)-activated RAW164.7 cells, RA concentration-dependently down-
regulated IL-6, TNF-α, and high mobility group box1 protein levels. RA also inhibited I kappa B
kinase pathway and modulated NF-κB. RA intravenous injection also decreased puncture-induced
lethality and cecal ligation in rats. Additionally, RA down-regulated serum IL-6 and TNF-α levels,
triggering receptor expressed on myeloid cells, high mobility group box1 protein, and endotoxin whilst
up-regulating the serum IL-6 level. Moreover, post-RA injection, a marked decrease in serum enzyme
activities was observed, along with amelioration of liver, lungs, and small intestine hemodynamics;
this anti-inflammatory mechanism may be explained through inhibition of NF-κB pathway activation
by inhibiting I kappa B kinase activity [89]. RA also decreased ROS production and protein and DNA
synthesis inhibition in a dose-dependent manner [90].
In extrahepatic cholestasis rat model by bile-duct ligation, RA showed hepatoprotective effect via
mechanisms involving resolution of oxidative burden and down-regulation of HMGB1/TLR4, NF-κB,
AP-1, and TGF-β1/Smad signaling [91].
3.7. Antidepressant Potential
RA effects at a dose of 0, 3, 10, or 30 mg/kg were investigated in female C57BL/6 mice for
60 min before pilocarpine (300 mg/kg) or pentylenetetrazol (PTZ, 60 mg/kg) injection. Generalized
seizure duration and myoclonic generalized tonic-clonic seizure latencies were analyzed by
electroencephalographic (EEG) and behavioral methods. The effect of an acute RA dose on mice was
also evaluated in behavior in the open field, rotarod, novel object recognition, and forced swim tests.
In the PTZ model, RA dose-dependently increased generalized seizures and latency to myoclonic jerks
and improved pilocarpine-induced myoclonic jerks’ latency. Additionally, RA (30 mg/kg) improved
the time at the center of the open field, the crossings number and the immobility time in forced swim
test [92].
Worldwide mood disorders are the most spreading forms of mental illness and, in main cases,
morbidity. According to the World Health Organization (WHO), depression is one of the top causes
of morbimortality throughout the world. Depression is a recurrent, potentially life-threatening,
and chronic mood disorder that has been estimated to affect about 21% of the world population [93].
RA administration (10 mg/kg, daily) in chronic stress Sprague Dawley rats changed depressive behaviors
in rats exposed to impulsive stress modal and restored hippocampal brain-derived neurotrophic
factor (BDNF) and pERK1/2 protein expression. Thus, RA could be conceived as a great molecule
in the treatment of depression and in triggering changes in BDNF levels and in ERK11/2 signaling
in pharmacological science [94]. In PC 12 cells, RA showed significant neurotrophic effects and
improved cholinergic functions in correlation with the ERK1/2 signaling pathway and MAPK. RA also
caused an extensive up-regulation of pyruvate carboxylase (PC) and tyrosine hydroxylase (TH),
involved in serotonergic, GABAergic, and dopaminergic pathways regulation, whereas against
corticosterone-induced toxicity it provides neuronal cells protection [95].
3.8. Nephroprotective Activity
Currently, the most often used antimicrobial agents provoke an acute renal injury in 60% of acquired
infections in hospitals with noticeable morbimortality rates [96]. Among them, aminoglycosides
181
Appl. Sci. 2019 , 9 , 3139
have been frequently used to treat bacterial infections, and gentamicin is the most commonly used
aminoglycoside, given its lower costs and lower rate of antibiotic-acquired resistance; nevertheless,
its therapeutic use at 80 mg/kg/day for more than 7 days induces nephrotoxicity in about 30% of
patients [97]. Acute renal toxicity characterization is assessed by the sudden decrease of kidney
function due to the accumulation of urea, creatinine, and other waste products. Gentamicin-induced
nephrotoxicity is related to enhanced oxidative stress levels, which may be a major contributing factor
for renal injury [98].
RA led to a decrease in serum blood urea nitrogen and creatinine levels in Sprague Dawley
rats and ultimately decreased myeloperoxidase and MDA levels. In fact, the level of incident injury
decreased in the RA-treated group. In addition, RA extensively reduced Bowman’s capsules dilatation,
glomerular necrosis, tubular epithelium degeneration, tubular epithelium necrosis and dilatation,
and focal glomerular necrosis [99].
RA at doses of 1, 2, and 5 mg/kg for 2 days significantly increased serum creatinine and
blood urea nitrogen levels and reduced cisplatin (CP)-induced histopathological changes. RA also
reduced CP-produced oxidative stress and amplified cytochrome P450 2E1 (CYP2E1), HO-1,
and renal-4-hydroxynonenal expression. Additionally, RA repressed TNF-α and NF-κB expression,
as stated through inflammation inhibition. Moreover, RA reduced p53, phosphorylated p53, and active
caspase-3-expression in kidney through exerting antiapoptotic activity [100]. RA also notably reduced
MDA, tubular necrosis, urea, and creatinine levels, and increased renal GSH, SOD, CAT, GPS, volume
density creatinine clearance, and PCT [101]. Finally, RA could provide protective effects against
6-hydroxydopamine-induced neurotoxicity via its antioxidant activity [102].
3.9. Anti-Aging Activity
RA administration could effectively reverse chaperones- and Pin1-induced abnormal changes and
suppress P-tau and insoluble P-tau formation, induced by chronic restraint stress (CRS), particularly in
middle-aged mice [103].
AD is a progressive neurodegenerative disorder that causes dementia in older people. Disease
indicators include the appearance of plaques and tangles in brain tissues, which progressively kill
neurons from brain cortex, amygdala, hippocampus, and other non-regeneratable brain regions.
Consequently, acetylcholine (ACh) levels decline, the widely known cholinergic deficit hypothesis
for AD. ACh has a significant role in brain functions, such as thinking, reasoning, remembering,
and behavioral abilities [104,105].
In AD, stress is an important risk factor, since it induces tau phosphorylation and enhances
tau insolubility in the brain. RA application is able to dominantly suppress the increase in
tau phosphorylation levels and insoluble P-tau formation, facilitated by chronic resistant stress,
and overturn the abnormal changes in middle-aged mice [103]. At 1.6, 16 and 32 mg/kg, RA exerted
markedly useful effects on memory and learning and also reduced the levels of protein carbonyls in
the hippocampus [106]. In ALS, a neurodegenerative disease, RA significantly delays motor neuron
dysfunction in paw grip endurance tests, through attenuating motor neurons degeneration and
extending the life span of ALS mice model, detected at later stages, and about 2% patients present an
associated mutation in the gene encoding Cu/Zn-SOD [107].
RA also exerted protective effects against 6-hydroxydopamine-facilitated neurotoxicity and
prevented 1-methyl-4-phenypyridinium effects in MES23.5 dopaminergic cells. In fact, 1-methyl-4-
phenylpyridinium treatment reduces cell viability and dopamine contents, as well as causes
apoptotic morphological changes. Additionally, 1-methyl-4-phenylpyridinium precedes mitochondrial
dysfunction, easily detected through inhibiting mitochondrial respiratory chain complex 1-associated
activity, suggesting mitochondrial transmembrane collapse and ROS generation. Thus, RA pretreatment
was able to restore mitochondrial respiratory chain complex 1 activity and to reverse the other MPP
positive damaging effects [91,92] partially. In mice, RA improves oxidative stress parameters and
mitochondrial respiratory chain activity [108]. RA also proved to be effective in preventing in vitro
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amyloid peptide aggregation and in delaying disease progression in animal models [109]. It also
provided neuroprotective effects against Aβ-induced toxicity by lowering lipid peroxidation, DNA and
ROS formation, and inhibiting phosphorylated p38 MAPK levels [110,111]. RA improved antioxidant
properties and healthspan via the IIS and MAPK pathways in Caenorhabditis elegans [112].
N2A cells’ H2O2-induced cytotoxicity is also positively affected by RA; in fact, it is able to attenuate
LDH, intercellular ROS, and mitochondrial membrane potential disruption. RA also promoted TH
and BDNF genes up-regulation and prevented genotoxicity [113,114]. Clovamide in combination with
RA, at the rate of 10–100 μM, in SH-SY5Y cells significantly enhanced PPARγ expression and inhibited
NF-κB translocation, respectively [115].
3.10. Anti-Allergic Activity
RA significantly decreased murine double minute (MDM) 2 and thymic stromal lymphopoietin
(TSLP) expression in induced mast cells proliferation. It also significantly decreased the levels of
phosphorylated signal transducer, IL-13, and transcription-6 activation in TSLP-stimulated HMC-1
cells. Moreover, RA triggered an increment of p53 levels, poly-ADP-ribose polymerase cleavage,
caspase-3 activation, and a reduction in Bcl2 and procaspase-3 levels. Furthermore, it significantly
reduced TNF-α, IL-6, and IL-1β production in TSLP-stimulated HMC-1 cells. It also reduced IL-4,
immunoglobulin E (IgE), and TSLP levels in short ragweed pollen-induced allergic conjunctivitis
mouse model [116].
In murine model of respiratory allergy caused by Bloma tropicalis (Bt) mite, RA led to a considerable
decrease in leukocytes or eosinophils numbers in bronchoalveolar lavage (BAL), of mucus presence in
the respiratory tract, reduced lung histopathological changes, and eosinophil peroxidase activity and
IL-4 changes [117,118]. At a dose of 1 or 5 μM in NC/Nga mice under specific pathogenic free conditions,
RA was shown to be the most effective treatment against 2,4-dinitrofluorobenzene (DNFB)-induced
AD-like skin lesion. Moreover, it suppressed IL-4 and interferon (INF) production by activated CD4+
cells. RA also inhibited skin lesions and ears thickness development and increased total serum IgE
levels in DNFB-treated NC/Nga mice [119]. Furthermore, it inhibited IgE levels increase in spleen,
nasal mucosa, and serum, inhibited the increase in rubs number, and reduced histamine levels in
ovalbumin unsensitized (OVA) mice. RA also inhibited protein levels and mRNA expressions of
IL-6, IL-1β, and TNF-α in nasal mucosa or spleen tissues in OVA-sensitized mice [120,121]. In a
murine model of allergic asthma triggered by house dust mites (HDMs), RA inhibited the boost up of
mononuclear, eosinophils, and neutrophils cells levels around airways and in BAL fluid. Moreover,
it also significantly inhibited IL-13 expression increased by HDM allergen [122].
RA (200 mg or 50 mg for 21 days) also reduced the number of eosinophils and neutrophils
considerably in nasal lavage fluid. Up-regulation of VCAM-1, COX-2, MIP-2, and ICAM-1
by 2-tetradecanoylphorbol 13-acetate (TPA) were significantly reduced with RA pretreatment.
ROS production detected as LPO, 8-hydroxy-2′deoxyguanosine (8OH-dG) and thiobarbituric acid
reactive substance (TBARS) and TPA levels were markedly reduced by RA pretreatment. Furthermore,
RA is conceived as a potential agent against seasonal allergic rhino conjunctivitis (SAR), through
mediated polymorphonuclear leukocytes (PMNL) infiltration inhibition [123].
RA also inhibited significantly the increases in eosinophils levels in BAL fluid along with murine
airways. In the lungs of sensitized mice, RA inhibited the increase in protein expression of IL-5, IL-4,
and eotaxin. Thus, RA seems to be a successful intervention for allergic asthma, given its ability to
increase chemokines, cytokines, and allergen-specific antibody levels [124]. Additionally, RA reduced
inflammation and allergic immunoglobulin responses occurring in mice PMNL. It also noticeably
increased the response rates for itchy eyes, watery eyes, and itchy nose and reduced eosinophils and
neutrophils levels in nasal lavage fluid of SAR [125].
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3.11. Anti-Inflammatory Activity
RA administration (40 mg/kg) in a rat model of sciatic nerve chronic constriction injury
(CCI)-induced neuropathic pain reduced spinal inflammatory markers, such as matrix metallopeptidase
2 (MMP2), prostaglandin E2 (PGE-2), IL-1β, and COX-2 [126]. In addition, RA administration (75, 150,
and 300 mg/kg) in hepatocellular carcinoma (HCC) for 10 days reduced inflammatory and angiogenic
factors levels, including TNF-α, IL-6, IL-1β, TGF-β, and VEGF. Moreover, it also decreased NF-κB and
p65 expression in the xenograft microenvironment [127].
On the other hand, RA (IC50 = 14.25 μM) inhibited LPS-induced NO production in RAW 264.7 cells.
It also repressed LPS-induced pro-inflammatory cytokines expression, including INF-β, MCP-1, iNOS,
IL-1β, IL-6, IL-10, and NF-κB activation. In dependent and independent pathways, down-regulation
of iNOS by RA was due to myeloid differentiation primary response gene 88 (MyD88). Additionally,
RA triggered HO-1 expression through inducing Nrf2 activity [92,128].
RA (5, 10, and 20 mg/kg) also inhibited Th2 cytokines in BAL fluid, increased inflammatory
cells, ameliorated hyper airway responsiveness (AHR), and reduced total IgE and Ova-specific IgE
concentrations in a murine model of asthma (female BALB/c mice). In upper airways, RA reduced the
number of mucus hypersecretion and inflammatory cells. It seems that RA protective effects might be
mediated by p38 phosphorylation, JNK, and ERK suppression. Additionally, RA pretreatment provoked
the reduction of Ym2, CC chemokine receptor 3 (CCR3), CCL11 (eotaxin), AMCase, and E-selectin
mRNA expression in lung tissues [129]. In SPI, RA noticeably increased antioxidant status and reduced
oxidative stress levels in Wistar rats post-SCI. It also improved inflammatory mechanisms through
pro-inflammatory cytokines reduction and NF-κB down regulation [69]. RA (10, 25, and 50 mg/kg)
also remarkably decreased the serum transaminases (ALT and AST) and LDH concentration in liver
ischemia-reperfusion rats. Furthermore, it reduced multiorgan dysfunction markers (lung, liver,
and kidney) through metalloproteinase-9 and NF-κB modulating [130]. RA also displayed both
peripheral and central antinociceptive effects and anti-inflammatory activity against chronic and acute
inflammation [83,131–133]. In Freund’s complete adjuvant (FCA)-induced arthritic rats, RA attenuates
inflammation [134].
RA also decreased blocked TNF-α-induced NF-κB activation and cytotoxicity, oxygen-glucose
deprivation (OGD)-induced apoptosis, and high-mobility group box1 (HMGB1) expression in SH-SY5Y
cells. It also decreased brain edema, reduced NF-κB activation and HMGB1 expression, and attenuated
histopathological damage at a dose of 50 mg/kg [135]. RA also considerably lowered allergic asthma
through a significant decrease in the number of leukocytes/eosinophils, of mucus present in the
respiratory tract, eosinophil peroxidase activity, and IL-4 and histopathological changes in lung BAL
fluid [117,136]. RA-derived water and ethanol extract also markedly inhibited LPS-stimulated PGE-2
and NO production in a dose-dependent manner in RAW 264.7 mouse macrophages [137].
4. Conclusions
Current evidence supports the deepened exploration of RA as a promising therapeutic agent
against a wide variety of modern lifestyle disorders (Table 1). However, mechanisms underlying
RA’s therapeutic activity need further investigation. Initial studies indicate that RA may act
through various mechanisms, such as exerting anti-inflammatory and antioxidant effects as well
as inhibiting cell proliferation, migration, and selectively inducing cancer cells apoptosis. In addition,
RA’s anti-angiogenic effects, as demonstrated through human umbilical vein endothelial cells
proliferation, migration, adhesion, and tube formation inhibition, suggest that it can be beneficial in
preventing tumor growth and metastasis. Thus, given the above-highlighted aspects, rosemary extract
can be conceived as a rich source of potential candidates to be included in the diet with promising
effects at pre-determined doses, avoiding toxicity.
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